(navigation image)
Home American Libraries | Canadian Libraries | Universal Library | Community Texts | Project Gutenberg | Children's Library | Biodiversity Heritage Library | Additional Collections
Search: Advanced Search
Anonymous User (login or join us)
Upload
See other formats

Full text of "medical books"

ARMY FM 4-02.283 

NAVY NTRP 4-02.21 

AIR FORCE AFMAN 44-161(1) 

MARINE CORPS MCRP 4-11.1B 



TREATMENT OF 

NUCLEAR AND 

RADIOLOGICAL 

CASUALTIES 



HEADQUARTERS, DEPARTMENTS OF THE ARMY, THE NAVY, AND 
THE AIR FORCE, AND COMMANDANT, MARINE CORPS 



DISTRIBUTION RESTRICTION B: Distribution authorized to U.S. Government agencies only because it 
contains copyrighted material that is not to be transmitted outside the U.S. Government. This determination was 
made on 20 December 2001. Other requests for this document will be referred to HQDA (DASG-HCD), 
51 09 Leesburg Pike, Falls Church, VA 22041 -3258. 

DESTRUCTION NOTICE: Destroy by any method that will prevent disclosure of contents or reconstruction of 
the document. 

20 December 2001 



This manual contains copyrighted material. 



FM 4-02.283 

NTRP 4-02.21 

AFMAN 44-161(1) 

MCRP4-11.1B 



FIELD MANUAL 

NO. 4-02.283 

NTRP 4-02.21 

AIR FORCE MANUAL 

NO. 44-161 (INTERSERVICE) 

MARINE CORPS 

MCRP4-11.1B 



HEADQUARTERS 

DEPARTMENTS OF THE ARMY, THE 

NAVY, AND THE AIR FORCE, AND 

COMMANDANT, MARINE CORPS 

Washington, DC 20 December 2001 



TREATMENT OF 
NUCLEAR AND RADIOLOGICAL CASUALTIES 



DISTRIBUTION RESTRICTION B: Distribution authorized to U.S. Government agencies only 
because it contains copyrighted material that is not to be transmitted outside the U.S. Govern- 
ment. This determination was made on 20 December 2001. Other requests for this document 
will be referred to HQDA (DASG-HCD), 51 09 Leesburg Pike, Falls Church, VA 22041 -3258. 



TABLE OF CONTENTS 



PREFACE 
CHAPTER 



CHAPTER 



Page 



vn 

1. INTRODUCTION 

1-1. Purpose and Scope 1-1 

1-2. Radiation Accidents 1-2 

-3. Nuclear Weapons Incidents 1-8 

-4. Terrorism and Radiological Dispersal Devices 1-9 

-5. Terrorism and a Single Nuclear Detonation 1-9 

-6. Nuclear Warfare 1-10 

-7. Global and Regional Threats 1-11 

2. HAZARDS OF NUCLEAR AND RADIOLOGICAL EVENTS 

-1 . General 2-1 

-2. Types of Ionizing Radiation 2-1 

-3. Units of Measure 2-2 

-4. Penetration and Shielding 2-4 

-5. Nuclear Detonation 2-6 

-6. Nuclear Detonation Blast Hazards 2-8 

-7. Nuclear Detonation Thermal Radiation Hazards 2-9 

-8. Nuclear Detonation Radiation Hazards 2-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



Page 



CHAPTER 



Section 



Section 



Section 



Section 



Section 



2-9. 
2-10. 



3-1. 
I. 

3-2. 

3-3. 

3-4. 
II. 

3-5. 

3-6. 

3-7. 

III. 

3-8. 

3-9. 
3-10. 
3-11. 

IV. 
3-12. 
3-13. 
3-14. 
3-15. 



CHAPTER 



16. 

17. 
V. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 

4. 

4-1. 
4-2. 



Range of Damage 2-12 

Radioactive Contamination Hazards 2-13 

TREATMENT OF HIGH-DOSE RADIOLOGICAL AND 
COMBINED INJURY CASUALTIES 

General 3-1 

Ionizing Radiation Effects on Cells and Tissues 3-1 

General 3-1 

Cellular Effects of Ionizing Radiation 3-2 

Relative Tissue Radiosensitivity 3-3 

Systemic Effects of High-Dose Radiation 3-5 

General 3-5 

Acute Radiation Syndrome 3-6 

Radiation-Induced Early Transient Incapacitation 3-11 

Diagnosis, Severity, and Triage of Radiation Casualties 3-12 

Clinical Findings 3-12 

Dosimetry 3-14 

Laboratory Testing 3-14 

Triage of Nuclear and Radiological Casualties 3-15 

Treatment of Radiation Subsyndromes 3-17 

First Aid 3-17 

Management of the Hematopoietic Syndrome 3-17 

Management of the Gastrointestinal Syndrome 3-21 

Management of the Cardiovascular/Central Nervous System 

Syndrome 3-22 

Recovery 3-22 

Summary of Medical Aspects of Acute Radiation Injury 3-22 

Combined Injury— Blast, Thermal, and Radiological Injuries 3-27 

General 3-27 

Blast Injuries 3-27 

Treatment of Blast Injuries 3-27 

Thermal Injury 3-28 

Determining Severity of Thermal Injuries 3-29 

Treatment of Thermal Injuries 3-30 

Hematopoietic Effects of Combined Injury 3-31 

Chemical Weapons and Radiation 3-31 

Biological Weapons and Radiation 3-32 

Immunization and Radiation 3-32 

RADIOACTIVE CONTAMINATION 

General 4-1 

Measuring Levels of Contamination 4-1 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



Page 

Section I. External Contamination, Irradiation, and Acute Local 

Radiation Injury 4-3 

4-3. External Irradiation 4-3 

4-4. Decontamination 4-3 

4-5. Local Tissue Irradiation 4-4 

4-6. Cutaneous Radiation Syndrome 4-5 

4-7. Treatment of the Cutaneous Radiation Syndrome 4-6 

Section II. Internal Contamination and Irradiation 4-8 

4-8. General 4-8 

4-9. Internalization of Radioactive Materials 4-8 

4-10. Internal Contamination Treatment 4-11 

CHAPTER 5. LOW-LEVEL RADIATION 

5-1 . Low-Level Radiation Characteristics and Hazards 5-1 

Section I. Low-Level Radiation Exposure 5-1 

5-2. Exposure Guidance 5-1 

Section II. Delayed/Late Health Effects 5-3 

5-3 . General 5-3 

5-4. Principles 5-3 

5-5. Types of Long-Term Effects 5-4 

5-6. Embryonic and Fetal Effects 5-4 

5-7. Reproductive Cell Kinetics and Sterility 5-5 

5-8. Carcinogenesis 5-5 

5-9. Cataract Formation 5-6 

Prevention, Initial Actions and Medical Care and Follow-Up 5-7 

Prevention 5-7 

Initial Actions 5-8 

Medical Care 5-8 

Medical Follow-Up 5-8 

Documentation of Radiation Exposure Records 5-10 

CHAPTER 6. PSYCHOLOGICAL EFFECTS AND TREATMENT OF 

PSYCHOLOGICAL CASUALTIES 

6-1 . General 6-1 

6-2. Radiation Dispersal Devices and Nuclear Incidents 6-1 

6-3. Nuclear Detonation 6-2 

6-4. Fallout Field 6-3 

6-5. Psychosocial Sequelae of Radiation Exposure 6-3 

6-6. Treatment 6-4 

6-7. Prevention and Risk Communication 6-5 

APPENDIX A. DEPLETED URANIUM 

A-l . General A-l 



Section 



III. 

10. 
11. 
12. 
13. 
14. 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



Page 



APPENDIX 



APPENDIX 



Section 



Section 



A-2. 
A-3. 
A-4. 
A-5. 



B. 

C. 

C-l. 



I. 

-2. 
-3. 
-4. 
-5. 
-6. 
-7. 



C- 
C- 

c- 
c- 
c- 
c- 

C-8. 

C-9. 
C-10. 
C-ll. 
C-12. 
C-13. 
C-14. 
C-15. 



-16. 
■17. 
-18. 
-19. 
-20. 
-21. 



C-22. 

C-23. 

II. 

C-24. 

C-25. 
C-26. 

C-27. 



Depleted Uranium Characteristics and Uses A-l 

Depleted Uranium Toxicity A-2 

Health Effects of Exposure to Depleted Uranium A-3 

Patient Management of Personnel Wounded by Depleted Uranium 

Munitions A-5 

MEDICATIONS B-l 

TREATMENT BRIEFS 

Scope of Treatment Briefs C-l 

Global Assumptions C-2 

Level of Care C-2 

Combined Injury C-2 

Wound Closure C-3 

Return to Surgery C-3 

Psychological Casualties C-3 

Decontamination C-4 

Incidence Rates C-4 

Evacuation C-4 

Patient Holding Capabilities C-4 

Blood Products C-5 

Patient Warming C-6 

Sterilization C-6 

C-Spine Management C-6 

Tetanus C-6 

Diets C-6 

Casts and Splints C-7 

Lab/X-ray/Pharmacy C-7 

Oxygen C-7 

Patient Personal Support Kits C-7 

Water C-7 

Linen C-7 

Refrigeration C-7 

Treatment Briefs C-8 

Treatment Brief No. 1: Radiation Exposure at 0.0-75 cGy Without 

Other Physical Injury C-8 

Treatment Brief No. 2: Radiation Injury at 75-125 cGy Without 

Other Physical Injury C-8 

Treatment Brief No. 3: Radiation Injury at 125-300 cGy Without 

Other Physical Injury C-9 

Treatment Brief No. 4: Radiation Injury at 300-530 cGy Without 

Other Physical Injury C-10 



IV 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Page 

C-28. Treatment Brief No. 5: Radiation Injury at 530-830 cGy Without 

Other Physical Injury C-l 1 

C-29. Treatment Brief No. 6: Radiation Injury at 830-1500 cGy Without 

Other Physical Injury C-12 

C-30. Treatment Brief No. 7: Radiation Injury > 1500 cGy Without 

Other Physical Injury C-13 

C-31. Treatment Brief No. 8: Radiation at 0-125 cGy With Nonoperative 

Trauma (Examples include concussion, simple lacerations, closed 

fractures, ligamental injuries, and so forth.) C-14 

C-32. Treatment Brief No. 9: Radiation at 125-530 cGy With Nonoperative 

Trauma (Examples include concussion, simple lacerations, closed 

fractures, ligamental injuries, and so forth.) C-15 

C-33. Treatment Brief No. 10: Radiation > 530 cGy With Nonoperative 

Trauma (Examples include concussion, simple lacerations, closed 

fractures, ligamental injuries, and so forth.) C-17 

C-34. Treatment Brief No. 11: Radiation at 0-125 cGy With Operative 

Trauma C-18 

C-35. Treatment Brief No. 12: Radiation at 125-530 cGy With Operative 

Trauma C-20 

C-36. Treatment Brief No. 13: Radiation > 530 cGy With Operative 

Trauma C-21 

C-37. Treatment Brief No. 14: Radiation at 0-125 cGy With Mild Burn C-23 

C-38. Treatment Brief No. 15: Radiation at 125-530 cGy With Mild Burn 

(Without treatment 90 percent mortality.) C-24 

C-39. Treatment Brief No. 16: Radiation > 530 cGy With Mild Burn 

(Without treatment 100 percent mortality.) C-25 

C-40. Treatment Brief No. 17: Radiation at 0-125 cGy With Moderate Burn C-26 

C-41. Treatment Brief No. 18: Radiation at 125-530 cGy With Moderate 

Burn (Without treatment 100 percent mortality.) C-27 

C-42. Treatment Brief No. 19: Radiation > 530 cGy With Moderate Burn 

(With or without treatment 100 percent mortality.) C-28 

C-43. Treatment Brief No. 20: Radiation at 0-125 cGy With Severe Burn 

(Without treatment 20 percent mortality.) C-29 

C-44. Treatment Brief No. 21 : Radiation at 125-530 cGy With Severe Burn 

(Without treatment 100 percent mortality.) C-3 1 

C-45. Treatment Brief No. 22: Radiation >530 cGy With Severe Burn 

(With or without treatment 100 percent mortality.) C-32 

C-46. Treatment Brief No. 23: Radiation at 0-125 With Operative Trauma 

and Mild Burn C-33 

C-47. Treatment Brief No. 24: Radiation at 125-530 cGy With Operative 

Trauma and Mild Burn (Without treatment 100 percent mortality.) C-34 

C-48. Treatment Brief No. 25: Radiation > 530 cGy With Operative 

Trauma and Mild Burn (With or without treatment 100 percent 

mortality.) C-36 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



Page 

C-49. Treatment Brief No. 26: Radiation at 0-125 With Operative Trauma 

and Moderate Burn (Without treatment 100 percent mortality.) C-37 

C-50. Treatment Brief No. 27: Radiation at 0-125 cGy With Operative 

Trauma and Severe Burn (Without treatment 100 percent mortality.) C-39 

C-51. Treatment Brief No. 28: Radiation > 125 cGy With Operative 

Trauma and Moderate or Severe Burn C-40 

GLOSSARY Glossary-1 

REFERENCES References-1 

INDEX Index- 1 



VI 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



PREFACE 

Purpose 

This publication serves as a guide and a reference for trained members of the Armed Forces Medical 
Services and other medically qualified personnel on the recognition and treatment of nuclear and radiological 
casualties. 

Scope 

a. This publication— 

(1) Classifies and describes potential nuclear and radiological threats and hazards. 

(2) Describes the biological aspects of blast, thermal radiation, and ionizing radiation and its 
effects on organs and systems of the body. 

(3) Describes procedures for first aid, medical diagnosing, treating, and management of 
nuclear and radiological casualties. 

b. The material in this publication is applicable to both the nuclear battlefield and to other 
operations where a high- or low-level radiation hazard exists; this includes military support to United States 
(US) civilian agencies during weapons of mass destruction (WMD) consequence management operations. 

c. The treatment modalities contained in this manual are based upon those described in the most 
recent North Atlantic Treaty Organization (NATO) Handbook on the Medical Aspects of Nuclear, Biological 
and Chemical (NBC) Defensive Operations AMedP-6(C), Ratification Draft; the Medical Management of 
Radiological Casualties Handbook, First Edition, and the recently approved Treatment Briefs. 

d. The use of the term "level of care" in this publication is synonymous with "echelon of care" 
and "role of care. " The term "echelon of care" is the old NATO term. The term "role of care" is the new 
NATO and American, British, Canadian, and Australian (ABC A) term. 

Standardization Agreements 

This manual is in consonance with NATO Standardization Agreements (STANAGs) and ABCA Quadripartite 
Standardization Agreements (QSTAGs): 

NATO ABCA 
STANAG QSTAG TITLE 

2068 Emergency War Surgery. 

2083 Commanders' Guide on Nuclear Radiation Exposure of Groups, Edition 6. 

vii 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



NATO ABCA 
STANAG QSTAG TITLE 

2461 NATO Handbook on the Medical Aspects of NBC Defensive Operations, 

AMedP-6(C). Volume I-Nuclear Ratification Draft. 

2473 Commanders' Guide on Low-Level Radiation (LLR) Exposure in Military 

Operations, Edition 1. 

2475 Planning Guide for the Estimation of NBC Battle Casualties (Nuclear), AMedP-8 

(A). Volume I. 

1263 Common Principles and Procedures for Critical Aspects of the Medical and 

Dental Treatment of Personnel. 

Implementation Plan 

Participating Service command offices of primary responsibility will review this publication, validate the 
information, reference, and incorporate it in Service and command manuals, regulations, and curricula as 
follows: 

a. Army. The Army will incorporate this publication in US Army training and doctrinal 
publications as directed by the Commander, US Army Training and Doctrine Command. Distribution is in 
accordance with initial distribution number 115861, requirements for FM 4-02.283. 

b. Marine Corps. The Marine Corps will incorporate the procedures in this publication in US 
Marine Corps training and doctrinal publications as directed by the Commanding general, US Marine Corps 
Combat Development Command. Distribution is in accordance with Marine Corps Publication Distribution 
System. 

c. Navy. The Navy will incorporate these procedures in US Navy training and doctrinal 
publications as directed by the Commander, Navy Warfare Development Command. Distribution is in 
accordance with MILSTRIP Desk Guide and NAVSOP Publication 409. 

d. Air Force. The Air Force will validate and incorporate appropriate procedures in accordance 
with applicable governing directives. Distribution is in accordance with AFI 33-360. 

e. Coast Guard. The Coast Guard will validate and refer to appropriate procedures when 
applicable. No material contained herein should conflict with Coast Guard regulations or other directives 
from higher authority, or supersede, or replace any order or directive issued by higher authority. 

User Information 

a. The US Army Medical Department Center and School developed this publication with the 
joint participation of the approving Service commands. 

viii 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



b. This publication reflects current Service and joint doctrine on prevention, protection, medical 
management, and treatment of nuclear and radiological casualties. 

c. We encourage recommended changes for improving this publication. Key your comments to 
the specific page and paragraph and provide a rationale for each comment or recommendation. Send 
comments and recommendations directly to— 

Army 

Commander 

US Army Medical Department Center and School 

ATTN: MCCS-FCD 

Fort Sam Houston, Texas 78234-5052 

DSN 471-9501/9524 COMM (210) 221-9501/9524 

Navy 

Commander 

Navy Warfare Development Command 

ATTN: N5 

686 Cushing Road 

Newport, Rl 02841-1207 

DSN 948-4201 COMM (401) 841-4201 

Air Force 

HQ Air Force Doctrine Center 

ATTN: DR 

155 North twining street 

Maxwell AFB, AL 361 1 2-61 1 2 

DSN 493-5645 COMM (334) 953-5645 

http://www.doctrine.af.mil 

Marine Corps 

Commanding General 

US Marine Corps Combat Development Command 

ATTN: C42 (Director) 

3300 Russell Road 

Quantico VA 22134-5001 

DSN 278-6234 COMM (703) 784-6234 

U. S. Coast Guard 

2100 Second Street, S.W. 
Washington D.C. 20593-0001 
Staff Symbol G-MOR, G-OPD 

ix 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



Gender Statement 

Unless this publication states otherwise, masculine nouns and pronouns do not refer exclusively to men. 

Use of Trade Names/Trademarks 

Use of trade names/trademarks in this publication is for illustrative purposes only. Their use does not 
constitute endorsement by the Department of Defense (DOD). 

References 

References listed should be consulted for details beyond the scope of this publication. 

Acknowledgments 

The Armed Forces Radiobiology Research Institute for allowing use of portions of the Medical Effects of 
Ionizing Radiation Course (CD-ROM). 

The National Academy of Sciences for use of portions of Potential Radiation Exposure in Military 
Operations, Protecting the Soldier Before, During, and After, published 1999. 

The National Council on Radiation Protection (NCRP) and Measurements for allowing use of portions of 
NCRP Report No. 65, Management of Persons Accidentally Contaminated With Radionuclides, 1979. 

To RAND, working jointly with the Advisory Panel, for allowing use of portions of the First Annual Report 
to The President and The Congress of the Advisory Panel To Assess Domestic Response Capabilities For 
Terrorism Involving Weapons of Mass Destruction, Part 1. Assessing the Threat, December 1999. Also, 
RAND is to be acknowledged for allowing use of portions of A Review of the Scientific Literature As It 
Pertains to Gulf War Illnesses, Volume 7, Depleted Uranium, 1999. 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 

CHAPTER 1 
INTRODUCTION 



1-1. Purpose and Scope 

a. This publication serves as a guide and a reference for trained members of the Armed Forces 
Medical Services on the recognition and treatment of nuclear warfare casualties and medical management 
of persons exposed to high and low-level radiation. The proliferation of nuclear material and technology 
has made the acquisition and adversarial use of nuclear and radiological weapons more probable. 
Additionally, military personnel may be deployed to areas that could be radiologically contaminated 
because of the presence of radioactive materials and nuclear facilities. Treatment protocols for radiation 
casualties are now effective, practical and possible, and must be part of US Armed Forces medical 
contingency planning efforts. In order to understand potential nuclear and radiological hazards, the entire 
spectrum of threat events, with examples, is discussed starting with paragraph 1-2. Currently, radiation 
accidents involving industrial or medical radiological material and nuclear weapons incidents are the most 
likely threat to US forces and civilians. The least likely threats are theater and strategic nuclear war (see 
Figure 1-1). 




MOST LIKELY 



ATTACKS WITH RDD OR ATTACKS 
AGAINST NUCLEAR FACILITIES 



SINGLE DETONATION OFA NUCLEAR 
DEVICE OR AN IMPROVISED NUCLEAR 
DEVICE 



THEATER 
NUCLEAR WAR 



STRATEGIC 
NUCLEAR WAR 



LEAST LIKELY 



Figure 1-1. Likelihood of radiation threat. 

b. Throughout the manual, both existing and the International System of Units (systeme 
international d'unites, abbreviated internationally as SI), are used to measure ionizing radiation. The 



1-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



existing and new units of measurement are discussed in detail in Chapter 2. For comparison purposes, a 
radiation unit conversion table is shown below. 

Table 1-1. Conversion Table 



EXISTING UNITS 


SI UNITS 


0.001 


rem 


1 


mrem 


= 


0.01 


mSv 






0.01 


rem 


10 


mrem 


= 


0.1 


mSv 






0.1 


rem 


100 


mrem 


= 


1 


mSv 


0.001 


Sv 


1 


rem 


1,000 


mrem 


= 


10 


mSv 


0.01 


Sv 


10 


rem 






= 


100 


mSv 


0.1 


Sv 


100 


rem 






= 


1,000 


mSv 


1 


Sv 


1000 


rem 












10 


Sv 


0.001 


rad 


1 


mrad 


= 


0.01 


mGy 






0.01 


rad 


10 


mrad 


= 


0.1 


mGy 






0.1 


rad 


100 


mrad 


= 


1 


mGy 


0.001 


Gy 


1 


rad 


1,000 


mrad 


= 


10 


mGy 


0.01 


Gy 


10 


rad 






= 


100 


mGy 


0.1 


Gy 


100 


rad 






= 


1,000 


mGy 


1 


Gy 


1000 


rad 












10 


Gy 


2.7x10-" 


Ci 






= 


1 


Bq 






0.001 


Ci 


1 


mCi 


= 


37 


MBq 






1 


Ci 


1000 


mCi 


= 


3.7 x10 1 ° 


Bq 







1-2. 



Radiation Accidents 



a. General. Radiation accidents are the most likely events that threaten US forces and civilians. 
A radiation accident is a situation in which there is a real or suspected unintentional exposure to ionizing 
radiation or radioactive contamination. According to the (Department Of Energy/Radiation Emergency 
Assistance Center/Training Site) Radiation Accident Registry, from 1944 to 2000, there have been 417 
radiation accidents worldwide. These accidents involved radiation devices (74 percent), radioisotopes (21 
percent), and criticality incidents (5 percent). It must be emphasized that radiation accidents could involve 
either high- or low-level radiation exposures. These exposures can result in varying levels of injuries 
including acute radiation syndrome (ARS), acute local radiation injury, combined injuries (radiation, 
thermal, or blast injuries), psychological consequences, and long-term stochastic effects. This paragraph 
will discuss the most prevalent radiation sources and accidents associated with these sources. Examples will 
be included where appropriate. For a detailed discussion of radiation sources and hazards, see US Army 
Center for Health Promotion and Preventative Medicine (USACHPPM) Technical Guide (TG) 238, Radio- 
logical Sources of Potential Exposure and/or Contamination, Draft, June 1999. 



1-2 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



b. Industrial Radiation Sources and Accidents. 

(1) Radiation devices and radioactive materials are used in industrial processes involved with 
agricultural practices, scientific research, manufacturing, sterilization, and radiography. In fact, most 
radiation accidents have involved industrial gamma and x-ray radiography (nondestructive inspection) 
devices and sources. These industrial and radiography sources are summarized in Table 1-2. Under 
normal operating conditions, most industrial sources of radiation present minimal exposure risks when used 
safely, but accidental exposures can result in serious consequences. US personnel must always be aware of 
the possible dangers from these sources, especially when conducting operations in areas previously subjected 
to ground and/or air combat. 



Table 1-2. Industrial Sources of Radiation 



LOCATIONS AND MATERIALS 


RADIATION SOURCES 


SOURCE STRENGTH 


COMMENTS 


Gauges, Sources, Static 
Eliminators. 


lridium-192, Cesium-137, 
Cobalt-60, Radium-226, 
Neutrons, Americium-241 , 
Polonium-210. 


Greater than about 4 TBq. 


Sealed sources, and if leaking, 
presents surface 
contamination. 


X-ray Machine Sterilizers, 
Processors, and Particle 
Accelerators. 


X-rays, Protons, Deuterons, 
Electrons, Gammas, 
Cesium-137, Cobalt-60. 


~4 TBq to -40 PBq. 


Anywhere in an industrial 
area. Be aware of possible 
activation products. 


Mineral Extraction and 
Processing, including 
phosphate fertilizers, oil, 
natural gas, and coal. 


Naturally occurring Radioactive 
Materials-Uranium, Thorium, 
and their progeny. 


Generally low level with 
external exposures from 
background level to about 
0.01 mSv (1 mrem). 


Dispersed low level material 
and scale build-up in piping. 
Also, in gauges as noted 
above. Radon is a possible 
concern. 


Power Sources. 


Plutonium-238, Strontium-90. 


Plutonium-238: Up to 4 GBq; 
Strontium-90: Up to 1 TBq. 


In equipment in isolated areas. 


Radioluminescent Materials. 


Promethium-147, Tritium, 
Radium-226. 


Up to tens of TBq. 


Various applications, and if 
leaking, surface contamination. 



(2) In February 1989, a radiation accident occurred at an industrial irradiation facility near 
San Salvador, El Salvador. Prepackaged medical products were sterilized at this facility by irradiation 
using an intensely radioactive Cobalt-60 source in a movable source rack. The accident happened when the 
source rack became stuck in the irradiation position, and the operator and two other workers entered the 
radiation room and attempted to free the source rack manually. The three workers were exposed to high 
radiation doses and developed ARS. Their initial hospital treatment and consequent specialized treatment 



1-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



were effective in countering the acute effects. However, the legs and feet of two of the three men were so 
seriously injured that amputation was required. The worker who had received the most exposure died six and 
a half months post-exposure due to residual lung damage exacerbated by injury sustained during treatment. 

c. Biomedical Sources. Biomedical sources of radiation are those devices or materials that are 
readily available at hospitals and some laboratories. They include sealed or encapsulated sources, unsealed 
sources, and machine-produced radiation. Of particular concern are teletherapy units, brachytherapy 
sources, and radionuclide generators. Cobalt-60 teletherapy units are currently used for the treatment of 
cancer throughout the world and may contain up to a 15,000 curie encapsulated source capable of delivering 
a dose rate of 350 cGy/min at 80 centimeters (cm). A life-threatening dose could be received in only a few 
minutes of exposure to unshielded source of this strength. For example, an explosion near a radiation 
therapy facility's Cobalt-60 unit could result in destruction of the shielding surrounding the source and 
spread radioactive material throughout the rubble of the target structure and possibly spread material outside 
of the building. Responding firefighters, rescuers, and the casualties themselves would be at high risk for 
exposure to the dispersed radioactive material. Medical sources of radiation are summarized in Table 1-3. 





Table 1-3. Medical Sources of Radiation 




LOCATIONS AND 


RADIATION SOURCES 


SOURCE STRENGTH 


COMMENTS 


MATERIALS 








Radiation Therapy Facility 


Cobalt-60 and Cesium-137 


80 cGy/min to 350 cGy/min 
at 80 cm when the source 
is unshielded. 


Found in therapy rooms. 


Sources and Applicators 


Cesium-137, lridium-1 92, 


Tens of MBq 


Therapy and nuclear medicine 




Radium-226, Phosphorous-32, 




areas. 




Strontium-90, lodine-125. 






Radiopharmaceuticals 


lodine-123, Phosphorous-32, 


Tens of MBq 


Storage, nuclear medicine 




Technetium-99 m , Thallium-201 




areas, and transportation. 




lodine-131, Strontium-89 


Hundreds of MBq 




X-ray machines and 


X-rays and electrons. 


~0.01 Gy per minute at the 


Radiology or therapy rooms. 


Accelerators 




source 





d. The Nuclear Fuel Cycle and Nuclear Reactors (Power Plants). The nuclear fuel cycle includes 
all the activities associated with the production of electricity from nuclear reactions. This includes mining, 
milling, conversion, enrichment, and fabrication of the fuel as well as the reaction triggered by the fuel, and 
the disposal of the spent fuel and other wastes. If released, high-level waste from the nuclear fuel cycle 
poses serious environmental and health concerns. US forces may be operating in a theater that has nuclear 
fuel processing facilities and nuclear reactors with varying degrees of safety and containment. Tactical 



1-4 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



considerations may require units to maneuver near these reactors, or to occupy areas in the vicinity of these 
facilities. Exposure of US Forces could occur if an accident in one of these facilities dispersed radiation 
into the surrounding environment. Of equal importance is that intentional exposure could occur if an enemy 
commander chose to destroy one of these nuclear reactors and its containment facility. This would result in 
both the disruption of electrical power and the potential for radiological contamination and thus incapacitation 
of large numbers of US military personnel operating in the vicinity of the facility. Examples of wastes from 
the nuclear fuel cycle are shown in Table 1-4. 



Table 1-4. Examples of Nuclear Fuel Cycle Wastes 



CYCLE PROCESS 


PHYSICAL 
STATE OF WASTE 


PRINCIPAL RADIONUCLIDES 


Mining and Milling 


Gaseous 


Bismuth-214; Polonium-210, 214, 218; Radon-222. 


Liquid and Solid 


Lead-210; Radium-226; Thorium-230; Uranium. 


Conversion and Enrichment; 


Liquid 


Protactinium-234; Radium-226; Thorium-234; Uranium-238. 


Fuel Fabrication 


Liquid and Solid 


Plutonium; Thorium; Uranium. 


Reactor Operations 


Gaseous 


Argon-41; Krypton-87, 89; Nitrogen-13; Xenon-138. 




Liquid and Solid 


Cobalt-58, 60; Chromium-51 ; lron-59; Hydrogen-3. 


Waste Reprocessing 


Gaseous 


Hydrogen-3; lodine-129, 131; Krypton-85; Xenon-133. 




Liquid and Solid 


Fission products; Americium, Curium, Plutonium. 



(1) Nuclear fuel processing. 

(a) There are several steps in the processing of the fuel that result in radioactive 
wastes. For example, milling waste contains long-lived radioactive materials and progeny in low 
concentrations and toxic materials such as heavy metals. The chemical conversion process of turning 
uranium hexafluoride to uranium dioxide produces liquid waste that contains chemical impurities, including 
fluorides. The fuel enrichment process leads to the production of material enriched in Uranium-235 for use 
in nuclear power reactors and weapons. Depleted uranium (DU) is a waste product of the uranium 
enrichment process which has found use in military aircraft as a counterweight and in armored vehicles and 
antiarmor munitions (see Appendix A). 

(b) An example of an exposure related to the nuclear fuel process is the large-scale 
radioactive waste problem at the Mayak military complex in the Ural Mountains. The contamination began 



1-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



in 1948, when the Mayak complex provided the Soviet Union with the material for its first atomic bomb. 
For over a decade, the facility was responsible for pumping 1.2 billion curies of cesium- and strontium- 
laced nuclear waste into the bottom of Lake Karachai. This resulted in nearly 24 times the radioactive 
content released by the Chernobyl reactor failure. During the summer of 1967, a portion of the lake 
evaporated due to hot and dry weather conditions. Radioactive dust spewed from the lake, affecting an 
estimated 41,000 people in an area of more than 40,000 square kilometers (kms). By 1990, radiation levels 
near the lakeshore were still high enough to provide a lethal dose within 60 minutes of exposure. Today, 
Lake Karachai remains the most contaminated spot on the earth's surface. 

(2) Nuclear reactors (power plants). As of 1999, there were 433 nuclear power plants in 
operation worldwide. The pressurized water reactor (PWR) is the most common type of nuclear power 
plant in the world. Waste from this type of a reactor is generated as liquid, solid, and gaseous effluents. 
Nuclear reactors produce several potentially dangerous radioactive materials such as Iodine-131 and -133, 
which can be taken up by the thyroid. The fission process also produces significant amounts of Cesium- 134 
and -137 that becomes uniformly distributed throughout the body and becomes a beta -gamma source 
irradiating all organs. Tritium may also present an exposure risk if allowed to accumulate in the liquid and 
gaseous effluents and in the surrounding environment. Reactor accidents are rare, but if an accident occurs, 
there are several exposure pathways including: 



ground (ground shine). 



External dose from a plume overhead (cloud shine) or radioactive material on the 

• Internal dose due to inhaling materials directly from the plume or from stirred up dust. 

• Ingestion of contaminated materials in or on food or water. 

(3) Examples of nuclear reactor accidents. There are three specific examples of accidents 
involving nuclear reactors that resulted in varying degrees of exposure. 

(a) In October 1957, a plume of radioactive contamination was carried into the 
atmosphere from a nuclear reactor fire at Windscale in Great Britain. Because of the inadequacy of the 
temperature measuring instrumentation, the control room staff mistakenly thought the reactor was cooling 
down too much and needed an extra boost of heating. Thus, temperatures were abnormally high when the 
control rods were withdrawn for a routine start to the reactor's chain reaction. The uranium and graphite 
ignited and sent temperatures soaring to 1,300 degrees centigrade. As the fire raged, radioactivity was 
carried aloft. Blue flames shot out of the back face of the reactor and the filters on the top of the chimneys 
could only hold back a small proportion of the radioactivity. An estimated 20,000 curies of radioactive 
iodine escaped along with other isotopes such as plutonium, cesium, and polonium. Eventually, the reactor 
was flooded with cooling water which put out the fire, and gradually the reactor was brought under control. 

(b) The Three Mile Island incident on March 28, 1979 in Pennsylvania, was due to a 
failure in an auxiliary component in the secondary system, which led to loss of the water supply to the steam 
generators. This resulted in lack of adequate cooling capability to remove the heat produced within the 
reactor. Part of the fuel melted, carrying fission products through the primary system into the pressurizer 

1-6 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



relief tank. This tank burst open under the rising pressure and fission gases were released into the 
containment, actuating all of the radioactivity alarms. After several confusing hours, the operator finally 
restored cooling to the reactor and reflooded the core. Before the operator finally isolated the containment, 
fission gases such as xenon and krypton escaped through the ventilation filters. However, there was no 
uncontrolled release of iodines or other aerosols since they were all trapped in the water and the filters. No 
biological effects were observed as a result of the radioactive materials released in the accident. 

(c) On April 26, 1986 a reactor at the Chernobyl power station located in the Ukraine, 
about 90 miles from Kiev, was destroyed in a catastrophic accident. The accident occurred during the 
running of safety test, not during the normal operation of the reactor. The test carried out at Chernobyl -4 
was designed to demonstrate that during an external electrical grid failure, a "coasting" turbine would 
provide sufficient electrical power to pump coolant through the reactor core while waiting for electricity 
from the back-up diesel generators. Poor test design and violation of safety regulations ultimately resulted 
in two explosions. One was a steam explosion; the other was an explosion of the fuel vapor. The 
explosions lifted the nuclear pile cap, allowing the entry of air, which reacted with the graphite moderator 
blocks to form carbon monoxide. This gas ignited and a reactor fire resulted. The end result was that about 
eight tons of fuel and highly radioactive fission products were ejected from the reactor along with a portion 
of the graphite moderator, which was also radioactive. These materials were scattered around the site, 
while cesium and iodine vapors were released into the atmosphere. 

e. Sources from United States Forces Commodities and Foreign Material. 

(1) United States forces use many radioactive commodities in equipment, vehicles, ships, 
aircraft, weapons systems, and so forth. Depleted Uranium is discussed separately in Appendix A. 
Depleted Uranium is not a chemical or a radiological threat. However, DU is a low-level radioactive 
material and, as such, it is discussed in this manual for convenient reference by medical professionals. 
Some of the most common radioactive sources in US material are: 

• Tritium (Hydrogen-3). Tritium is the heaviest isotope of hydrogen and is a low 
energy beta emitter with a physical half-life of 12 years. Tritium is generally used in devices requiring a 
light source, such as watches, compasses, and fire control devices for tanks, mortars, and howitzers. Only 
a release of a large amount in a closed space can cause an exposure of clinical importance. 

• Nickel-63. Nickel-63 is a pure beta emitter with a radiological half-life of 92 years, 
and is used in the chemical agent monitor (CAM). The beta energy of Nickel-63 is too low to penetrate the 
dead layer of skin; however, efforts should be taken to prevent internalization. 

• Cesium- 137. Cesium- 137 is used in the soil density and moisture tester (Campbell 
Pacific Model MC-1). Cesium-137 emits a beta particle as it decays to Barium-137, which in turn decays 
by emitting gamma rays. The beta hazard is minimal since the radioactive source is shielded in double 
encapsulated stainless steel. However, placing the source close to the body (such as in a pocket) for an 
extended period of time can cause clinical injury. 

• Thorium-232. Thorium -232 is a naturally occurring radioisotope of thorium and is 
an alpha emitter. When thorium is heated in air, it glows with a white light. For this reason, one of the 

1-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



major uses of thorium has been the Welsback lantern mantle used in portable gas lanterns. Thorium-232 is 
also used in radiac sets AN/VDR-2, AN/PDR-54, and the AN/PDR-77 for use as calibration check sources. 
Thorium-coated optics are found on many night vision devices and thermal optic fire control systems. Also, 
heat resistant thorium alloys are used in the combustor liner for the Abrams tank turbine engine and on 
various military aircraft engines. In general, Thorium-232 presents a minimal hazard, but care should be 
taken to avoid internalization of any particles from damaged components or during metal working activities. 

• Americium-241 . Americium-241 is used as a sealed source in the M43A1 Chemical 
Agent Detector that is a component of the M8A1 alarm. Americium-241 is primarily an alpha emitter and a 
very low energy gamma emitter. External exposure is not a concern unless large amounts of the substance 
are located in one area and personnel are in close contact for an extended period of time. 

(2) Similar to US forces commodities, some foreign materiel contains radioactive sources. 
Although these sources do not present a hazard to personnel working close to them, it is important to be 
aware of their presence, as they could be dangerous if the equipment has been damaged or tampered with. 
See USACHPPM TG 238 for detailed descriptions of radioactive sources in foreign materiel. 

1-3. Nuclear Weapons Incidents 

a. All nuclear weapons contain a conventional high explosive component, and in any accident 
involving this type of weapon, there is a risk of either an explosion of this material, or a fire. Either may 
occur during an accident with the weapon, resulting in the device's radioactive material being dispersed into 
the environment. The principal fissile materials in nuclear weapons (Uranium-235 and Plutonium-239) are 
basically alpha particle emitters, and therefore, internalizing these particles is the principal hazard. However, 
there are weak X and gamma ray emissions associated with alpha particle decay. These weak X and gamma 
radiations from unfissioned bomb material are not very penetrating, and the intensity is reduced by 
approximately one-half for every 5.0 millimeter (mm) of tissue or water. Actual nuclear detonations due to 
accidents and/or mishandling are considered to be highly unlikely. 

b. A few very serious incidents involving nuclear weapons have occurred throughout the world. 
However, the Palomares incident remains today the most severe accident in US nuclear weapons history. In 
January 1966, a B-52 bomber carrying four hydrogen bombs collided in midair with a KC-135 tanker 
during high altitude refueling operations near Palomares, Spain. The KC-135's 40,000 gallons of jet fuel 
ignited, killing all four tanker crew members and three bomber crewmen. Four of the bomber's crew 
parachuted to safety. Wreckage from the accident fell across approximately 100 square miles of land and 
water. Of the four H-bombs aboard, two of the weapons containing high explosive material exploded on 
ground impact, releasing radioactive materials, including plutonium, over the fields of Palomares. A third 
nuclear weapon fell to earth but remained relatively intact. The last one fell into the Mediterranean and was 
not recovered until 7 April 1966. Land areas contaminated with nuclear material were remediated within 
weeks of the accident. Contaminated soil was removed and shipped in metal drums to the Savannah River 
Site in South Carolina, and buried there (1,600 tons). Arable soil contaminated at lower levels of radiation 
was watered down and plowed to 30 cm deep in order to dilute the contaminated soil and reduce surface 
contamination of radionuclides. The exteriors of homes were hosed down with water to remove surface 
contamination. 

1-8 



FM4-02.283/NTRP4-02.21/AFMAN44-161(l)/MCRP4-11.1B 



1-4. Terrorism and Radiological Dispersal Devices 

a. Another threat facing US Armed Forces and civilians today are terrorists and organized crime 
groups who could potentially use Radiological Dispersal Devices (RDD). An RDD, as defined by a 1979 
US DOD report to a US/Soviet committee on disarmament, is any device, including any weapon or 
equipment other than a nuclear explosive device, that is specifically designed to employ radioactive material 
by disseminating it to cause destruction, damage, fear, or injury by means of the radiation produced by the 
decay of such material. They are ideal weapons for terrorism and can be used to intimidate and deny access 
to an area by spreading radioactive material. Environmental radiological problems are of special concern 
since at very low levels of radiation there will not be any immediate outward signs of exposure. Note that 
RDDs may have a strong psychological impact on troops as well as the civilian population. 

b. RDDs are low-technology devices that may use biomedical sources, industrial radioactive 
material, and/or radioactive waste as its core element in the device. Potential radioactive material for 
RDDs include medical radiation therapy sources such as Cobalt-60 and Cesium- 137, nuclear reactor fuel 
rods (Uranium-235, Plutonium-239), and radiography/gauging material (Cobalt-60, Cesium-137, Iridium- 
192, Radium-226). Any radioactive material will present safety risks to the terrorists themselves, and 
would present serious difficulties for any adversary attempting to store, handle, and disseminate it effectively. 
Overall, RDDs could involve— 

• Radioactive material combined perhaps with conventional high explosive. 

• Medical and/or industrial isotopes. 

• Cobalt, cesium, iodine, plutonium, and spent nuclear fuels. 

• Unsophisticated delivery systems. 

c. Another type of RDD would be the malicious distribution of sealed radioactive sources. This 
is simply spreading the radioactive material by abandoning the material in a populated or sensitive area. In 
one of the few recorded incidents of terrorists actually using radioactive materials, Chechen rebels placed 
Cesium-137 in a busy Moscow park in November 1995. The material was packed in a protective canister, 
and thus posed a minimal health threat. However, the incident embarrassed the Russian government, which 
was probably the Chechens' ultimate goal. 



1-5. Terrorism and a Single Nuclear Detonation 

a. The reasons that terrorists may perpetrate a WMD attack include a desire "to annihilate their 
enemies," to instill fear and panic in order to undermine a governmental regime, to create a means of 
negotiating from a position of strength, or to cause a great social and economic impact. 1 A single nuclear 



1 . First Annual Report to The President and The Congress of the Advisory Panel to Assess Domestic Response Capabilities for Terrorism 
Involving Weapons of Mass Destruction, I. Assessing the Threat (The Rand Corporation, 1999). 

1-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



detonation could achieve all of these objectives. State-sponsored terrorism is regarded as a form of 
surrogate warfare and is a critical intelligence collection objective since more than 20 countries are suspected 
of proliferating NBC weapons technology (see Table 1-5). 

b. Terrorists who are able to acquire nuclear weapons and/or special nuclear material (SNM) 
represent a major potential threat to US security and that of other nations. After the collapse of the Soviet 
Union, Western fears about the security of Russian strategic and nonstrategic nuclear weapons were 
heightened. However, it now appears that the weapons are more secure than had been initially feared. 
Where there may be particular concern is during their transportation for maintenance or dismantling, when 
the Russian weapons apparently are not subject to the same strict security measures. 2 

c. Terrorists who were either unable or unwilling to steal a nuclear device, or were unsuccessful 
in obtaining one on the putative black market, might attempt to build one themselves. Acquiring or 
processing SNM, that is, either highly enriched uranium (HEU) or plutonium is extremely difficult. 
Although much of the information about nuclear weapons design and production has become public 
knowledge during the past 50 years, it is still extraordinary for nonstate entities to attempt to embark on a 
nuclear weapons research and development program. A successful program hinges on obtaining enough 
fissile material to form a supercritical mass for the nuclear weapon to permit a chain reaction. Also, the 
device must also be small and light enough to be carried by a given delivery vehicle. If stringent conditions 
are not met, the terrorist ends up with a device that cannot produce any significant nuclear yield, but will 
instead function as an RDD. 3 (Terrorists may also develop weapons known as improvised nuclear devices 
[IND]. Such devices may be fabricated in a completely improvised manner, or may be a modification to a 
US or foreign nuclear weapon.) Finally, any nuclear weapons program will, by nature, involve a number 
of people, and significant resources, equipment, and facilities. This activity will increase the risk of 
exposure of the terrorist group to detection by intelligence and law enforcement agencies. 4 

1-6. Nuclear Warfare 

In the cold war environment, there were two basic scenarios for an exchange of nuclear weapons: either a 
general strategic exchange of large-yield thermonuclear weapons, or the limited use of nonstrategic nuclear 
weapons on a theater battlefield. 

a. Strategic Nuclear War. Strategic nuclear war would use weapons that generally range in yield 
from hundreds of kilotons (KT) to multiples of megatons (MT). They are designed to destroy large 
population centers, destroy or disrupt national and strategic nuclear forces and their command and control 
(C2), and to destroy or disrupt national infrastructure, logistics, and warfighting capabilities. The exchange 
of multiple strategic nuclear weapons would result in catastrophic casualty numbers, which would overwhelm 
surviving local medical resources. Military personnel who are nominally capable of returning to short-term 
duty would be utilized despite significant radiation injury. Casualties would receive medical care and 
evacuation as soon as conditions permit according to mass casualty contingency plans. The only 



2. Ibid. 

3. Ibid. 

4. Ibid. 



1-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



examples of this type of nuclear strike were the destruction of Hiroshima and Nagasaki in August of 1945. 
Even though the 1945 weapons were of a relatively low yield as compared to today's weapons, their 
employment was to accomplish strategic objectives. This event is now considered the least likely threat. 

b. Theater Nuclear War. In the cold war environment, theater nuclear war planning envisioned 
the use of both small, low-yield tactical nuclear weapons and larger yield theater-level weapons. Low-yield 
tactical nuclear weapons (delivered by tube artillery or medium battlefield rockets) were planned for use 
against specific enemy units, key terrain on the battlefield, nuclear capable enemy units, or for shock value 
against specific troop concentrations. Generally, these would rarely exceed 10 KT. Also, there were a 
number of atomic demolition munitions (ADM) present on both sides during the cold war. Since low-yield 
tactical weapons have been removed from the inventory, it is no longer appropriate to use the term 
"tactical." The term "nonstrategic" is now used to describe the US theater-level capability. Current US 
theater-level nuclear weapons include gravity bombs, air launched cruise missiles (ALCM), and Tomahawk 
land attack missile/nuclear (TLAM/N). These larger yield (up to 400 KT) theater weapons would normally 
be used at the operational level against theater targets such as enemy long-range nuclear weapons systems, 
ports, airfields, and theater level logistic bases. They would also provide a deterrence and response to 
either the enemy's use, or threat of use, of any WMD. While large numbers of casualties would likely be 
generated within a given area, medical care would be available outside the area of immediate destruction. 
For a given nuclear detonation, casualties would depend on population density, terrain, weapon yield, 
weapon employment technique, and other factors. Casualties could also be produced at a later time due to 
fallout. The primary patient management concept would be to evacuate and distribute casualties to all 
available medical treatment facilities (MTFs). 

1-7. Global and Regional Threats 

Certain countries have embarked on extensive efforts to acquire and develop nuclear, biological, and 
chemical weapons. Depending on their delivery systems, these weapons can pose a regional and a global 
threat (see Table 1-5). The Defense Intelligence Agency (DIA) has estimated that the Middle East will 
become the region of greatest concern in terms of nuclear weapons over the next 10 to 20 years. They 
judge certain states in this region will be able to begin stockpiling nuclear weapons in the next two decades; 
much sooner if they are successful in purchasing fissile material, or if they are successful in purchasing 
complete weapons. 



Table 1-5. Summary of Nuclear Weaponry Material and Delivery Systems by Country 



COUNTRY 


WEAPON/ 
MATERIAL ACQUIRED 


DELIVERY SYSTEMS 
(does not include dual use aircraft) 


PRIMARY SUPPLIERS 


Iran 


1 000 MW reactor under 
construction; seeks to establish 
a complete nuclear fuel cycle 
capability. 


SCUDSRBM 

Shahab-3 MRBM (prototype) 


Russia 

China 



1-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-1 1.1 B 



Table 1-5. Summary of Nuclear Weaponry Material and Delivery Systems by Country (Continued) 



COUNTRY 


WEAPON/ 
MATERIAL ACQUIRED 


DELIVERY SYSTEMS 
(does not include dual use aircraft) 


PRIMARY SUPPLIERS 


Iraq 


Unknown 


Al-Samoud SRBM 


Unknown; under United 






Ababil-100SRBM 


Nations restrictions. 


North Korea 


1 to 2 nuclear weapons; enough 


SCUD SRBM 


China 




Plutonium for several more. 


Nodong MRBM 
Taepodong LRBM 




Libya 


Unknown 


Ballistic missiles still under development. 


Russia 

Eastern Europe 

Iran 


India 


Unknown number of nuclear 


Agni-2 MRBM 


Russia 




weapons; underground tests in 




Western Europe 




May of 1998. 






Israel 


Estimated 100 -200 nuclear 
weapons; several reactors, fuel 
processing sites, and storage areas. 


Jericho-1,-2 MRBM 


France 


Pakistan 


Unknown number of nuclear 


Ghauri MRBM 


Russia 




weapons; tested in late May 




China 




of 1 998. 




Western Europe 


China 


450 nuclear weapons; numerous 


DF-5, -31,-41 LRBM 


N/A 




reactors, fuel processing sites, 


DF -3, -4, -21 MRBM 






and storage facilities. 


JL-1 SLBM (LRBM) 




Former Soviet 


21 ,000 nuclear weapons; numerous 


Over 800 strategic LRBM 


N/A 


Union (FSU) 


reactors, fuel processing sites, and 
storage areas. 


Over 250 SLBMs 





1-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

CHAPTER 2 
HAZARDS OF NUCLEAR AND RADIOLOGICAL EVENTS 



2-1. General 

This chapter covers basic biophysical and biological effects of ionizing radiation, and blast and thermal 
effects in order to form a foundation for understanding the clinical aspects of radiation injury and combined 
injury covered later in the manual. It must be emphasized that when dealing with an actual nuclear 
detonation, blast and thermal injuries in most cases will far outnumber radiation injuries. However, 
radiation effects are considerably more complex and varied than are blast or thermal effects, and are also 
subject to considerable misunderstanding. Also, radiation effects will predominate in RDD events and 
nuclear accidents. Since data from human experience are limited, much of the information in this chapter 
is based upon experimental information from animal studies. 

2-2. Types of Ionizing Radiation 

Ionizing radiation is simply nuclear radiation in the form of particles or electromagnetic waves (photons) 
that, as it passes through matter, causes atoms to become electrically charged or ionized. In living tissues, 
these electrically charged ions produced by radiation may effect normal biological processes. There are 
only four types of ionizing radiation of biological significance. These four types of radiation are classified 
into two categories— particulate and nonparticulate. Particulate ionizing radiation types are alpha particles, 
beta particles, and neutrons. The nonparticulate radiation type is electromagnetic radiation (photons of x-rays 
and gamma rays). Certain aspects of their mechanisms of interaction with living tissue are discussed below. 

a. Particulate Ionizing Radiation. 

(1) Alpha radiation. An alpha particle is a helium nucleus consisting of two protons and two 
neutrons all strongly bound together by nuclear forces. Although highly ionizing, alpha particles are only 
slightly penetrating. They are generally emitted by high atomic number elements such as polonium, 
uranium, plutonium, and americium. If the source of the radiation is external to the body, all of the alpha 
radiation is absorbed in the superficial layers of dead cells within the stratum corneum, or any outer clothing 
or covering. Because of this, alpha radiation is not an external hazard. If alpha-emitting material is 
internally deposited, all the radiation energy will be absorbed in a very small volume of tissue immediately 
surrounding each particle. Beyond a radius of about 0.02 millimeters, the deposition of energy is very small. 
The high radiation doses within this critical radius are lethal to the cells immediately adjacent to the source. 
Thus, while extremely high radiation doses may be deposited in the few cells immediately surrounding a 
source of alpha radiation, regions outside this irradiated volume are not affected. However, internal 
deposition of alpha particles is important in terms of causing long-term radiation injury. Many alpha- 
emitting materials also emit gamma radiation, and this more penetrating gamma radiation may irradiate 
tissues far from the areas of deposition. 

(2) Beta radiation. Beta particles are identical to atomic electrons but, like alpha particles, 
they are ejected from a nucleus when the nucleus rearranges itself into a more stable configuration. 
Radioactive materials that emit beta particles are generally the by-products of fission of heavy nuclides such 
as plutonium. These by-products include elements such as Cesium-137, Strontium-90, and Iodine-131. Beta 

2-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



particles can only penetrate a few millimeters of tissue. If the beta-emitting material is on the surface of the 
skin, the resulting beta irradiation causes damage to the epithelial basal stratum. The lesion initially appears 
similar to a superficial thermal burn but significantly more damage has actually occurred. If the radionuclide 
is incorporated internally, the damage will be in small spheres of tissue around each fragment or radioactive 
source. However, internal exposures to beta radiation can be more homogeneous if associated with 
ingestion of a soluble nuclide in foodstuffs. The total tissue damage is a function of the number of such 
sources within the affected tissue volume, the nuclide's intrinsic radioactivity, and the radiosensitivity of the 
tissue. Dead cells are replaced quickly in most tissues. The less dense energy deposition of beta radiation 
may simply damage rather than kill affected cells, thereby causing cells to become malignant or otherwise 
malfunction, which in turn, may lead to late effects (see Chapter 5). 

(3) Neutron radiation. Neutrons are electrically neutral, yet because of their relatively large 
mass, they can severely disrupt atomic structures. Neutrons are produced in the processes of nuclear 
fission and fusion. Compared to gamma rays, neutrons can cause much more damage to tissue. Collisions 
with atomic nuclei slow down a neutron so it may undergo nuclear capture. In nuclear capture, the neutron 
is actually absorbed into the target nucleus making the nucleus unstable and, therefore, radioactive. 

b. Electromagnetic (Nonparticulate "Photon") Ionizing Radiation. Gamma and x-rays constitute 
the most abundant form of ionizing radiation associated with a nuclear detonation. Most radioactive 
materials also emit gamma or x-ray radiation as part of their decay processes. Gamma rays and x-rays 
have energy and momentum, but no mass, and travel at the speed of light (3 x 10 8 meters per second). They 
possess no net electrical charge. The only difference between the gamma and x-ray photons is that gamma 
rays originate from the nucleus of an atom while x-rays are produced whenever high-velocity electrons 
strike a material object or when an orbital electron moves from an outer to inner shell. Photons are highly 
penetrating and a large fraction may pass through the human body without interaction. Consequently, energy 
deposition can occur anywhere in the body along a photon's path. A significant portion of the body may be 
exposed to gamma radiation during a nuclear detonation, a nuclear reactor accident, or because of an 
industrial accident. This is in marked contrast to the highly localized exposure pattern that occurs with alpha 
and beta radiation. High-energy gamma emitters deposited within the body may also result in total body 
irradiation just as effectively as exposure to external sources. 

2-3. Units of Measure 

There are several different, but interrelated, methods of measuring and quantifying ionizing radiation. For 
comparison purposes, existing and new units of measurement are discussed in this paragraph (also, see 
Table 1-1). 

a. Exposure. Exposure is defined for gamma and x-rays in terms of the amount of ionization they 
produce in air. The unit of exposure is called the roentgen (R) and is defined as: 1 R = 2.58 x 10~ 4 Coulombs 
per kilogram in air (C/kg-air). From a clinical standpoint, it must be remembered that some radiation passes 
through a volume of material or tissue without interacting and, therefore, does no damage. Therefore, while 
exposure measurements are a key element in making a diagnosis, they are only a part of the overall analysis. 

b. Absorbed Dose. Although the concept of exposure provides a measurement standard for 
electromagnetic radiation in air, additional concepts are needed for all types of radiation and its interaction 

2-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



with other materials, especially living tissue. Absorbed dose is defined as the radiation energy absorbed per 
unit mass. The traditional unit of absorbed dose is the rad (radiation absorbed dose), and is defined as 100 
ergs of energy deposited per gram of medium. The SI unit of measure for absorbed dose is the Gy, defined 
as one joule of energy deposited per one kilogram of medium. It is easy to convert the two, since 1 Gy equals 
100 rads (see Figure 2-1). 

Rad 

1 rad = 100 ergs/gram 

Gray 

1 Gy = 1 joule/kilogram = 100 rads 

Figure 2-1. Units of absorbed dose. 

c. Dose Equivalent. 

(1) It is recognized that the absorbed dose needed to achieve a given level of biological 
damage is often different for different kinds of radiation. Dose equivalent allows for the different biological 
effectiveness of different types of radiation and provides for measurement of biological damage, and 
resulting risk, from a radiation dose. When radiation is absorbed in biological material, ionizations occur in 
a localized fashion along the tracks of the particular photon or particle with a pattern that depends upon the 
type of radiation involved. As a result, the spatial distribution of the ionizing events produced by different 
radiations varies greatly. Linear energy transfer (LET) is the energy transferred per unit length of the 
track. Different types of radiation have different LET rates, and therefore, the higher the LET, the more 
effective the radiation is at producing biological damage. Low LET radiations (gamma and x-rays) are 
generally sparsely ionizing and they more randomly interact with molecules along their path. Conversely, 
high LET radiations (neutrons and alpha particles) are more uniformly and densely ionizing. To account for 
the differences in LET, each type of radiation has a different quality factor (QF). The QF relates the amount 
of biological damage caused by any type of radiation to that caused by the same absorbed dose of gamma or 
x-rays (see Table 2-1). The QF is then used to determine the equivalent dose. 

Table 2-1. Quality Factors for Various Radiation Types 



RADIATION TYPE 


QUALITY FACTOR 


X-, gamma-, and beta-rays 


1 


Alpha particles, fission fragments, and heavy nuclei 


20 


Neutrons 


3-20* 



Values of quality factors for neutrons are dependent upon the energy of the neutron. 

2-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



(2) The dose equivalent then, is a measure of the actual biological damage in tissue. The 
traditional unit of equivalent dose is the rem, which is equal to the absorbed dose, or the rad, multiplied by 
the QF. The SI unit is the Sv (see Figure 2-2). One rem is 100 ergs per gram, and 1 Sv is 1 joule per 
kilogram. Also, just as 1 Gy is 100 rads, 1 Sv is 100 rems. 

Rem = QF x Rad 

Sievert = QF x Gy 

1 Sv = 1 joule/kilogram = 100 rem 

Figure 2-2. Units of equivalent dose. 

d. Dose Rate. Dose rate is the dose of radiation per unit of time. An example would be centiGray 
per hour (cGy/hr). 

e. Activity. The activity level of a radioactive material is simply a measure of how many atoms 
disintegrate (decay) per a unit of time. The existing unit for this is the Ci. The Ci is based on the activity of 
1 gram of radium-226, or 3.7 x 10 10 radioactive disintegrations per second. The SI unit for measuring the 
rate of nuclear transformations is the Bq. The Bq is defined as one radioactive disintegration per second (see 
Figure 2-3). 

Curie 

1 Ci = 3.7 x 10 10 nuclear transformations per second 

Becquerel 

1 Bq = 1 nuclear transformation per second 
1 Bq = 2.7x10 11 Ci 

Figure 2-3. Units of activity. 

f. Half-life. Activity is tied to a physical property of a radionuclide known as the half-life. The 
half-life of a radionuclide is the amount of time it takes one-half of the nuclei to decay. Thus, after 1 half- 
life, l h of the original amount remains. After 2 half-lives, X U remains, and after 3 half-lives, Vs remains, 
and so forth. A substance with a short half-life decays quickly with a comparatively high radioactivity level. 
A substance with a long half-life decays slowly with a comparatively low radioactivity level. The half-life of 
radionuclides range from fractions of a second (Polonium-212 with a half-life of 0.0000003 seconds), to 
billions of years (Bismuth-209 with a half-life of 2 x 10 18 years). 

2-4. Penetration and Shielding 

Personnel can be shielded from ionizing radiation by various materials. Properly shielding personnel 
requires knowledge of the type and penetration characteristics of the radiation involved (see Figure 2-4). 

2-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



ALUMINUM LEAD 



CONCRETE 



ALPHA 



BETA 




GAMMA, X-RAYS 



NEUTRONS 



Figure 2-4. Radiation penetration and shielding. 



a. Alpha Shielding. Alpha particles are heavily charged particles with a very low penetration 
range in air. They can be stopped with a sheet of paper or at the superficial layers of skin; therefore, any 
light clothing or gloves used to prevent contamination of underlying clothing or the body will provide 
protection from this type of radiation. 

b. Beta Shielding. Beta emitters present two potential external radiation hazards: the beta 
particles themselves, and the x-rays they can produce when they strike certain materials such as lead. 
Although beta particles can travel significant distances in air, materials such as aluminum, plastic, or glass 
can provide appropriate shielding. However, these emitters should be handled with care. Because the lens 
of the eye is radiosensitive, eye protection in the form of goggles or a protective mask are recommended 
when working with high energy beta emitters. 

c. Gamma Shielding. Gamma rays and x-rays are more difficult to shield as they are typically 
more penetrating than alpha and beta particles. Shielding of gamma ray photons is a function of absorber 
thickness and density, and is based on the probability that the gamma ray photons will interact with the 
medium through which they pass. As the thickness of an absorber is increased, the intensity of the gamma 
radiation will decrease. Higher density media like lead, tungsten, steel, and concrete are good shielding 
material against gamma ray photons. However, no matter how thick or dense a gamma or x-ray shield is, 
some of the photons will still get through. 

d. Neutron Shielding. Lead and other high-density materials do not provide effective shielding 
against neutrons. Neutron shielding is more complicated than shielding against gamma or x-rays due to the 
difference in the way neutrons interact with matter. The most effective materials in slowing down neutrons 
are the light elements, particularly hydrogen. Many hydrogenous materials, such as water or paraffin make 
efficient neutron shields. 



2-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



2-5. Nuclear Detonation 

A nuclear detonation results from the formation of a supercritical mass of fissile material, with a near 
instantaneous release of nuclear binding energies and large-scale conversion of mass to energy. Fission is 
the process where a heavier unstable nucleus divides or splits into two or more lighter nuclei, and, with 
certain materials, substantial amounts of energy are released. The materials used to produce nuclear 
explosions are the readily fissile isotopes of uranium or plutonium: Uranium-235 and Plutonium -239. 
Modern weapons may boost their yield by incorporating a fusion element, which may be regarded as the 
opposite of fission. It is the combining of two light nuclei to form a heavier nucleus (thermonuclear 
reaction). The only practical way to obtain the temperatures and pressures required for fusion is by means 
of a fission explosion. Consequently, weapons with fusion components contain a basic fission component. 

a. Basic Detonation Characteristics. The destructive action of conventional explosions is almost 
entirely due to the transmission of energy in the form of a blast wave and the resultant projectiles (shrapnel). 
The energy of a nuclear explosion is transferred to the environment in three distinct forms— blast, thermal 
radiation, and nuclear radiation. The energy distribution among these three forms will depend on the 
weapon yield, the location of the burst, and the characteristics of the environment. The energy from a low 
altitude atmospheric detonation of a moderate-sized weapon in the KT range is distributed roughly as follows 
(see Figure 2-5): 

• Fifty percent as blast. 

• Thirty-five percent as thermal radiation, which is made up of a wide range of the 
electromagnetic spectrum including infrared, visible, and ultraviolet light and some soft x-rays. 




INITIAL 
RADIATION 



RESIDUAL 
RADIATION 



Figure 2-5. Energy partition from a nuclear detonation. 



2-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



• Fifteen percent as ionizing radiation, including 5 percent as initial (or prompt) radiation 
emitted within the first minute after detonation, consisting chiefly of neutrons and gamma rays, and 10 
percent as residual nuclear radiation (fallout). 

It should be noted that the distribution of energy is significantly altered in an enhanced radiation nuclear 
weapon (neutron bomb). A neutron bomb is designed specifically to reduce the energy that is dissipated as 
blast and heat and increase the amount of initial nuclear radiation. Its approximate energy distribution is 30 
percent blast, 20 percent thermal, 45 percent initial radiation, and 5 percent residual radiation. 

b. Types of Bursts. The altitude at which the weapon is detonated will largely determine the 
relative effects of blast, heat, and nuclear radiation. Nuclear explosions are generally classified as 
airbursts, surface bursts, subsurface bursts, or high altitude bursts. 

(1) Airburst. An airburst is an explosion in which a weapon is detonated in air at an altitude 
of sufficient height that the fireball does not contact the surface of the earth. The altitude of an airburst can 
be varied to obtain maximum blast effects, maximum thermal effects, desired radiation effects, or a 
balanced combination of these effects. Burns to exposed skin may be produced over many square kilometers 
and eye injuries over a still larger area. Initial nuclear radiation will be a significant hazard with smaller 
weapons, but the fallout hazard can be ignored, as there is essentially no fallout from an airburst. The 
fission products are generally dispersed over a very large area unless there is local rainfall, which would 
result in a more localized fallout pattern. In the vicinity of ground zero, there may be a small area of 
neutron-induced ground activity (NIG A) that could be hazardous to troops required to pass through the area. 
The NIGA hazard is temporary, lasting only a few days to a few weeks. 

(2) Surface burst. A surface burst is an explosion in which a weapon is detonated on, or 
slightly above, the surface of the earth so that the fireball actually touches the land or water surface. Under 
these conditions, the area affected by the blast, thermal radiation, and initial nuclear radiation will be less 
than that for an airburst of similar yield, except in the region of ground zero where destruction is 
concentrated. In contrast with airbursts, local fallout can be a hazard over a much larger downwind area 
than that affected by blast and thermal radiation. 

(3) Subsurface burst. A subsurface burst is an explosion in which the point of the detonation 
is beneath the surface of the land or water. Cratering will generally result from an underground burst, just 
as for a surface burst. If the burst does not penetrate the surface, the only other hazard will be from ground 
or water shock. If the burst is shallow enough to penetrate the surface, blast, thermal, and initial nuclear 
radiation effects will be present, but will be less than for a surface burst of comparable yield. Local fallout 
will be very heavy if surface penetration occurs. 

(4) High altitude burst. A high altitude burst is one in which the weapon is exploded at a high 
altitude (typically above 50 km) so that it generates an intense electromagnetic pulse (EMP) which can 
significantly degrade the performance of, or destroy sophisticated electronic equipment. Significant 
ionization of the upper atmosphere (ionosphere) can occur and this radiation can travel for hundreds of miles 
before being absorbed. For example, a high altitude burst of strategic weapons could be employed with the 
intent of causing severe disruption or destruction of national command, control, communications, computers, 

2-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



and intelligence systems. There are no known adverse biological effects of EMP at exposure levels below 
the established protection standards. 

2-6. Nuclear Detonation Blast Hazards 

There are two basic types of blast forces which occur simultaneously in a nuclear detonation blast wave; 
these are direct blast wave overpressure forces, measured in terms of atmospheres of overpressure; and 
indirect blast wind drag forces, normally measured in the velocities of the winds which cause them. The 
most important blast effects, insofar as production of casualties requiring medical treatment is concerned, 
will be those due to the blast wind drag forces (see paragraph 2-9, Range of Damage). However, direct 
blast effects can contribute significantly to the immediate deaths and injuries sustained close to the point of 
detonation. Personnel in fortifications or unbuttoned armored vehicles who are protected from radiation and 
thermal and blast wind effects, may be subjected to complex patterns of direct overpressures since blast 
waves may be reflected and reinforced within them. Blast effects will also be present to a much lesser 
extent when an RDD uses a conventional explosive as the dispersal mechanism. 

a. Direct Blast Injury. When the blast wave acts directly upon a resilient target such as the 
human body, rapid compression and decompression result in transmission of pressure waves through the 
tissues. These waves can be quite severe and will result in damage primarily at junctions between tissues of 
different densities (bone and muscle) or at the interface between tissue and air spaces (lung tissue and the 
gastrointestinal [GI] system). Perforation of the eardrums would be a common, but a minor blast injury. 
However, direct blast injuries will not occur by themselves; in general, other effects, such as indirect 
blast wind drag injuries and thermal injuries are so severe at the ranges associated with these 
overpressures that patients with only direct blast injuries will comprise a very small part of the patient 
load. The range of overpressures associated with lethality can vary greatly. It has been estimated that 
overpressures as low as 193 kilopascal (kPa) (1.9 atmospheres [atm]) can be lethal, but that survival is 
possible with overpressures as high as 262 kPa (2.5 atm). It is important to note that the human body is 
remarkably resistant to direct blast overpressure, particularly when compared with rigid structures such as 
buildings. 

b. Indirect Blast Wind Drag Forces. The drag forces of blast winds are proportional to the 
velocities and duration times of those winds, which in turn vary with distance from the point of detonation, 
yield of the weapon, and altitude of the burst. These winds are relatively short in duration but are extremely 
severe and may reach several hundred km per hour. Indirect blast injuries will occur as crush and 
translational injuries, and as missile injuries. Casualties will be thrown against immobile objects and 
impaled by flying debris; therefore, solid organ, extremity, and head injuries will be commonplace. The 
distance from the point of detonation at which severe indirect injury will occur is considerably greater than 
that for serious direct blast injuries. 

(1) Crush and translational injuries. The drag forces of the blast winds are strong enough to 
displace even large objects, such as vehicles, or to cause the collapse of large structures, such as buildings. 
These events can result in very serious crush injuries, similar to injuries seen in earthquakes and conventional 
bombings. A human body can itself become a missile, and be displaced a variable distance and at variable 
velocities depending upon the intensity of the drag forces and the nature of the environment. The resulting 

2-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



injuries sustained are termed translational injuries. The probability and the severity of the injury depend on 
the velocity of the human body at the time of impact. 

(2) Missile injury. The number of missiles that can be generated by the blast winds depends 
to some extent upon the environment, that is, different terrain types will have different quantities of material 
available for missile production. However, the drag forces of the blast winds produced by nuclear 
detonations are so great that almost any form of vegetation or structure, if present, will be broken apart or 
fragmented into a variety of missiles. Multiple and varied missile injuries will be common. The probability 
of a penetrating injury increases with increasing velocity, particularly for small, sharp missiles such as 
glass fragments. Heavier objects require higher kinetic energies to penetrate, therefore, heavy blunt 
missiles will not ordinarily penetrate the body, but can result in significant injury, particularly fractures. 



2-7. Nuclear Detonation Thermal Radiation Hazards 

In a nuclear warfare environment, thermal burns will be the most common injuries, subsequent to both the 
thermal pulse, and the fires it ignites. The thermal radiation emitted by a nuclear detonation causes burns in 
two ways, by direct absorption of the thermal energy through exposed surfaces (flash burns), or by the 
indirect action of fires caused in the environment (flame burns). The relative importance of these two 
processes will depend upon the nature of the environment. If a nuclear weapon detonation occurs in easily 
flammable surroundings, indirect flame burns could possibly outnumber all other types of injury. 



NOTE 

Because of the complexity of burn treatment and the increased 
logistical requirements associated with the management of burns, they 
will constitute the most difficult problem faced by the medical service. 



a. Flash (Thermal Pulse) Burns. Since the thermal pulse is direct infrared, burn patterns will be 
dictated by spatial relationships and clothing pattern absorption. Exposed skin will absorb the infrared in a 
variable pattern and the victim will be burned on the side facing the explosion. Persons shaded from the 
direct light of the blast are protected. Light colors will reflect the infrared, while dark portions of clothing 
will absorb it and cause pattern burns. Historical records from Hiroshima and Nagasaki bombings indicate 
that, in some cases, dark-colored clothing actually burst into flames and ignited the undergarments, causing 
flame burns. At temperatures below those required to ignite clothing, it is still possible to transfer sufficient 
thermal energy across clothing to the skin to produce flash burns; however, clothing significantly reduces the 
effective range producing partial thickness burns. It must be remembered that close to the fireball, the 
thermal output is so great that everything is incinerated. The actual range out to which overall lethality 
would be 100 percent will vary with yield, position of burst, weather, the environment and how soon those 
burned can receive medical care. The mortality rate among the severely burned is much greater without 
early resuscitative treatment. 

2-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



b. Flame Burns. Flame burns result from exposure to fires caused by the thermal effects in the 
environment, particularly from the ignition of clothing. This could be the predominant cause of burns 
depending upon the number and characteristics of flammable objects in the area. Firestorm and secondary 
fires will cause typical flame burns, but they will also be compounded by closed space fire injuries. Patients 
with toxic gas injury from burning plastics and other material, superheated air inhalation burns, steam burns 
from ruptured pipes and all other large conflagration-type injuries will require treatment. Complications 
arise in the treatment of skin burns created, in part, from the melting of man-made fibers. Therefore, it is 
recommended that clothing made of natural fibers, or flame resistant clothing (for example, Nomex) should 
be worn next to the skin. The variables of environmental flammability are too great to allow prediction of 
either the incidence or the severity of flame burns. The burns themselves will be far less uniform in degree, 
and will not be limited to exposed surfaces. For example, the respiratory system may be exposed to the effects 
of hot gases, and respiratory system burns are associated with severe morbidity and high mortality rates. 

c. Eye Injuries. Since most personnel will not have access to specialized protective goggles, 
there will be numerous eye injuries that will require treatment because of the intense light produced by a 
nuclear explosion. Sudden exposures to high-intensity sources of visible light and infrared radiation can 
cause eye injury, specifically to the chorioretinal areas. Factors that determine the extent of eye injury 
include pupil dilation, spectral transmission through the ocular media, spectral absorption by the retina and 
choroid, length of time of exposure, and the size and quality of the image. Direct vision optical equipment 
such as binoculars will increase the likelihood of damage. Night vision devices (NVDs) electronically 
amplify the ambient light, and they also detect infrared energy, the major component of the thermal pulse. 
However, most NVDs automatically shutdown when an intense burst of energy hits the device. Eye injury 
is due not only to thermal energy but also to photochemical reactions that occur within the retina with light 
wavelengths in the range of 400 to 500 nanometers (nm), in addition to thermal and blast effects. 

(1) Flash blindness. Flash blindness occurs with a sudden peripheral visual observation of a 
brilliant flash of intense light energy; for example, a fireball. This is a temporary condition that results from 
a depletion of photopigment from the retinal receptors. The duration of flash blindness can last several 
seconds when the exposure occurs during daylight. The blindness will then be followed by a darkened 
afterimage that lasts for several minutes. At night, flash blindness can last for up to 30 minutes and may 
occur up to 100 km from the blast (see Figure 2-6). 

(2) Retinal burns. Direct observation of a brilliant flash of light in the wavelengths of 400 to 
1,400 nm can cause macular-retinal burns. Burns of the macula will result in permanent scarring with 
resultant loss in visual acuity. Burns of the peripheral regions of the retina will produce scotomas (blind 
spots), but overall visual acuity will be less impaired. These burns can occur at extended distances 
depending upon yield (see Figure 2-6). 

2-8. Nuclear Detonation Radiation Hazards 

a. Initial Radiation . About 5 percent of the energy released in a nuclear airburst is transmitted in 
the form of initial neutron and gamma radiation. The neutrons result almost exclusively from the energy 
produced by fission and fusion reactions. The initial gamma radiation includes that arising from these 
reactions, as well as that from the decay of short-lived fission products. The intensity of the initial nuclear 

2-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radiation decreases rapidly with distance from the point of burst. The character of the radiation received at 
a given location also varies with distance from the explosion. Near the point of the explosion, the neutron 
intensity is greater than the gamma intensity, but reduces quickly with distance. The range for significant 
levels of initial radiation does not increase markedly with weapon yield. Therefore, the initial radiation 
becomes less of a hazard with increasing yield, as individuals close enough to be significantly irradiated are 
killed by the blast and thermal effects. With weapons above 50 KT, blast and thermal effects are so much 
greater in importance that prompt radiation effects can be ignored (see paragraph 2-9). 



NIGHT 



CLEAR DAY 



FLASHBLINDNESS 
RETINAL BURNS 



1000 t 



</> 

c 
o 
+■< 
o 

!2 

CO 
Q 

_l 

LLJ 

>- 

z 
Q 

CO 

O 



100 - 



O 10: 



Q. 
X 
LU 




HOB = 
3,000 METERS 

I 



32 64 96 128 

SAFE SEPARATION DISTANCE 
(kilometers) 



160 



Figure 2-6. Flash blindness and retinal burn safe separation. 



b. Residual Radiation. Residual ionizing radiation from a nuclear explosion arises from a variety 
of sources but is primarily in the form of NIGA and radioactive fallout. 

(1) Fission products. There are over 300 different fission products produced during 
detonation. Many of these are radioactive with widely differing half-lives. Some fission products have half- 
lives lasting only fractions of a second, while other materials can be a hazard for months or years. Their 
principal mode of decay produces beta and gamma radiation. 



2-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



(2) Unfissioned nuclear material. Nuclear weapons are relatively inefficient in their use of 
fissile material, and much of the uranium and plutonium is dispersed by the explosion without undergoing 
fission. Such unfissioned nuclear material decays primarily by the emission of alpha particles and is of 
relatively minor importance as long as it remains outside of the body. Also, the neutrons that are emitted as 
part of the initial nuclear radiation will cause activation of the weapon residues. 

(3) Neutron induced ground activity. If atomic nuclei in soil, air, and water are exposed to 
neutron radiation and capture neutrons, they will, as a rule, become radioactive (NIG A) depending on their 
composition and distance from the burst. They then decay by emission of beta and gamma radiation over an 
extended period of time. For example, a small area around ground zero may become hazardous as a result 
of exposure of the minerals in the soil to initial neutron radiation. This is normally a negligible hazard 
because of the limited area involved. 

(4) Fallout. 

(a) In a nuclear weapon surface burst, large amounts of earth or water will be vaporized 
by the heat of the fireball and drawn up into the radioactive cloud, especially if the explosive yield exceeds 10 
KT. This material will become radioactive when it condenses with fission products and other radioactive 
contaminants or if it becomes neutron-activated. These materials will then be dispersed by atmospheric 
winds and, depending upon meteorological conditions, will gradually settle to the earth's surface as fallout. 
The larger particles will settle back to earth within 24 hours as local fallout. Severe local fallout 
contamination can extend far beyond the blast and thermal effects, particularly in the case of high yield 
surface detonations. In cases of water surface (and shallow underwater) bursts, the particles tend to be 
lighter and smaller. This produces less local fallout but extends the spread of contamination out over a 
greater area. For subsurface bursts, there is an additional phenomenon called base surge. The base surge 
is a cloud that rolls outward from the bottom of the column produced by a subsurface explosion. 

(b) Scavenging refers to processes that increase the rate at which radioactivity is 
removed from the fallout cloud and deposited on the earth's surface. Precipitation scavenging is the process 
in which rain or snow falls through the fallout cloud and carries contaminated particles down with it. 
Precipitation scavenging occurs in two forms— rainout and washout. Rainout occurs when a rain cloud 
forms within the fallout cloud, while washout occurs when the rain cloud forms above the fallout cloud. The 
strength of the rain and the length of time the radioactive cloud is washed markedly affect the percentage of 
radioactivity scavenged. Evidence indicates that washout is far less effective than rainout. Even in the case 
of an airburst, which does not usually produce early fallout, rainout or washout can cause significant 
contamination on the ground as a result of scavenging of radioactive debris. This contamination is typically 
found in concentrated hotspots created between ridges in the earth's surface or wherever rainwater collects. 

2-9. Range of Damage 

Table 2-2 shows the ranges in kilometers of biological damage for the hazards discussed above. The ranges 
noted are for weapons of various yields including very low yield INDs. These effects were calculated using 
Lawrence Livermore National Laboratory's Hotspot, Version 8.0, simulating a surface burst with 25-mile 
visibility, and no intervening shielding or sheltering. 

2-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table 2-2. Comparison of Weapons Effects by Yield in Kilometers 



WEAPON EFFECT 


WEAPON YIELD (KT) 




0.01 KT 


0.1 KT 


1 KT 


10 KT 


100 KT 


1 MT 


Blast: Lethality 1 














Threshold: 30 psi (30-50) 


0.038 


0.081 


0.18 


0.38 


0.81 


1.8 


50%: 50 psi (50-75) 


0.030 


0.065 


0.14 


0.30 


0.65 


1.4 


100%: 75 psi (75-115) 


0.025 


0.055 


0.12 


0.25 


0.55 


1.2 


Blast: Lung Damage 














Threshold: 8 psi (8-15) 


0.074 


0.16 


0.34 


0.74 


1.6 


3.4 


Severe: 20 psi (20-30) 


0.046 


0.098 


0.21 


0.46 


0.98 


2.1 


Blast: Eardrum Rupture 














Threshold: 5 psi 


0.096 


0.21 


0.44 


0.96 


2.1 


4.4 


50%: 14 psi 


0.055 


0.11 


0.25 


0.54 


1.1 


2.5 


Thermal: Skin Burns 2 














50% First degree (2-3 cal/cm 2 ) 


0.13 


0.37 


1.2 


3.4 


8.3 


17 


50% Second degree (4-5 cal/cm 2 ) 


0.089 


0.24 


0.86 


2.5 


6.5 


14 


50% Third degree (6-8 cal/cm 2 ) 


0.073 


0.18 


0.71 


2.1 


5.6 


12 


Retinal burns (0.0001 cal/cm 2 ) 


10 


20 


33 


49 


66 


84 


Flash blindness (0.16 cal/cm 2 ) 


0.44 


1.3 


3.7 


9 


18 


31 


Ionizing Radiation Effects 














100% death, < 1 day: 10,000 cGy 


0.14 


0.21 


0.36 


0.66 


1.1 


1.9 


100% death, few days: 1000 cGy 


0.21 


0.36 


0.65 


1.0 


1.6 


2.4 


50% death, weeks: 450 cGy 


0.25 


0.45 


0.77 


1.2 


1.7 


2.6 


< 5% deaths, years: 100 cGy 


0.36 


0.64 


1.0 


1.5 


2.0 


3.0 


Start acute effects: 50 cGy 


0.43 


0.75 


1.1 


1.6 


2.2 


3.1 



1 Blast lethality data is only for direct pressure effects. 

2 50% incidence rates are limited to exposed skin. 



2-10. Radioactive Contamination Hazards 

Radioactive material released to the environment can pose both internal and external contamination hazards 
to forces operating in these environments. External hazards are generally associated with skin con- 
tamination, and include the biological effects of cutaneous irradiation, and increased probabilities of internal 
contamination. Internal contamination hazards are associated with the exposure of internal organs from 



2-13 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radioactive material that has been taken into the body via inhalation, ingestion, or absorption through the skin 
or a wound. For a detailed discussion of contamination see Chapter 4, Radioactive Contamination. 

a. External Contamination. Significant amounts of radioactive material may be deposited on 
personnel and ground surfaces after the use of nuclear weapons and/or RDD; and after the destruction of 
nuclear reactors; nuclear accidents; or improper radiological waste disposal. In severe cases of fallout 
contamination, lethal doses (LDs) of external radiation may be incurred if protective or evasive measures 
are not undertaken. Military operations in these contaminated areas could result in military personnel 
receiving sufficient radiation exposure or particulate contamination to warrant medical evaluation and 
remediation. In general, the external contamination hazard to both the patient and attending medical personnel 
will be so negligible that NECESSARY MEDICAL OR SURGICAL TREATMENT MUST NOT BE 
DELAYED BECAUSE OF POSSIBLE CONTAMINATION. If external contamination is detected, internal 
contamination may also be present. 

b. Internal Contamination. In a nuclear explosion, more than 300 radioactive isotopes are 
released into the biosphere, of which about 40 are produced in sufficient abundance and with sufficiently long 
half-life to be of significance. This fallout may be deposited onto clothing and/or skin and, then, may enter 
the body. In a nuclear reactor accident scenario, radionuclides may enter the body through wounds, or 
gaseous material or particulate matter which may be inhaled and subsequently absorbed or deposited 
throughout the respiratory tract. Radioactive material that falls onto food or into the water supply or that is 
transferred from hand to mouth may be ingested. A source of chronic exposure is radioactive material 
incorporated into the food chain, as in the case of contaminated cow's milk and mushrooms in countries of 
the former Soviet Union after the Chernobyl accident. Other sources of internal contamination are medical 
misadministration and the internalization of radioactive materials from an RDD. 



2-14 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



CHAPTER 3 



TREATMENT OF HIGH-DOSE RADIOLOGICAL 
AND COMBINED INJURY CASUALTIES 



3-1. 



General 



This chapter discusses the treatment of casualties who have suffered high-dose radiological injuries and/or 
combined injuries. In a nuclear detonation roughly 15 percent of the casualties can result from radiation 
exposure alone. Only a small percentage of the physical trauma casualties will not have some form of 
radiation injury that will complicate their recovery (see Table 3-1). Casualties from a nuclear detonation 
that have been exposed to extremely high doses of radiation are normally in the range where they would be 
killed or severely injured by the blast and thermal effects. However, in the more likely scenarios involving 
RDD or nuclear incidents, high dose radiological casualties without some form of trauma may be 
encountered. Because of this, and because of the complexities involved with treating ionizing radiation 
injuries, management of radiological casualties will be discussed first. Treatment of combined injuries 
follows in a later section. A detailed list of medications used in treatment is presented in Appendix B. Also, 
Appendix C contains patient descriptions involving radiation doses and combined injuries. These descriptions 
are termed Treatment Briefs (TBs). They may help physicians and other medical staff as quick reference 
material for the treatment of radiation and combined injury casualties. 



Table 3-1. Predicted Distribution of Injuries Sustained from a Nuclear Detonation 



INJURY TYPES 


PERCENTAGE OF TOTAL INJURIES 


Radiation only 


15 


Burn only 


15 


Wound only 


3 


Irradiation, Burns, and Wounds 


17 


Irradiation and Burns 


40 


Irradiation and Wounds 


5 


Wounds and Burns 


5 


Combined Injury Total 


67 



Section I. IONIZING RADIATION EFFECTS ON CELLS AND TISSUES 



3-2. General 

A wide range of biological effects in cells and tissues may follow exposure to ionizing radiation. These may 
include rapid death following extremely high radiation doses of penetrating whole-body radiation, or delayed 
radiation effects following lower doses. Differing biological factors such as animal species and age, as well 



3-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



as radiological factors, such as the type of radiation, dose, and dose rate (see Chapter 2), produce variations 
of response in biological systems. 

3-3. Cellular Effects of Ionizing Radiation 

a. General. Observed cellular effects of radiation are similar for different types and doses of 
ionizing radiation, and are related to two modes of action in the cell. Direct action is when the radiation hits 
a particularly sensitive atom or molecule (such as deoxyribonucleic acid [DNA]) in the cell. This damage is 
sometimes irreparable with the cell either dying or malfunctioning. Indirect action is when the radiation 
damages a cell by interacting with water molecules within the cells of the body. The interaction with the 
water molecules leads to the creation of unstable, toxic hyperoxide molecules that lead to damage in other 
subcellular structures within the cell. 

b. Relative Cellular Radios ens itivity. Cellular radiosensitivity tends to vary inversely with the 
degree of cell differentiation. In fact, cells may be classified in decreasing order of sensitivity into four 
categories— vegetative cells, differentiating cells, totally differentiated cells, and fixed nonreplicating cells. 

(1) Vegetative cells. These cells are generally the most radiosensitive. Examples include— 



• 



Free stem cells of hematopoietic tissue (hemocytoblasts, primitive lymphoblasts, 
primitive erythroblasts, and primitive myeloblasts). 

• Dividing cells deep in the intestinal crypts. 

• Primitive spermatogonia in the epithelium of the seminiferous tubules. 

• Granulosa cells of developing and mature ovarian follicles. 

• Basal germinal cells of the epidermis. 

• Germinal cells of the gastric glands. 

• Lymphocytes. 

• Mesenchymal cells. 

(2) Differentiating cells. These cells are somewhat less sensitive to radiation. They are 
relatively short-lived and include the first generation produced by division of the vegetative mitotic cells. 
They usually continue to divide a limited number of times and differentiate to some degree between 
divisions. As differentiation occurs, radiosensitivity decreases. The best examples of this type of cell are 
the dividing and differentiating cells of the granulocytic and erythrocytic series in the bone marrow. 

(3) Totally differentiated cells. These cells are relatively radioresistant. They normally 
have relatively long life spans and do not undergo regular or periodic division in the adult stage, except under 

3-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



abnormal conditions such as following damage to, or destruction of a large number of these cells. This class 
includes hepatocytes, cells of interstitial gland tissue of the gonads, smooth muscle cells, and vascular 
endothelial cells. 

(4) Fixed nonreplicating cells. This group of cells is the most radioresistant and includes the 
long-lived neurons, striated muscle cells, short-lived polymorphonuclear granulocytes and erythrocytes, 
spermatids and spermatozoa, and the superficial epithelial cells of the alimentary tract. They are highly 
differentiated morphologically and highly specialized in function. They do not normally divide, and some 
types, such as neurons, do not divide under any circumstances. 

3-4. Relative Tissue Radiosensitivity 

The relative radiosensitivity of a specific tissue depends upon its component cell sensitivities. Table 3-2 lists 
various tissues and organs in decreasing order of radiosensitivity. Characteristics of specific tissues in 
critical organ systems are discussed in the following paragraphs. 



Table 3-2. Relative Radiosensitivity of Various Tissues Based on Parenchymal Hypoplasia 



ORGANS 


RELATIVE 
RADIOSENSITIVITY 


CHIEF MECHANISM OF 
PARENCHYMAL HYPOPLASIA 


Lymphoid organs; bone marrow, testes and 


High 


Destruction of parenchymal cells, especially 


ovaries; small intestines; embryonic tissue 




the vegetative or differentiating cells 


Skin; cornea and lens of eyes; gastrointestinal 


Fairly high 


Destruction of vegetative and differentiating 


organs: cavity, esophagus, stomach, rectum 




cells of the stratified epithelium 


Growing cartilage; the vasculature; 


Medium 


Destruction of proliferating chondroblasts or 


growing bones 




osteoblasts; damage to the endothelium; 
destruction of connective tissue cells and 
chondroblasts or osteoblasts 


Mature cartilage or bone; lungs; kidneys; liver; 


Fairly low 


Hypoplasia secondary damage to the fine 


pancreas; adrenal gland; pituitary gland 




vasculature and connective tissue elements 


Muscle; brain; spinal cord 


Low 


Hypoplasia secondary damage to the fine 
vasculature and connective tissue elements, 
with little contribution by the direct effects on 
parenchymal tissues 



3-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



a. The Hematopoietic System. 

(1) The hematopoietic cells in the bone marrow have a high turnover rate. In addition, bone 
marrow has a large number of hematopoietic cells in reserve. In other words, a large fraction of the 
hematopoietic system in the bone marrow is normally nonfunctioning but has the potential to be functional if 
required. The bone marrow contains three cell renewal systems or lines of cells— the erythropoietic (red 
cell) system, the myelopoietic (white cell) system, and the thrombopoietic (platelet) system. The time 
cycles and cellular distribution patterns and postirradiation responses of these three systems are quite 
different. Studies suggest that a pluripotential stem cell gives rise to these three main cell lines in the bone 
marrow. Beyond this pluripotential stem cell, however, each cell renewal system or line of cells consists of 
a specific stem cell compartment for the production of erythrocytes, leukocytes (lymphocytes, granulocytes, 
monocytes, and so forth), or platelets; a specific compartment for dividing and differentiating erythrocytes, 
leukocytes, or platelets; a specific compartment for maturing (nondividing) erythrocytes, leukocytes, or 
platelets; and a specific compartment for mature, functional erythrocytes, leukocytes, and platelets. 
Research studies suggest that each of these cell renewal systems operates under the influence of regulating 
factors, primarily at the stem cell level, through a negative feedback system initiated in large measure by 
the level of mature circulating cells in the peripheral blood. 

(2) Radiation exposure at an LD 50 level will deplete the hematological stem cell population 
drastically. As the functional, mature cells die, they cannot be replaced, and the overall population of these 
mature cells in the system decreases with the resultant clinical consequences. When the capability for stem 
cells to mature is recovered, a gradual return of a functional cellular population ensues. 

b. The Gastrointestinal System. 

(1) The vulnerability of the small intestine to radiation is primarily due to the cell renewal 
kinetics of the intestinal villi. This is where epithelial cell formation, migration, and loss occur. The four 
cell compartments involved are: The stem and proliferating cell compartment, the maturation compartment, 
the functional compartment, and the extrusion zone compartment. Stem cells and proliferating cells move 
from crypts in the villi into a maturation compartment at the neck of the crypts. Then, functionally mature 
epithelial cells migrate up the villus wall and are extruded at the villus tip. In man, the overall transit time 
from stem cell to extrusion on the villus is estimated at 7 to 8 days. 

(2) Because of the high turnover rate occurring within the stem cell and the proliferating cell 
compartment of the crypt, marked damage occurs in this region by whole body radiation doses above the 
mid-lethal range. Destruction, as well as mitotic inhibition, occurs within the highly radiosensitive 
proliferating cell compartment within hours after high dose radiation exposure. Maturing and functional 
epithelial cells continue to migrate up the villus wall and are extruded, although the process is slowed. 
Shrinkage of villi and morphological changes in mucosal cells occur as new cell production is diminished 
within the crypts. This eventually results in denudation of the intestinal mucosa. Concomitant injury to the 
microvasculature of the mucosa and submucosa in combination with this epithelial cell denudation results in 
hemorrhage and marked fluid and electrolyte loss contributing to shock. These events normally occur within 
one to two weeks after irradiation. A second mechanism of injury has recently been detected at the lower 
range of the GI syndrome, or before major denudation occurs at higher doses of radiation. This response is 

3-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



a functional increase in fluid and electrolyte secretion from the epithelial cells without visible cell damage. 
This second mechanism may have important implications for fluid replacement therapy. 

c. Cardiovascular/Central Nervous Systems. 

(1) At extremely high doses (2000 cGy-3000 cGy and higher), damage to the central nervous 
system and cardiovascular systems are severe and irreversible. The damage is related to interruptions of 
the normal regulatory control systems, such as controlling responses in heart rate, respiration, blood 
pressure, body temperature, and so forth. However, the visible morphological changes at the cell level of 
the central nervous system (CNS) are limited to a few tissues, including the granule cell layer of the 
cerebellum and the meningeal lining of the brain. Also, there is a breakdown of the blood-brain barrier that 
leads to cerebral edema. 

(2) Also, the microvasculature of all tissue and organ systems is susceptible to damage by 
ionizing radiation exposure. The amount of tissue damage and the degree to which repair ensues are 
dependent on the level and duration of exposure, on the extent of tissue exposed, and on the type of radiation. 
Exposure-induced lesions on luminal surfaces of endothelial cells appear to provide initial sites for 
thrombogenic foci, that not only extends endothelial damage with resulting changes in vessel wall 
permeability, but also activates a reparative molecular cascade in an attempt to correct the vascular defect. 
The major molecular players in this cascade include von Willenbrand factor (vWf, clotting factor-8) which 
is released from damaged endothelial cells; the selected binding of angiogenic cytokines (angiogenic and 
platelet-derived endothelial growth factors) which stimulate the regrowth of damaged endothelial sites; and 
finally, the damage-mediated release of cytokines by blood platelets and lymphocytes. These cytokines 
selectively stimulate proliferation of new perivascular elements. Within limits of exposure, this repair 
sequence commonly results in a restructured, fully functional vessel. 

Section II. SYSTEMIC EFFECTS OF HIGH-DOSE RADIATION 

3-5. General 

This section focuses on the systemic effects of high dose radiation resulting from nuclear warfare or a high- 
dose radiation incident. Examples of a high-dose radiation incident would be: 

• An actual nuclear detonation resulting from a special weapon accident. 

• When weapons or fuel-grade nuclear material is allowed to form a critical mass ("a criticality 
incident"). 

• Or when an individual is exposed to a highly concentrated form of radioactive material, as 
would be present in irradiator facilities or from unshielded spent nuclear reactor fuel. 

Whole body irradiation is potentially the most damaging radiation. However, partial body irradiation is most 
likely to occur in both tactical scenarios and in radiological incidents since terrain, obstacles, shielding, and 

3-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



so forth would preclude whole body exposure. Therefore, partial exposure would limit the amount of 
radiation actually transmitted to the body. Specific organ irradiation due to internal and external 
contamination is discussed in Chapter 4, Radioactive Contamination. 

3-6. Acute Radiation Syndrome 

a. General. Acute radiation syndrome is a complex clinical presentation of injuries that occur 
after exposure to a high dose of ionizing radiation. The clinical presentation is dependent on the type, rate, 
and dose of radiation received. Acute radiation syndrome has been encountered after the detonation of 
nuclear weapons, after industrial radiation accidents, after planned radiotherapy, and so forth. There are 
three phases to the acute radiation syndrome: A prodromal or initial phase occurring during the first few 
hours after exposure; a latent phase, which becomes shorter with increasing dose of radiation exposure; and 
a manifest phase in which the clinical illness appears. 

(1) Prodromal or initial phase. The prodromal symptoms (prodrome) include the rapid onset 
of nausea, vomiting, and malaise. This is a nonspecific clinical response to acute radiation exposure. The 
speed of onset and duration of symptoms vary with the degree of exposure to acute doses of radiation, but are 
not diagnostic of the degree of radiation injury. An early onset of symptoms in the absence of associated 
trauma does suggest a large radiation exposure. 

(2) Latent phase. Following recovery from the prodromal phase, there will be a latent phase 
during which the exposed individual will be relatively symptom free. The length of this phase varies with the 
dose and the nature of the later manifest phase. The latent phase is longest preceding the bone-marrow 
depression of the hematopoietic syndrome and may vary between 2 and 6 weeks. It is somewhat shorter 
prior to the GI syndrome, lasting from a few days to a week. It is shortest of all preceding the neurovascular 
syndrome, lasting only a matter of hours. These times are exceedingly variable and may be modified by the 
presence of other disease or injury, or by medical intervention. 

(3) Manifest phase. This phase is when the clinical symptoms associated with the major 
organ system involved (marrow, intestine, neurovascular system) become evident. The clinical symptoms 
are classified under three subsyndromes. The details of each of the three subsyndromes are described in 
paragraph 3 -6c. 

b. Lethality /Lethal Dose. 

(1) Without medical intervention. In the following sections, the term lethal dose may be used. 
For example, a dose that is lethal to 50 percent of a given population within a specific time frame after 
exposure is annotated as LD 50 . The LD 50 may define acute lethality, but can be modified to allow for 
mortality over a specific length of time. The common time periods used are 30 days for most small 
laboratory animals and 60 days for large animals and man. The specific time period is indicated by a second 
number in the subscript: LD 50/ 3 and LD 50/60 indicate 50 percent mortality within 30 days and 60 days 
respectively. Figure 3-1 is a graphic representation of a typical mortality response to radiation. The LD 50 
of radiation that will kill 50 percent of exposed persons within a period of 60 days without medical 
intervention (LD 50/60 ) is an acute dose to the whole body of approximately 450 cGy, as measured in free 
air. Medically, other figures of interest are the dose that will kill virtually no one (LD 5 ) and the dose that 

3-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



will kill virtually everyone (LD 95 ). Approximations of those doses are within the free in air ranges of 200 to 
300 cGy and 600 to 700 cGy, respectively. These values are important in determining treatment priorities. 















90 
80 
70 

E 60 

H 

A 50 

T 40 

% 30 

20 

10 








A 


w 








/ 


T 






i 


f 








/ 


r 








/ 










/ 








a 


f 








J 








A 


/ 








<*m 


V 





















200 



400 
Dose (cGy) 



600 



Figure 3-1. Lethality as a function of dose. 



(2) With medical intervention. Adequate medical intervention significantly increases the 
LD 50 and markedly diminishes mortality. Figure 3-2 shows the impact of medical intervention on lethal 
doses (adapted from the U.S. Army Human Response Dose Committee Meeting minutes, 10 October 
2000). The LD 50 for radiation moves from approximately 400 cGy to approximately 600 cGy if the exposed 
service member receives timely medical treatment that is generally available within a theater of operations. 

c. Acute Radiation Subsyndromes. The subsyndromes of acute radiation syndrome include the 
hematopoietic, gastrointestinal, and cardiovascular/CNS syndromes. The syndromes are dose dependent, 
interrelated and cumulative. As dose is increased, the hematopoietic system, gastrointestinal system and 
cardiovascular/central nervous systems are each affected in turn, based largely on the radiosensitivity of the 
underlying cell and tissue system. Clearly, a dose sufficient to impact the gastrointestinal system will also 



3-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



impact the hematopoietic system. Doses sufficient to impact the CNS system result in lethality before 
expression of the lower dose syndromes. The syndromes are discussed in turn below. 



MORTALITY 


MILITARY W/O I 
TREATMENT | 






1 CHERNOBYL 




50% 




FACTOR OF 1.5 

INCREASED 

SURVIVABILITY 

DUE TO TREATMENT 




NAGASAKI ^fe/W | 


' / 






/ 1 
/ i i 








M 


ILITARY 

//TREATMENT 






/ i / 
/ i / 
/ i / 

/ / 


V 



410 615 

DOSE(cGy) 



Figure 3-2. Estimates of medical intervention on dose effect models. 



(1) Hematopoietic syndrome. Patients who received doses of radiation in the range of 200 to 
600 cGy will have depression of bone marrow function with cessation of blood cell production leading to 
pancytopenia. Changes within the peripheral blood profile will occur as early as 24 hours after irradiation (see 
Figure 3-3). The exact time sequence of the depression of various circulating cell lines will vary. Lymphocytes 
will be depressed most rapidly and erythrocytes least rapidly. Other leukocytes and thrombocytes will be 
depressed somewhat less rapidly than lymphocytes. If the bone marrow depression is the result of multiple, 
fractionated exposures, or to an exposure that occurs over a period of hours to days, it may be difficult to 
estimate when the depression will occur. A reasonable average time for onset of clinical problems of bleeding 
and anemia and decreased resistance to infection is 2 to 3 weeks. If an infection occurs, there may be little 
clinical response because of the concomitantly depressed inflammatory response. 

(a) Erythropoiesis . The erythropoietic system is responsible for the production of 
mature erythrocytes (red cells). Because immature erythroblasts and proerythroblasts proliferate rapidly, 
they are markedly sensitive to cell killing by ionizing radiation. Death of stem cells and of those within the 
dividing and differentiating compartment are responsible for the depression of erythropoietic marrow. If 
sufficiently severe, this depression is responsible for the subsequent radiation-induced anemia. Because of 
the relatively slow turnover rate, approximately one percent loss of red cell mass per day, evidence of 
anemia is usually manifested after depression of the other cell lines. This system has a marked propensity 
for regeneration following irradiation. After sublethal exposures, marrow erythropoiesis normally recovers 
slightly earlier than granulopoiesis and thrombopoiesis and occasionally overshoots the baseline level before 
levels at or near normal are reached. 



3-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



o 
08 § 

HI X 



>- 
o 
o 



if) 

_! 

X 
D. 
O 

a. 

> \- 

-I 3 
HI 



3 16 r 

z 

EQ 12 - 

O 1Z| ^ 



o 

s 

LLI 

X 



o 

LU 

X 



14 

12 

10 

8 



S 16 

z 

CD 12 

O ^ 



2 



14 
12 - 
10 - 

8 - 

6 

4|- 

2 





t 1 1 1 1 1 1 1 1 1 1 r 

1 Gy 



THROMBOCYTES 

y 



HEMOGLOBIN, 




J I L 



LYMPHOCYTES 

| | I 



/ 



10 



20 



30 



40 



50 



60 



t 1 1 1 1 1 1 1 1 1 1 r 

3Gy 
THROMBOCYTES 




73 
O 

-i. CD 

s ° 

H 

m 

V) 



20 30 40 

TIME (days) 



Figure 3-3. Hematological response to whole-body exposure of 1 Gy (100 cGy) and 3 Gy (300 cGy). 

(b) Lymphopoiesis. Lymphocytes are the most radiosensitive cells of the hematopoietic 
system. Shortly after exposure to ionizing radiation, mature lymphocytes show early necrosis and immature 
splenic lymphocytes have evidence of chromatin clumping and early necrotic changes. Lymph nodes show 
nuclear debris within hours of irradiation. The number of cells in the blood forming organs is not related to 
radiation dose, but further cell reproduction seems to be inhibited. Surviving lymphocytes may have either 
an increased cellular metabolism or altered behavior. The greater the radiation exposure, the more 
profound the lymphopenia. The leukopenia will begin within hours and proceed to its nadir within 48 to 72 
hours. The fall in circulating lymphocytes can be utilized as a crude biodosimetry tool to estimate the 
effective radiation dose received. The steeper the fall in circulating lymphocytes, the higher the dose and 
the more severe the injury (see paragraph 3-10). 

(c) Leukopoiesis. The function of the myelopoietic cell renewal system is mainly to 
produce mature granulocytes (neutrophils, eosinophils, and basophils) for the circulating blood. The most 



3-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



important type in this cell line are the neutrophils because of their role in combating infection. The stem 
cells and those developing cells within the dividing and differentiating compartment are the most 
radiosensitive. Three to seven days are normally required for the mature circulating neutrophil to form 
from its stem cell precursor stage in the bone marrow. Mature functional granulocytes are available upon 
demand from venous, splenic, and bone marrow pools. Following an initial increase in circulating 
granulocytes (of unknown etiology), these pools are normally depleted before granulocytopenia is evident 
soon after radiation-induced bone marrow injury. Because of the rapid turnover in the granulocyte cell 
renewal system (approximately 8-day cellular life cycle), evidence of radiation damage to marrow 
myelopoiesis occurs in the peripheral blood within 2 to 4 days after whole-body irradiation. Recovery of 
myelopoiesis lags slightly behind erythropoiesis and is accompanied by rapid increases in numbers of 
differentiating and dividing forms in the marrow. Prompt recovery is occasionally manifested and is 
indicated by increased numbers of band cells in the peripheral blood. 

(d) Thrombopoiesis . The thrombopoietic cell renewal system is responsible for the 
production of platelets (thrombocytes). Platelets are produced by megakaryocytes in the bone marrow. 
Both platelets and mature megakaryocytes are relatively radioresistant, however the stem cells and immature 
stages are very radiosensitive. The transit time through the megakaryocyte proliferating compartment in 
man ranges from 4 to 10 days. Platelets have a life span of 8 to 9 days. The time of beginning platelet 
depression is influenced by the normal turnover kinetics of cells within the maturing and functional 
compartments. Thrombocytopenia is reached in 3 to 4 weeks after doses of 200-600 cGy, and occurs from 
the killing of stem cells and immature megakaryocyte stages with subsequent maturational depletion of 
functional megakaryocytes. Regeneration of thrombocytopoiesis after sublethal irradiation normally lags 
behind both erythropoiesis and myelopoiesis. Supranormal platelet numbers overshooting the preirradiation 
level have occurred during the intense regenerative phase in human nuclear accident victims. Blood 
coagulation defects with concomitant hemorrhage constitute important clinical sequelae during the 
thrombocytopenic phase of bone marrow and GI syndromes. 

(2) Gastrointestinal syndrome. 

(a) The gamma radiation doses that will result in the GI syndrome are higher than those 
that will cause the hematopoietic syndrome alone. An acute dose that will cause this syndrome will be at 
least 800 cGy. Some facets of the GI syndrome may manifest at doses of 600 cGy depending on abdominal 
dose and individual sensitivity. Conversely, exposures to high doses at low dose rates or as fractionated 
exposures (multiple individual exposures totaling a specific dose) may not cause it. Regardless of the dose 
involved, the GI syndrome has a very serious prognosis, because it will almost always be accompanied by 
bone marrow suppression. 

(b) The effects of radiation on the GI tract and the associated symptomatology can be 
categorized into four major phases that correspond to the elapsed time from exposure to manifestation. 
These phases are— 

• The Prodromal Phase, in which nausea, vomiting, and diarrhea occur minutes 
to hours after exposure. 

• The Latent Phase, which lasts a few days to a week. 
3-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



• The Manifest Phase, in which the patient experiences severe fluid loss, 
hemorrhage, and diarrhea. The pathologic basis for this syndrome is an early physiologic derangement of 
the epithelial cells followed by a combination of severe loss of intestinal mucosa and injury to the fine 
vasculature of the submucosa. 

• The Chronic Phase, in which survivors may develop fibrosis, bleeding, and 
fistulas months to years after exposure. 

(3) Cardiovascular/central nervous system syndrome. This syndrome is associated only with 
very high acute doses of radiation. The lower limit is probably 2000 cGy, although hypotension (significant 
decline in systemic blood pressure) may be seen at even lower doses. Because of the very high doses of 
radiation required to cause this syndrome, personnel close enough to a nuclear detonation to receive such 
high doses would generally be located well within the range of 100 percent lethality due to blast and thermal 
effects (see paragraph 3-7). 

(a) Acute radiation doses of 3000 cGy and above uniformly bring death within 72 hours 
and usually between 24 to 48 hours, well before the insult to the GI or bone marrow systems becomes 
clinically apparent. Doses in this range cause significant direct effects as well as the free radical overload 
of the cells and basement membranes of the microcirculation system. This leads to massive loss of serum 
and electrolytes through leakage into the extravascular space, circulatory collapse, edema, increased 
intracranial pressure, and cerebral anoxia among other damage. 

(b) In less than an hour and possibly within minutes of exposure, patients receiving 
these doses begin experiencing prodromal symptoms: a burning sensation of the skin within minutes and 
severe nausea and usually projectile vomiting within an hour. The symptoms, which are severe and may last 
more than 24 hours, also include diarrhea that is occasionally bloody, cutaneous edema and erythema, 
hypotension, hyperpyrexia, disorientation, prostration, loss of coordination, and possibly seizures. Following 
the prodromal phase, there may be a brief latent phase of apparent clinical improvement; but this will last 
only in the range of hours to days. Finally, the victim will succumb to a complex of gross CNS dysfunction 
and total cardiovascular (CV) collapse, leading to a relatively prompt and inevitable death. 

3-7. Radiation-Induced Early Transient Incapacitation 

Early Transient Incapacitation (ETI) is a temporary inability to perform physically or cognitively demanding 
tasks, and is associated with very high acute doses of radiation (lower limit is approximately 2000 cGy). The 
latent period is very short, varying from several hours to 1 to 3 days. Hypotension, emesis, and/or diarrhea 
may accompany a progressive deteriorating state of consciousness as a result of vascular instability. Death 
typically occurs within a few days. Convulsions without increased intracranial pressure may or may not occur. 

a. The frequency of incapacitation produced by a given radiation dose is proportional to the 
demands or the level of stress of the task being performed. Current combat casualty criteria are based on 
the incapacitating dose levels for both physically demanding tasks and undemanding tasks. They do not 
include combat ineffectiveness due to partially degraded performance that may result from slower reaction 
to the task, task stress, or prodromal effects of acute radiation sickness. Exposure to doses of ionizing 

3-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radiation of approximately 2000 cGy results in an immediate precipitous decline in cerebral blood flow 
(CBF), which is followed by a partial recovery at 20 to 30 minutes, and subsequent slower secondary 
decrease in CBF, thereafter, accompanied by parallel changes in systemic blood pressure. The activity of 
certain brain enzymes involved in neurotransmitter metabolism is also considerably affected during ETI. 

b. For yields of 5 KT or less, initial nuclear radiation will be the dominant casualty producer on 
the battlefield. Military personnel close enough to ground zero who receive an acute incapacitation dose of 
2000 cGy would more likely die due to blast and thermal effects. However, in nuclear detonations above the 
atmosphere with essentially no blast, very high fluxes of ionizing radiation may extend out far enough to 
result in high radiation doses to aircraft crews. Such personnel could conceivably manifest ETI, 
uncomplicated by blast or thermal injury. Also, personnel protected from blast and thermal effects in 
shielded areas could also sustain doses that might manifest as ETI. Doses in this range could also result 
from military operations in a reactor facility or a fuel processing plant where personnel are accidentally or 
deliberately injured by a nuclear criticality event. Personnel suffering from ETI will become performance 
degraded almost immediately and combat ineffective within several hours. However, they will not die until 
5 to 6 days after exposure unless they received other injuries that would make them more susceptible to 
death from the radiation dose. 



Section III. DIAGNOSIS, SEVERITY, AND TRIAGE 
OF RADIATION CASUALTIES 



3-8. Clinical Findings 

A precise history of exposure may be very difficult to obtain, since many individuals may not know that they 
actually have been exposed to radiation, particularly if the exposure is due to fallout, or due to exposure to a 
low-level radiation source. One of the sources of information available to the medical staff is the medical 
military physicist (that is, the Army 72A, Air Force 43EX, 43YX, or Navy 0847 officers). Also, unit NBC 
personnel and chemical defense unit personnel can provide unit operational history information and perhaps 
collective unit exposure data. However, an accurate and prompt diagnosis of radiation sickness is based 
primarily upon the clinical picture presented by the patient. The key signs and symptoms of radiation 
sickness that would make one suspicious that radiation exposure has occurred are described below. Some of 
these signs and symptoms, along with the information provided in Table 3-3, can help the clinician to 
estimate the approximate severity of the potential exposure. 

a. Nausea and Vomiting. Nausea and vomiting occur with increasing frequency as the radiation 
dose exceeds 100 to 200 cGy. Their onset may be seen as long as 6 to 12 hours postexposure and usually 
subsides within the first day for these lower doses. The occurrence of vomiting within the first two hours is 
usually associated with a severe radiation dose. Vomiting within the first hour, especially if accompanied by 
explosive diarrhea, is associated with doses that frequently prove fatal. Due to the transient nature of these 
symptoms, it is possible that the patient will have already passed through the initial phase of GI distress 
before being seen by a physician. It will be necessary to inquire about these symptoms at the initial 
examination. 

3-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



NOTE 

The use of antiemetics, such as granisetron, has been approved by the 
FDA for prophylactic use for high-dose radiation exposure. Medical 
personnel may encounter patients whose nausea and vomiting 
symptoms have been reduced or mitigated by use of this drug. 



b. Hyperthermia. Casualties who have received a potentially lethal radiation injury show a 
significant rise in body temperature within the first few hours postexposure. Although the number of cases 
is few and is frequently overlooked, this condition appears to be a consistent finding. The occurrence of 
fever and chills within the first day postexposure is associated with a severe life-threatening radiation dose. 
Hyperthermia may occur in patients who receive lower, but still serious radiation doses (200 cGy or more). 

c. Erythema. A person who has received a whole body dose of more than 1000 cGy will develop 
erythema within the first day postexposure. Erythema is less frequently seen with lower doses (200 cGy or more). 

d. Hypotension. A noticeable and sometimes clinically significant decline in systemic blood pressure 
has been recorded in victims who have received a supralethal whole body radiation dose. A severe hypotensive 
episode was recorded in one person who had received several thousand cGy. In persons who received several 
hundred cGy, a drop in systemic blood pressure of more than 10 percent has been noted. Severe hypotension 
after irradiation is associated with lethal injury. However, if the radiation dose has been determined to be 
less than 1000 cGy, then a physical injury should be suspected as being responsible for the hypotension. 

e. Neurologic Dysfunction. Experience indicates that almost all persons who demonstrate obvious 
signs of damage to the CNS within the first hour postexposure have received a supralethal dose. Symptoms 
include mental confusion, convulsions, and coma. Intractable hypotension will probably accompany these 
symptoms. Without aggressive medical support, these patients succumb within 48 hours. 





Table 3-3. Dose, Onset, and Duration of Symptoms 




DOSE (cGy) 


SYMPTOMS 


ONSET 


DURATION 


0-35 


None 


N/A 


N/A 


35-75 


Mild Nausea, Headache 


6 Hours 


12 Hours 


75-1 25 


Nausea/Vomiting (30%) 


3-5 Hours 


24 Hours 


125-300 


Nausea/Vomiting (70%) 


2-3 Hours 


3-4 Days 


300-530 


Nausea/Vomiting (90%) 
Diarrhea (10%) 


2 Hours 
2-6 Hours 


3-4 Days 
2-3 Weeks 


530-830 


Severe Nausea/Vomiting (90%) 
Diarrhea (10%) 


1 Hour 
1-8 Hours 


Direct Transit into 
Gl Syndrome 


830-3000 


Severe Nausea/Vomiting (90%) 
Disorientation (1 00%) 


3-10 Min 
3-10 Min 


Persists Until Death 
30 Min-10 Hours 



3-13 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



3-9. Dosimetry 

Dosimetry, at the present time, is useful in that it can help determine that an exposure has occurred, but it 
will not give an entirely adequate picture that can be used to determine either the extent of radiation injury or 
the prognosis. Dosimeters cannot tell whether a radiation exposure is whole body or partial body, and, they 
do not display the dose rate of the exposure. Generally, they may not differentiate between single exposures 
and multiple exposures unless they are read at regular intervals. However, in a mass casualty situation in an 
operational theater where time is critical, decisions based only on dosimetric data may be all that is 
practical. 

3-10. Laboratory Testing 

a. The most useful forward laboratory procedure to evaluate marrow depression is the peripheral 
blood count. The resultant lymphocyte levels may be used as a biologic dosimeter to help make the diagnosis 
and determine the severity of radiation injury only (see Figure 3-4). In the event of combined injuries, the use 
of lymphocytes may be unreliable because patients who have received severe burns or multisystem trauma 
often develop lymphopenia. The rate and degree of decrease in blood cells are dose dependent. An initial 
baseline sample should be obtained as early as possible after irradiation. Blood samples should be taken at 
least daily during the first 2 weeks. More frequent sampling will increase the reliability of dose estimates. 
A useful rule of thumb: if lymphocytes have decreased by 50 percent and are less than 1 .0 x 10 9 /1 within 
24-48 hours, the patient has received at least a moderate dose of radiation. However, all personnel with 
lymphocyte levels of less than 2000/mm 3 at 24 hours postirradiation are candidates for treatment. 

ABSOLUTE 

LYMPHOCYTE 

COUNT 

RELATIONSHIP 3000 

BETWEEN 
EARLY CHANGES 
IN PERIPHERAL 
BLOOD LYMPHOCYTE 
COUNTS AND 2000 

DEGREE OF 
RADIATION INJURY 



1000 

500 











|v 


NORMAL 
" RANGE 






\\\ 


- MODERATE 

- SEVERE 

VERY 
SEVERE 




\N 


-INJURY 








Ih LETHAL 





1 2 

TIME (DAYS) 

Figure 3-4. Lymphocyte nomogram. 



3-14 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



b. Other medical assays can be used to determine the severity of exposure. Table 3-4 (adapted 
from AMedP-6(C), NATO Handbook on Medical Aspects of NBC Operations, Ratification Draft) lists 
clinical laboratory test and the treatment level where they should be performed. 

Table 3-4. Medical Assay of the Radiological Patient 





LOCATION/FACILITY 




DECONTAMINATION 


MEDICAL TREATMENT 


HOSPITAL 


TERTIARY CARE 


TEST 


POINT 


UNIT (LEVEL 2) 


(LEVEL 3) 


(LEVEL 4) 


Nasal swabs for 


+ 








inhalation of 










contaminants 










External contamination 


+ 




+ 




Urine and stool sample for 




Baseline sample 


24 hour sample 


+ 


internal contamination 










Complete Blood Count 


If practical 


Baseline sample 


Daily for 2 weeks 


Daily for 2 weeks 


(CBC)/platelets 




and then daily 






Absolute Lymphocyte 




Every 4-1 2 hours 


Every 4-12 hours 




Count 




for 3 days 






Human Leukocyte Antigen 




Draw sample 


Draw sample before 


Draw sample before 


(HLA) subtyping 






lymphocyte count falls 


lymphocyte count falls 


Cytomegalovirus (CMV) 






+ 


+ 


Hemoglobin Agglutinin 






+ 


+ 


Human Syncytial Cell 








+ 


Virus Antibodies 










Human Immunovirus 






+ 


+ 


Vesiculovirus 








+ 


Lymphocyte Cytogenetics 




Draw sample 


Draw sample before 
lymphocyte count falls 


+ 



+ Indicates test should be performed at this location/level of care. 



3-11. Triage of Nuclear and Radiological Casualties 

Casualty diagnosis and triage are linked in that diagnosis is an individual casualty determination, while triage 
takes that individual casualty information and applies it to a medical unit operational priority. This is 



3-15 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



especially the case in a mass casualty situation in times of nuclear war or during consequence management 
of a catastrophic nuclear incident. A mass casualty situation is one where the number of patients requiring 
care exceeds the capabilities of treatment personnel and facilities. For example, the detonation of the high 
explosive (HE) component of a nuclear weapon (such as at Palomares, Spain) in a densely populated area 
can result in 50 patients requiring immediate care, yet the closest treatment facility can only provide for 10 
patients. Thus, correct triage and evacuation procedures are essential. 

a. Triage classifications for nuclear patients differ from conventionally injured patients. Because 
survivable radiation injury is not manifested until days to weeks after exposure, triage is based primarily on 
the presentation of conventional injuries and is then modified by radiation injury level. That is, triage and 
care of any life-threatening injuries should be rendered without regard for the probability of radiation 
exposure or contamination. The physician should make a preliminary diagnosis of radiation injury only for 
those patients who display the appropriate radiation exposure symptoms, such as nausea, vomiting, diarrhea, 
hyperthermia, and so forth. The DIME method of triage codes is used for patient classification. That is, 
D = Delayed, I = Immediate, M = Minimal, and E = Expectant. Nuclear patient triage classifications 
are as follows: 

(1) Delayed treatment group (D). Those needing surgery, but whose conditions permit delay 
without unduly endangering safety. Life-sustaining treatment such as intravenous fluids, antibiotics, splinting, 
catheterization, and relief of pain may be required in this group. Examples are fractured limbs, spinal 
injuries, and uncomplicated burns, and all casualties with only radiation injury who do not exhibit gross 
neurological symptoms. In the face of trauma combined with radiation injury, all surgical procedures must 
be completed within 36-48 hours of radiation exposure, or delayed until at least two months after the injury. 
Consequently, combined injury patients become the highest priority immediately after those requiring life or 
limb-saving surgery. 

(2) Immediate treatment group (/). Those requiring immediate lifesaving surgery. 
Procedures should not be time-consuming and should concern only those with a high chance of survival, such 
as respiratory obstruction and accessible hemorrhage. Pure radiation injury is not acutely life-threatening 
unless the irradiation is massive. If a massive dose has been received, then the patient is classified as 
expectant (E). 

(3) Minimal treatment group (M). Those with relatively minor injuries who can be helped by 
untrained personnel, or who can look after themselves, such those who have minor fractures or lacerations. 
Buddy care is particularly important in this situation. Patients with radiological injury should have all 
wounds and lacerations cleaned meticulously and then closed. 

(4) Expectant treatment group (£). Those with serious or multiple injuries requiring intensive 
treatment, or with a poor chance of survival. These patients receive appropriate supportive treatment 
compatible with resources, which will include large doses of analgesics as applicable. Examples are severe 
head and spinal injuries, widespread burns, or neurological symptoms from massive doses of radiation. 
These casualties may be removed from this category as additional medical assets become available. 

b. Table 3-5 provides radiation dosage, degradation of treatment, and treatment priorities for 
radiation and combined injuries. 

3-16 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table 3-5. Radiation Dosage and Treatment Priority 



SERIAL STARTING PRIORITY 


FINAL PRIORITY 




LESS THAN 150 CGY 


GREATER THAN 150 CGY 


GROSS NEUROLOGICAL SYMPTOMS 


Radiation Only 
I 

D 
M 

E 


DUTY, D, or M * 
I 
I 

D" 

E 


D** 

I 

I 

D 

E 


E 
E 
E 
E 
E 



* Placement in one of the categories is dependent upon command guidance, the tactical situation, and availability of replacements. 
Select DUTY if mission completion is mandatory regardless of casualty rate. Select M if less than 50 cGy and combat operations 
are ongoing. Select D if combat personnel resources are adequate. 

** Includes the probable requirements for antibiotics and transfusion at a later time. This classification does not suggest that the 
patient is not in need of treatment, but rather that he does not need immediate specialized care. Marrow resuscitative therapy 
should begin as soon as practical. 



Section IV. TREATMENT OF RADIATION SUBSYNDROMES 



3-12. First Aid 

There is no direct first aid for radiological casualties. The first action in dealing with these casualties is to 
administer first aid for any conventional injuries, such as combat wounds, blast injuries, and thermal burns 
in accordance with the procedures in FM 21-11, First Aid for Soldiers. 

3-13. Management of the Hematopoietic Syndrome 

The primary goal of treating the hematopoietic patient is a reduction in both the depth and duration of 
leukopenia. The therapeutic modalities for treatment will vary according to the medical facility, the current 
medical knowledge and experience of the providers, the number of casualties, and the available resources to 
treat the patients. In the patient with signs and symptoms consistent with hematopoietic syndrome, changes 
within the peripheral blood profile can occur as early as 24 hours after irradiation. Therefore, blood 
specimens should be drawn for biodosimetry analysis. The tendency toward uncontrolled hemorrhage, 
decreased resistance to infection, and anemia will vary considerably from as early as 10 days to as much as 
6 to 8 weeks after exposure. However, a reasonable average time for the onset of bleeding and anemia and 
decreased resistance to infection is 2 to 3 weeks postexposure. 

a. Conventional Therapy of Neutropenia and Infection. The prevention and management of 
infection is the mainstay of therapy. There is a direct relationship between the degree of neutropenia and the 



3-17 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



increased risk of infectious complications. Antibiotic prophylaxis should be considered in afebrile patients 
at the highest risk for infection. These patients have profound neutropenia ( < 1 .0 x 10 9 cells/1 or 1000 cells/ 
ml) with an expected duration of greater than 7 days. Although the degree of neutropenia is the greatest risk 
factor for developing infection, other factors also influence the choice to start treatment and the medications 
that are to be used to treat the patient. Such factors include duration of neutropenia, bactericidal functionality 
of surviving neutrophils, alteration of physical defense barriers, the patient's endogenous microflora, and 
organisms endemic to the hospital and community. As the duration of neutropenia increases, the risk of 
secondary infections such as invasive mycoses also increases. Some of the recommended medications (see 
Appendix B) for prophylaxis are Ciprofloxacin as an antibiotic, Acyclovir as an antiviral agent, and 
Fluconazole (Diflucan) as an antifungal agent. 

b. Prevention of Infection. Initial care of medical casualties with moderate and severe radiation 
exposure should probably include early institution of measures to reduce pathogen acquisition, with emphasis 
on low microbial content food, acceptable water supplies, frequent handwashing (or wearing of gloves), and 
air filtration. During the neutropenic period, prophylactic use of selective gut decontamination with 
antibiotics that suppress aerobes but preserve anaerobes has been used, but is dependent upon the clinical 
setting, provider preference, and the resources available. These measures can help control the alimentary 
canal source (mouth, esophagus, and intestines) of postinjury infections. Maintenance of gastric acidity 
(avoidance of antacids and H 2 blockers) may prevent bacteria from colonizing and invading the gastric 
mucosa and may reduce the frequency of nosocomial pneumonia due to aspiration of these organisms. The 
use of Sucralfate or Prostaglandin analogues may prevent gastric hemorrhage without decreasing gastric 
activity. When possible, an early oral feeding is preferred to intravenous feeding in order to maintain the 
immunologic and physiologic integrity of the gut. Surgical implantation of a subcutaneously tunneled central 
venous catheter can be considered to allow frequent venous access, but meticulous attention to proper care 
is necessary to reduce catheter associated infections. 

c. Management of Infection. 

(1) The management of established or suspected infection (neutropenia and fever) in irradiated 
persons is similar to that used for other febrile neutropenic patients, such as solid tumor patients receiving 
chemotherapy. First, an empirical regimen of antibiotics should be selected, based on the pattern of 
bacterial susceptibility and nosocomial infections in the particular institution and the degree of neutropenia. 
Broad spectrum empiric therapy with high doses of one or more antibiotics should be initiated at the onset of 
fever. Aminoglycosides should be used cautiously due to associated toxicities. Therapy should be continued 
until the patient is afebrile for 24 hours and the absolute neutrophil count (ANC) is greater than or equal to 
0.5 x 10 9 cells/1 (500 cells//d). Combination regimens often prove to be more effective than monotherapy. 
The potential for additivity or synergy should be present in the choice of antibiotics (see Appendix B). 

(2) Modifications of this initial antibiotic regimen should include a thorough evaluation of 
the history, physical findings, laboratory data (including appropriate cultures and a chest radiograph), and 
epidemiological information. Antifungal coverage with Amphotericin B should be added, if indicated, for 
patients who remain persistently febrile for 7 days or more on antibiotic therapy in association with 
clinical evidence of infection, or if they have new fever on or after day seven of treatment with antibiotics. 
If there is evidence of resistant gram-positive infection, Vancomycin should be added. If diarrhea is 
present, stool cultures should be examined for Salmonella, Shigella, Campylobacter, and Yersinia. If 

3-18 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



oral/pharyngeal mucositis and/or esophagitis are present, then empiric use of antiviral and/or antifungal 
therapy should be considered. 

(3) Surveillance cultures may be useful for monitoring acquisition of resistant bacteria 
during prophylaxis and emergence of fungi. A once or twice weekly sampling of surveillance cultures from 
natural orifices and skin folds (for example, axillae, groin) would be reasonable, but should be modified 
based on the institutional patterns of nosocomial infections. A chest radiograph should be considered at 
initiation of empiric therapy. This may aid in definitive diagnosis of a new pulmonary infiltrate obtained 
during the course of neutropenia. The principles described above are generally applicable to the febrile 
neutropenic patient and provide a foundation upon which a specific initial regimen may be selected. These 
principles are summarized as follows: 

• Principle 1 : The spectrum of infecting organisms and antimicrobial susceptibility 
patterns vary both among institutions and over time. 

• Principle 2: Life-threatening, gram-negative bacterial infections are universal 
among neutropenic patients, but the prevalence of life-threatening, gram-positive bacterial infections varies 
greatly among institutions. 

• Principle 3: Current empiric antimicrobial regimens are highly effective for initial 
management of febrile, neutropenic episodes. 

• Principle 4: Search for the nidus of infection, that is, look for the reason the patient 
is infected, and eliminate it. 

Overall recommendations for managing infections are summarized as follows: 

• A standardized plan for management of febrile, neutropenic patients must be devised. 

• Empiric regimens must contain antibiotics broadly active against gram-negative 
bacteria, but antibiotics directed against gram-positive bacteria need be included only in institutions where 
these infections are prevalent. 

• No single antimicrobial regimen can be recommended above all others, as 
pathogens and susceptibility vary with time. 

• If infection is documented by cultures, the empiric regimen may require adjustment 
to provide appropriate coverage for the isolate. This should not narrow the antibiotic spectrum while the 
patient is neutropenic. 

d. Immune Globulin Administration. Immune globulins have not been shown to be beneficial for 
radiation casualties on a general basis. However they may be beneficial in bolstering the diminished 
immunoglobulin (Ig) blood plasma levels that are critical in combating a variety of infectious agents or in 
selectively controlling the pathogenic responses related to septic shock and associated overexpression of 
inflammatory cytokines. 

3-19 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



e. Hematopoietic Growth Factors {Cytokines). Hematopoietic growth factors, such as 
granulocyte-colony stimulating factor (G-CSF) (filgrastim [Neupogen®]) and granulocyte macrophage-CSF 
(GM-CSF) (sargramostim [Leukine®]), are potent stimulators of hematopoiesis and shorten the time of 
recovery of neutrophils. The risk of infection and subsequent complications are directly related to depth and 
duration of neutropenia. In severe radiation-induced myelosuppression, where clinical support in the form 
of antibiotics and fresh, irradiated platelets or whole blood is used concurrently with G-CSF or GM-CSF, a 
marked reduction in infectious complications translates to reduced morbidity and mortality. Currently, 
G-CSF is the preferred cytokine because of its relatively low cost, greater efficacy, and fewer side effects. 
An additional benefit of the cytokines is their ability to increase the functional capacity of the neutrophil and 
thereby contribute to the prevention of infection as an active part of cellular host defense. 

/. Thrombocytopenia and Anemia. 

(1) Conventional therapy of thrombocytopenia. The requirement for platelet support depends 
on the patient's condition. In irradiated patients with or without other major medical problems (infection, GI 
problems, or trauma), the platelets should be maintained at greater than 20 x 10 9 /1. Analysis of platelet 
counts versus hemorrhage suggests that 10 x 10 9 /1 is adequate in the absence of any indication of 
accompanying frank hemorrhage. If surgery is needed, the platelet count should be greater than 50 x 10 9 /1. 
Transfusion of platelets remains the primary therapy to maintain adequate platelet counts. As general 
supportive measures, one should avoid the use of aspirin and nonsteroidal, anti-inflammatory drugs. Limited 
platelet support is likely to come from random donors. Should refractoriness develop, family members as 
well as HLA-compatible donors from the general population can be considered as platelet donors. The use 
of platelet products from which white blood cells have been removed is desirable to minimize both 
allosensitization and the risk of transmission of viral illnesses, such as cytomegalovirus. All blood products 
should receive 2000 cGy of radiation and should be filtered before infusion to prevent graft-versus-host 
disease through infusion of mononuclear cells present in the products. If an allotransplant is contemplated, 
the use of platelets from related donors should be avoided. 

(2) Growth factor /cytokine therapy for thrombocytopenia. Use of thrombopoietic agents 
after radiation injury is of questionable efficacy. Currently, there is no proven benefit in the bone marrow 
transplant model. Further drug development may alter the accepted pattern of care. 

(3) Conventional therapy of anemia. Transfusion of packed red blood cells (PRBCs) remains 
the primary therapy to maintain hemoglobin above 8 gm/dl. Packed red blood cell transfusions should be 
irradiated, leukocyte-filtered (whenever possible), and from an unrelated donor if allogeneic transplantation 
is a consideration. Risks of PRBC transfusion may include CMV transmission and alloimmunization. 
Gamma irradiation of blood products with 2000 cGy will diminish graft versus host reactions common in 
radiation casualties. 

(4) Erythropoietin therapy of anemia. Use of erythropoietin (Epo) after radiation injury is not 
recommended even though it is likely to be safe. Endogenous Epo levels are often already elevated after 
highly cytotoxic therapy and evidence of benefit is not yet available from clinical chemotherapy models. 
Anemia is not generally life-threatening in this situation. 

g. Bone Marrow/Stem Cell Transplantation. Stem cell transplantation usually has a limited role in 
the management of radiation casualties and can only be applied at select Level 5, fixed Continental United 

3-20 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



States (CONUS) facilities. If possible, HLA typing should be done early. Also, the decision to pursue a 
transplant must occur within two weeks of initial acute exposure to the patient. Candidates for such 
transplants generally have had whole body doses in the 700 to 1000 cGy range, and only a fraction of these 
patients would pass screening tests before actually receiving a tissue transplant. 

3-14. Management of the Gastrointestinal Syndrome 

a. During the manifest phase, fluids and electrolytes should be administered to prevent or correct 
dehydration. If blood transfusions are administered, the blood should be irradiated to diminish graft versus 
host reactions. Diarrhea associated with the prodromal and subacute phases of GI injury is most likely 
related to neurohumoral factors affecting GI motility and transport. Loss of the epithelial cell lining is not 
observed until later during the manifest phase of GI injury. As a result, treatment for postirradiation 
diarrhea will require several different approaches. For the early prodromal and subacute phases of 
diarrhea, agents directed against, or counteracting the effects of neurohumoral factors on GI cells should be 
considered. These include antidiarrheal/antisecretory agents such as anticholinergics, Metamucil, 
Amphojel, and Loperamide. Loperamide may offer distinct advantages as the drug affects both intestinal 
cell transport and motility, each of which may contribute to diarrhea. Antisecretory agents, however, will 
be of limited effectiveness against the acute phase of GI injury, during which the loss of epithelial cell lining 
has progressed to denudation of the intestine (See Appendix B). 

b. Sufficient data concerning the efficacy of cytokines on gut-related growth factors and elemental 
diets in stimulating GI regeneration are not yet available. Therefore, specific therapies to stimulate 
proliferation and/or to maintain the intestinal cell lining following radiation exposure cannot be recommended. 

c. The use of antibiotics should be considered for specific infections. Prophylactic use of 
selective gut decontamination with antibiotics that suppress aerobes but preserve ordinarily commensal 
anaerobes has been used but is dependent upon the clinical setting, provider preference, and the resources 
available. In the future, the capability to maintain intestinal integrity following radiation exposure may 
reduce any emphasis on gut decontamination. 

d. The bactericidal effect of gastric acid on intestinal flora is well known. However, gastric acid 
also stimulates pancreatic and biliary secretions, both of which have adverse effects on postirradiation GI 
integrity. Reduction of gastric acidity may be beneficial in the GI syndrome. Thus, the need to maintain gut 
integrity may preempt the desire to stimulate normal bactericidal mechanisms by increasing gastric acid 
secretion. 

e. At the present time, it is believed that enteric feeding may be the best alternative even for those 
patients with radiological enteric mucosal damage. The direct stimulation by nutrient drips appears to 
stimulate mucosal crypt formation. This regeneration of the damaged mucosal barriers inhibits bacterial 
movement from the lumen into the interstitial spaces. There is very limited research into this treatment 
regimen in the irradiated casualty, however, in nonirradiated trauma patients, total parenteral nutrition 
(TPN) is inferior to direct enteric feedings. These data have not been replicated in trauma combined with 
radiation injury. 

3-21 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



3-15. Management of the Cardiovascular/Central Nervous System Syndrome 

As mentioned earlier, this syndrome is associated with very high acute doses of radiation, probably within 
the 2000 to 4000 cGy range. Shock accompanies these high doses, due to a massive loss of fluid into 
extravascular tissues through leaky vascular beds. The ensuing problems from edema, increased intracranial 
pressure, and cerebral anoxia can bring death in approximately 2 days. Radiation doses in this range are 
uniformly fatal regardless of therapies attempted. Therefore, aggressive medical support with pressors, 
fluids, steroids, and the like will bring only temporary improvement and may only serve to prolong suffering. 
Thus, therapy should include only palliative measures such as opiates or tranquilizers. 

3-16. Recovery 

Repopulation occurs by stem cell proliferation and is a particularly important recovery mechanism for both 
the bone marrow and the GI tract whenever the radiation exposure has been large enough to reduce cell 
numbers. Stem cells divide normally in both these tissues, because stem cell turnover is required to 
compensate for the normal continuous removal of differentiated cells. Stem cell division will be accelerated 
by large doses of radiation, just as any other severe insult would do. The effects of small doses are not 
recognized soon enough for accelerated proliferation to take place. In bone marrow, large macrophage 
cells produce factors and cytokines that either stimulate or shut down the stem cells that are the progenitors 
of the erythropoietic, granulopoietic, or thrombopoietic series of blood cells. The "factor producing" cells 
influence one another and depress the production of one factor while the opposite is being produced. Stem 
cell responses continue until the factor is changed. 

3-17. Summary of Medical Aspects of Acute Radiation Injury 

Tables 3-6 through 3-9 summarize the current ideas on the treatment of radiation casualties at progressively 
increasing dose levels. The treatment modalities are meant as guidelines for medical officers during war 
conditions. Also, see Appendix C, Treatment Briefs. 



3-22 



Table 3-6. Medical Aspects of Radiation Injury (0 to 300 cGy) 





DOSE 


INITIAL 


INITIAL 


ANTIEMETIC 


MEDICAL 


INDICATED 


DISPOSITION 


DISPOSITION 


CLINICAL REMARKS 




(estimate) 


SYMPTOMS 


SYMPTOMS 


PRETREAT- 


PROBLEMS 


MEDICAL 


WITHOUT 


WITH 










INTERVAL 


MENT 




TREATMENT 


MEDICAL 


MEDICAL 










ONSET-END 


EFFECT 






CARE 


CARE 






0-35 cGy 


None 


N/A 


Dry mouth. 
Headache. 


Anxiety 


Reassurance. 
Counsel at 
redeployment. 


Duty 


Duty 


Potential for combat anxiety 
manifestation. 




35-75 cGy 


Nausea, mild 
headache. 


ONSET 6 hrs. 
END12hrs. 


Not determined 


Anxiety 


Reassurance. 
Counsel at 
redeployment. 


Duty 


Duty 


Mild lymphocyte depression within 
24 hrs. 




75-125 cGy 


Transient mild 


ONSET 3-5 


5-30% of 


Potential for 


Debridement 


Restricted duty. 


Restricted duty. 


Moderate drop in lymphocyte, 






nausea, 


hrs. 


personnel 


delayed 


and primary 


No further 


No further 


platelet, and granulocyte counts. 






vomiting in 


END 24 hrs. 


nauseated 


traumatic and 


closure of any 


radiation 


radiation 


Increased susceptibility to 






5-30% of 




without emesis. 


surgical wound 


and all wounds. 


exposure, 


exposure. 


opportunistic pathogens. 






personnel. 






healing, 
minimal clinical 
effect. 


No delayed 
surgery. 


elective 
surgery, or 
wounding. 








125-300 cGy 


Transient mild 


ONSET 2-3 


Decreased 


Significant 


Fluid and 


LD 5 toLD, 


Restricted duty. 


If there are more than 1.7 X 10 9 






to moderate 


hrs. 


vomiting. 


medical care 


electrolytes for 




No further 


lymphocytes per liter 48 hrs after 






nausea and 


END 2 days. 




may be 


Gl losses. 


Restricted duty. 


radiation 


exposure, it is unlikely that an 






vomiting in 




Possible 


required at 3-5 




No further 


exposure, 


individual has received a fatal 






20-70% of 




increase of 


wks for 


Consider 


radiation 


elective 


dose. 






personnel. 




fatigability. 


10-50% of 


cytokines for 


exposure, 


surgery, or 








Mild to 






personnel. 


immunocom- 


elective 


wounding. 


Patients with low (300-500) or 






moderate 






Anticipated 


promised 


surgery, or 




decreasing lymphocyte counts, or 






fatigability and 






problems 


patients (follow 


wounding. May 




low granulocyte counts should be 






weakness in 






should include 


granulocyte 


require delayed 




considered for cytokine therapy 






25-60% of 






infection, 


counts). 


evacuation 




and biologic dosimetry using 






personnel. 






bleeding, and 
fever. 

Wounding or 
burns will 
geometrically 
increase 




from theater 
during nuclear 
war IAW 
command 
guidance. 




metaphase analysis where 
available. 


CO 










morbidity and 










to 
w 










mortality. 











o 

k) 
00 
CO 



73 

■o 

I 

o 

k) 



I 



O 

73 

■o 



DO 



CO 



Table 3-7. Medical Aspects of Radiation Injury in Nuclear War (300 to 530 cGy) 



DOSE 


INITIAL 


INITIAL 


ANTIEMETIC 


MEDICAL 


INDICATED 


DISPOSITION 


DISPOSITION 


CLINICAL REMARKS 


(estimate) 


SYMPTOMS 


SYMPTOMS 


PRETREAT- 


PROBLEMS 


MEDICAL 


WITHOUT 


WITH 








INTERVAL 


MENT 




TREATMENT 


MEDICAL 


MEDICAL 








ONSET-END 


EFFECT 






CARE 


CARE 




300-530 cGy 


Transient 


Nausea/ 


Undetermined 


Frequent 


Fluid and 


LD, to LDso 


Increased 


Moderate to severe loss of 




moderate 


vomiting 




diarrheal stools, 


electrolytes for 




percentage of 


lymphocytes. Follow counts q6h 




nausea and 


ONSET 2 hrs. 




anorexia, 


Gl losses. 


Survivors may 


survivors may 


in first few days if possible for 




vomiting in 


END 3-4 




increased fluid 




be able to return 


be able to 


prognosis. 




50-90% of 


days. 




loss, ulceration, 


Consider 


to light duty after 


return to duty 






personnel. 






death of crypt 


cytokines for 


5 wks. 


after 5 wks. 


Moderate loss of granulocytes 






Diarrhea 




cells and 


immunocom- 


No further 


No further 


and platelets. Hair loss after 14 




Early: Mild to 


ONSET at 10 




Peyer"s Patch 


promised 


radiation 


radiation 


days. Thrombocytopenic purpura 




moderate 


days. 




lymphoid tissue. 


patients (follow 


exposure. 


exposure. 


appears after 3 wks. Consider 




fatigability 


END 2-3 






granulocyte 






cytokine therapy and biologic 




and 


wks. 




Increased 


counts). Specific 


May require 


May require 


dosimetry using metaphase 




weakness in 






infection 


antibiotic 


delayed 


evacuation 


analysis where available. 




80-100% of 






susceptibility 


therapy for 


evacuation from 


from theater 






personnel. 






during immuno- 
compromised 
time frame. 

Bleeding 
diathesis at 3-4 
wks due to 
megakaryocyte 
loss. 


infections. 

May require Gl 
decontamination 
with quinolones, 
use alimentary 
nutrition. 


theater. 


for adequate 
therapy. 


Loss of crypt cells and Gl barriers 
may allow pathogenic and 
opportunistic bacterial infection. 
Use alimentary nutrition to 
encourage crypt cell growth. 
Avoid parenteral nutrition and 
central intravenous lines. 

Anticipate anaerobic colonization. 

All surgical procedures must be 
accomplished in initial 36-48 hrs 
after irradiation. Any additional 
surgery must be delayed until 6 
wks postexposure. 



o 

!° 

Ko 

00 
CO 



73 
■o 
■&■ 

I 

o 
ro 



l 



O 

73 
■0 



00 



Table 3-8. Medical Aspects of Radiation Injury in Nuclear War (530 to 830 cGy) 



Ol 



DOSE 


INITIAL 


INITIAL 


ANTIEMETIC 


MEDICAL 


INDICATED 


DISPOSITION 


DISPOSITION 


CLINICAL REMARKS 


(estimate) 


SYMPTOMS 


SYMPTOMS 


PRETREAT- 


PROBLEMS 


MEDICAL 


WITHOUT 


WITH MEDICAL 








INTERVAL 


MENT 




TREATMENT 


MEDICAL 


CARE 








ONSET-END 


EFFECT 






CARE 






530-830 cGy 


Moderate to 


ONSET under 


None 


At 10 days to 5 


Tertiary-level 


LD 5 o to LD M 


Early evacuation 


Practically no lymphocytes 




severe nausea 


1 hr 




wks, 50-100% 


intensive care 




to tertiary-level 


after 48 hrs. Severe drop in 




and vomiting in 


END 




of personnel 


required to 


At low end of 


medical center 


granulocytes and platelets 




50-90% of 


indeterminate, 




will develop 


improve survival. 


exposure range, 


before onset of 


later. In pure radiation 




personnel. 


may proceed 




pathogenic and 




death may occur 


manifest illness. 


exposure scenarios, these 






directly to Gl 




opportunistic 


Fluid and 


at 6 wks in more 




patients will require highest 




Early: 


syndrome 




infections, 


electrolytes for Gl 


than 50% of 


Patients will 


priority evacuation. The 




Moderate 


without a 




bleeding, fever, 


losses, may 


personnel. 


require 


latent period between 




fatigability and 


break. 




loss of appetite, 


require 




extensive 


prodromal symptoms and 




weakness in 






Gl ulcerations, 


transfusion 


At high end of 


reverse isolation 


manifest illness may be very 




80-100% of 






bloody 


and/or colloids. 


exposure range, 


to prevent cross 


short. When this radiation 




personnel, 






diarrhea, 




death may occur 


contamination 


injury is combined with any 




frequent 






nausea, severe 


Cytokines for 


in 3-5 wks in 90% 


and nosocomial 


significant physical trauma, 




diarrhea. 






fluid and 
electrolyte 
shifts, third 
space losses, 
capillary leak, 
and 
hypotension. 


immunocom- 
promised patients 
Specific antibiotic 
therapy for 
infections, to 
include 
antifungals. 

Will require Gl 
decontamination 
with quinolones, 
use alimentary 
nutrition. 


of personnel. 


infection. 


survival rates will approach 
zero. All surgical 
procedures must be 
accomplished in initial 
36-48 hrs after irradiation. 
Any additional surgery must 
be delayed until 6 wks 
postexposure. 

Partial marrow shielding 
may complicate bone 
marrow transplant. Steroid 
therapy is ineffective. 



o 

!° 

k> 

00 
CO 



73 
■o 
■&■ 

I 

o 

k) 



I 



O 

73 

■o 



DO 



CO 



Table 3-9. Medical Aspects of Radiation Injury in Nuclear War {830 to 3000+ cGy) 



DOSE 


INITIAL 


INITIAL 


ANTIEMETIC 


MEDICAL 


INDICATED 


DISPOSITION 


DISPOSITION 


CLINICAL REMARKS 


(estimate) 


SYMPTOMS 


SYMPTOMS 


PRETREAT- 


PROBLEMS 


MEDICAL 


WITHOUT 


WITH MEDICAL 








INTERVAL 


MENT 




TREATMENT 


MEDICAL 


CARE 








ONSET-END 


EFFECT 






CARE 






830-3000+ 


Severe 


ONSET less 


None 


LD 10 oat10Gy 


Supportive 


LD90 to LD, o 


If assets are 


Bone marrow totally depleted 


cGy 


nausea, 


than 3 minutes. 




death at 2-3 


therapy in 




available, then 


within days. Bone marrow 




vomiting, 


END death. 




wks. Minimal if 


higher dosage 


Expectant 


early evacuation 


transplant may or may not 




fatigability, 






any break 


ranges. 


category 


to tertiary-level 


improve ultimate outcome, due 




weakness, 






between 


Aggressive 




medical center 


to late radiation pneumonitis 




dizziness, and 






prodromal 


therapy if pure 




during manifest 


and fibrotic complications. 




disorientation. 






syndrome and 


radiation injury 




illness. 


Even minor wounds may prove 




Moderate to 






manifest 


and some 




Patients will 


ultimately fatal. 




severe fluid 






illness. At high 


evidence of 




require 






and electrolyte 






radiation 


response. 




extensive 


Aggressive therapy is indicated 




imbalance, 






levels, CNS 






reverse isolation 


when resources are available 




hypotension, 






symptoms 






to prevent cross 


and transport to a tertiary care 




possible high 






predominate, 






contamination 


medical center is possible. 




fever, and 






with death 






and nosocomial 






sudden 






secondary to 






infection. 






vascular 






cerebral 






Most patients 






collapse. 






vascular 
incompetence. 






will remain 
expectant. 





o 

!° 

Ko 
00 

CO 



73 

■0 

I 

o 
10 



1 



O 

73 

■0 



00 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Section V. COMBINED INJURY— BLAST, THERMAL, 
AND RADIOLOGICAL INJURIES 



3-18. General 

A combined injury is when a radiation injury is combined with the effects of blast trauma and/or thermal 
burn injury from a nuclear detonation. Combined injuries will be the norm when dealing with nuclear 
detonations (two-thirds of the casualties will have combinations of injuries from the detonation). Chemical 
and biological weapons effects are not combined injuries in the classical sense, but are discussed in this 
section since there is a potential for combined use of NBC weapons. 

3-19. Blast Injuries 

The blast injuries caused by nuclear weapons, or from high explosive components of nuclear weapons and 
RDDs, will frequently be complicated by associated thermal and/or radiation injuries. The diagnosis of 
blast injuries can often be difficult because there is often unrecognized internal injury. About half of the 
patients seen will have wounds to their extremities. In those with injuries to the thorax, abdomen, and head, 
the distribution is about equal. Injuries of the thorax, neck, and the head will be responsible for a large 
percentage of deaths because these types of injuries have a high probability of immediate fatality. 

3-20. Treatment of Blast Injuries 

Normally, treatment is divided into the following four basic phases— 

a. Resuscitative Phase {First Aid). Missile, crush, and translational injuries are generally 
manifested as wounds of the head, neck, face, chest, stomach, and extremities (fractures) and require 
immediate attention at the individual level. Blast casualties will require evaluation for acute trauma in 
accordance with advanced trauma life support standard therapies. Lifesaving resuscitative measures 
designed to prepare the patient for definitive surgical treatment come first. These include the establishment 
of the airway assuring the adequacy of respiration, replacement of lost blood and fluids, and splinting of 
possible fractures, particularly those involving the cervical vertebrae. Some resuscitative measures must 
be started prior to evacuation, particularly if ground transportation is used rather than helicopter evacuation. 
All wounds are considered to be contaminated because of infection-producing organisms (germs) and 
radiological material due to fallout. That a wound is contaminated does not lessen the importance of 
protecting it from further contamination, therefore, first aid providers must dress and bandage a wound as 
soon as possible to prevent further contamination. For a detailed discussion on first aid for typical blast 
injury wounds, see FM 21-11, First Aid for Soldiers . 

b. Surgical Phase. Definitive surgery should be done after resuscitative measures have been 
used to stabilize the patient. Occasionally, lifesaving surgery must be done without delay, but normally 
there is time to prepare patients for surgery if they have survived long enough to reach a treatment facility. 

3-27 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



The treatment of blast injuries is best managed by applying accepted principles of combat surgery as outlined 
in the Textbook of Military Medicine, Part I, Volume 5, Conventional Warfare, Ballistic, Blast and Burn 
Injuries (Chapters 5-9). Of note, traditionally, combat wounds are not closed primarily due to the high level 
of contamination, devitalized tissue, and the subsequent morbidity and mortality associated with closed 
space contamination. In the case of the radiation combined injury patient, wounds that are left open and 
allowed to heal by secondary intention will serve as a potentially fatal nidus of infection. If at all possible, 
wounds should be closed primarily within 36 to 48 hours of radiation exposure. If surgery is required and 
cannot be completed at forward locations, patients with moderate injury will need early evacuation to a level 
where surgical facilities are immediately available. 

c. Recovery Phase. In the immediate postoperative period, patients require minimal movement. 
Transportation to other facilities should be delayed until the patient's condition has stabilized. 

d. Convalescent Phase. Patients in this phase of treatment should be evacuated back to specialized 
convalescent facilities in order to keep the patient load of supporting hospitals as low as possible. Many 
injuries may require a prolonged recovery period before the individual has recovered to the point where he 
can resume his duties. Both the convalescent and recovery phases will be more protracted with the addition 
of a radiation injury. 

e. Orthopedic Injuries. Special circumstances exist for the treatment of orthopedic injuries that 
are associated with radiation exposure. Research with rabbit long bones demonstrates lack of adequate callus 
formation and subsequent nonunion in the irradiated animal. That is, animals that receive no treatment for 
irradiation will have nonunion of fractures. There has been no research into modern techniques of orthopedics 
and wound healing in the irradiated patient. At present, it is recommended that any reconstructive surgery 
be delayed until complete healing of the radiation injury has occurred. There has also been no documentation 
of the effects of aggressive medical resuscitation in these patients. Primary amputation may be the most 
efficacious method of dealing with severely injured extremities. Conservative attempts at salvage by 
repeated debridement and reconstruction may well result in disaster for the irradiated patient. 

/. Tetanus. All personnel receive mandatory immunization with tetanus toxoid when they enter 
active duty. However, members of today's professional military may serve many years after their initial 
immunizations; if they have not received a recent booster, they are at risk of developing tetanus if they are 
wounded. Therefore, all casualties, regardless of their injuries, will receive a tetanus toxoid booster (see 
Appendix C, paragraph C-15). 



3-21. Thermal Injury 

Thermal burns caused by fire, hot objects, hot liquids, and gases or by a nuclear detonation or fireball often 
cause extreme pain, scarring, or even death. Experimental data demonstrate that the mortality of patients 
with thermal burns markedly increases when combined with exposure to radiation. Burn patients with 50 
percent mortality may be transformed into more than 90 percent mortality when irradiated with doses as small 
as 150 cGy. Therefore, this may be considered the most significant type of combined injury. Infection is the 
primary cause of death in these patients, since full-thickness burns are ideal for naturally culturing bacteria. 

3-28 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



3-22. Determining Severity of Thermal Injuries 

Certain factors are of prime importance in the early evaluation of burns because of their relation to overall 
prognosis. These factors include— 

• Area of the burn expressed in percentage of body surface involved. 

• Involvement of critical areas and organs: for example, the head and respiratory tract. 

• Depth of burn: superficial (first- or second-degree), deep (second-degree), and full thickness 
(third-degree). 

a. Area of burn. The most accurate way to estimate the severity of the burn is to measure the 
extent of the body surface burned. Direct measurement is difficult, and a shortcut method of estimating the 
percent of the body surface involved can be very useful. The "Rule of Nines" method is a simple and 
reasonably reliable guide in which the various parts of the body are divided into surface areas of 9 percent 
each (or multiples of 9 percent) as shown in Table 3-10. 

Table 3-10. Rule of Nines for Establishing Extent of Body Surface Burned 

ANATOMIC SURFACE % OF TOTAL SURFACE 

Head and Neck 9 = 9 

Anterior Trunk 2x9 = 18 

Posterior Trunk 2x9 = 18 

Upper Limbs 9 ea = 18 

Lower Limbs 18ea = 36 

Genitalia and Perineum 1 = 1 



As the percent of body surface burned increases, predicted morbidity and mortality increases sharply. 
Burns that cover 20 percent or more of the body surface can be fatal without treatment. Determination of the 
percent of the body surface involved will aid in planning resuscitative treatment and estimating fluid 
requirements during the first 48 hours after the burn injury. Patients with severe burns will suffer extensive 
fluid and electrolyte losses, resulting in severe hypovolemic shock requiring aggressive fluid replacement 
therapy as early as possible. 

b. Involvement of critical organs. When certain organ systems are involved, the clinical effects 
of burns are potentially more serious in spite of the fact that only a small fraction of the body is involved. 

(1) Head and neck burns. Burns of the head and neck can be associated with upper respiratory 
tract edema, which can result in respiratory obstruction. 

3-29 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



(2) Burns of the deep respiratory tract. These injuries may result in pulmonary edema with 
a resultant high probability of mortality. 

c. Depth of burn. Burns are classified on the basis of the depth of the injury. 

(1) Superficial or partial skin thickness burns. These are superficial and painful lesions 
which affect only the epidermis. These burns will heal readily if treated appropriately. 

(2) Deep or full-thickness burns. These burns require extensive resuscitation and surgical 
intervention. They involve the full thickness of the skin and usually result in healing by scarring which 
causes contractions and loss of function. 

3-23. Treatment of Thermal Injuries 

a. Proper first aid will minimize further injury of the burned area, and generally includes 
performing the basic lifesaving measures, lifting away any clothing covering the burned area, and applying 
a field dressing to the burn. For a detailed discussion on first aid for burns, see FM 21-11, First Aid for 
Soldiers. 

b. Initial treatment of burn patients will be resuscitative. When such patients are first seen, a 
simple plan of treatment must include maintenance of airway with ventilation support as needed; adequate 
fluid therapy; and careful maintenance of medical records. 

(1) Maintenance of airway. This is of particular importance in head and neck burns or in 
unconscious patients. If large numbers of patients are seen requiring transportation over long distances 
early in the postburn period, tracheotomies or intubation may have to be done on a routine basis. These 
procedures done prior to the onset of edema are much easier to perform than when they are done after 
edema has resulted in respiratory obstruction. When only small numbers of patients require treatment, 
tracheotomies are rarely required. 

(2) Fluid therapy. The shock that is associated with an extensive burn will be severe, and 
survival of these patients depends upon adequate, balanced fluid replacement therapy. Standard formulae 
for determining the fluid requirements of burn patients have been developed and can be used in combat. The 
basic principle in these formulae is that the amount of fluid required is proportional to the percent of body 
surface burned and body weight. Detailed fluid resuscitation procedures can be found in The Textbook of 
Military Medicine, Part I, Volume 5, Conventional Warfare, Ballistic, Blast and Burn Injuries, Chapter 11. 

(3) Input and output records. It is extremely important to accurately follow the input and 
output of fluids in burn patients even to the point of catheterizing patients to accurately track output. It would 
be impossible to modify fluid therapy according to individual needs without accurate records. Combat 
medical records, however, must be simple and should be attached to the patient so that they accompany him 
during evacuation. 

c. Care of Burn Wound. Although the first priority in patient care is resuscitation, proper care of 
the burn wound is essential both for survival as well as for optimum healing and preservation of function. As 

3-30 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



soon as the patient's overall condition permits, after hospitalization, initial debridement and cleaning of the 
burn should be done. The main purpose of this treatment is to remove foreign material and dead tissue to 
minimize infection. Thorough irrigation and the application of topical antimicrobial creams such as Mafenide 
Acetate Cream and Silver Sulfadiazine Cream and sterile dressings should complete the initial procedures. 
Special attention should be given to critical areas such as the hands and surfaces over joints. No studies are 
available regarding the use of modern skin graft techniques in these combined irradiation-burn injuries. 
Also, no data is available regarding the response to clostridial infection, but strong consideration should be 
given to the use of tetanus toxoid boosters as mentioned for wounds in paragraph 3-20. Patients whose burns 
are contaminated by radioactive material should be gently decontaminated to minimize absorption of these 
materials through the burned skin. Most radiological contaminants will remain in the burn eschar when it 
sloughs. Again, see Chapter 11, The Textbook of Military Medicine, Part I, Volume 5, Conventional 
Warfare, Ballistic, Blast and Burn Injuries for a detailed discussion of this issue. 

3-24. Hematopoietic Effects of Combined Injury 

Radiological injury significantly compounds the morbidity and mortality of patients with other injuries by 
compromising the integrity of the hematopoietic and immune systems. Early healing and active biological 
damage control systems rapidly deplete reserves that are then unable to regenerate due to the radiation 
injury. Since reserves are depleted and consumed without adequate regeneration, pancytopenia develops 
more rapidly than in the pure radiologically injured patient. Anemia results from the poor production of new 
erythrocytes. Therefore, acute blood loss that occurs as a result of a physical trauma cannot be replenished 
by increased marrow output. Likewise, megakaryocytes are unable to replicate as platelets are consumed. 
Fibroblasts that promote wound healing are damaged by irradiation and do not replicate at a normal rate. 
Immunosuppression is magnified due to the more rapid depletion and slower production of lymphocytes and 
neutrophils which increases the risk of infection (see Table 3-11). 

Table 3-11. Hematopoietic Effects of Combined Injury 



RADIATION TRAUMA 

Anemia Depletion of vascular reserves. 

Bleeding Abnormal clotting; increased viscosity. 

Infection Consumption of marrow progenitors. 



3-25. Chemical Weapons and Radiation 

Mustard agents and radiation can cause many similar effects at the cellular level. Therefore, their use in 
combination will likely increase morbidity. The immediate effects of the chemical agents must be countered 
before attention is paid to the effects of radiation that may not manifest for days or weeks. Research into 
these combined effects is only now just beginning. For example, little is known about the combined effect of 

3-31 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radiation and nerve agents. However, radiation will lower the threshold for seizure activity and thus may 
enhance the effects of nerve agents on the CNS. 

3-26. Biological Weapons and Radiation 

There is currently insufficient data to reliably predict casualties from combined injuries of subclinical or 
sublethal doses of ionizing radiation and exposure to aerosols with biological warfare (BW) agents or 
exposure to infectious diseases. Research suggests a shortened fatal course of disease when a virulent strain 
virus is injected into sublethally irradiated test models, since even minimally symptomatic doses of radiation 
depress the immune response and will dramatically increase the infectivity and apparent virulence of 
biological agents. Biological weapons may be significantly more devastating against a population which has 
recently been irradiated. Alternatively, the lethality resulting from radiation exposure may be significantly 
higher in populations with existing high incidence of infectious disease that may have already compromised 
population health. Usually ineffective portals of infection which are made accessible by partial 
immuno incompetence may cause unusual infection profiles. 

3-27. Immunization and Radiation 

Recent research indicates that previous immunizations may provide some protection by way of circulating 
antibodies against infectious agents in casualties with significant radiological injury. Although leukocyte 
numbers and function decrease following irradiation, circulating antibodies are not appreciably affected by 
ionizing radiation. However, the secondary response of the irradiated immune system to previously 
recognized antigens has not been thoroughly evaluated. Consequently, passive immunization against tetanus 
may be indicated in the presence of tetanus-prone injuries despite a nominally adequate prior immunization 
status. Killed virus vaccines may fail to elicit an adequate immunogenic response because of the loss of 
lymphocytes. As a precaution, live-agent vaccines should be avoided because the use of live-agent vaccines 
after irradiation injury could conceivably result in disseminated infection from the inoculated strain. No 
data are available on this phenomenon, but experience with immunocompromised patients predicts its 
occurrence. Preliminary investigations with nonvirulent agents and radiation injury indicate a significant 
level of infection will occur. Therefore, inoculation with live-virus vaccines should be postponed until after 
complete recovery of the immune system. Killed viral and bacterial vaccines may likewise fail to elicit an 
adequate immunogenic response. Little data are available concerning the effect of ionizing radiation on cell- 
mediated immunity. 



3-32 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

CHAPTER 4 
RADIOACTIVE CONTAMINATION 



4-1. General 

As mentioned in Chapter 2, radioactive material released into the environment can pose both internal and 
external contamination hazards to personnel operating in either nuclear detonation or LLR environments. 
External hazards are generally associated with skin contamination, and include the biological effects of local 
tissue and cutaneous irradiation, and increased probabilities of internal contamination. Internal 
contamination hazards are associated with the exposure of internal organs from radioactive material that 
has been taken into the body via inhalation, ingestion, or absorption through the skin or a wound. 



4-2. Measuring Levels of Contamination 

A number of methods are used to detect contamination and to estimate the extent of contamination. Direct 
methods include measuring skin contamination with hand-held radiation detection, identification, and 
computation (RADIAC) instruments, or internal contamination with specialized instruments placed outside 
the body (in-vivo monitoring). Models of how the radionuclide is metabolized in the body are then used to 
estimate the total amount of radioactivity that was originally inhaled, ingested, or introduced through a 
wound. Indirect methods of assessing internal contamination measure the concentration of a given nuclide in 
the urine or feces (in-vitro monitoring). Metabolic models of systemic excretion are then used to estimate 
the original amount of radioactive material internalized at the time of exposure. These estimates of the 
original intake of radioactive material, in turn, can be used to estimate patient organ doses, total effective 
doses, and aid in determining long-term patient risks of adverse health effects, and guide treatment protocols 
to reduce contamination levels. 

a. Direct External Contamination Assessment. Surface detectors are usually used for skin and 
wound monitoring in the field. The most common form of surface detector is the tube or pancake Geiger- 
Muller probe contained as part of AN/VDR-2, AN/PDR-77, or ADM-300 RADIAC Sets. The use of these 
sets allows operational forces to survey patients for external contamination, determine whether 
decontamination efforts have been effective, or establish when forces have exceeded operational exposure 
guidance (OEG) levels. Specialized small probes may be used for deep wounds and can be cold sterilized 
for this purpose. Contaminated wounds with alpha particles are difficult to detect because blood or body 
issue may block the radiation. Therefore, alpha contamination measurement usually relies on the detection 
of gamma/beta radioactivity of daughter products or other contaminants. 

b. Direct Internal Contamination Measurement. Direct measurement methods use instru- 
mentation external to the body to measure contamination within the body. The advantage of direct 
measurement is that it allows for a "direct" assessment of internal contamination without relying on 
uncertain excretory rates that are necessary to interpret urine and fecal bioassay data. Disadvantages are 
that measurements can only be made for nuclides that emit penetrating radiations (x-rays and gamma rays); 
also, measurements can be influenced by external contamination and background radiation levels. Both 
total- and partial -body counters exist. Partial -body counters are used for chest and thyroid measurements. 
Chest counters detect respiratory tract levels of contaminants such as plutonium and uranium. Whole-body 

4-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



counters can either scan the whole body or "look at" the whole body to give total estimates of internal 
contamination. 

c. Indirect Contamination Measurement. 

(1) Skin and nasal swipes are used to indicate the extent and type of contamination that has 
been internalized. Nasal swipes are taken bilaterally, using moistened, cotton-tipped applicators to swab the 
nares. The swabs are then placed individually in test tubes or envelopes, which are labeled with the 
subject's name and the sample collection time and date. The swipes are sent to a laboratory where 
contamination can be measured, or dried and quick scanned locally. The detection of radioactive material in 
the nares usually indicates respiratory inhalation. However, under some situations inhalation exposures 
may not have an accompanying positive nasal result. 

(2) Bioassay sampling of urine and feces provides indirect measurement of internal 
contamination. Radioactivity and concentration of the nuclide in urine and feces depend on many factors, 
including medical intervention and individual metabolic and clearance rates. Subsequent estimates of the 
amount of radioactive material initially inhaled and ingested are prone to significant variance. 5 However, 
in-vitro monitoring provides the only acceptable assay technique for alpha and pure beta emitting 
radionuclides which cannot be assayed through in-vivo methods. Metabolic models are used to estimate 
internal contamination based on average human metabolic and clearance rates. Bioassay sampling and 
excretion data are the principal methods of determining the presence of alpha and pure beta emitters, which 
are the most hazardous internal contaminants. Initial samples to be used to establish baseline levels of urine 
and fecal radioactivity should be obtained from a patient as soon as practical. Measures should be taken to 
avoid the accidental contamination of these samples. For example, contaminated clothing from the victim 
should be removed and initial skin decontamination steps should be accomplished before sampling, and 
gloves should be worn by all personnel handling capture containers. Bioassay accuracy depends on baseline 
levels, multiple postexposure samples, and knowledge of the precise time of contamination and type of 
contaminant(s). Table 4-1 shows general guidelines for bioassay sampling. A detailed discussion of 
radiation measurement techniques including bioassay sampling can be found in Chapter 4 of NCRP Report 
No. 65, Management of Persons Accidentally Contaminated With Radionuclides. 

Table 4-1 . Guidelines for Bioassay Sampling 



OPTIMUM SAMPLE TIME AFTER EXPOSURE 



MATERIAL 


FECES 


URINE 


QUANTITY 


Plutonium 

Uranium 

Tritium 


24 hours 
24 hours 
N/A 


2-3 weeks 
24 hours 
12 hours 


24 hour total 
24 hour total 
1 voiding 



5. National Council on Radiation Protection (NCRP) and Measurements Report No. 65, 1979. 



4-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Section I. EXTERNAL CONTAMINATION, IRRADIATION, 
AND ACUTE LOCAL RADIATION INJURY 



4-3. External Irradiation 

The most serious injuries resulting from radiation accidents have been due to penetrating radiation from 
external sources. 6 External contamination by radionuclides can occur when an individual or unit traverses a 
contaminated area without appropriate protection, or remains in a hazardous downwind area when fallout 
occurs. If the individual is wounded while in the contaminated area, he may become internally contaminated. 
The radioactive contamination hazard of injured personnel to both the patient and attending medical personnel 
will be negligible, so necessary medical or surgical treatment must not be delayed because of possible 
contamination. 

a. Medical personnel minimize the risk of exposure by following decontamination principles 
similar to those for BW and CW agents. If circumstances allow, medical personnel should don protective 
clothing before coming into contact with contamination. Protective clothing consists of gloves, overshoes, 
and a plastic apron. Surgical gowns are acceptable. Contain irrigation fluid in holding tanks and bag 
contaminated clothing and medical supplies and give them to radiation safety personnel. US medical 
personnel are subject to the same OEG as other military personnel. It should be noted that the highest actual 
dose recorded for a US health care worker was only 0.014 cGy, which occurred during the care of a 
radiation accident victim of a commercial nuclear power plant accident. That dose approximates the dose 
received during a single chest radiograph. 

b. Use beta-gamma and alpha monitoring instruments for the initial radiation survey of the skin 
and clothing. If contamination is present on the clothing, remove it and repeat the monitoring over the 
patient's skin. Contaminants may be held to the surface of the skin by electrostatic forces, surface tension, 
or binding with skin proteins. Skin penetration is relative to the type of radiation. Alpha particles from 
radionuclides on the skin surface do not reach the basal cell layer of the epidermis. Beta particles are 
reduced by a factor of two for every 1 mm of skin. Skin on most areas of the body has a depth of 2 mm. The 
epidermis is approximately 0.1 mm in depth, except over areas of external friction. Those areas include the 
palms, digits, and soles of the feet where the thickness of the stratum corneum can reach 1.4 mm. Medical 
military physicists use the estimate of skin radiation dose at the basal epithelium, since that is the area that 
lies adjacent to the small blood vessels of the dermis, and is the area that can be affected by beta and gamma 
radiation. Gamma-radiation emitters may cause whole-body irradiation, while beta emitters left on the skin 
may cause significant burns and scarring. However, it is highly improbable for a patient to be so 
contaminated that he is a radiation hazard to health care providers. 

4-4. Decontamination 

Decontamination is usually performed during the care of such patients by emergency service personnel and 
ideally, prior to the arrival at medical facilities. As this will not always be possible, decontamination 



6. Ibid. 



4-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



procedures should be part of the operational plans and procedures of all divisions and departments. This 
ensures flexibility of response and action and will prevent delay in needed medical treatment. The simple 
removal of outer clothing and shoes will, in most instances, effect a 95% (military) and 90% (civilian) 
reduction in the patient's contamination. The presence of radiological contamination can be readily 
confirmed by slowly passing a radiation detector (RADIAC) over the entire body. Open wounds should be 
covered prior to decontamination of surrounding skin. Contaminated clothing should be carefully removed, 
placed in marked plastic bags, and removed to a secure location within a contaminated area. Bare skin and 
hair should be thoroughly washed, and if practical, the effluent should be sequestered and disposed of 
appropriately. See FM 8-10-7, Health Service Support in a Nuclear, Biological, and Chemical Environment 
for a detailed discussion on patient decontamination. 

a. Skin Decontamination. Skin decontamination should be undertaken to decrease the risk of 
acute dermal injury, to lower the risk of internal contamination of the patient, and to reduce the potential of 
contaminating medical personnel and the environment. After the patient's clothing is removed, washing the 
patient with soap and water is 95 percent effective because soap emulsifies and dissolves contamination. 
Gentle brushing or the use of an abrasive soap or abrasive granules dislodges some contamination physically 
held by skin protein, or removes a portion of the horny layer of the skin. Addition of a chelating agent helps 
by binding the contaminant in a complex as it is freed from the skin. The stratum corneum of the epithelium 
is replaced every 12 to 15 days, thus, contamination that is not removed and is not absorbed by the body will 
be sloughed within a few days. 

b. Decontamination Techniques. Avoid unnecessary damage to the skin; cease washing before 
abrasion occurs. If washing will not remove stubborn hand and distal extremity skin contamination, wrap 
the contaminated area and, over time, sweating will decrease contamination. To decontaminate hair, use 
any commercial shampoo without conditioner. Conditioners bind material to hair protein, making 
contamination removal more difficult. Consider clipping hair to remove contaminants. Do not remove 
eyebrows without significant cause since they grow back slowly if at all. For skin and wound decon- 
tamination, use a cleaning solution. Suggested solutions are- 
Soap and water or normal saline. 
Betadine and water. 
Phisoderm and water. 
Hydrogen peroxide. 

Dakin solution (0.25 percent sodium hypochlorite). 
0.05% chlorine solution (household bleach diluted with water at a ratio of 100 to 1). 

4-5. Local Tissue Irradiation 

Local irradiation of tissues occurs when highly radioactive material, such as an industrial radiography 
source, is placed in proximity to tissue. As radiation intensity increases because of increasing proximity to 

4-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



the source, the tissue immediately adjacent to the source receives a tremendous dose. The total body dosage 
may be only 200 cGy, but the local skin dose can easily be in the thousands of cGy (see Table 4-2). 

Table 4-2. Local Tissue Damage 



DOSAGE (CGY) 


SYMPTOM 


TIME POST-EXPOSURE 


>300 


Epilation 


2-3 weeks 


-600 


Erythema 


Minutes to weeks 


>600 


Edema 


Minutes to weeks 


1 000-2000 


Blistering 


2-3 weeks 


-3000 


Ulceration 


1-2 months 


5000-6000 


Gangrene, necrosis, deep ulceration 


Weeks 



a. Initial skin changes will be similar to those of Cutaneous Radiation Syndrome (CRS) (see 
paragraph 4-6), but with penetrating gamma radiation, damage will be seen in the deeper tissues over time. 
Development of deep-base ulcers with marked erythema at the margins is common. Granulation tissue 
develops and months can be required for healing. 

b. Deep tissues respond in a similar fashion if the radioactive source is placed in their immediate 
proximity. Radiotherapy literature is the best source of information concerning injury to specific tissues and 
anatomic structures. 



4-6. Cutaneous Radiation Syndrome 

Acute skin injury occurs with radiation doses ranging from several hundred to 2000+ cGy. Delayed, irre- 
versible changes of the skin usually do not develop as a result of sublethal whole body irradiation, but instead 
follow higher doses limited to the skin. These changes are a common complication in radiation therapy, but 
they should be uncommon in nuclear warfare. They could occur with an RDD if there is heavy contamination 
of bare skin with beta emitter materials, or due to mishandling of an industrial radiography source. 

a. Cutaneous Radiation Effects. Effects follow a distinct clinical pattern that defines the CRS. 
The different steps of development, including the symptoms, are summarized in Table 4-3. Within minutes 
to hours after exposure an erythematous reaction develops that may be associated with a burning urticaria. 
This transient prodromal phase usually lasts less than 36 hours. It is followed by a clinically inapparent 
latent phase. The manifest phase is characterized by occurrence of an intensively erythematous skin, which 
may show scaling and desquamation. In more severe conditions, subepidermal blisters and even ulcerations 
may develop. Though similar skin lesions are produced by thermal injury, the time course and underlying 
processes involved in the development of the CRS are so different from thermal burns that the term radiation 
burns or beta-burns are considered inappropriate and misleading for this clinical condition and should 
therefore be abandoned. 



4-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table 4-3. Clinical Stages of the Cutaneous Radiation Syndrome 



STAGE 


DEFINITION 


SYMPTOMS 


OCCURRENCE 
(POSTEXPOSURE TIME) 


DURATION 


SYNONYMS 


1 


Prodromal 


Erythema itch 


Minutes to hours 


4 to 36 hours 


Early erythema 


2a 


Manifest 


Erythema 


Days to 2 weeks 


2 to 1 2 weeks 


Main erythema 


2b 


Manifest 


Blisters; Dry/moist 

desquamation 

Burn 


Days to 2 weeks 


2 to 1 2 weeks 


Main erythema 


2c 


Manifest 


Ulcers 


Days to 2 weeks 


2 to 1 2 weeks 


Main erythema 


3 


Subacute 


Erythema; Ulceration 


6 to 9 weeks 


2 to 4 months 


Late erythema 


4 


Chronic Fibrosis 


Keratosis; Ulceration 
Telangiectatic 


Indefinite to 2 years 


Progressive 




5 


Late 


Neoplasia; Ulceration 
Angiomas 


Years to decades 


Indefinite 





b. Chronic Cutaneous Radiation Syndrome. In the chronic stage of the CRS, three clinical 
manifestations dominate the course: 

• Radiation keratoses can develop in any exposed area. These lesions must be considered 
precancerous and should be monitored thoroughly. Single lesions may be excised. 

• Radiation fibrosis is caused by an increase of collagenous tissue from dermal and 
subcutaneous fibroblasts and may lead to pseudoatrophy of fatty tissue. Fibrosis may lead to vasculature 
occlusion and cause secondary ulceration. 

• Telangiectasis are a characteristic sign of the chronic stage of the CRS in humans. Apart 
from cosmetic disfiguring, they may cause a permanent itching sensation and a disturbing feeling of warmth. 

4-7. Treatment of the Cutaneous Radiation Syndrome 

Standardization of treatment is difficult to achieve due to the rarity of this syndrome. An established 
treatment scheme does not exist. Differing procedures in documentation of accidents further reduce the 
comparability of therapeutic efforts in differing accident situations. Whatever the circumstance, treatment 
must provide symptomatic relief and minimization of additional risk to the patient. Recommended therapies, 
dosages, and the therapeutic outcome are summarized in Table 4-4. 

a. Experience in the management of the manifest stage of CRS is limited to radiotherapy patients. 
In these conditions, an erythematous and erosive condition occasionally occurs, that is often associated with 



4-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



a burning itch. Treatment with Loratadine, a non-sedating and mast-cell-stabilizing antihistamine, induced 
a marked relief of these symptoms and a shortening of the erythematous phase. Topical steroids generally 
have been used with success. Additional treatment modalities that have been reported to be of value in the 
manifest stage are cleansing of the oral cavity and administration of pilocarpine for prevention of mucositis. 
Heparinization and antibiotic prophylaxis for bacterial and viral infections may be beneficial. 



Table 4-4. Symptom-Oriented Therapy for the Cutaneous Radiation Syndrome 



SYMPTOM 


TREATMENT 


APPLICATION 


DOSAGE 


RESULT 


SIDE EFFECTS 


Pruritus 


Antihistamines 


Oral 


As appropriate 


Relief of itch 


Sedation 


Erythema 


Steroids 


Topical 


2 X daily 


Alleviation 


None when used less 
than 3 weeks 


Blisters 


Steroids TCDO 


Wet dressing 


3 X daily 


Alleviation 




Dryness 


Linoleic acid cream 


Topical 


1 X daily 


Inhibition of 
water loss 




Keratoses 


Tretinoin 


Topical 


1 X daily 


Clearance 


Irritation; 




Acitretin 


Oral 


0.1-0.3 mg/kg 


moderate 


dryness of lips 


Inflammation 


Mometasone 


Topical 


3-4 X week 


Alleviation 




Fibrosis 


IFN gamma 


Subcutaneous 


50 mg 3 X week 


Reduction 


Fever 




PTX and 


Oral 


400 mg 3 X daily 


Reduction 






Vitamin E 




+ 300 mg 1 X daily 







b. Treatment modalities for the chronic stage of the CRS were developed from Chernobyl 
sequelae and from therapeutic irradiation patients. Chernobyl patients responded well to a basic therapy 
with a linoleic acid ointment that blocked transepidermal water loss. Symptomatic telangiectasias 
disappeared after treatment by an Argon laser. Tretinoin cream 0.005 percent applied once daily, led to 
clearance of focal and patchy radiation keratoses, however, the cream appeared to cause more irritation 
than is common in patients with actinic keratoses. Intermittent anti-inflammatory treatment with topical 
nonatrophogenic steroids (Mometasone Buroate) was necessary. In more extensive lesions, oral application 
of the retinoid Acitretin (0.1-0.2 mg/kg daily) was used, analogous to the reported treatment of radiation- 
induced keratoacanthomas. 

c. Subcutaneous administration of Interferon (IFN) has been beneficial to patients with severe 
and extensive radiation fibrosis (IFN gamma, 50 mg subcutaneously three times per week for 18 months). 
Using a protocol for scleroderma patients, fibrosis may be reduced almost to the level of uninvolved 
contralateral skin. Side effects included low-grade fever to 38.5 °C after the first two injections. The 



4-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



efficacy of IFN gamma may be explained in part by its antagonistic effect towards the cytokine TGF-beta, 
which is of importance for the induction of radiation fibrosis. Another therapeutic option for radiation 
fibrosis is the combined administration of PTX (400 mg three times daily) and vitamin E (400 mg once 
daily). This regimen, applied for a minimum of 6 months, ameliorated persistent radiation fibrosis that had 
been progressive for over 20 years. Topical dressings of TCDO induce considerable granulation and re- 
epithelization in erosive skin conditions. Radioprotective properties of TCDO have been reported in 
experimental models that also demonstrated regenerative capacities in complicated wounds. 

d. Appropriate surgical procedures include excision of ulcers and contractures, wound closure by 
split and full thickness skin grafts, and in certain instances, vascularized flaps. Grafts usually heal without 
complications, including situations where the surrounding tissue may be affected by late radiation effects. 
The surgical experience, derived from patients with skin fibrosis after deeply penetrating radiation therapy, 
was that skin grafts do not heal if the surrounding affected tissue is not completely removed. 

Section II. INTERNAL CONTAMINATION AND IRRADIATION 



4-8. General 

Internal irradiation occurs when unprotected personnel ingest or inhale radioactive contaminants, or have 
contaminants become internalized via a traumatic wound. Large intakes of some radioactive contaminants 
pose significant health risks. These risks are largely long-term in nature and depend not only on the type and 
concentration of the radioactive contaminant absorbed, but also on the health background of the exposed 
individual. Potential cancers of the lung, liver, thyroid, stomach, and bone among others are the principal 
long-term health concerns (see Chapter 5). Contamination evaluation and therapy must never take 
precedence over treatment of conventional acute injuries. However, early recognition of internal 
contamination provides the greatest opportunity for removal of the contaminant, thus reducing the potential 
for further injury. See National Council on Radiation Protection and Measurements (NCRP) Report No. 
65, Management of Persons Accidentally Contaminated With Radionuclides, for further detailed information 
on internal irradiation. 



4-9. Internalization of Radioactive Materials 

The severity of internal contamination is dependent on the same processes that determine clinical severity 
related to exposure to nonradioactive toxins. Severity is dependent on the route of exposure, chemical and 
physical form of the nuclide, total intake of the radionuclide(s), and its distribution and metabolism within 
the body. 

a. Intake. In order of decreasing frequency, contaminants enter the body principally by the 
following four routes: 

• Inhalation. 
4-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



• Ingestion. 

• Wound contamination. 

• Skin absorption. 

(1) Inhalation. Inhalation is the primary intake route for radioactive contamination. 
Absorption is dependent on the particle size of the contaminant and on its solubility in the lung. The 
contaminant's particle size determines its deposition within the respiratory tract. For example, particles 
smaller than 5 microns will reach the alveolar area. Those smaller than 1 micron will be naturally respired 
as the individual breathes out and those between 1 and 5 microns will be deposited in the alveoli. Ninety 
percent of the particles greater than 5 microns never reach the alveoli. For those particles deposited in any 
area of the respiratory tract, their absorption depends on the chemical solubility of the contaminant. Soluble 
particles will be absorbed directly into the circulatory system through either the blood stream or the 
lymphatic system and will ultimately be distributed throughout the body. The rate of absorption will probably 
be quicker via the alveoli than via the upper respiratory tract due to the enhanced blood supply in the alveolar 
beds. Insoluble particles will remain within the respiratory tract. Those insoluble particles within the upper 
respiratory tract will be cleared by the mucociliary apparatus but until they are cleared, they will continue to 
irradiate the surrounding tissues which can lead to fibrosis and scarring in the respiratory tract. In addition, 
most of the secretions from the upper respiratory tract will reach the pharynx and be swallowed and result 
in internal exposure through the GI tract (see Table 4-5). 



Table 4-5. Clearance Times of Various Branches of the Human Respiratory Tract 

for Insoluble Particulates 



STRUCTURE 


CLEARANCE TIME (HOURS) 


CUMULATIVE TIME (HOURS) 


Trachea 


0.1 


0.1 


Bronchi 


1.0 


1.1 


Bronchioles 


4.0 


5.1 


Terminal Bronchioles 


10.0 


15.1 


Alveoli 


100+ days 


100+ days 



(2) Ingestion. Radioactive material can enter the GI tract through eating contaminated 
foodstuffs, transferring contamination from hands to mouth, or by swallowing contaminated mucous 
transported to the pharynx from contamination in the lung. Absorption of the radionuclide through the crypts 
of the small intestine is dependent again on the contaminant's physical and chemical characteristics. 
However, most ingested heavy metal radionuclides will pass through the gastrointestinal tract without being 
absorbed into the systemic circulation. For example, only 20 percent of radium that is ingested is absorbed, 
only 30 percent of strontium that is ingested is absorbed, but 100 percent of tritium, iodine, and cesium that 



4-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



are ingested is absorbed. It is the large intestine that receives the greatest radiation exposure due to the 
slower transit time for ingested materials. Clearance times of the human GI tract are shown in Table 4-6. 



Table 4-6. Clearance Times of the Human Gastrointestinal Tract 



ORGAN 


MEAN EMPTYING TIME 
(HOURS) 


AVERAGE OCCUPANCY TIME 
(HOURS PER DAY) 


Stomach 
Small Intestine 
Upper Large Intestine 
Lower Large Intestine 


1 

4 

13-20 

24 


6 

14 
18 
22 



(3) Wound contamination. Wounds are classified as abrasions, lacerations, or punctures. 
The differing characteristics of each type of wound affect the absorption and decontamination of radioactive 
substances. Abrasions present a large surface area denuded of intact skin that decreases the skin barrier 
and increases the potential for absorption. Generally, they are easy to decontaminate due to easily accessible 
contaminants. Lacerations also are easy to decontaminate because the contaminated tissue can be excised. 
Puncture wounds, however, are difficult to decontaminate because of poor access to the contaminants and 
because of difficulty in determining the depth of the wound as well as the depth of contamination. Solubility, 
acidity /alkalinity, tissue reactivity, and particle size affect the absorption of a contaminant within a wound. 
For example, the more soluble the contaminant, the greater the absorption rate. In addition, comparatively 
smaller particles may be phagocytized in the tissues more rapidly and thus internalized more rapidly. 

(4) Skin absorption. The skin acts as a physical barrier with the horny epithelial layer acting 
as the primary barrier. Percutaneous absorption occurs by passive diffusion, and is not a major concern 
except with tritium. Skin that has been mechanically damaged, as from repeated abrasive scrubbing, allows 
for greater absorption. Skin that has been exposed to certain chemicals like dimethyl sulfoxide is also more 
permeable. Absorption through sweat glands and hair follicles is a minor concern since, overall, they 
constitute only a small surface area. 

b. Distribution. Once a radionuclide is absorbed, it is distributed throughout the body via the 
circulatory and lymphatic systems. The rate of distribution to each organ is relative to the lymphatic or 
blood flow through that organ and the metabolic rate of the organ. Deposition is related to the ease of 
transport of the radionuclide or its metabolites across cell barriers in a given organ, and the metabolic 
processes of the tissue that may involve an affinity for a given radionuclide or nuclide metabolites. 

c. Metabolism and Excretion. After uptake into a particular organ, a radionuclide will be 
metabolized according to its chemical properties and will be excreted either in its original state or as a 
metabolite. The biologic half-life of a radionuclide, determined by its rate of metabolism and excretion, is 
as important as its radiological half-life in determining the significance of the exposure to a specific tissue. 



4-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Most ingested heavy metal nuclides (depending upon the oxide state) will pass through the gastrointestinal 
tract unchanged. The primary routes of excretion for absorbed radionuclides are through the urinary tract 
via the kidneys, the GI tract via the liver and common bile duct, and the lungs. Minor routes of excretion 
include sweat, saliva, milk, and seminal fluid. In general, compounds that are water soluble are excreted 
through the urine, while lipid-soluble compounds are excreted via the bile into the intestine. 

4-10. Internal Contamination Treatment 

a. Immediate Care. As discussed earlier, skin or wound contamination is almost never 
immediately life threatening to the patient or to medical personnel. Therefore, attending to conventional 
trauma injuries is the first priority. As soon as the patient's condition permits, steps should be taken to 
determine if internal contamination has occurred. Nasal swab samples for radioactivity should be obtained 
as early as possible. However, under some situations inhalation exposures may not have an accompanying 
positive nasal result. If contamination is present, especially in both nostrils, it is presumptive evidence that 
inhalation of a contaminant has occurred. A urine sample and feces sample should also be collected to help 
determine whether internal contamination has occurred. 7 Advice on collection procedures are discussed in 
detail in the NCRP Report No. 65, and may also be provided by a medical military physicist. 

b. Treatment Procedures. Treatment of persons with internal contamination focuses on reducing 
the radiation dose from absorbed radionuclides and hence the risk of long-term biological effects. Two 
general processes are used to achieve this goal: reducing the absorption of radionuclides and their deposition 
in target organs and increasing excretion of the radionuclides from the body. A number of procedures are 
available for respiratory contamination and GI contamination. As with any medical treatment, the clinician 
should consider the risks and benefits to the patient. The benefit of removing the radioactive contaminant 
using modalities associated with significant side effects and morbidity must be weighed against the short- 
and long-term effects of contamination without treatment. The radioactivity and the toxicity of the 
internalized radionuclide must also be considered. Risk estimates include professional judgment combined 
with the statistical probability of radiation-induced diseases occurring within a patient's lifetime. Some of 
the immediate simple treatment procedures include: 8 

(1) Oral and nasopharyngeal irrigation. 

(2) Stomach lavage until stomach washings are relatively free of radioactive material. 

(3) Emetics to induce vomiting. Emetics are most effective when taken with 200-300 ml of 
water. However, they are contraindicated if the state of consciousness is impaired, such as in the states of 
shock or inebriation, or after ingestion of corrosive agents or petroleum hydrocarbons. 

(4) Purgatives or laxatives to enhance intestinal motility. 

(5) Enemas or colonic irrigations to reduce the time radioactive materials remain in the colon. 



7. Ibid. 

8. Ibid. 



4-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



c. Therapeutic Agents. The most important considerations in treatment are the selection of the 
proper drug for a particular radionuclide, and the timely administration of the drug after the exposure. 
Some of the treatment agents which could be used are presented below, with specifics for each agent shown 
in a detailed listing in Appendix B, and in NCRP Report No. 65. 

(1) Prussian blue. The US Food and Drug Administration has removed earlier restrictions 
on the use of Prussian Blue (ferric ferrocyanide) in the US. It has been approved as an investigational new 
drug, and the Radiation Emergency Assistance Center/Training Site (REAC/TS) has the license for research 
use. Prussian blue is indicated for treatment of cesium, thallium, and rubidium contamination. This 
chemical is not absorbed by the GI tract and it works through two modes of action. It decreases the 
absorption of many radionuclides into the GI tract, and removes some radionuclides from the capillary bed 
surrounding the intestine and prevents their reabsorption. Prussian Blue is most effective when given early 
after ingestion and serially thereafter. 

(2) Blocking and diluting agents. Blocking and diluting agents work by preventing the uptake 
of a radionuclide in a target organ or by overwhelming the organ with stable compounds that reduce the 
uptake and incorporation of the radionuclide into that target organ. Potassium iodide is an excellent example 
of a blocking agent, and must be given before or within 6 hours of exposure to radio iodine (see Table 4-7). 



Table 4-7. Recommended Prophylactic Single Doses of Stable Iodine 



AGE GROUP 


MASS OF TOTAL 
IODINE 


MASS OF Kl 


MASS OF KIO 3 


VOLUME OF LUGOLS 
SOLUTION 


Adults/adolescents 


100mg 


130mg 


170mg 


0.8 ml 


(over 12 yrs) 










Children (3-12 yrs) 


50 mg 


65 mg 


85 mg 


0.4 ml 


Infants (1 mo-3 yrs) 


25 mg 


32.5 


42.5 


0.2 ml 


Neonates (birth— 1 mo) 


12.5mg 


16mg 


21 mg 


0.1 ml 



(3) Mobilizing agents. Mobilizing agents are compounds that increase the excretion of 
internal contaminants. Examples of mobilizing agents are the antithyroid medications— (propylthiouracil, 
methimazole, and potassium thiocyanate), ammonium chloride, and diuretics. 

(4) Chelating agents. Chelators are a specific type of mobilizing agent that enhances the 
elimination of metals from the bloodstream before they reach target organs. For example, chelation is 
ineffective at removing plutonium already deposited in the bone. Chelators are organic compounds (ligands) 
that exchange less firmly bonded ions for metal ions. This stable complex, the chelator and the metal, is then 
excreted by the kidney. Chelation therapy has been used for enhanced elimination of lead, mercury, 
arsenic, and other heavy metals. In addition, chelation therapy has been used to treat internal radiation 
contamination on a limited basis. When used to treat internal radiation contamination, radioactivity levels 



4-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



from samples of urine and feces must be followed as well as radioactivity levels based on total body and 
chest counts. Continuation of therapy is determined by assessing chelation yield in urine and feces with 
remaining body burden. No serious toxicity in humans has been reported when chelators are used in 
recommended doses. Examples of chelators include meso-2,3-dimercaptosuccinic acid (DMSA), 2,3- 
dimercapto-1-propanesulfonic acid (DMPS), calcium diethylenetriaminepentaacetic acid (CaDTPA), and 
DTP A. 



4-13 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

CHAPTER 5 
LOW-LEVEL RADIATION 



5-1. Low-Level Radiation Characteristics and Hazards 

a. For purposes of this manual, LLR patients are those who have received doses of 75 cGy or 
less. Low-level radiation may be present in dispersed radioactive material in solid, liquid, gaseous, or 
vapor form, or in the form of discrete point sources. All of the types of radiation described in Chapter 2 
(alpha, beta, neutron, and gamma) may be emitted by the material present in LLR sources. Sources of LLR 
were discussed in detail in Chapter 1 , and are generally radioactive material from nuclear facilities (power 
plants), industrial and medical commodities, RDDs, nuclear weapons incidents, and military commodities. 

b. The current threat to US Forces involve primarily terrorist actions with improvised nuclear 
devices or RDDs, and hazards due to nuclear incidents. In contrast to the risks associated with nonstrategic 
or strategic nuclear war, the risk of exposure to low-level radiation is more limited geographically, involves 
a limited number of individuals, requires more documentation of exposure history and treatment, and the 
immediate health risks to exposed personnel are generally much lower. Except in rare circumstances, the 
radiation doses received if these hazards are encountered would likely be well below those that would cause 
observable deterministic health effects, with only minor changes in blood CBCs expected at the highest 
doses in this range. However, they could be above the US and host nation occupational dose limits that are 
applied to civilian workers and military personnel assigned to routine duties involving radiation exposure. 
Because of this, doctrine development goes beyond helping military personnel to survive acute radiation 
injuries. It now includes medical care and follow-up for delayed health effects from low-level radiation 
exposures (primarily the development of radiation induced cancer). This chapter will cover low-level 
radiation exposure guidance, delayed/late health effects, prevention, medical care for exposed personnel, 
long-term medical follow-up, and documentation of medical records. Further, these medical considerations 
will likely be a part of the commander's operational plan. 

Section I. LOW-LEVEL RADIATION EXPOSURE 

5-2. Exposure Guidance 

a. In peacetime while not deployed, radiation exposures of service members whose normal 
operational duties include, for example, handling of military radioactive commodities, are governed by 
Department of Defense Instruction (DODI) 6055.8, Occupational Radiation Protection Program, federal 
regulations governing radiation protection, and service specific instructions and regulations. These 
limitations are comparable to civilian worker protection regulations that govern radiation protection 
"practices." However, they do not specifically address nonoccupational exposures for military operations, 
such as a maneuver unit moving into a radiologically hazardous area. Radiation exposure control measures 
in these situations must balance the requirement to adequately protect individual service members with 
mission execution. The fundamental radiation protection principle of ALARA (as low as reasonably 
achievable) still applies. 

b. The occupational annual dose limit is 5 cGy, while 75 cGy is the threshold for the development 
of acute health affects that become a concern in nuclear war. The most current exposure guidance between 

5-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



these two limits is found in Table 5-1 which is from NATO STANAG 2473, Commanders Guide on Low- 
Level Radiation (LLR) Exposure in Military Operations. The exposure guidance applies to missions with 
durations ranging from minutes to one year. The risks associated with radiation exposure within this range 
of 5 to 75 cGy are confined primarily to the risk of increased incidence of malignant diseases, including solid 
tumors and leukemias (see Section II, Delayed/Late Health Effects). Added to this table, are medical notes 
for each RES and the stochastic risk of long-term health effects as adapted from AMedP-6(C), NATO 
Handbook on Medical Aspects of NBC Operations, Ratification Draft. Military operations may require that 
national peacetime regulations governing exposure be exceeded, as when performing humanitarian, 
lifesaving, and/or emergency operations. All exposure to radiation must be justified by necessity and 
subjected to controls that maintain doses within the concept of ALARA. Refer to STANAG 2473, Annexes 
C and D for exposure limits while operating in contaminated areas. 



Table 5-1. Low-Level Radiation Guidance for Military Operations 



TOTAL CUMULATIVE 

DOSE (SEE 

NOTES 1 AND 2) 


RADIATION 

EXPOSURE STATE 

CATEGORY 


RECOMMENDED 
ACTIONS 


STOCHASTIC 
RISK 


MEDICAL 
NOTES 


0-0.05 cGy 





-None 


Normal Risk: < 0.004% 


US baseline 20% 
lifetime risk of fatal 
cancer. 


0.05-0.5 cGy 


1A 


-Record individual dose readings. 
-Initiate periodic monitoring 
(including air and water). 


Up to 0.04% increased 
risk of lifetime fatal 
cancer. 


None 


0.5-5 cGy 


1B 


-Record individual dose readings. 
-Continue monitoring. 
-Initiate rad survey. 
-Prioritize tasks. 

-Establish dose control measures 
as part of operations. 


0.04%-0.4% increased 
risk of lifetime cancer. 


Reassurance 


5-10 cGy 


1C 


-Record individual dose readings. 
-Continue monitoring. 
-Update survey. 

-Continue dose control measures. 
-Execute priority tasks only 
(see note 3). 


0.4%-0.8% increased 
risk of lifetime fatal 
cancer. 


Counsel regarding 
increased long- 
term risk; no live 
virus vaccines 
for 3 months. 


10-25 cGy 


1D 


-Record individual dose readings. 
-Continue monitoring. 
-Update survey. 

-Continue dose control measures. 
-Execute critical tasks only 
(see note 4). 


0.8%-2% increased 
risk of lifetime fatal 
cancer. 


Potential for 
increased 
morbidity of other 
injuries or 
incidental disease. 



5-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table 5-1. Low-Level Radiation Guidance for Military Operations {Continued) 



TOTAL CUMULATIVE 


RADIATION 


RECOMMENDED 


STOCHASTIC 


MEDICAL 


DOSE (SEE 


EXPOSURE STATE 


ACTIONS 


RISK 


NOTES 


NOTES 1 AND 2) 


CATEGORY 








25-75 cGy 


1E 


-Record individual dose readings. 


2%-6% increased 


Increased 






-Continue monitoring. 


risk of lifetime fatal 


morbidity of other 






-Update survey. 


cancer. 


injuries or 






-Continue dose control measures. 




incidental 






-Execute critical tasks only 




disease. 






(see note 4). 







NOTES: 



The use of the measurement multiple of Sv is preferred in all cases However, due to the fact that normally the military has only 

the capability to measure cGy, as long as the ability to measure in mSv is not possible, NATO forces will use cGy. For whole 

body irradiation, 1 cGy = 1 cSv. 

All doses should be kept ALARA. This will reduce individual soldier risk as well as retain maximum operational flexibility for 

future employment of exposed soldiers. 

Examples of priority tasks are those missions to avert danger to persons or to prevent damage from spreading. 

Examples of critical tasks are those missions required to save lives. 



Section II. DELAYED/LATE HEALTH EFFECTS 



5-3. 



General 



Delayed health effects may appear months to years after irradiation and include a wide variety of effects 
involving almost all tissues or organs. Some of the possible delayed consequences of radiation injury are 
carcinogenesis, cataract formation, chronic radiodermatitis, and decreased fertility. However, it should be 
emphasized that many victims of exposure to radiation do not manifest late term effects. The Hiroshima, 
Nagasaki, and Russian experiences have not shown any genetic effects in humans. At the lower levels of 
exposure (background levels to 75 cGy), the risk of effects such as cancer and genetic effects tends to be 
stochastic in nature, relating more to a stochastic response in exposed populations than to exposed individuals. 
Health risks incurred tend to be long-term in nature, and not immediate, therefore lacking significant 
operational impact. These risks may, however, manifest themselves as a significant disease long after the 
completion of the military operation. 

5-4. Principles 

In relation to associated long-term health risks, several principles need to be reviewed. For purposes of 
radiation protection, it is assumed that the risk of stochastic health effects is proportional to the dose 



5-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



received. In addition, biological factors relative to the irradiated individual should be considered; for 
example, age and sex of the individual, health status, and the individual's genetic makeup. In addition to the 
total dose factor, radiological parameters that factor into long-term health risks include— 

• Exposure rate and quality of the radiation. 

• Location of the source (external versus internal). 



• 



Nature of exposure (continuous versus fractionated versus protracted; prompt external 



exposure versus chronic dosing). 



• Time after exposure and requisite repair times and latency times required for pathologies to 
manifest. 



5-5. Types of Long-Term Effects 

a. Deterministic effects are those that require a certain threshold dose to be exceeded before the 
effect is observed, and for which the severity of the effect is proportional to dose. They include both acute 
and delayed effects. While individual variations will occur due to individual sensitivity, the severity of the 
effect is still directly dose related. Tissue fibrosis, chronic immune system suppression, reproductive tissue 
dysfunction, and selected ocular problems are some of the more common and serious symptoms of the late- 
arising deterministic pathologies. Formation of ocular cataracts is the most common delayed radiation 
injury. Higher doses tend to increase the degree of opacity and shorten the period of latency. Immune 
system defects occur at doses of 50 cGy and larger. 

b. A stochastic effect is a consequence based on statistical probability. For radiation, tumor 
induction is the most important long-term sequelae for a dose of less than 100 cGy . Most of the data utilized 
to construct risk estimates are taken from radiation doses greater than 100 cGy, and then extrapolated down 
for low-dose probability estimates. There is no substantive epidemiological data that demonstrates stochastic 
health effects for whole body doses less than 10 cGy. Subsequently, there is considerable scientific debate 
on the actual dose-response relationship for low-level exposures. 



5-6. Embryonic and Fetal Effects 

Radiation-induced embryonic/fetal effects have been clearly documented by the increased mental retardation 
in Japanese children irradiated in utero as result of the nuclear bomb detonations over Hiroshima and 
Nagasaki. The direct military relevance of these fetal effects (as well as related ones, including 
microcephaly, microphthalmia, reduced growth, skeletal defects, neoplasias, and cataracts) is questionable. 
Further, the embryonic responses appear to have a broad exposure threshold for induction, with significant 
responses being noted only at doses greater than 15 cGy. The current normal incidence rate of occurrence 
of congenital abnormalities is 3 to 5 percent of live births. No increase in this rate has ever been observed 
among radiation exposed humans. 

5-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



5-7. Reproductive Cell Kinetics and Sterility 

a. Despite the high degree of radiosensitivity of some stages of germ cell development, the testes 
and ovaries are only transiently affected by single sublethal doses of whole body irradiation and generally go on to 
recover normal function. Temporary male sterility due to damage to spermatogonia will occur after 15 cGy of 
local or whole body irradiation. As this is a maturation depletion process, the azoospermia will not occur until two 
months after irradiation. Protracted radiation exposure will cause a more prolonged episode of azoospermia. 
Serum levels of testosterone will be unaffected. Female reproductive tissues appear more resistant. 

b. When chromosome aberrations are produced in somatic cells, the injury is restricted to the 
specific tissue or cell system. However, when aberrations occur in germ cells, the effects may be reflected 
in subsequent generations. Most frequently, the stem cells of the germ cell line do not develop into mature 
sperm cells or ova, and no abnormalities are transmitted. If the abnormalities are not severe enough to prevent 
fertilization, the developing embryos will not be viable in most instances. Only when the chromosome damage 
is very slight and there is no actual loss of genetic material will the offspring be viable and abnormalities be 
transferable to succeeding generations. These point mutations become important at low radiation dose levels. 
In any population of cells, spontaneous point mutations occur naturally. Radiation increases the rate of these 
mutations and thus increases the abnormal genetic content of future cellular generations. 

5-8. Carcinogenesis 

Irradiation of almost any part of the body increases the probability of cancer. The type formed depends on 
such factors as area irradiated, radiation dose, age, and other demographic factors. Irradiation may either 
increase the absolute incidence of cancer or accelerate the time or onset of cancer appearance, or both. 
There is a latent period between the exposure and the clinical appearance of the cancer. In the case of the 
various radiation-induced cancers seen in man, the latency period may be several years. Latent periods for 
induction of skin cancers in man have ranged from 10 to 50 years after therapeutic x-ray exposures, to a 
reported 15 years for bone tumors after radium exposure. This latency related to bone tumors is very 
dependent upon the dose and type of radiation emitted by the radionuclide. 

a. A leukemogenic effect was expected and found among Hiroshima and Nagasaki survivors. 
The peak incidence occurred 6 years after exposure and was less marked for chronic granulocytic leukemia 
than for acute leukemia. British men receiving radiotherapy for spondylitis showed a dose response 
relationship for leukemia, with peak incidence occurring 5 years after the first exposure. Studies have 
demonstrated that ionizing radiation can induce more than one kind of leukemia in man, but not chronic 
lymphocytic leukemia. 

b. It is difficult to address the radiation-induced cancer risk of an individual patient due to the 
already high background risk of developing cancer over a lifetime. Current National Academy of Sciences 
reports estimate that the lifetime risk of fatal cancer occurrence is increased by 770 cases per 100,000 persons/10 
cGy for males and 810 cases per 100,000 persons/10 cGy for females. To illustrate this effect, the US 
background lifetime fatal cancer incidence rate is 20,000 cases per 100,000 persons. Therefore, if a mixed 
group of 100,000 people receive 10 cGy single dose irradiation, instead of 20,000 cancers, approximately 
20,800 fatal cancers would occur. Deciding which 800 of these 20,800 cases were radiation-induced is 

5-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



impossible. National cancer incidence rates vary as do the corresponding risk estimates, and account should 
be taken of these variables. 

c. The more important radiobiological conditions that factor into cancer induction (or for that 
matter any of the somatic effects) include those parameters previously mentioned, namely dose, dose-rate, 
and radiation quality. Cancer is not a single disease, but a complex of diseases comprised of both cancers of 
the blood (leukemias), and cancers of solid tissues of both epithelial and mesothelial origins. The radiogenic 
nature of these specific cancers differs substantially. Bone tumors (osteosarcomas) serve as a good 
example, as they are prominent late arising pathologies associated with internally deposited, bone-seeking 
radionuclides such as Strontium-90. However, bone tumors are rarely associated with the cancers that stem 
from exposure to external radiation sources such as Cobalt-60. 

d. Cancer types that are unequivocally inducible by ionizing radiation are the lymphohematopoietic 
cancers, cancers of the lung, mammary tissues, liver, thyroid, colon, stomach, pancreas, salivary glands, 
and kidneys. Cancers with either a low incidence or a low probability of induction include cancers of the 
larynx, nasal sinuses, parathyroid, nervous tissue, and connective tissue. Cancers that are probably not 
inducible include the chronic lymphocyte leukemias and cancers of the uterus, cervix, prostate, testis, 
mesentery, and mesothelium. The nominal risks for radiation induced cancers and fatal cancers for the 
general population are given in Table 5-2. The information presented is an International Council on Radiation 
Protection (ICRP) summary of risks as presented in the reference manual for the Oak Ridge Institute for 
Science and Education course on Medical Planning and Care in Radiation Accidents. Note that these values 
should not be used to interpret individual risks, which are dependent on numerous factors such as age, sex, 
heredity and environment. 



Table 5-2. International Council on Radiation Protection Summary of Risks per Milligray 



EFFECT 


RISK PER MILLIGRAY 


Hereditary 


10 x 10- 6 (all generations) 


Cancer 


Fatal Probability 


Leukemia (active marrow) 


5 x 1 0- 6 


Skin 


0.2 x 10" 6 


Breast (females only) 


4x 10" 6 


Stomach 


11 x 1 0- 6 


Sum of fatal cancer risk for whole 


50 x 10" 6 (1 in 20,000) 


body irradiation (males and females) 




Baseline cancer mortality 


0.15(1 in 6.7) to 0.25 (1 in 4) 



5-9. Cataract Formation 

A late effect of eye irradiation is cataract formation. It may begin anywhere from 6 months to several years 
after exposure. While all types of ionizing radiation may induce cataract formation, neutron irradiation is 



5-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



especially effective in its formation, even at relatively low doses. Cataract formation begins at the posterior 
pole of the lens and continues until the entire lens has been affected. Growth of the opacity may stop at any 
point. The rate of growth and the degree of opacity are dependent upon the dose as well as the type of 
radiation. According to BEIR V, Health Effects of Exposure to Low Levels of Ionizing Radiation, cataract 
formation has been observed in atomic bomb survivors from exposures estimated at 60 to 150 cGy. 
However, the threshold in persons treated with x-rays to the eye range from about 200 cGy for a single 
exposure to more than 500 cGy for multiple exposures over a period of weeks. A 50 percent cataract risk 
has been estimated at acute doses of approximately 300 cGy. This estimate assumes a low LET exposure, 
and it has been recently suggested that with high LET particle irradiation, the initiating cataractogenic dose 
might be considerably lower, well within 70 cGy. 



Section III. PREVENTION, INITIAL ACTIONS 
AND MEDICAL CARE AND FOLLOW-UP 



5-10. Prevention 

Military operations may require that regulations governing occupational exposure be exceeded. However, 
all exposure to radiation must be justified by necessity and subjected to controls that maintain doses 
ALARA. There are several measures commanders and units can take to prevent or reduce radiation 
exposure. For example, the commander may establish individual protective clothing measures, such as 
specifying mission-oriented protective posture (MOPP) levels. For a detailed discussion of protective 
measures, see FM 3-4, NBC Protection, which is under revision as a multiservice manual. Medical 
personnel contribute to the prevention effort by providing input into the following staff actions: 

• A risk assessment that includes analysis of intelligence information on the area of operations. 
This analysis should provide information on civil nuclear facilities, industrial radioactive sources, and 
medical radioactive sources present in the area of operations. 

• Development of contingency plans that deal with the most likely risks. These plans should 
identify the potential risks, possible incident scenarios, and medical response actions. The plan should also 
specify dose limits and identify RADIAC equipment available. 

• When the possibility of exposure exists, equip deploying forces with dosimeters and other 
radiation detection devices. Within equipment constraints, equip as many individuals as possible. Priority 
will go to units which have the greatest risk of exposure. Ensure that medical facilities conduct radiation 
detection as part of initial patient medical survey/entry procedures. 

• Establishment of hazard avoidance measures including control and restriction of entry into 
nuclear installations and radioactive areas, ensuring personnel do not tamper with radiological containers, 
and clearance of suspected radioactive waste dumps. 

5-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



5-11. Initial Actions 

If personnel encounter a radiological hazard, initial actions may include evacuation from the area, calling in 
the proper NBC reports, informing the local civil authorities, and requesting specialized monitoring and 
survey teams. At this time, medical personnel will provide input into staff estimates and plans that will 
establish control measures to contain the LLR hazard. This would include advice on modifying the 
commander's OEG and adherence to established guidance. The medical staff must also advise the 
commander on the monitoring and dose recording of those individuals, who for operational reasons, must 
remain within the hazard area. 



5-12. Medical Care 

Medical care following exposure to low-level radiation involves the diagnosis and management of both the 
early and delayed deterministic events from doses above threshold levels (bone marrow depression, skin 
injuries), and the management of stochastic effects, primarily nonspecific tumors and leukemia that may 
become clinically evident years after exposure to radiation. Within the low-level dose range (5 to 75 cGy), 
the greatest risk is the appearance of stochastic effects, that is, the appearance of benign and malignant 
tumors and leukemia years after the event. However, because of the uncertainty of the dose that may be 
received during certain situations, deterministic effects may appear within months of certain types of acute 
exposures. 

a. Early and Delayed Deterministic Effects. It is unlikely that symptoms of deterministic effects 
will appear due to acute whole or partial body radiation doses of less than 100 cGy . Early evidence of acute 
radiation-induced cellular injury, for example, structural changes in the chromosomes of some circulating 
lymphocytes, and falls in the absolute lymphocyte and sperm counts, is, however, clinically detectable in 
asymptomatic individuals who have received lower doses. 9 

b. Stochastic Effects. The primary stochastic late effect of exposure to radiation is the 
development of radiation-induced tumors and leukemia (see paragraph 5-8). Radiation-induced or radiogenic 
tumors are histologically and clinically indistinguishable from spontaneously occurring tumors. Their 
diagnosis, treatment, and management are the same as those for spontaneously occurring cancers of the 
same type. 10 

5-13. Medical Follow-Up 

The low-level dose range (5 to 75 cGy) is unlikely to cause delayed acute or chronic deterministic effects. 
Therefore, this paragraph will address medical follow-up actions involved with the main long-term effect of 
radiation exposure— malignant disease. 11 



9. Potential Radiation Exposure in Military Operations, Protecting the Soldier Before, During, and After (National Academy of Sciences, 1999). 

10. Ibid. 

11. Ibid. 



5-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



a. Medical Assessment. Medical assessment is the evaluation of the basic parameters of general 
and radiological health status after a known or suspected exposure to radiation or radioactive contamination. 
Such an evaluation may be prompted by the development of nonspecific symptoms, trauma, or an observed 
degradation of individual performance during or after a military operation conducted in an area of known or 
suspected radiation or radioactive contaminants. Personnel are not likely to develop symptoms of acute 
radiation exposure at the low-level dose range; however, medical assessment is recommended after 
personnel exit radiologically hazardous areas. The purpose of the assessment of asymptomatic individuals 
in these situations is to— 

• Rule out that personnel were exposed to higher than expected doses. 

• Obtain baseline clinical data to assist in estimating the individual's radiation dose. 

• Establish a basis for recommendations regarding the individual's need for medical care, 
periodic monitoring, or specific testing. 

b. Medical Monitoring. 

(1) Medical monitoring is a systematic screening of a population of asymptomatic individuals 
for preclinical disease with the purpose of preventing or delaying the development and progression of 
chronic disease in those individuals. However, medical monitoring after radiation exposure is not routinely 
suggested or practiced for individuals with known or suspected exposures to radiation. An exposure or a 
presumed exposure to radiation is not, by itself, sufficient to justify a medical monitoring program. The 
decision about whether a medical monitoring program is appropriate and necessary in a given situation 
should be based on the consideration of a number of factors including a rigorous cost-benefit analysis. This 
analysis should take into account the following considerations: 

• The certainty, type, intensity, and duration of the dose concerned. 

• The history and population prevalence of the disease concerned. 



• 



The effectiveness, sensitivity, specificity, and potential hazardous side effects of 



available screening tests. 

• If test results are positive, the availability, benefits, and risks of treatment protocols. 

(2) The latent period between radiation exposure and the development of a clinically detectable 
tumor or leukemia may have an effect on the design of a screening program. For the US Armed Forces, 
personnel are usually between 20 and 40 years of age when they are exposed, and most radiation-induced 
tumors would be expected to become clinically evident when they are older than 40, and in most cases, older 
than 50. Since most cancers occur spontaneously at older ages (older than 50 years) without exposure to 
radiation, few tests have shown to be of benefit in terms of improving either survivability or quality of life. 
Tests that have been recommended include the pap smear, prostate-specific antigen tests, and 
mammography. Since the risk of cancer in nonexposed populations is high over a normal lifetime, the risk 

5-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



of radiation-induced tumors due to exposure to low-level radiation would always be far less than the risk of 
normal spontaneous incidence. 

(3) The Institute of Medicine in their committee report: Potential Radiation Exposure in 
Military Operations (1999), recommends the establishment of registries for tracking individuals who have 
received cumulative effective doses in excess of 5 cGy. This action may be helpful in addressing follow-on 
health related issues. The committee also recommends that annually, and upon demobilization or discharge, 
potentially exposed military personnel should be given a written record of their radiation exposure with 
estimated doses (annual and cumulative), even if the doses are zero. 

5-14. Documentation of Radiation Exposure Records 

a. The OEG concept requires that all units maintain radiation exposure records. Currently, US 
Army records are based on platoon-level data received daily, or after a mission in a radiological contaminated 
area. The unit dose is an average of the doses to individuals in the unit who have dosimeters, usually two per 
squad in the US Army. Therefore, the US Army assumes that each soldier receives an individual dose equal 
to that of the average for the platoon. The records are usually kept by the unit chemical officer at battalion 
level. When a soldier transfers out of an exposed unit, the RES for that platoon is noted in the soldier's 
personnel file. When possible, soldiers are reassigned to platoons with the same RES category. Although 
this might create personnel strength management problems, it is intended to prevent personnel from 
incapacitation due to overexposure to radiation in future operations. The other services have service 
specific requirements to maintain radiation dose records. Individual dosimetry should be requested if the 
situation warrants, since individual dosimetry can greatly assist with patient assessment and management. 

b. In an LLR environment, STANAG 2473, Commanders Guide on Low Level Radiation (LLR) 
Exposure in Military Operations, not only reinforces the requirement to maintain dose records, it also 
stipulates that "commanders will need to be aware of individual dose histories when planning future 
operations at risk of LLR exposure." Clearly, the intent is to equip all service members in the unit with 
appropriate dosimeters if the unit anticipates conducting operations in a radiologically hazardous area. The 
NATO NBC Medical Working Group is currently developing STANAG 2474, Low-Level Radiation Dose 
Recording in order to clarify record-keeping requirements. 



5-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



CHAPTER 6 



PSYCHOLOGICAL EFFECTS AND TREATMENT 
OF PSYCHOLOGICAL CASUALTIES 



6-1. General 

In a nuclear war scenario, psychological casualties would seem to be insignificant compared to the casualties 
from physical trauma, but they can dramatically alter the outcome of a battle. The neuropsychiatric 
casualties of World War II were the largest single cause of lost military strength in that war. The Arab- 
Israeli Yom Kippur War of 1973 lasted only 3 weeks, but psychiatric casualties were 23 percent of all 
nonfatal casualties. Complicating matters further, psychological stress can mimic the early symptoms and 
signs of acute radiation injury. Gastrointestinal symptoms (nausea, vomiting and diarrhea), fatigue, and 
headaches were frequently seen symptoms during episodes of battle fatigue in World War II. In RDD or 
nuclear incident scenarios, psychological stress is also a factor. Even if neuropsychiatric trauma does not 
produce a casualty, it can degrade the performance of normal duties. Slightly altered reaction times, 
attention, or motivation have important consequences across the entire spectrum of military operations. 
Regardless of the situation, it must be emphasized that the most extreme psychological damage occurs when 
physiological symptoms from an unknown toxic exposure become manifest. Significant degradation in 
performance may occur as military personnel become concerned about the material they were exposed to, 
the dose, and the long-term effects of that exposure. 



6-2. Radiation Dispersal Devices and Nuclear Incidents 

Although RDDs and nuclear incidents lack the destructive power of a nuclear detonation, the psychological 
impact of these events might impede military operations by denying key terrain or installations and by 
degrading unit morale and cohesiveness. If an incident occurs in a civilian setting, psychological stress is 
expected to increase. Material in this paragraph is an estimate of the problems likely to be encountered, 
since an RDD has not yet been employed against US forces or civilians, and approximately 35 years have 
passed since US forces have dealt with a major nuclear incident (Palomares, Spain). 

a. Psychological Effects of RDDs and Nuclear Incidents. The use of an RDD or a nuclear 
incident would be expected to produce acute anxiety effects, including psychosomatic effects such as nausea 
and vomiting. Symptoms of acute radiation sickness in just a few personnel might trigger an outbreak of 
similar symptoms in the unit and/or in the civilian populace. Emergency personnel responding to the 
incident may have a false perception of the threat that has little connection to the actual physical hazard 
present. Experience from industrial accidents shows that both real and imagined illnesses may be attributed 
to radiation exposure. The severity of the psychological effects of an RDD or a nuclear incident will depend 
on the nature of, and the extent of the physical effects. Malicious use of a sealed source of radioactivity left 
in an area of personnel traffic would pose only an external radiation hazard, which depending on the dose 
received, may lead to acute radiological injury. Similarly, an RDD that distributes radioactive material 
using passive means would likely generate a contamination hazard with little, if any acute physical injury. 
However, blast injuries, in addition to radiation effects, may be caused by an RDD that uses a conventional 
explosion, or if the high explosive component of a nuclear weapon detonates. The greater the number of 

6-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



casualties from the blast and a generally more chaotic situation will intensify the level of stress on military 
personnel and likely produce more psychological casualties. 

b. Incidence. Exposure, or perceived exposure to radiation can be expected to increase the 
number of psychological stress casualties. The number of casualties will also depend on the level of 
leadership, cohesiveness, and morale in the unit. Long-term chronic psychological stress patterns could be 
expected to arise from the uncertainty about the effects of exposure to radiation. Some of the potential 
effects include phobias, depression, and post traumatic stress disorder. An RDD or a nuclear incident 
within a civilian population center may produce more detrimental psychological effects to military personnel 
than if it occurred in a strictly military operations area. Recently, the military has seen increased stability 
and support operations, where closer relationships may exist between civilians and military personnel. 
Requests for treatment of civilian casualties, especially women and children, after an incident might 
markedly increase the psychological impact on military personnel. A civilian mass casualty situation could 
severely overload emergency medical operations and increase distress in military personnel. Behaviors 
such as altruism, heroism, and loyalty to comrades typically seen in units with exceptional esprit de corps, 
may alleviate some of the psychological stress. 



6-3. Nuclear Detonation 

Personnel witnessing a nuclear detonation are likely to suffer sensory overload as well as the fear of injury 
or death. Depending upon the yield of the weapon and the distance, the service member may see a brilliant 
flash that temporarily blinds him, hear a deafening explosion at incredible decibels, suffer thermal injury, 
feel the shock of blast winds, and then experience the ground quaking beneath his feet. At night, flash 
blindness could affect personnel miles beyond the range of any other acute effects. Some personnel may 
have immediate adverse psychological reactions, even in the absence of actual physical injury. 

a. Contrary to media portrayals of disasters, mass panic is rare in disaster situations. It seems to 
occur primarily in situations where there are limited avenues of escape and possible entrapment, such as 
mine fires or mine collapses, sinking ships, or fires in crowded areas where exit routes are limited. The 
most frequent psychological effect after disasters is a temporary emotional disruption where people are 
stunned or dazed. This transient response may last minutes to days. Typically, such individuals will be able 
to respond to strong leadership and direction. Another psychological response is to become more efficient in 
the face of danger; this is more likely in well-trained units with high morale. A third type of response would 
be that of a psychological casualty, where the transient emotional disruption is continued and more severe. 
Reactions include stunned, mute behavior, tearful helplessness, apathy, inappropriate activity, and 
preoccupation with somatic symptoms (often of emotional origin). 

b. Somatic effects such as nausea, vomiting, diarrhea, and a feeling of weakness or fatigue would 
be likely to occur. These individuals may exhibit helpless, aimless, or disorganized behaviors. In the 
aftermath of the Hiroshima and Nagasaki bombings, some people were stunned into meaningless, repetitive 
behaviors with no obvious goal orientation or survival value. Some wandered uselessly in the debris, with no 
conscious effort to either escape or aid others. Many withdrew into an apathy approaching catatonia, 
apparently shutting themselves off from the outside world. 

6-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



6-4. Fallout Field 

The most stressful effects of a fallout field or contaminated area are likely to be the uncertainties of the 
levels of radiation present, lack of defined boundaries of the area, and the perceived acute and chronic 
effects of radiation. A chronic level of high stress will also exist when monitoring an area for radiation 
hazards. Stress in this situation resembles that of troops clearing an area of mines or patrolling a booby- 
trapped area. Military personnel may not know their individual exposure since only unit dosimetry may be 
available. They may fear that they are getting a much larger dose than deemed wise, especially if there is 
a lack of trust in the leadership. Stress levels can be decreased with positive identification that defines the 
contamination field and with proper training of military personnel as to the actual hazards and their effects. 



6-5. Psychosocial Sequelae of Radiation Exposure 

a. Psychosocial Sequelae. Even in the absence of actual exposure, fear that one has been exposed 
to radiation may cause psychosocial sequelae. Since fear and anxiety are stressors, the person may 
experience psychosomatic symptoms, some of which may mimic early ARS symptoms. For example, in 
the accident at Three Mile Island in 1979, surveys of the surrounding population found an increase in such 
psychosomatic symptoms as nausea, anorexia, and skin rashes, even though there was no detectable 
radiation exposure in most of these areas. At Goiania, Brazil, after scavengers opened a medical 
radiotherapy device containing radiocesium, approximately 5,000 of the first 60,000 persons (8 percent) to 
be screened for radioactive contamination showed symptoms of acute stress or allergies such as a rash 
around the neck and upper body, vomiting, and diarrhea. However, none of these individuals were 
contaminated. Thus, the perceptions and preconceptions about radiation may be just as important as the 
radiation itself in terms of subsequent pathology. 

b. Psychological Factors at Chernobyl. 

(1) Many of the recovery team members, liquidators, called in to help with the cleanup of the 
reactor at Chernobyl were military personnel. A study of Estonian liquidators found no increases in cancer, 
leukemia, or overall mortality, but they did find an increase in suicide. A study of Latvian liquidators found 
that almost half had psychosomatic disorders. The fear of radiation in the liquidators was probably enhanced 
by their lack of knowledge, the misinformation published in the media, and a distrust of the Red Army's 
record of the radiation doses. An epidemic of vegetative dystonia occurred in liquidators and people from 
the contaminated areas. The symptoms of vegetative dystonia resemble the medically unexplained physical 
symptoms (MUPS) seen in Agent Orange Syndrome and Gulf War Illness, as well as neurocirculatory 
asthenia or effort syndrome that was prevalent during and after both World Wars. The vegetative dystonia 
was more prevalent in liquidators who suffered acute radiation sickness, but was also seen in others who 
suffered no acute effects. 

(2) Many people living upwind of Chernobyl and hundreds of miles away received detectable 
doses of radiation equivalent to, or less than a doubling of the normal background radiation level. Some 
people became so afraid of the fallout that their whole lives began to revolve around avoidance. Whenever 
possible, they refused to go outside or eat locally grown produce. Some sank into deep despair and 

6-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



committed suicide rather than risk what they believed would be the inevitable and horrible effects of 
radiation. Such severe reactions were referred to as radiophobia by the media. However, those with social 
support were better able to handle the increased psychological stress. 



6-6. Treatment 

a. The treatment of psychological stress resulting from actual or perceived exposure to radiation 
is the same as that for battle fatigue. The principles of proximity, immediacy, expectancy, simplicity 
(PIES) are the cornerstones of treatment— 

• Proximity means to treat the psychological casualty as close as possible to the unit and the 
area from which he came, so as to prevent evacuating a casualty to a distant medical facility. 

• Immediacy refers to initiating treatment as soon as possible to prevent the strengthening 
of maladaptive habits and the self-perception of illness or disability. 

• Expectancy means that medical personnel should convey the positive expectation that the 
casualty will fully recover and be able to return to duty after a short break from the operation. 

• Simplicity refers to the use of simple, brief, and straightforward methods to restore 
physical well being and self-confidence. 

b. Generally, treatment modalities consist of the following— 

(1) Reassurance and suggestion that the situation will improve. Psychological casualties are 
suggestible early in their disruptive phase and simple reassurance using a positive, direct approach is usually 
successful. The individual should be made to feel that he or she has an excellent chance of recovery, which 
is true in most cases. 

(2) Rest with removal from immediate danger. A short period of rest in a safe area is of 
great benefit. 

(3) Elimination of negative emotions by expression of those emotions (catharsis). Retention 
of fear and anxiety by the more severely incapacitated frequently blocks effective communication. When 
the patient expresses his or her feelings, this tends to remove the block. This communication is essential 
before the individual can recover enough to rejoin the activities of his or her group or unit. 

c. Sedatives or tranquilizers should be avoided unless they are essential to manage sleep or 
agitated behavior. Stress casualties should only be evacuated to the next higher echelon if their symptoms 
make them too disruptive to manage at a given echelon. Similarly, hospitalization should be avoided unless 
absolutely necessary, and those requiring hospitalization should be transferred to a non-hospital treatment 
setting as soon as their condition permits. 

6-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



6-7. Prevention and Risk Communication 

a. Prevention. Prevention, when possible, is always preferred to treatment. Prior to deployment 
to an area where nuclear and radiological hazards are present, medical personnel can implement programs 
on behalf of the line commanders that instruct their units about radiation and its effects. In general, troops 
who are psychologically prepared for specific stresses are better able to endure them and will suffer fewer 
and less severe adverse reactions. This same principle is widely used in preparing troops to cope with 
MOPP gear, chemical agent exposure, and other adverse environments. Postexposure training will be 
much less effective. Lack of information about the physical hazards of radiation increases the incidence of 
fear and anxiety in troops regardless of the actual physical hazard. Units should have operational RADIAC 
equipment and dosimeters. Normally, only unit dosimetry readings are possible. Dosimeters should be 
issued to each individual in accordance with the commander's priorities and equipment availability 
constraints. Individual dose information can therefore be provided to alleviate fears of receiving large 
doses. In fallout fields, combat stress is reduced by positively identifying and assessing the radiation field, 
its boundaries, the exposure levels and the risks associated with continued exposure. Primary and backup 
personnel should be fully trained in proper equipment operation and in proper NBC reporting procedures 
and formats. 

b. Risk Communication. 

(1) To effectively communicate risks, the training should be tailored in layman's terms, it 
should be realistic and accurate, and it should highlight practical (not theoretical) measures on self-protection. 
Specific training in radiation effects, radiation protection, radiation risk communication and psychological 
casualty prevention should be given. The principles of minimizing time, increasing distance, and increasing 
shielding from a radiation source should be introduced as ways of decreasing radiation exposure. Service 
members should gain an understanding that exposure to natural sources of radiation is continuous throughout 
life. Normal background radiation levels, medical exposures, and exposures from expected missions should 
all be put in context with one another. Questions about increased cancer risks from potential mission 
exposures should be answered with relation to normal cancer incidence rates. For fallout fields, troops 
should understand that decontamination is the simple act of dusting oneself off (or changing clothes) and 
washing exposed skin areas with soap and water. In addition to training military units, radiation training 
must also be provided to deploying mental health personnel. 

(2) The credibility of leaders, and the trust on which that credibility is based, must be 
maintained. Leaders must keep troops informed on possible mission exposures, realistic risk estimates, unit 
dose information from RADIAC equipment, and other information that removes ambiguities and 
uncertainties in any given situation. Leaders must address, and not dismiss, real concerns. Leaders should 
know the OEG for their mission, the radiation exposure state (RES) of their unit, and the risks associated 
with their mission. They should have an understanding of acute radiation exposure hazards in comparison 
with the immediate dangers of conventional combat. They should also understand the potential for long-term 
health risks when troops receive radiation exposures. Leaders should also be knowledgeable on how to 
request assistance in interpreting risks associated with radiation exposures or with readings from RADIAC 
equipment. 



6-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

APPENDIX A 
DEPLETED URANIUM 



A-l. General 

Depleted uranium is neither a weapon of mass destruction nor a chemical or radiological hazard. It is also 
not a nuclear or a radiological weapon. The hazards associated with DU are comparable to other munitions. 
Depleted uranium is included in this manual for the convenient access of information by military medical 
personnel. Depleted uranium munitions and armor plating proved their effectiveness during Operation 
Desert Storm (ODS). In fact, DU armor and munitions were so successful that other nations are now using, 
or developing DU munitions and armor plating. Therefore, in any future conflict involving antiarmor 
weapons systems using kinetic energy (KE) ammunition, it is likely that the enemy will use DU munitions 
against US ground forces. This appendix will discuss the characteristics of DU, toxicity and health risks, 
and clinical treatment of personnel wounded by DU munitions. 

A-2. Depleted Uranium Characteristics and Uses 

Depleted uranium is a heavy, silvery-white metal when freshly machined. It is a little softer than steel, 
ductile and slightly paramagnetic. In air, DU becomes coated with a layer of oxide that gives it a dull black 
or yellow color. Chemically and toxicologically, DU has the same characteristics as natural uranium. 
Natural uranium is predominantly Uranium-238 (U-238) by weight, but also contains isotopes U-234 and 
U-235. As part of the nuclear fuel cycle, natural uranium is processed in enrichment facilities to obtain 
uranium with a higher U-235 content; this is called enriched uranium. The enriched uranium is then used in 
nuclear reactors and nuclear weapons. The waste product of the enrichment process is uranium that has a 
lower content of U-235 and is known as DU because it is depleted of the high activity radioactive isotope. 
Therefore, it is less radioactive than natural or enriched uranium. Table A-l shows an isotope comparison 
between DU and natural uranium. Alpha, beta, and gamma radiation are emitted from DU, but because of 
the long half-life of U-238, the specific activity is relatively low. For example, to obtain one curie of 
radioactivity from DU would require a single piece weighing 6,615 pounds. DU also contains trace amounts 
of transuranics: Plutonium-238, 239/240, Neptunium-237, Americium-241. It also contains trace amounts 
of Uranium-236 and Technetium-99. These amounts are so low that they do not increase the toxicological 
risk, and increase the radiation dose by much less than one percent. 



Table A-l. Comparison Between Depleted Uranium and Natural Uranium 

URANIUM ISOTOPE NATURAL URANIUM DEPLETED URANIUM 

U-234 0.0057% 0.0005% 

U-235 0.7204% 0.2500% 

U-238 99.2739% 99.7495% 

TOTAL 1 00% 1 00% 



A-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



a. Because of its high density and structural properties, DU is useful for conventional munitions 
and as part of US tank armor. Depleted uranium armor is the most effective armor for protection against all 
types of munitions, including KE munitions made out of tungsten carbide and DU. The Abrams tank family 
(Ml, IPM1, M1A1, and M1A2) has an improved hull armor envelope that does not contain DU. However, 
M1A1 heavy armor (HA) and MlA2s have armor modules on the existing left and right frontal turret 
armor. The DU in these modules is completely encapsulated in steel. The front slope of the turrets of these 
tanks has a radioactive signature; a little less than 0.005 mSv/hour. 

b. Depleted uranium is also used offensively in antiarmor ammunition. The combination of high 
hardness, strength, and density makes DU alloys well suited for KE ammunition. Another useful property 
of DU is that as it moves through the armor it maintains the sharpness of the penetrator, further enhancing 
its penetrating power. (The fact that tungsten carbide and other types of tungsten penetrators do not sharpen 
on impact— but in fact mushroom to a certain extent— is one reason they are less effective for overcoming 
armor plating.) Current US weapons systems and their associated DU munitions are shown in Table A-2. 
In general, DU ammunition may only be fired during combat and, similar to other types of service 
ammunition, is not fired in peacetime training. DU is fired on ranges for testing and quality assurance 
purposes on ranges which have been approved and licensed by the Nuclear Regulatory Commission (NRC). 

Table A-2. List of Depleted Uranium Munitions by Weapons System 

TANK AMMUNITION TANK AMMUNITION BRADLEY FIGHTING A-10 HARRIER PHALANX 

105 mm 120 mm 25 mm 30 mm 25 mm 20 mm 

M1919 PGU-14/B PGU-20 MK-149 

PGU-14A/B 
PGU-14B/B 
PGU-14A/A 



A-3. Depleted Uranium Toxicity 

Although DU is not a chemical or radiological hazard, it can present a chemical toxicity hazard and perhaps 
a long-term radiological health risk under some conditions when it is introduced internally to the body. Some 
risks associated with DU munitions have been evaluated experimentally, some risks are still under study, 
and some risks were identified from practical experience during ODS. Depleted uranium internalization via 
inhalation is the primary concern. 

a. When a kinetic energy penetrator strikes armor plating, a pyrophoric effect occurs. That is, a 
very fast moving, dense heavy metal penetrator striking steel armor will produce a white-hot ignition (flash) 
at the point of penetration. This pyrophoric effect occurs with either a conventional tungsten carbide 
penetrator (although to a lesser extent) or a DU penetrator. With a DU round, the penetration process 
generates high concentrations of airborne, breathable, DU oxides and high velocity shards of metal that can 
cause serious wounds. Data gathered from tests and friendly fire incidents show that only personnel in, on, 
or near (within 50 meters) the target vehicle at the time the vehicle was struck by a DU penetrator may 

A-2 



M774 


M827 


M833 


M829 


M900 


M829A1 




M829A2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



internalize DU in excess of safety standards. This internalization takes place through inhalation, ingestion, 
wound contamination, and embedded DU fragments. Almost as soon as the round hits and the dust has 
settled, the levels of airborne DU on the outside of the vehicle will rapidly fall to levels that are much lower 
than the safety standards prescribed by Occupational Safety and Health Act (OSHA) and the NRC. It is 
important to place the possible hazards due to DU penetration into perspective. When a DU penetrator 
strikes a vehicle, the effects include a spray of molten metal, shards of both penetrator and vehicle armor, 
and secondary explosions in stored ammunition. The interior of the struck vehicle will be contaminated with 
both DU dust and fragments, and with other materials generated from burning interior components. 
Therefore, medical personnel need to focus on managing the more immediate severe conventional injuries 
such as blast and ballistic wounds, burns, and inhalation injuries derived from the initial penetration as well 
as from secondary fires or explosions. 

b. Inhaled uranium compounds may be metabolized, and result in urinary excretion of these 
compounds. Absorption will be determined by the solubility of the uranium. While soluble salts such as 
chlorides are readily absorbed, DU metal is not. Consequently, shortening gastrointestinal transit time will 
diminish adsorption. 



A-4. Health Effects of Exposure to Depleted Uranium 

a. General. The Gulf War was the first time there was widespread use of DU, so there is 
relatively little experience in dealing with the health effects of this material. However, since 1993, the 
Department of Veterans Affairs (VA) has been conducting a follow-up of 33 Gulf War veterans who were 
seriously injured in friendly fire incidents involving DU. Many of these veterans continue to have medical 
problems relating to the physical injuries they received during these incidents. About half of this group still 
have DU metal fragments in their bodies. This follow-up effort and other related studies indicate that the 
major health concerns about internalized DU relate to its chemical toxicity as a heavy metal rather than to its 
radioactivity, which is very low. In fact, DU is classified in the lowest hazard class of all radioactive 
materials. (See the Rand Report, A Review of the Scientific Literature as it Pertains to Gulf War Illness, 
Volume 7, Depleted Uranium, for a detailed discussion of the health effects of DU.) 

b. External Exposure. Depleted uranium emits alpha, beta, and weak gamma radiation. Due to 
the metal's high density, much of the radiation never reaches the surface of the metal. It is thus "self- 
shielding". Also, intact DU rounds and armor are packaged to provide sufficient shielding to stop the beta 
and alpha radiations. Gamma radiation exposure is minimal. After several months of continuous operations 
in an armored vehicle completely loaded with DU munitions, crew exposures might exceed peacetime 
general population exposure limits but would not exceed peacetime occupational exposure limits. Hence, 
DU is not a serious irradiation threat. 

c. Internal Exposure. In a ground combat environment, routes of internal exposure are generally 
inhalation, ingestion, wound contamination and embedded fragments. For example, the pyrophoric effect 
produces uranium dusts or aerosol particles, which can be inhaled resulting in uranium entering the blood 

A-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



from the lungs. 12 Also, some inhaled uranium and some of the uranium originally in the lungs ends up in 
the GI tract as a result of mucociliary clearance from the respiratory tract and subsequent swallowing. In 
the case of embedded fragments, uranium is introduced to the body as the fragments slowly dissolve. 
Uranium accumulates to some degree in all organs, however, the kidney is considered to be the target organ 
for uranium chemical toxicity. 13 Gulf War veterans with embedded DU fragments have shown higher than 
normal levels of uranium in their urine since monitoring began in 1993. The key to the health effect is the 
amount internalized. Studies have shown that safety standards for internalized uranium may be exceeded 
only for personnel who were in, on, or near (less than 50 meters) an armored vehicle at the time the vehicle 
was struck by DU. 

d. Chemical Toxicity. In 1997, 29 of the original 33 Gulf War veterans were reevaluated. Of 
those evaluated, about half were identified as having retained DU fragments. The majority of these 
individuals had elevated 24-hour urinary uranium levels. This suggests that DU was being dissolved in body 
fluids; thus, these metal fragments are not entirely inert. Although these individuals have an array of health 
problems, many of which are related to their combat injuries, to date all tests for kidney function have been 
normal. Laboratory tests also found DU in semen in samples from some, but not all, veterans exposed 
to DU. To date, all babies fathered by these veterans between 1991 and 1997 have had no birth defects. 
Wounds that contain DU may develop cystic lesions that alter and allow the absorption of the uranium metal. 
This has been demonstrated in two veterans of the Persian Gulf War who were wounded by DU frag- 
ments that were subsequently removed. Of the known casualties wounded by DU munitions, all have 
elevated urinary concentrations of uranium. Studies in scientific models have demonstrated that uranium 
will slowly be distributed systemically with primary deposition in the bone and kidneys from these wounds. 
Scientific data now demonstrate skeletal and renal deposition of uranium secondary to implanted DU 
fragments. There is uncertainty over the toxic level for long-term chronic exposure to internal uranium 
metal, but no renal or skeletal damage has been documented to date in Gulf War veterans with embedded 
DU fragments. 

e. Radiological Toxicity. The biological properties of uranium in the body and its absorption from 
the GI and respiratory tracts are reasonably well known from occupational exposures (for example, 
uranium miners), studies of normal environmental intake, and animal studies. There is no evidence of 
cancer or any other negative health effect related to the radiation received from exposure to natural 
uranium, whether inhaled or ingested, even at very high doses. There is evidence of lung cancer in uranium 
miners from previous epidemiological studies, but this is related to exposure to a combination of airborne 
short-lived decay products of radon and other air toxicants, such as silica dust, diesel fumes, and cigarette 
smoke. Based on the distribution in the body and the known body organ content, no health effects from 
radiation would be expected even for high occupational exposures. This results mainly because of the low 
radioactivity of natural uranium and the inability to get enough into the body to deliver a radiation dose that 
could be significant in causing cancer. The same would be true for DU. Studies have not shown a 
link between the inhalation or ingestion of either natural uranium or depleted uranium and any form of 
cancer. 



12. Harley, Naomi H., et al., A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol. 7, Depleted Uranium (The 
Rand Corporation, 1999). 

13. Ibid. 

A-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



A-5. Patient Management of Personnel Wounded by Depleted Uranium Munitions 

a. Determining the Presence of Depleted Uranium. 

(1) There are several situational indicators pointing to the presence of DU that may have 
been observed by the patient or other members of the unit: 

• Patient's vehicle was struck by a KE penetrator. 

• Patient's vehicle was struck by friendly fire from US tanks or aircraft. This alone 
does not confirm DU was used since US weapons systems fire a variety of antiarmor munitions. 

• An observer reports that he saw a white hot flash and sparkler-like burning 
fragments when the vehicle was struck (pyrophoric effect). Again, this alone does not necessarily confirm 
a DU munition, since all KE penetrators present a white hot flash to a certain extent. 

• Patient's medical card stated suspected wounding with DU munitions or inhalation 
of DU particles. 

(2) Because of DU's high density, fragments are readily visible on a radiograph and will 
appear similar to steel or lead fragments in the body. However, radiography alone is not sufficient to 
determine the presence of DU, since there will be some soldiers in vehicles struck by DU munitions that will 
have embedded metallic fragments from the vehicle's armor and other components. Also, shards from 
tungsten carbide penetrators will cause similar wounds and will appear radiographically the same. 

(3) If readily available, Radiac Meter AN/VDR-2 with the beta shield open may be used to 
monitor wounds, burns, or suspected sites with embedded fragments. This will confirm DU wound 
contamination, and will provide confirmation of wound decontamination. UNDER NO CIRCUMSTANCES 
SHOULD TREATMENT BE DELAYED IN ORDER TO OBTAIN AN AN/VDR-2. 

(4) Operation Desert Storm experience showed that the most sensitive indicator that DU has 
been internalized is a uranium urine bioassay. In general, embedded DU fragments will slowly dissolve and 
be transported in the blood. Eventually, the patients will excrete uranium in the urine. The level of uranium 
in the urine will remain constant for long periods of time. Results of the medical monitoring of patients from 
ODS showed that the highest uranium urine levels were on the order of 30 to 40 micrograms of total uranium 
per gram of creatinine. The monitoring was initiated in 1993, and the levels have remained generally 
constant. In all likelihood, the levels were higher at the time the soldiers were wounded. How much higher 
is not known. See Memorandum For The Commander, USA AMEDD Center and School, dated 9 April 
1999, Subject: Policy for the Treatment of Personnel Wounded by Depleted Uranium Munitions for detailed 
procedures on conducting DU urine bioassays. 

b. Clinical Treatment of Personnel Wounded By DU Munitions. 

(1) Casualties may have DU contamination on their clothing and skin. UNDER NO 
CIRCUMSTANCES SHOULD CASUALTY EXTRACTION, TREATMENT, OR EVACUATION BE 

A-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



DELAYED DUE TO THE PRESENCE OF DU. Standard aidman procedures for treating combat wounds 
should be followed. 

(2) Wounds and burns should be cleaned and debrided using standard surgical procedures. 
Normal "universal precautions" (surgical gloves, surgical mask, and throwaway surgical gowns) are more 
than adequate to protect medical personnel from accidental contamination with DU. Items contaminated 
with DU should be disposed of using standard universal precaution procedures. The use of a sensitive 
radiation meter may assist in wound debridement and cleaning. The AN/VDR-2 RADIAC Meter with the 
beta window open may assist in locating DU contamination in the wound or burn. UNDER NO 
CIRCUMSTANCES SHOULD REQUIRED TREATMENT BE DELAYED TO PERFORM THIS 
MONITORING. 

(3) Embedded DU fragments in wounds should be removed using standard surgical criteria 
(see Emergency War Surgery NATO Handbook, 1988), except that large fragments (greater than 1 cm in 
diameter) should be more aggressively removed unless the medical risk to the patient is too 
great. 

(4) Monitoring of kidney function is recommended for those patients who have contaminated 
wounds or embedded DU fragments. The monitoring should follow the current protocol in use by the 
Baltimore VA Depleted Uranium Program. 

(a) As with all heavy metals, the kidney is one of the organs most sensitive to uranium 
toxicity. Recommended tests include urinalysis, 24-hour uranium urine bioassay, serum blood urea nitrogen 
(BUN), creatinine, beta-2-microglobulin, and creatinine clearance. 

(b) Chelation therapy is not recommended based upon current estimates of DU 
exposure. 

(5) Once the patient is in recovery, he should be informed of the risks associated with 
internalized DU. The key point is that the presence of any DU fragments in the service member's body 
presents no risks to family members. As with other heavy metals retained in the body, the DU in all bodily 
fluids (urine, feces, sweat, saliva, and semen) present absolutely no hazard to the soldier or the people he 
has contact with. Also, no special precautions are required by anyone having contact with the patient. 



A-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

APPENDIX B 
MEDICATIONS 



Table B-l is a listing of medications available for use when treating nuclear and radiological casualties. 
Stockage levels of specific medications will be as authorized by unit assemblages and standard operating 
procedures (SOP). The medications are grouped according to general category (for example, "antidiarrheal 
agents"), and information is given on trade name, generic name, class, and so forth. 



Table B-l. Medications 



TRADE NAME 


GENERIC NAME 


CLASS 


DOSE/ROUTE 


INDICATION 


NOTES 


Systemic Antibiotics 


Cipro 


ciprofloxacin 


Antibiotic 


500mgPO/IVQD 


Bacterial prophylaxis 
when neutropenic 




Flagyl 


metronidazole 


Antibiotic 


7.5 mg/kg PO/IV q 6 hrs 
(maximum 4 grams QD) 


Anaerobic infections 




Garamycin 


gentamicin 


Antibiotic 


3-5 mg/kg/day IV in divided 
doses 


Gram (-) infections 


Monitor peak and trough 
levels 


Principen 


ampicillin 


Antibiotic 


150-200 mg/kg/day in divided 
doses q 3-4 hrs 


Gram (+) infections 




Vancocin 


vancomycin 


Antibiotic 


1 gram IV q 12 hrs 


Gram (+) infections 


Monitor peak and trough 
levels 


Topical Antibiotics 


Silvadene Cream 


silver sulfadiazine 


Antibiotic 


Apply 1/16" QD or BID 


Gram (-) and gram (+) 
infections, including 
pseudomonas 


Adjunctive therapy for 
patients with 2 and 3 
degree bums 


Sulfamylon Cream 


mafenide acetate 


Antibiotic 


Apply 1/16" QD or BID 


Gram (-) and gram (+) 
infections, including 
pseudomonas 


Adjunctive therapy for 
patients with 2 and 3 
degree bums 






Sy 


stemic Antifungal Agents 






Abelcet 


amphotericin B lipid 
complex 


Antifungal 


5 mg/kg/day IV 


Invasive fungal 
infections 


Use if refractory to 
or intolerant of 
amphotericin B 


AmBisome 


amphotericin B 
liposome 


Antifungal 


3-5 mg/kg/day IV 


Invasive fungal 
infections 


Use if refractory to 
or intolerant of 
amphotericin B 


Diflucan 


fluconazole 


Antifungal 


400 mg PO/IV QD 


Fungal prophylaxis when 
neutropenic 




Fungizone 


amphotericin B 


Antifungal 


0.5-1.5 mg/kg/day IV 


Invasive fungal 
infections 


Slow IV, extreme side 
effects 


S 


/stemic Antiviral Agents 


Cytovene-IV 


ganciclovir 


Antiviral 


5 mg/kg IV BID for 7 days 
then 5 mq/kq IV QD 


CMV 




Zovirax 


acyclovir 


Antiviral 


400 mg PO TID or 500 mg IV 
TID 


Viral prophylaxis when 
neutropenic 




Colony Stimulatinq Factors (CSF) 


Leukine 
(GM-CSF) 


sargramostim 


CSF 


500 meg SQ QD 


Neutropenia 


Hematopoietic Growth 
Factor 


Neumega 


oprelvekin 


CSF 


50 meg/kg SQ QD 


Thrombocytopenia 


Questionable efficacy 


Neupogen 
(G-CSF) 


filgrastim 


CSF 


5 meg/kg SQ/IV QD 


Neutropenia 


Hematopoietic Growth 
Factor 



B-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table B-l. Medications (Continued) 



TRADE NAME 


GENERIC NAME 


CLASS 


DOSE/ROUTE 


INDICATION 


NOTES 


Procrit (Epogen) 


erythropoietin 


CSF 


150-300 units SQ/IV three 
times per week 


Anemia 


Questionable use for 
radiation casualties 


General Comments: In order to achieve the maximum clinical response, G-CSF or GM-CSF should be started within 24 to 72 hours subsequent to the 
exposure. This provides the opportunity for maximum recovery. CSF administration should continue daily to reach the desired effect of an absolute 
neutrophil count of 1 .0 x 1 9 /l. The predominant side effect noted with administration of G-CSF (filgrastim) is medullary bone pain, which may be observed 
shortly after initiation of G-CSF treatment, and again just before onset of neutrophil recovery from nadir. G-CSF may also exacerbate preexisting 
inflammatory conditions. The most noted side effects with administration of GM-CSF (sargramostim) are fever, nausea, fatigue, headache, bone pain, and 
mvalqia. 


Antidiarrheal Agents 


Imodium 


loperamide 


Antidiarrheal 


4 mg PO then 2 mg after each 
unformed stool (max 16 mg 
QD) 


Diarrhea 


Rule out infectious cause 
first 


Lomotil 


diphenoxylate 


Antidiarrheal 


2 tablets POQID 


Diarrhea 


Rule out infectious cause 
first 


Gastric Acid "Neutralizes" 


Amphojel 


aluminum hydroxide 


Antacid 


10mlq4-6hrsprn 


Hyperacidity 




Carafate 


sucralfate 


Cytoprotectant 


1 gram PO QID 


Erosive esophagitis and 
gastritis 




Histamine Receptor Antagonists 


Prilosec 


omeprazole 


Gastric acid 
pump inhibitor 


20 mg PO QD 


Erosive esophagitis and 
gastritis 




Tagamet 


cimetidine 


M2 Blocker 


800 mg BID 


Erosive esophagitis and 
gastritis 


Parenteral doses for 
erosive esophagitis and 
gastritis unestablished 


Zantac 


ranitidine 


H2 Blocker 


150 mg PO BID or 50 mg IV q 

8hrs 


Erosive esophagitis and 
gastritis 




General Comments: The term "neutralizer" is used here in a general sense to refer to agents that decrease the effects of gastric acid on the lining of the Gl 
tract, even though the mechanism may be different. Amphojel directly neutralizes the effect of gastric acid; Carafate forms a sucralfate-albumin film that 
provides a barrier to diffusion of hydrogen ions and protects the lining of the Gl tract; omeprazole suppresses gastric acid secretion by specific inhibition of 
the H7K* ATPase enzyme system at the secretory surface of the gastric parietal cell; and Zantac and Tagamet inhibit basal gastric acid secretions by 
reversibly inhibiting the action of histamine at the histamine H 2 -receptors, including those on the gastric cells. 


Antiemetics 


Compazine 


prochlorperazine 


Antiemetic 


5-10mqPO/IVq6hrs 


Nausea/Anxiety 




Kytril 


granisetron 


Antiemetic 


1 mcg/kg IV QD or 1 mg PO 
BID 


Nausea/Vomiting 




Phenergan 


promethazine 


Antiemetic 


12.5-50 mg PO/IM/PR q 4-6 
hrs 


Nausea 




Reglan 


metoclopramide 


Antiemetic/ 
Prokinetic 


10mgPO/IM/IVQID 


Nausea 




Zofran 


ondansetron 


Antiemetic 


8 mg IV q 6-8 hrs or 8 mg PO 
q 8-12 hrs 


Nausea/Vomiting 




Analgesics 


Demerol 


meperidine 


Opioid Analgesic 


50-150 mg PO/IV/IM q 3-4 hrs 


Pain/Rigor 


Consider as pretreatment 
for amphotericin B 


Dilaudid 


hydromorphone 


Opioid Analgesic 


2-4mgPOq4-6 hrs or 1-2 
mq IV/IM q 4-6 hrs 


Pain 




Morphine 


morphine sulfate 


Opioid Analgesic 


0.1-0.2 mg/kg (up to 15 mg) 
SQ/IV/IM q 4 hrs 


Pain 




Percocet 


oxycodone and 
acetaminophen 


Opioid Analgesic 


1 tablet PO q 6 hrs 


Pain 




Tylenol 


acetaminophen 


Analgesic/ 
Antipyretic 


650-1000 mgPOq 6 hrs 


Pain/Fevers 


Use as pretreatment for 
amphotericin B and blood 
products 


Tylenol #3 


acetaminophen with 
codeine 


Opioid Analgesic 


1-2 tablets POq 4 hrs 


Pain 





B-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table B-l. Medications (Continued) 



TRADE NAME 


GENERIC NAME 


CLASS 


DOSE/ROUTE 


INDICATION 


NOTES 


Selective Gut Decontamination 


Bactrim 


Co-trimoxazole 

(Trimethoprim- 
Sulfamethoxazole) 


Antibiotic 


Two tablets q 8 hrs PO (total 
of 6 tablets QD) 


Selective Gut 
Decontamination 




Mycostatin 


nystatin 


Antifungal Agent 


6x10 6 IU/day 


Selective Gut 
Decontamination 




Noroxin 


norfloxacin 


Antibiotic 


400mgBIDPO 


Selective Gut 
Decontamination 




General Comments: Antibiotics and antifungal agents can be used to reduce the colonization of intestinal mucosa by opportunistic pathogens. Total 
intestinal decontamination is difficult to achieve, and it creates further vulnerability to colonization by antibiotic-resistant pathogens. However, selective 
decontamination with oral antibiotics has already been tested clinically, and it offers promise for the management of mass casualties who have been 
exposed to midlethal radiation. The oral administration of specific antibiotics eliminates opportunistic pathogens but leaves intact the relatively benign 
intestinal flora. These benign flora increase resistance to colonization by occupying binding sites and creating an environment that is inhospitable to 
pathogens. This approach eliminates the need for elaborate methods of isolation. 


Antihistamines 


Allegra 


fexofenadine 
HCI 


Antihistamine 


60 mg PO BID 


Allergies 


Used for bone pain due to 
Neupogen 


Benadryl 


diphenhydramine 


Antihistamine 


25-50 mg PO/IV/IM q 4-6 hrs 


Nausea/Allergies 


Use as pretreatment for 
amphotericin B and blood 
products 


Claritin 


loratadine 


Antihistamine 


10mgQD 


Allergies/Urticaria 


Relief of itching in CRS 


Therapeutic Agents for Cutaneous Radiation Syndrome ( 


Topical Steroids (Elocon or Mometasone is an example of a 
medium-strenqth corticosteroid shown to be successful) 


Apply topically BID 


Erythema, inflammation 


Rx of manifest stage of 
CRS 


Linoleic Acid 


Apply topically QD 


Skin Dryness 


Rx of manifest stage of 
CRS 


Retin-A Cream 
0.05% 


tretinoin 




Apply topically QD 


Keratoses 


Rx of chronic stage of 
CRS; causes skin 
irritation, dryness 


Soriatane 


acitretin 


Retinoid 


25-50 mg QD with the main 
meal 


Keratoses 


Rx of chronic stage of 
CRS; multiple side 
effects, administered only 
with MD supervision 




interferon gamma 




50mcgSQ3x per week for 
1 8 months 


Severe radiation fibrosis 


Rx of chronic stage of 
CRS 


Trental 


pentoxifylline 

and 
Vitamin E 




pentoxifylline 400 mg TID 

and 
Vitamin E 300 mg QD 
for a minimum of six months 


Radiation fibrosis 


Rx of chronic stage of 
CRS 


General Comments: Experience in the management of the manifest stage of CRS is limited to radiotherapy patients. The treatment modalities for the 
chronic stage of CRS were developed from treatment of clinical sequelae in victims of the Chernobyl incident and from treatment of clinical sequelae in 
therapeutic irradiation patients. 


Medications for Treating Internal Contamination 




Prussian Blue 

(ferrihexacyano- 

ferrate[ll]) 


Absorption 
Reducer and 
Mobilizing Agent 


1 gm in 1 00-200 ml of water 
PO TID for several days 


Rx for internal 
contamination with 
cesium, rubidium, and 
thallium 


Most effective when given 
early after ingestion and 
serially thereafter 


General comments: Not absorbed by the Gl tract. Decreases the absorption of radionuclides into the Gl tract and removes some radionuclides from the 
capillary bed surroundinq the intestine and prevents their absorption. 




potassium iodide 


Blocking Agent 


130 mg PO followed by 130 
mg QD x 7 days if indicated 


Rx for internal 
contamination with 
iodine 


Decreases the uptake of 
iodine in the thyroid gland 


General Comments: If given within 30 minutes of exposure to iodine-1 31 , potassium iodide prevents the uptake of iodine-1 31 by the thyroid gland. If given 
within the first 6 hours, the blocking effectiveness is 50 percent. At 24 hours, its blocking effect is zero. Potassium perchlorate (200 mg by mouth daily) 
may be qiven to individuals who are sensitive to iodine. 



B-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Table B-l. Medications (Continued) 



TRADE NAME 


GENERIC NAME 


CLASS 


DOSE/ROUTE 


INDICATION 


NOTES 




strontium lactate 


Blocking Agent 


500to1,500mgPOQDfor 
several weeks 


Rx for internal 
contamination with 
strontium-85 and 
strontium-90 


Decreases uptake in bone 
and testes 




propylthiouracil, 
methimazole, and 
potassium 
thiocyanate 


Mobilizing 
Agents 


propylthiouracil: 100mgPOq 
8 hrs for 8 days 
methimazole: 10 mg PO q 
8 hrs for 2 days; reduce to 
5 mq PO q 8 hrs for 6 days 


Rx for internal 
contamination with 
iodine 




General Comments: Propylthiouracil, methimazole, and potassium thiooyanate increase the rate of excretion of iodine. However, the toxicity of these three 
drugs and their relative ineffectiveness make them less appealing than potassium iodide. 




ammonium chloride 


Mobilizing 
Agent/De- 
mineralizing 
Agent 


3 gm TID PO 


Rx for internal 
contamination with 
strontium 




General Comments: Ammonium chloride mobilizes strontium from body tissues and, if given with calcium gluconate intravenously, causes a 40 percent to 
75 percent decrease in body stores of strontium over a period of 3 to 6 days. The combined treatment is most effective if given early after strontium 
deposition, but some effectiveness is still demonstrated if qiven as late as 2 weeks after deposition. 




Water 




Force fluids 


Rx for internal 
contamination with 
tritium 


Isotopic Dilution 




sodium bicarbonate 




Slow IV infusion of 
bicarbonated physiological 
solution (250 ml at 14%) 


Rx for internal 
contamination with 
uranium 


Alkalinizes the urine and 
produces a uranyl 
bicarbonate that is less 
nephrotoxic 




Dimercaprol 
(British Anti-Lewisite 
[BAL]) 




One ampule (300 mg) IM q 4 
hrs for 3 days (first test for 
sensitivity with Vt ampule) 


Rx for internal 
contamination with 
polonium, mercury, 
arsenic, bismuth, and 
gold 


Promotes excretion 
May cause toxicity 




calcium gluconate 




20% solution, 10 ml given IV 
QD or BID may be tried 


Rx for internal 
contamination with 
radium 


Displaces the radium 




barium sulfate 




1 00 gm BaS04 in 250 ml of 
water 


Rx for internal 
contamination with 
strontium and radium 


Inhibits absorption 




sodium alginate 




10 gm in a large glass of 
water 


Rx for internal 
contamination with 
calcium and barium 


Inhibits absorption 




D-Penicillamine 


Chelation Agent 


1 gm IV QD or 0.9 mg PO q 4- 
6 hrs 


Rx for internal 
contamination with 
copper, polonium, lead, 
mercury, and gold 






CaEDTA 


Chelation Agent 


75 mg/kg/day in 250-500 ml in 
5% glucose in water; 
maximum total dose not to 
exceed 550 mq/kq 


Rx for internal 
contamination with lead, 
plutonium, and 
americium 




General Comments: CaEDTA (calcium ethylenediaminetetraacetate) was used extensively in the past. Given IV or IM, it is associated with a lot of local 
pain at the injection site and significant side effects includinq Gl upset, bone marrow depression, and nephrotoxicity. 




DTPA 


Chelation Agent 


1 gm CaDTPA in 500 ml 5% 
DAN IV over 60 minutes or 1 
gm (4 ml) in 6 ml of 5% D/W 
by slow IV injection (1 minute) 


Rx for internal 
contamination with rare 
earths, plutonium, 
transplutonics, and 
yttrium. 




General Comments: The chelator DTPA (diethylenetriaminepentaacetic acid), in the zinc or calcium salt state, forms stable soluble complexes with a large 
number of metal ions. When DTPA releases its calcium or zinc, it binds to soluble plutonium, americium, or curium and carries it to the kidneys where it is 
then excreted in the urine. No accumulation of DTPA occurs in tissues or specific organs. Calcium DTPA (CaDTPA) is approximately ten times more 
effective than ZnDTPA (zinc DTPA) for initial chelation of transuranics. Therefore, CaDTPA should be used whenever larger body burdens of transuranics 
are involved. DTPA has been shown to greatly reduce the uptake of absorbed Pu-239 if given within an hour of contamination. With repeated dosing, 
CaDTPA can deplete the body of zinc and, to a lesser extent, manganese. Zinc replacement therapy is recommended when repeated dosing is done due 
to loss of the body's zinc stores. The most effective dose schedules have not been determined, but as with other therapies, it is more effective the earlier it 
is given. Alternate dosing schedules to those discussed above are as follows: Both of the salts above can be given intravenously or as a nasal inhalant. 
Dose recommendations are, for adults, 1 gm in 1 00 to 250 cc of normal saline infused IV over 3 to 4 minutes and repeated on 5 successive days per week. 
Given through the aerosolized route, 1 qm in a 4 cc vial is placed in a nebulizer, and the entire volume is inhaled over 3 to 4 minutes and repeated daily. 



B-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

APPENDIX C 
TREATMENT BRIEFS 



C-l. Scope of Treatment Briefs 

In this appendix, 28 patient categories involving a range of radiation doses are briefly described. Several 
patient categories involve radiation alone, and others describe patients receiving radiation in combination 
with trauma and/or burns. These descriptions are termed Treatment Briefs (TBs) and are derived from the 
work of the 1999—2000 Nuclear Warfare Casualty Panel of the Joint Readiness Clinical Advisory Board 
(JRCAB). The primary purpose of the Treatment Briefs is to help the JRCAB develop medical planning 
tools and resource estimates. The TBs are not designed or intended as medical protocols. However, 
physicians and other medical staff may find much of the information helpful as quick reference material for 
treatment of radiation casualties. Table C-l below lists the 28 Treatment Briefs in accordance with dose 
range and combined injury, if applicable. In addition to the assumptions specifically provided in each 
Treatment Brief, the assumptions and background information that are in Section I are applied to all 
Treatment Briefs. 



Table C-l. List of Treatment Briefs 



TREATMENT BRIEF 


DOSE RANGE (cGy) 


COMBINED INJURY 


1 


75 


None 


2 


75-125 


None 


3 


1 25-300 


None 


4 


300-530 


None 


5 


530-830 


None 


6 


830-1 500 


None 


7 


>1500 


None 


8 


0-125 


Nonoperative trauma 


9 


1 25-530 


Nonoperative trauma 


10 


>530 


Nonoperative trauma 


11 


0-125 


Operative trauma 


12 


1 25-530 


Operative trauma 


13 


>530 


Operative trauma 


14 


0-125 


Mild burn 


15 


1 25-530 


Mild burn 


16 


>530 


Mild burn 


17 


0-125 


Moderate burn 


18 


1 25-530 


Moderate burn 


19 


>530 


Moderate burn 


20 


0-125 


Severe burn 


21 


1 25-530 


Severe burn 


22 


>530 


Severe burn 


23 


0-125 


Operative trauma and mild burn 


24 


1 25-530 


Operative trauma and mild burn 


25 


>530 


Operative trauma and mild burn 


26 


0-125 


Operative trauma and moderate burn 


27 


0-125 


Operative trauma and severe burn 


28 


>125 


Operative trauma and moderate or severe burn 



C-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Section I. GLOBAL ASSUMPTIONS 



C-2. Level of Care 



Levels of Care are defined by capability rather than on unit size and geographical locations on the battlefield. 
The levels of care are: 

a. Level 1A. Self-care/Buddy care/Combat Medic/Corpsman. 

b. Level IB. Combat Medic/Corpsman/Battalion Aid Station/Surface Combatant Ships/ Am- 
phibious Casualty Receiving Treatment Ship/Wing Support Squadron Aid Station. 

c. Level 2. Level 2 may include Forward Surgical Resuscitation, defined as surgery that focuses 
on specific lifesaving practices. These practices include management of severe bleeding, airway 
compromise, life threatening chest injuries, and preparation of casualties for evacuation. Based on the 
concept of the "Golden Hour" of trauma treatment, Level 2 would receive some, but not all, of the patients 
that are acutely injured in combat requiring expeditious surgery to save life or limb. Level 2 will usually 
provide resuscitative level care and surgical interventions to improve patient chances for transport to 
Level 3. However, if it is possible to provide Level 3 care at the Level 2 facilities without jeopardizing the 
mission, then Level 3 care may be done on a case-by-case basis. This may include holding patients up to 72 
hours. Note that an Army FST will only hold patients for recovery, then move them to the supported 
medical company for evacuation. 

d. Level 3. Level 3 is the first level at which patients are admitted into a hospital for medical 
treatment within the theater of operations. Patients that cannot receive definitive care and RTD within the 
time allocated by the theater medical evacuation policy are stabilized and evacuated out of the theater. 
Typical Level 3 facilities are combat support hospitals and USAF air transportable general hospitals. 

e. Level 4. Level 4 is the highest level of care provided in theater. Patients that cannot receive 
definitive care and RTD within the theater evacuation policy are further stabilized and evacuated out of the 
theater. Typical Level 4 facilities are field hospitals or general hospitals. 

C-3. Combined Injury 

Combined injuries include thermal burn/blast trauma/radiation injuries and are discussed in Treatment 
Briefs 14—28. These briefs are based on thermal injury being the dominant determinant of morbidity and 
mortality. Human data sets regarding treatment of radiation combined injuries are scarce. General 
descriptions of trauma and burns assumed in the combined injury Treatment Briefs are provided below. 

a. Nonoperative Blast Trauma. Examples include concussion (without intracranial hemorrhage), 
simple lacerations, closed fractures, ligamental injuries, simple pneumothorax, and so forth. 

b. Operative Blast Trauma. Examples include open fractures, major lacerations, hemo- 
pneumothorax, and so forth. 

C-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



c. Burns. All burns (including White Phosphorous) will be treated with moist dressings and/or 
absorbent gel -type dressing materiel and antibacterial agents. This is due to the removal of cupric sulfate 
from the world market. Percentages of body surface area (BSA) are approximations: 

• Mild Burns: 1st degree— 1 to 100 percent BSA; 2d degree— 1 to 15 percent BSA; 3d 
degree— 1 to 5 percent BSA. 

• Moderate Burns: 2d degree— 16 to 30 percent BSA; 3d degree— 6 to 15 percent BSA. 

• Severe Burns: 2d degree— > 30 percent BSA; 3d degree— 20 percent BSA. 



C-4. Wound Closure 

a. All Level 2 operative procedures for trauma will be left open (irrigated, debrided, packed, and 
dressed only). An exception includes patients exposed to radiation with operative trauma. Wounds that are 
left open and allowed to heal by secondary intention will serve as a potentially fatal nidus of infection in the 
radiologically injured patient. Wound healing is markedly compromised within hours of radiation injury. If 
at all possible, wounds should be closed primarily as soon as possible. Extensive debridement of wounds 
may be necessary in order to allow this closure. 

b. Traditionally, combat wounds are not closed primarily due to the high level of contamination, 
devitalized tissue, and the subsequent morbidity and mortality of the closed-space contamination. In the case 
of the radiation/combined injury patient, aggressive therapy will be required to allow survival. The decision 
to amputate an extremity that in ordinary circumstances would be salvageable will rest with the surgeon in 
the first two days following the combined injury. No studies are available regarding the use of aggressive 
marrow resuscitation as described for the physically wounded patient. 

c. All surgical procedures must be accomplished within 36 to 48 hours of radiation injury. If 
surgery cannot be completed at far-forward locations, patients with moderate injury will need early 
evacuation to a level where surgical facilities are immediately available. 

C-5. Return to Surgery 

If not evacuated within 72 hours, there will be a percentage of patients that will require a return to surgery. 
If there is radiation exposure, the return to surgery must be anticipated within 36 to 48 hours post- 
irradiation. 



C-6. Psychological Casualties 

The Treatment Briefs do not address psychological and related combat stress casualties associated with 
nuclear warfare (see Chapter 6). 

C-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-7. Decontamination 

Decontamination is not included in the Treatment Briefs. Not all casualties exposed to radiation will be 
contaminated. A quick survey of casualties with a RADIAC meter can determine if contamination is 
present. Decontamination is highly desirable prior to treatment of all casualties contaminated with 
radioactivity. This should consist of destruction of uniforms/clothes, washing the casualty with soap and 
water, and washing personal items (glasses, etc.) with soap and water. See Chapter 4 of this manual and 
FM 8-10-7 for more information on patient decontamination. 

C-8. Incidence Rates 

The Treatment Briefs assume that 100 percent of the force exposed to radiation will eventually enter the 
medical system. Therefore, the statistics in the Treatment Briefs for the incidence of symptoms, for 
example, nausea and vomiting, is based on doctrine that considers the total population exposed. The 
percentages for providing treatment, determining evacuation, and RTD are planning estimates. The 
mortality rates used for patient conditions are sequential and represent estimates of "middle of the road" 
patient expectations. Thus, 50 percent mortality at Level 1, with 50 percent mortality at Level 2, and 50 
percent mortality at Level 3, will result in 88 percent mortality and 12 percent salvage rate for in-theater 
care. 



C-9. Evacuation 

The assumed evacuation policy is that evacuation from the theater for nonreturn to duty personnel is 7 to 15 
days from time of injury. Note that the Theater Commander sets the actual evacuation policy. Expected 
evacuation times are as follows: 

• MEDEVAC Transport Categories (Level to Level of Care): 2 Hours = Urgent; 4 hours = 
Priority; 6 hours = Routine 

• AIRE VAC Transport (Out of theater): 6 Hours = Urgent; 24 Hours = Priority; 72 Hours = 
Routine 

C-10. Patient Holding Capabilities 

Level 1 has no holding capability. Those Level 2 facilities with holding capability may RTD or will have 
materials to provide nursing care up to 72 hours if unable to evacuate, except as otherwise noted. The 
holding capability at Level 2 is highly varied between the Services as shown below: 

Air Force MFST— None 

Air Force MASF— 2 hours 

Air Force EMEDS Basic— 24 hours 

C-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Air Force EMEDS + 10 AFTH— 7 days (evacuate when stable) 

Air Force EMEDS + 25 AFTH— 7 days (evacuate when stable) 

Air Force EMEDS ATH— 30 days 

Marine Surgical Company— 72 hours 

Army Forward Support Medical Company with FST attached— 40 cots and 8 ICU/Recovery beds — 
30 surgical procedures over 72 hours (10 per 24 hours) and holds 1 to 6 hours for postoperative recovery. If 
evacuation assets are not available, patients would be transferred to the patient holding section of the FSMC 
for up to 72 hours. 

Army FST— 8 ICU/Recovery beds holding for 1 to 6 hours. Doctrinally always collocated with 
FSMC and dependent for power, lab, x-ray, and so forth. 

Navy Primary Casualty Receiving & Treatment Ships— 72 Hours. 

C-ll. Blood Products 

a. Current doctrine states that group O blood— packed cells (85 percent Rh Positive and 15 
percent Rh Negative (for Rh Negative females) will be available at Level 2. Albumin (100 ml 25 percent 
can) is also available as a volume expander. Fresh frozen plasma (FFP), type-specific blood and platelet 
concentrate would not generally be available. Irradiated blood products (2000 cGy) will generally not be 
available at Level 2 and 3. Limited storage capacity of 50 units per field medical refrigerator exists at Level 
2, and maximums are usually set at this level on the amount of blood to be transfused to any specific patient. 
The Armed Services Blood Program Office's planning factor of 4 units per wounded in action/nonbattle 
injury casualty is intended for the entire continuum of care and not identified on level of care. Table C-2 
shows supply planning factors for Level 2 and 3 matrices for blood products and crystalloid fluid. All Class 
IV hemorrhage patients will require large bore vascular access. 

Table C-2. Level 2 and 3 Blood Product Matrices 



LEVEL 2 BLOOD USE ASSOCIATED WITH HEMORRHAGE CLASSIFICATION 
Hemorrhage Classification Blood Albumin 

Class II 

Class III 0.5 Units 2 (200 ml) 

Class IV 2 Units 4 (400 ml) 

LEVEL 3 BLOOD USE ASSOCIATED WITH HEMORRHAGE CLASSIFICATION 
Hemorrhage Classification Blood Crystalloid Albumin 

Class II 4 Liters 

Class III 2 Units 8 Liters 2 (200 ml) 

Class IV 2 Units plus 4 Units FFP 12 Liters 4 (400 ml) 



C-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



b. Blood products should be irradiated for nuclear casualties exposed to radiation levels of 300 
cGy or greater and requiring transfusions. Blood products provided to radiation casualties should be 
irradiated at a dose of 2000 cGy prior to administration to diminish incidence of transfusion-related graft 
versus host disease. Irradiated blood products will likely be in short supply and might be nonexistent within 
theater medical supply system. 

C-12. Patient Warming 

Warming techniques for all patients will be accomplished to the maximum extent possible, given the 
situation. These techniques include wrapping the patient, utilization of ventilation heater valve, warming 
blood/IVs/irrigation fluids through the use of fluid warmers, warming blankets, and controlling environ- 
mental temperature as much as possible. All Level 2 and 3 fluid and blood resuscitation requires at least one 
blood/fluid warmer per litter/bed in EMT, OR, and ICU. 

C-13. Sterilization 

The preferred method for instrument reuse is sterilization. However, weight and volume constraints may 
prevent resupply of sterilized instrumentation and/or sterilization capability. Therefore, high-level 
disinfectants may be used. 

C-14. C-Spine Management 

The data regarding actual incidence of cervical spine injuries in combat do not warrant the added burden of 
cervical collars and spine boards to treat all potential cervical spine injuries. Collars and boards should be 
used only in the limited number of patients with very high suspicion of cervical/spine injury. 

C-15. Tetanus 

Tetanus toxoid usage will be high. By definition, all traumatic wounds will be "dirty" and should require 
boosters within 5 years of most recent booster. The current booster schedule is every 10 years. Patients 
should receive tetanus toxoid booster at the point where they receive their in-theater surgical care, at Level 3, 
or at a point prior to transport out of theater. Tetanus toxoid will not be available at Level 2. It is assumed 
anyone deploying will have had at least one tetanus immunization in their lifetime. According to the Center 
for Disease Control, there has never been a recorded case of tetanus in a person having received at least one 
tetanus during their lifetime. Up to a 72 hour delay between Level 2 and Level 3 should not present a risk of 
tetanus to previously immunized individuals. 

C-16. Diets 

Unless otherwise stated in the briefs: 

• ICU patients will be NPO. Special diets will be specified. 

C-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



• ICW patients will advance to regular diet as tolerated. 

• MCW patients will advance to regular diet as tolerated. 

C-17. Casts and Splints 

To reduce weight and volume requirements, all casting/splinting will be done with polymer based casting 
and fiberglass tape in preference to plaster cast. No plaster will be available. 

C-18. Lab/X-ray/Pharmacy 

Diagnosis and treatment is driven by clinical examination with laboratory testing and x-rays being used for 
confirmation only when absolutely necessary. Point of care testing, with laboratory service support, is the 
optimal choice. 

C-19. Oxygen 

Oxygen cylinders are hazardous cargo, require a tremendous amount of weight and volume capacity, and 
are not readily available for resupply/refill. In the absence of an oxygen generator, oxygen should be used 
only if absolutely necessary due to these limiting factors. 

C-20. Patient Personal Support Kits 

It will be assumed that supplies issued to patients will be transferred with the patient rather than reissuing 
supplies such as admission kits, irrigation kits, and so forth. This will markedly reduce the logistical load for 
patient support items. 

C-21. Water 

Water sources will be limited. Conservation of potable water is critical. 

C-22. Linen 

Linen will not meet the demand in mass casualty (MASCAL) or patient care surges. Timely resupply of 
clean linen is unreliable. Disposable linen is the product of choice. 

C-23. Refrigeration 

There is no refrigeration at any Level 1 facility. Refrigeration exists at some Level 2 and at all Level 3 
facilities. 

C-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Section II. TREATMENT BRIEFS 



C-24. Treatment Brief No. 1: Radiation Exposure at 0.0-75 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Real or suspected exposure; vital signs (VS): stable; ambulatory patient; alert; 
oriented, anxious; 5 percent nausea, mild headache. 

Treatment: Reassurance. Routine ground transport 95 percent, RTD 5 percent. 

LEVEL IB 

Assumptions: VS: stable. Ambulatory patient; alert; oriented, anxious; 5 percent nausea, mild 
headache. 

Treatment: Consultation with Combat Stress Control Unit (CSCU), reassurance, PO pain 
medication 10 percent; PO antiemetics 5 percent. RTD 95 percent, routine ground transport 5 percent. 

LEVEL 2 

Assumptions: VS: stable, ambulatory patient; alert; oriented, anxious; 100 percent nausea, mild 
headache; automated differential cell counter available. 

Treatment: 25 percent IV fluids laboratory report (LR); rest, 75 percent PO antiemetics and 25 
percent IV antiemetics; reassurance/counseling. LAB: 100 percent CBC with differential for lymphocyte 
count every 12 hours for two days for prognosis and determination of RTD. LAB: 100 percent draw one 
blood specimen per patient for biodosimetry red top tube (clot) (keep refrigerated) for radiation exposure 
documentation; 100 percent RTD. 

C-25. Treatment Brief No. 2: Radiation Injury at 75-125 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Real exposure; VS: stable; ambulatory patient; alert; oriented, anxious; 5 to 30 
percent nausea/vomiting; mild headache; pretreatment with PO antiemetics may block nausea. 
Treatment: Reassurance. Routine ground transport 100 percent. 

LEVEL IB 

Assumptions: VS: stable to mild tachycardia. Ambulatory patient; alert; oriented, anxious; 5 to 30 
percent nausea/vomiting; mild headache. 

Treatment: Consultation with CSCU, reassurance; PO pain medication 10 percent; antiemetics 30 
percent; further nonmedical radiation exposure must be limited; RTD 50 percent, routine ground transport 
50 percent. 

LEVEL 2 

Assumptions: VS: stable to mild tachycardia. Ambulatory patient; alert; oriented, anxious; nausea/ 
vomiting 15 to 60 percent; headache; automated differential cell counter available. 

Treatment: 60 percent IV fluids LR, rest, 60 percent IV antiemetics; reassurance/counseling. 
Consultation with CSCU. LAB: 100 percent draw one blood specimen per patient for biodosimetry (red top 

C-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



tube [clot] [keep refrigerated]) for radiation exposure documentation; 100 percent CBC with differential for 
lymphocyte count every 12 hours for two days for prognosis; 80 percent RTD, routine ground transport 20 
percent. 

LEVEL 3 

Assumptions: VS: stable to mild tachycardia. Ambulatory patient; alert; oriented, anxious; nausea/ 
vomiting 5 to 10 percent; headache; automated differential cell counter available. Only 10 percent of 
casualties reporting to Level IB will ultimately reach Level 3. 

Treatment: EMT: VS; primary assessment, 10 percent IV antiemetics. LAB: 100 percent CBC 
with differential one time. 

OR: None. 
WARDS: ICU: None. 
ICW: None. 

MCW: VS once daily; supportive care; push PO fluids, advance diet. 
LAB: Serial CBC with differential every 12 hours times two days. RTD 100 percent. 

C-26. Treatment Brief No. 3: Radiation Injury at 125-300 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Significant exposure; VS: stable to tachycardia; ambulatory patient; alert; oriented, 
anxious; 20 to 70 percent nausea/vomiting (n/v); mild headache; 25 to 60 percent mild to moderate fatigability 
and weakness; pretreatment with antiemetics decreases vomiting. 

Treatment: Reassurance. Routine ground transport 100 percent. 

LEVEL IB 

Assumptions: Significant exposure; 5 percent mortality if untreated in 30 days; VS: stable to 
tachycardia; ambulatory patient; alert; oriented, anxious; 20 to 70 percent n/v; mild headache; 25 to 60 
percent mild to moderate fatigability and weakness; pretreatment with antiemetics decrease vomiting. 

Treatment: VS: start IV LR in 20 percent; reassurance, pain medication 10 percent; PO antiemetics 
50 percent; further radiation exposure strictly limited to medical diagnostic procedures; routine ground 
transport 100 percent. 

LEVEL 2 

Assumptions: Significant exposure; 5 percent mortality if untreated in 30 days; VS: stable to 
tachycardia; ambulatory patient; alert; oriented, anxious; 20 to 70 percent n/v; mild headache; 25 to 60 
percent mild to moderate fatigability and weakness; pretreatment with antiemetics decrease vomiting, 
automated differential cell counter available. 

Treatment: IV fluids 50 percent, rest, 70 percent PO antiemetics, reassurance/counseling. LAB: 
CBC with differential for lymphocyte count every 12 hours for prognosis; routine ground transport 100 
percent. Since no patients will RTD, biodosimetry will be deferred to Level 3. 

LEVEL 3 

Assumptions: Significant exposure; 5 percent mortality if untreated; VS: stable to tachycardia; 
ambulatory patient; alert; oriented, anxious; 10 to 30 percent n/v; mild headache; 25 to 60 percent mild to 

C-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



moderate fatigability and weakness; pretreatment with PO antiemetics decrease vomiting, automated 
differential cell counter available. Confirmation of radiation injury requires two days observation. 

Treatment: EMT: VS; primary assessment, PO antiemetics. LAB: 100 percent draw one blood 
specimen per patient for biodosimetry red top tube (clot) (keep refrigerated) for radiation exposure 
documentation; 100 percent CBC with differential. 
OR: None. 

WARDS: ICU: None. 
ICW: None. 

MCW: 100 percent of patients arriving at Level 3; VS; supportive care; 
push PO fluids, diet as tolerated. LAB: serial CBCs with differential every 12 hours. Cytokines (G-CSF 
480 meg subcutaneous daily) in 10 percent of patients; routine air transport 100 percent of patients admitted 
to MCW. 



C-27. Treatment Brief No. 4: Radiation Injury at 300-530 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Dangerous exposure; VS: stable to tachycardia; ambulatory patient; alert; oriented, 
anxious; 50 to 90 percent n/v; 10 percent diarrhea; 60 to 90 percent moderate fatigability and weakness; 
pretreatment with antiemetics may decrease vomiting. 

Treatment: Reassurance. Routine ground transport 100 percent. 

LEVEL IB 

Assumptions: Dangerous exposure; 5 to 50 percent mortality within 30 days if untreated; VS: stable 
to tachycardia; ambulatory patient; alert; oriented, anxious; 50 to 90 percent n/v; 60 to 90 percent moderate 
fatigability and weakness; pretreatment with antiemetics may decrease vomiting. 

Treatment: VS: start IV LR in 80 percent; reassurance; PO antiemetics 90 percent; no further 
radiation exposure allowable; routine ground transport 100 percent. 

LEVEL 2 

Assumptions: Dangerous exposure; 5 to 50 percent mortality within 30 days if untreated; VS: stable 
to tachycardia; ambulatory patient; alert; oriented, anxious; 50 to 90 percent n/v; 60 to 90 percent moderate 
fatigability and weakness; automated differential cell counter available; pretreatment with antiemetics may 
decrease vomiting. 

Treatment: Rest; IV fluids LR 100 percent. LAB: 25 percent electrolytes once daily times two 
days; 90 percent (45 percent PO and 45 percent injectable) antiemetics; counseling. LAB: CBC with 
differential for lymphocyte count every 12 hours for 24 to 36 hours for prognosis. Isolate from communicable 
diseases; urgent air transport 20 percent/urgent ground transport 80 percent. 

LEVEL 3 

Assumptions: Dangerous exposure; 5 to 50 percent mortality if untreated; VS: stable to tachycardia; 
ambulatory patient; alert; oriented, anxious; 30 to 60 percent n/v; 60 to 90 percent moderate fatigability 
and weakness; pretreatment with antiemetics may decrease vomiting; automated differential cell 
counter. 

C-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Treatment: EMT: VS; primary assessment, 60 percent (30 percent PO and 30 percent injectable) 
antiemetics. LAB: 100 percent CBC with differential, 100 percent draw one blood specimen per patient for 
biodosimetry red top (clot) (keep refrigerated) for radiation exposure documentation. 
OR: None. 
WARDS: ICU: None. 

ICW: 10 percent of patients arriving at Level 3; VS: qid; supportive care; 
100 percent of patients require IV LR fluids (4 liters/day); clear liquids. LAB: 100 percent electrolytes 
once daily, serial CBCs with differential every 12 hours daily. Cytokines (G-CSF 480 meg subcutaneous 
daily) in 100 percent of patients; draw blood specimens for HLA typing (three yellow top tubes); reverse 
isolation. Patients admitted to ICW priority air transport 100 percent. 

MCW: 90 percent of patients arriving at Level 3; VS; supportive care; 
push PO fluids, advance diet. LAB: serial CBCs with differential every 12 hours. Cytokines (G-CSF 480 
meg subcutaneous daily) in 100 percent of patients. Reverse isolation. Draw blood specimens for HLA 
typing (three yellow top tubes). Patients admitted to MCW— routine air transport 100 percent. 



C-28. Treatment Brief No. 5: Radiation Injury at 530-830 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Critical exposure; VS: tachycardia; litter 50 percent, ambulatory 50 percent alert; 
oriented, anxious; 80 to 100 percent n/v; 10 percent diarrhea; 90 to 100 percent moderate to extreme 
fatigability and weakness; pretreatment with antiemetics is ineffective. 

Treatment: Urgent ground transport 100 percent. 

LEVEL IB 

Assumptions: Critical exposure; 50 to 95 percent mortality within 30 days if untreated; VS: 
tachycardia; litter 50 percent, ambulatory 50 percent alert; oriented, anxious; 80 to 100 percent n/v; 90 to 
100 percent moderate to extreme fatigability and weakness; pretreatment with antiemetics is ineffective. 

Treatment: VS once, start IV LR in 100 percent; injectable antiemetics 100 percent; pain 
medications 10 percent; isolate from communicable diseases; no further radiation exposure allowable; 
urgent ground transport 30 percent/urgent air transport 70 percent with overflight to Level 3 if possible. 

LEVEL 2 

Assumptions: Overflight if possible. Critical exposure; 50 to 95 percent mortality if untreated; VS: 
tachycardia; litter 50 percent, ambulatory 50 percent alert; oriented, anxious; 80 to 100 percent n/v; 10 
percent diarrhea; 90 to 100 percent moderate to extreme fatigability and weakness; pretreatment with 
antiemetics is ineffective. 

Treatment: VS; start IV LR in 100 percent; injectable antiemetics 100 percent; reverse isolation; no 
further radiation exposure allowable; urgent transport 100 percent to Level 3. 

LEVEL 3 

Assumptions: Critical exposure; 50 to 95 percent mortality if untreated; VS: tachycardia; litter 50 
percent, ambulatory 50 percent; alert; oriented, anxious; 30 to 70 percent n/v; 10 percent diarrhea; 90 to 100 
percent moderate to extreme fatigability and weakness; pretreatment with antiemetics is ineffective. 

C-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Automated differential cell counter available. Comment: Air evacuated by day 4, if unable to evacuate by 
day four post exposure, antibiotic and antivirals will be needed along with surveillance cultures. 

Treatment: EMT: VS once; primary assessment, 70 percent injectable antiemetics, 100 percent 
IV LR. LAB: Draw one blood specimen per patient for biodosimetry red top (clot) (keep refrigerated) for 
radiation exposure documentation; CBC with differential. 
OR: None. 
WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3. VS: qid; supportive 
care; 100 percent of patients require IV fluids (LR, 4 liters/day), NPO 50 percent, clear liquids 50 percent. 
LAB: Serial CBCs with differential every 12 hours for the first four days. Cytokines (G-CSF 480 meg 
subcutaneous daily) in 100 percent of patients; 10 percent antidiarrheal medications; reverse isolation. 
Draw blood specimens for HLA typing three yellow top tubes. Patients admitted to ICW— Urgent air 
transport 100 percent to Level V treatment facility. 

MCW: None. 

C-29. Treatment Brief No. 6: Radiation Injury at 830-1500 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Critical exposure; VS: tachycardia; litter 100 percent, 90 to 100 percent disoriented, 
anxious; immediate onset of 100 percent n/v; diarrhea 10 percent; 100 percent extreme fatigability and 
weakness; pretreatment with antiemetics is ineffective. 

Treatment: Urgent ground transport 100 percent. 

LEVEL IB 

Assumptions: Critical exposure; 100 percent mortality within 15 to 30 days if untreated; VS: 
tachycardia, hypotension 25 percent; litter 100 percent, disoriented 90 to 100 percent, anxious; immediate 
onset of 100 percent n/v; 10 percent diarrhea; 100 percent extreme fatigability and weakness; pretreatment 
with antiemetics is ineffective. 

Treatment: VS: once; start IV LR in 100 percent; injectable antiemetics 100 percent; IV/IM 
morphine 25 percent; no further radiation exposure allowable; urgent ground transport 100 percent. 

LEVEL 2 

Assumptions: Critical exposure; 100 percent mortality if untreated; VS: tachycardia, hypotension 
25 percent, 50 percent low grade fever; litter 100 percent, disoriented 90 to 100 percent, anxious; 100 
percent immediate onset of n/v; 10 percent diarrhea; 100 percent extreme fatigability and weakness; 
pretreatment with antiemetics is ineffective. Automated differential cell counter available. 

Treatment: VS, start IV LR in 100 percent; injectable antiemetics 100 percent; antidiarrheal 
medication 10 percent. LAB: CBC with differential every 12 hours. Comment: Attempt reverse isolation; 
no further radiation exposure allowable; urgent ground transport 100 percent to Level 3. 

LEVEL 3 

Assumptions: Critical exposure; mortality 100 percent if untreated; VS: tachycardia, hypotension 
25 percent, low grade fever 50 percent; litter 100 percent, disoriented 40 to 70 percent, anxious; 40 to 70 
percent immediate onset of n/v; 10 percent diarrhea; 100 percent extreme fatigability and weakness; 
pretreatment with antiemetics is ineffective. Automated differential cell counter available. 

C-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Treatment: EMT: VS once; primary assessment, injectable antiemetics. LAB: Draw one blood 
specimen per patient for biodosimetry red top (clot) (keep refrigerated) for radiation exposure documenta- 
tion; CBC with differential. 

OR: None. 

WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3; VS, supportive care; 100 
percent IV fluids (LR 4 liters/day), NPO 50 percent, clear liquids 50 percent. 

LAB: 100 percent serial CBCs with differential every 12 hours daily, electrolytes 
q24h. Cytokines (G-CSF 480 meg subcutaneous daily) in 100 percent of patients; 10 percent antidiarrheal 
medications; reverse isolation. 100 percent draw blood specimens for HLA typing three yellow top tubes 
acid-citrate dextrose (ACD) (keep refrigerated). Patients admitted to ICW —100 percent urgent air trans- 
port to a Level V treatment facility. If unable to evacuate by day four postexposure, blood products (pref- 
erably irradiated to 2000 cGy), antibiotics, antivirals, antifungals, and surveillance cultures will be needed. 

MCW: None. 



C-30. Treatment Brief No. 7: Radiation Injury >1500 cGy Without Other Physical Injury 

LEVEL 1A 

Assumptions: Lethal exposure; 95 to 100 percent mortality even with treatment; VS; unstable; litter 
100 percent, disoriented 75 percent, anxious; 100 percent immediate onset of nausea/vomiting/diarrhea 
(n/v/d); 100 percent extreme fatigability and weakness; pretreatment with antiemetics is ineffective. 

Treatment: Urgent ground transport 100 percent. 

LEVEL IB 

Assumptions: Lethal exposure; 95 to 100 percent mortality even with treatment; VS, unstable; litter 
100 percent, disoriented 75 percent, anxious; 100 percent immediate onset of n/v/d; 100 percent extreme 
fatigability and weakness; pretreatment with antiemetics is ineffective. 

Treatment: VS: once; start IV LR in 25 percent; injectable antiemetics 100 percent; 100 percent IM 
morphine 2 to 4 mg q 1 to 4 hours as needed; no further radiation exposure allowable; routine ground 
transport 100 percent to Level 2. Comment: Those patients with neurologic signs are expectant. 

LEVEL 2 

Assumptions: Lethal exposure; 95 to 100 percent mortality even with treatment; VS; unstable; litter 
100 percent, disoriented 75 percent, anxious; 100 percent immediate onset of n/v/d; 100 percent extreme 
fatigability and weakness; pretreatment with antiemetics is ineffective. Automated differential cell counter. 
Expectant patients (with neurologic deficits) 75 percent, nonexpectant 25 percent. 

Treatment: For all (100 percent): VS prn; antiemetics IV, IM morphine 2 to 4 mg q 1 to 4 hours as 
needed for pain; antidiarrheal medications. Nonexpectant (25 percent): maintain IV LR. LAB: CBC with 
differential every 12 hours. Attempt reverse isolation; no further radiation exposure allowable; urgent 
ground transport (25 percent). Expectant (75 percent): Routine ground transport 75 percent. 

LEVEL 3 

Assumptions: Lethal exposure; 95 to 100 percent mortality even with treatment; VS, unstable; litter 
100 percent, neurological casualties (75 percent) admitted to MCW for palliative care; 25 percent admitted 

C-13 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



to ICW (no neurologic signs); 100 percent n/v/d; 100 percent extreme fatigability and weakness. Automated 
differential cell counter. Eventual mortality at this level is estimated at 80 percent. 

Treatment: EMT: VS: once; maintain IV LR in 25 percent; injectable antiemetics 100 percent; 
100 percent IV/IM morphine 2 to 4 mg once if needed. LAB: 100 percent of patients need blood drawn for 
biodosimetry (red top clot) (keep refrigerated) for radiation exposure documentation. In those without 
neurologic signs (25 percent of patients), CBC with differential and electrolytes; reverse isolation. 

OR: None. 

WARDS: ICU: None. 

ICW: 25 percent of patients arriving at Level 3; VS q4h; supportive care; 
100 percent IV fluids (LR 4 liters per day), NPO 100 percent. LAB: 100 percent serial CBCs with 
differential every 12 hours daily, 100 percent electrolytes q24h. Cytokines (G-CSF 480 meg subcutaneous 
daily) in 100 percent of patients; 100 percent antidiarrheal medications. Eventual mortality is 80 percent 
from this radiation exposure; reverse isolation. Draw blood specimens for HLA typing three yellow top 
tubes (ACD) 100 percent (keep refrigerated). Note: If unable to evacuate by day four postexposure, blood 
products preferably irradiated to 2000 cGy, antibiotics, antivirals, antifungals, and surveillance cultures will 
be needed. Patients admitted to ICW— Urgent air transport 100 percent air evacuate to Level V treatment 
facility. 

MCW: 75 percent of patients arriving at Level 3; palliative care; 100 
percent morphine IV every 1 to 4 hours daily as needed for pain (mortality 100 percent). Patients admitted 
to MCW— 100 percent mortality. 

C-31. Treatment Brief No. 8: Radiation at 0-125 cGy With Nonoperative Trauma (Examples 
include concussion, simple lacerations, closed fractures, ligamental injuries, and so forth.) 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 50 percent litter patient (from morphine)/50 
percent ambulatory patient (no morphine); VS stable; severe pain in upper extremity; neurovascular status 
intact; no significant hemorrhage; moderate deformity of elbow noted; alert; oriented. Radiation effects 
include: apprehension and agitation; n/v 5 to 30 percent; mild headache; pretreatment with antiemetics 
decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: Sling and swathe extremity; 50 percent patients IM morphine; dress open wounds; 
reassurance; 100 percent routine ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 50 percent litter patient/50 percent ambulatory 
patient; VS stable; severe pain in upper extremity; neurovascular status intact; no significant hemorrhage; 
moderate deformity of elbow noted; alert; oriented. Radiation effects include: apprehension and agitation; 
n/v 5 to 30 percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation does not 
contribute to mortality at this level. 

Treatment: VS: start IV LR in 50 percent; sling and swathe extremity; IM morphine 50 percent; 30 
percent PO antiemetics promethazine; reassurance; 100 percent routine ground transport. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 50 percent litter patients/50 percent ambulatory 
patients; VS stable; severe pain in upper extremity; neurovascular status intact in 99 percent; no significant 

C-14 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



hemorrhage; moderate deformity of elbow noted. Radiation effects include: apprehension and agitation; 
n/v 5 to 30 percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation may 
contribute to morbidity at this level. 

Treatment: IV/IM morphine; IV fluids LR 80 percent, rest, 30 percent PO antiemetics, reassurance/ 
counseling. X-ray, neurovascular checks, one percent axillary block and fasciotomy and/or attempted 
reduction for compartment syndrome and vascular compromise; splint extremity; sling applied; saline lock. 
LAB: CBC with differentials twice daily until transferred; 100 percent routine ground transport. 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; 50 percent litter patients/50 percent ambulatory 
patients; VS stable; x-ray reveals fracture, dislocation of elbow; neurovascular status intact; no other 
apparent injuries. Radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild headache; 
pretreatment with antiemetics decreases vomiting; radiation may contribute to morbidity at this level. 

Treatment: EMT: VS; primary assessment. LAB: 100 percent CBC with differential; draw one 
blood specimen per patient for biodosimetry (red top tube [clot] [keep refrigerated]) for radiation exposure 
prognosis. Maintain IV; 50 percent IM/IV morphine; orthopedist consult; doppler assessment; x-ray: 
elbow, humerus, forearm; compartment pressure assessment 10 percent; orthopedist reduces 90 percent 
in EMT and places arm in posterior plaster long arm splint and sling; x-ray: repeat of elbow after 
reduction. 

OR: 10 percent have open reduction with possible fixation of fracture with plates and 
screws/K-wires; further definitive stabilization may be required at higher level; fasciotomy of forearm and 
application of long arm splint under axillary block; IV antibiotics; x-ray: elbow; 2 liters RL; OR table 
time— 180 min. Digital portable radiography in OR. 
WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3. VS; 100 percent IV LR; 
IV antibiotics (10 percent) for operative cases; IV/IM morphine; elevate limb; neuro and circulatory 
checks; doppler; dressing changes; CBC with differentials twice daily times four days; reverse isolation. 
Priority air transport 100 percent. 

MCW: None. 

C-32. Treatment Brief No. 9: Radiation at 125-530 cGy With Nonoperative Trauma (Examples 
include concussion, simple lacerations, closed fractures, ligamental injuries, and so forth.) 

LEVEL 1A 

Assumptions: Significant radiation exposure; 75 percent litter patient/25 percent ambulatory patient; 
VS stable; severe pain in upper extremity; neurovascular status intact; no significant hemorrhage; moderate 
deformity of elbow noted; alert; oriented. Radiation effects include: apprehension and agitation; n/v 50 to 90 
percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics decrease 
vomiting; radiation does not contribute to mortality at this level. 

Treatment: Sling and swathe extremity; 75 percent IM morphine; dress open wounds; reassurance; 
100 percent routine ground transport. 

LEVEL IB 

Assumptions: Significant radiation exposure; 75 percent litter patient/25 percent ambulatory patient; 
VS stable; severe pain in upper extremity; neurovascular status intact; no significant hemorrhage; moderate 

C-15 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



deformity of elbow noted; alert; oriented. Radiation effects include: apprehension and agitation; n/v 50 to 90 
percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics decreases 
vomiting; radiation does not contribute to mortality at this level. 

Treatment: VS: start IV LR in 90 percent; sling and swathe extremity; IM morphine 100 percent; 
90 percent PO/IM antiemetics; reassurance; further radiation exposure strictly limited to medical diagnostic 
procedures; 100 percent routine transport. 

LEVEL 2 

Assumptions: Significant and potentially lethal radiation exposure; 75 percent litter patients/25 
percent ambulatory patients; VS stable; severe pain in upper extremity; neurovascular status intact in 99 
percent; no significant hemorrhage; moderate deformity of elbow noted. Radiation effects include: 
apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; 
pretreatment with antiemetics may decrease vomiting; radiation contributes to morbidity at this level. 
Automated cell counter available. 

Treatment: IV/IM morphine; IV fluids LR 100 percent; rest; 90 percent PO antiemetics, counseling. 
X-ray, neurovascular checks, one percent axillary block and fasciotomy and/or attempted reduction for 
compartment syndrome and vascular compromise. Splint extremity; sling applied; saline lock. LAB: CBC 
with differentials twice daily until transferred; 100 percent routine ground transport. 

LEVEL 3 

Assumptions: Significant and potentially lethal radiation exposure; 75 percent litter patients/25 
percent ambulatory patients; VS stable; x-ray reveals fracture, dislocation of elbow; neurovascular status 
intact; no other apparent injuries. Radiation effects include: apprehension and agitation; n/v 50 to 90 per- 
cent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics may decrease 
vomiting; radiation contributes to morbidity at this level. Radiation will contribute to morbidity at this level 
due to immunosuppression. 

Treatment: EMT: VS; primary assessment. LAB: CBC with differential, 100 percent draw one 
blood specimen per patient for biodosimetry red top tube (clot) (keep refrigerated) for radiation exposure 
prognosis; maintain IV; 75 percent IM/IV morphine. Orthopedist consult; doppler assessment; x-ray: 
elbow, humerus, forearm; compartment pressure assessment 10 percent; orthopedist reduces 90 percent 
in EMT and places arm in posterior plaster long arm splint and sling; x-ray: repeat of elbow after 
reduction. 

OR: 10 percent have open reduction with possible fixation of fracture with plates and 
screws/K-wires; further definitive stabilization may be required at higher level; fasciotomy of forearm and 
application of long arm splint under axillary block; IV antibiotics; x-ray: elbow; 2 liters RL. OR table 
time— 180 minutes. Digital portable radiography in OR. 
WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3. VS; 100 percent IV LR; 
IV antibiotics (10 percent) for operative cases; IV/IM morphine; elevate limb; neuro and circulatory 
checks; doppler; dressing changes. Administer cytokines (480 meg G-CSF) subcutaneous daily in 100 
percent; CBC with differentials twice daily. Draw blood specimens for HLA typing (three yellow top tubes 
[ACD] [keep refrigerated]). Reverse isolation. Patients admitted to ICW— 10 percent early mortality due 
to combination of surgery and high dose radiation; 90 percent priority air transport. 

MCW: None. 

C-16 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-33. Treatment Brief No. 10: Radiation >530 cGy With Nonoperative Trauma (Examples 
include concussion, simple lacerations, closed fractures, ligamental injuries, and so forth.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable; severe 
pain in upper extremity; neurovascular status intact; no significant hemorrhage; moderate deformity of 
elbow noted; alert; oriented. Extreme radiation doses will cause neurological deficits; additional radiation 
effects include: apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment 
with antiemetics may have no effects; radiation may contribute to morbidity at this level. 

Treatment: Dress open wounds; reassurance; sling and swathe extremity; IM morphine; 100 
percent priority ground transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable; severe 
pain in upper extremity; neurovascular status intact; no significant hemorrhage; moderate deformity of 
elbow noted. Extreme radiation doses will cause neurological deficits; additional radiation effects include: 
apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics 
may have no effects; radiation may contribute to morbidity at this level. Critical radiation injury with 
persistent central neurological signs places 10 percent of patients in expectant category at this level. 

Treatment: VS; start IV LR in nonexpectant patients (90 percent of patients); sling and swathe 
extremity; IM morphine 100 percent; 90 percent PO/IM antiemetics; reassurance. Note: All surgery must 
be completed within 36—48 hours; evacuation to a level of care that can provide appropriate wound closure 
surgery is essential. 90 percent priority ground transport; 10 percent routine ground transport. 

LEVEL 2 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable; severe 
pain in upper extremity; neurovascular status intact in 90 percent; no significant hemorrhage; moderate 
deformity of elbow noted. Extreme radiation doses will cause neurological deficits; additional radiation 
effects include: apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment 
with antiemetics may have no effects; radiation may contribute to morbidity at this level. Critical radiation 
injury with persistent central neurological signs places 20 percent of patients in expectant category at this 
level. 

Treatment: VS; Maintain IV LR in nonexpectant patients (80 percent of patients); IV/IM morphine; 
x-ray, neurovascular checks, one percent axillary block and fasciotomy and/or attempted reduction for 
compartment syndrome and vascular compromise; splint extremity; sling applied; saline lock. LAB: CBC 
with differentials twice daily until transferred. Note: All surgery must be completed within 36 to 48 hours; 
evacuation to a level of care that can provide appropriate wound closure surgery is essential. Attempt 
reverse isolation. 80 percent priority air transport; 20 percent routine air transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable; x-ray 
reveals fracture, dislocation of elbow; neurovascular status intact in 90 percent of patients arriving at 
Level 3; no other apparent injuries. Radiation effects include: apprehension and agitation; n/v 100 percent; 
fatigue and weakness 100 percent; pretreatment with antiemetics may have no effects; radiation may 

C-17 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



contribute to morbidity at this level. Critical radiation injury with persistent central neurological signs 
places 30 percent of patients in expectant category at this level. 

Treatment: EMT: VS; primary assessment, maintain IV; 100 percent IM/IV morphine; 
orthopedist consult; doppler assessment; x-ray: elbow, humerus, forearm; compartment pressure 
assessment 10 percent; orthopedist reduces 90 percent in EMT and places arm in posterior plaster long arm 
splint and sling; x-ray: repeat of elbow after reduction. LAB: (for nonexpectant patients— 70 percent); CBC 
with differential for radiation exposure; 100 percent draw one blood specimen per patient for biodosimetry 
(red top [clot] [keep refrigerated]) for prognosis. 

OR: 10 percent have open reduction with possible fixation of fracture with plates and 
screws/K-wires; further definitive stabilization may be required at higher level; fasciotomy of forearm and 
application of long arm splint under axillary block; IV antibiotics; x-ray: elbow; 2 liters RL; OR table 
time— 180 minutes. Digital portable radiography in OR. 

WARDS: ICU: None. 

ICW: 70 percent of patients arriving at Level 3; VS; 100 percent IV LR; 
IV antibiotics (10 percent) for operative cases; IV/IM morphine; elevate limb; neuro and circulatory 
checks; doppler; dressing changes. Administer cytokines (G-CSF 480 meg subcutaneous daily) in 100 
percent; CBC with differentials twice daily. Three yellow top tubes (ACD) for HLA typing, keep 
refrigerated. Reverse isolation. Patients admitted to ICW: Mortality 5 percent at this level at 5 to 7 days, 
95 percent priority air transport. 

MCW: Expectant patients only (30 percent of patients arriving at Level 3); 
IV/IM morphine as needed. Patients admitted to MCW: Mortality 100 percent by seven days. 



C-34. Treatment Brief No. 11: Radiation at 0-125 cGy With Operative Trauma 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; litter patient; alert, cooperative and oriented; 
VS: pulse greater than 100, B/P 100/60, no respiratory distress, evidence of closed intra-abdominal 
hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decrease vomiting and possibly increase fatigability; radiation 
does not contribute to mortality at this level. 

Treatment: Start IV 100 percent (LR); reassurance; 100 percent priority ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 5 to 30 
percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation does not contribute to 
mortality at this level. 

Treatment: VS: Maintain IV LR in 100 percent; stabilization and IM morphine; reassurance; 30 
percent treatment with antiemetics; 10 percent cervical spine stabilized; 100 percent urgent air transport. 
Note: All surgery must be completed within 36 to 48 hours; evacuation to a level of care that can provide 
appropriate urgent surgery. 

C-18 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 5 to 30 
percent; mild headache; pretreatment with antiemetics decrease vomiting and possibly increase fatigability; 
radiation may contribute to morbidity at this level. 

Treatment: 25 percent exploratory laparoscopy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 
hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter. Remaining 75 percent: IV fluids LR 100 percent; rest; 30 percent IV/IM antiemetics; 
reassurance/counseling. Note: All surgery must be completed within 36 to 48 hours; evacuation to a level of 
care that can provide appropriate urgent surgery. If appropriate surgery has been provided at this level, then 
routine evacuation (25 percent) to Level 3; otherwise urgent air transport (75 percent). 



LEVEL 3 

Assumptions: Real or suspected radiation exposure; litter patient; Class III hemorrhage; VS: 
pulse 120, B/P 100/70, respirations normal; alert; oriented. Radiation effects include: apprehension 
and agitation; n/v 5 to 30 percent; mild headache; pretreatment with antiemetics decreases vomiting; 25 
percent will receive appropriate wound closure surgery at Level 2; radiation may contribute to morbidity at 
this level. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube; LAB: 100 percent CBC with 
differential, UA, TC for 4 units; x-rays: chest, 50 percent pelvis films. LAB: 100 percent draw one blood 
specimen per patient for biodosimetry red top tube (clot) (keep refrigerated), for radiation exposure 
prognosis. 

OR: 75 percent of patients arriving at Level 3. Laparotomy and drainage of liver 
injury under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters RL; 2 units blood; 
arterial line 10 percent. Lab: CBC, blood gases; OR table time— 120 minutes. Note: All surgery must be 
completed within 36 to 48 hours of radiation exposure. 

WARDS: 25 percent of patients arriving at Level 3— direct admit from Level 2. 

ICU: 100 percent of patients arriving at Level 3. VS; maintain IV fluids; IV 
antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent maintain 
ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain central 
line and monitoring and arterial line; cardiac monitor and pulse oximeter; dressing reinforcement; dc 
central/arterial line before leaving ICU. LAB: CBC with differential twice daily, electrolytes, clotting 
studies, Amylase, LFTs on admission; x-ray: chest, 10 percent c-spine. Consider cytokines (G-CSF 480 
meg subcutaneous daily). 

ICW: 100 percent of patients arriving at Level 3 will be transferred 
from ICU by day 2. VS; IVs with IV antibiotics; parenteral pain medications; 25 percent on 2 by mask; 
Foley catheter care; maintain NG tube; NPO; dressing reinforcement; drain care. Consider cytokines 
(G-CSF 480 meg subcutaneous daily); CBC with differentials three times daily. Routine air transport 100 
percent. 

MCW: None. 

C-19 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-35. Treatment Brief No. 12: Radiation at 125-530 cGy With Operative Trauma 

LEVEL 1A 

Assumptions: Significant radiation exposure; 100 percent litter patient; alert, cooperative and 
oriented; VS pulse greater than 100, B/P 100/60, no respiratory distress, evidence of closed intra-abdominal 
hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild 
headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics decrease vomiting; radiation 
does not contribute to mortality at this level. 

Treatment: Start IV 100 percent (LR); reassurance; 100 percent priority ground transport. 

LEVEL IB 

Assumptions: Significant radiation exposure; 100 percent litter patients; alert, cooperative and 
oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra-abdominal 
hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild 
headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics decrease vomiting; radiation 
contributes to morbidity at this level. 

Treatment: VS; maintain IV LR in 100 percent; stabilization and IM morphine; reassurance; 90 
percent Kytril IV; 10 percent cervical spine stabilized; 100 percent urgent air transport. Note: All surgery 
must be completed within 36 to 48 hours; evacuation to a level of care that can provide appropriate urgent 
surgery. 

LEVEL 2 

Assumptions: Significant and potentially lethal radiation exposure; 100 percent litter patients; alert, 
cooperative and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of 
closed intra-abdominal hemorrhage and injury. Radiation effects include apprehension and agitation; n/v 50 
to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with antiemetics may 
decrease vomiting; radiation contributes to morbidity at this level. Automated cell counter available. 

Treatment: 25 percent exploratory laparotomy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 
hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter. Remaining 75 percent: 90 percent IV antiemetics (Kytril), counseling. LAB: CBC with 
differentials twice daily until transferred. Note: All surgery must be completed within 36 to 48 hours; 
evacuation to a level of care that can provide appropriate urgent surgery. If appropriate surgery has been 
provided at this level, then routine evacuation (25 percent) to Level 3; otherwise urgent air transport (75 
percent). 

LEVEL 3 

Assumptions: Significant and potentially lethal radiation exposure; litter patient; Class III 
hemorrhage; VS: pulse 120, B/P 100/70, respirations normal; alert; oriented. Radiation effects include 
apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; 
pretreatment with antiemetics may decrease vomiting; radiation contributes to morbidity at this level. 25 
percent will receive appropriate surgery at Level 2; radiation will contribute to mortality and morbidity at 
this level. Radiation at this level combined with trauma multiplies mortality rates over baseline values. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube; lab: CBC with differential, UA, TC 

C-20 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



for 4 units; x-rays: chest, 50 percent pelvis films, 90 percent IV antiemetic (Kytril); 100 percent draw one 
blood specimen per patient for biodosimetry red top tube (clot). 

OR: 75 percent of patients arriving at Level 3. Laparotomy and drainage of liver 
injury under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters LR; 2 units blood; 
arterial line 10 percent. LAB: CBC, blood gases; OR table time— 120 minutes. Note: All surgery must be 
completed within 36—48 hours of radiation exposure. 

WARDS: ICU: 100 percent of patients arriving at Level 3. VS; maintain IV fluids; 
IV antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent 
maintain ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain 
central line and monitoring and arterial line; cardiac monitor and pulse oximeter; dressing reinforcement; 
dc central/arterial line before leaving ICU. LAB: CBC with differential twice daily, electrolytes, clotting 
studies, Amylase, LFTs on admission; x-ray: chest, 10 percent c-spine. Administer cytokines (G-CSF 480 
meg subcutaneous daily) in 100 percent. 100 percent draw blood specimens for HLA typing (three yellow 
top tubes [ACD] [keep refrigerated]). Reverse isolation. 

ICW: 100 percent of patients arriving at Level 3 will be transferred from 
ICU by day 2. VS; IVs with IV antibiotics; parenteral pain medications; 25 percent on 2 by mask; Foley 
catheter care; maintain NG tube; NPO; dressing reinforcement; drain care. Administer cytokines (G-CSF 
480 meg subcutaneous daily) in 100 percent. LAB: CBC with differentials twice daily. 100 percent draw 
blood specimens for HLA typing (three yellow top tubes [ACD]; keep refrigerated). Reverse isolation. 100 
percent urgent air transport. 

MCW: None. 



C-36. Treatment Brief No. 13: Radiation >530 cGy With Operative Trauma 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patient; VS: pulse greater than 
100, B/P 100/60, no respiratory distress, evidence of closed intra-abdominal hemorrhage and injury. 
Extreme radiation doses will cause neurological deficits; additional radiation effects include: apprehension 
and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics may have 
no effects; radiation may contribute to morbidity at this level. Critical radiation injury with major trunk and/ 
or head trauma places patient in expectant category. 

Treatment: Start IV 100 percent (LR) reassurance. Patients with major trauma and high dose 
radiation have the lowest transport priority; 95 percent expectant patients routine ground transport; 5 percent 
nonexpectant patients urgent ground transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS: pulse greater 
than 100, B/P 100/60, no respiratory distress; evidence of closed intra-abdominal hemorrhage and injury. 
Extreme radiation doses will cause neurological deficits; additional radiation effects include: apprehension 
and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics may have 
no effects; radiation contributes to morbidity at this level. Critical radiation injury with major trunk and/or 
head trauma places patient in expectant category. 

Treatment: VS: Maintain IV LR in 5 percent (nonexpectant); stabilization and IM morphine; 
reassurance; 90 percent Kytril IV; 10 percent cervical spine stabilized; 5 percent Overfly— urgent air 

C-21 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



transport, 95 percent routine ground transport. Note: All surgery must be completed within 36 to 48 hours; 
evacuation to a level of care that can provide appropriate urgent surgery. 

LEVEL 2 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS: pulse greater 
than 100, B/P 100/60, no respiratory distress; evidence of closed intra-abdominal hemorrhage and injury. 
Extreme radiation doses will cause neurological deficits; additional radiation effects include: apprehension 
and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics may have 
no effects; radiation contributes to morbidity at this level. Critical radiation injury with major trunk and/or 
head trauma places the patient in expectant category. Radiation at this level combined with trauma 
multiplies mortality rates over baseline values. 

Treatment: Parenteral pain medications (morphine); 100 percent routine ground transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure; litter patient; Class III hemorrhage; VS: pulse 
120, B/P 100/70, respirations normal. Extreme radiation doses will cause neurological deficits; additional 
radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; 
pretreatment with antiemetics may have no effects; radiation contributes to morbidity and mortality at this 
level. Critical radiation injury with major trunk and/or head trauma places patient in expectant category. 
Radiation at this level combined with trauma multiplies mortality rates over baseline values. 

Treatment: EMT: VS; primary assessment, 3 percent of patients arriving at Level 3 are 
nonexpectant requiring surgery. IV restarted, give 2 liters LR; 2d IV started; IV antibiotics; parenteral 
morphine; Foley catheter; NG tube; LAB: CBC with differential, UA, TC for 4 units; x-rays: chest, 50 
percent pelvis films, 90 percent IV antiemetic (Kytril); 97 percent of patients arriving at Level 3 are 
expectant and transferred to MCW. One hundred percent of patients arriving at Level 3 draw one blood 
specimen per patient for biodosimetry red top tube (clot). 

OR: 3 percent of patients arriving at Level 3. Laparotomy and drainage of liver injury 
under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters RL; 4 units blood; 
arterial line 10 percent. LAB: CBC, blood gases; OR table time— 120 minutes. Note: All surgery must be 
completed within 36 to 48 hours of radiation exposure. 

WARDS: ICU: 3 percent of patients arriving at Level 3. VS; maintain IV fluids; IV 
antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent maintain 
ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain central 
line and monitoring and arterial line; cardiac monitor and pulse oximeter; dressing reinforcement; dc 
central/arterial line before leaving ICU. LAB: CBC with differential twice daily, electrolytes, clotting 
studies, Amylase, LFTs on admission. Administer cytokines (480 meg G-CSF) subcutaneous daily in 100 
percent. Draw blood specimens for HLA typing (three yellow top tubes ACD; [keep refrigerated]). 
Reverse isolation. Patients admitted to ICU— 100 percent of patients to ICW after two days. 

ICW: 3 percent of patients arriving at Level 3 will be transferred from 
ICU by day 2. VS; IVs with IV antibiotics; parenteral pain medications; 25 percent on 2 by mask; Foley 
catheter care; maintain NG tube; NPO; dressing reinforcement; drain care. Administer cytokines (G-CSF 
480 meg subcutaneous daily) in 100 percent. LAB: CBC with differentials twice daily; 100 percent draw 
blood specimens for HLA typing (three yellow top tubes [ACD] [keep refrigerated]). Reverse isolation. 

MCW: Expectant patients only (97 percent of patients arriving at Level 3); 
IM pain medications as needed. Patients admitted to MCW— mortality 90 percent by seven days. 

C-22 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-37. Treatment Brief No. 14: Radiation at 0-125 cGy With Mild Burn 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; VS stable, 
alert and oriented; additional radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decrease vomiting; radiation does not contribute to mortality at this 
level. 

Treatment: Clean and dress burns; pain medication; reassurance; 100 percent routine ground 
transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; VS stable, 
alert and oriented; additional radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decrease vomiting; radiation does not contribute to mortality at this 
level. 

Treatment: VS; stabilization, IV LR; pain medication; reassurance; 100 percent routine ground 
transport. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; VS stable, 
alert and oriented. Additional radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decreases vomiting; radiation does not contribute to mortality at 
this level. 

Treatment: IV fluids LR (1 Liter); pain medication; moist cool compress/bulky dressing, one 
percent of patients receive 2 (carbon monoxide poison), rest, reassurance/counseling. LAB: CBC with 
differentials twice daily until transferred; routine ground/air transport 100 percent. 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; VS stable, 
alert and oriented; additional radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decrease vomiting; radiation does not contribute to mortality at this 
level. 

Treatment: EMT: VS; primary assessment. LAB: 100 percent draw one blood specimen per 
patient for biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure 
prognosis; tetanus toxoid; topical antibiotics. 

OR: 1 percent of patients arriving at Level 3; 1 percent escharotomy, under MAC 
anesthesia, maintain IVs; topical burn agents; wound dressing; OR table time 60 minutes. 
WARDS: ICU: None. 

ICW: 30 percent of patients arriving at Level 3. CBC with differentials 
twice daily. Patients admitted to ICW— routine air transport 100 percent. 

MCW: 70 percent of patients arriving at Level 3, VS; supportive care; 
push PO fluids, advance diet. LAB: 100 percent CBC with differentials twice daily; topical burn agents; 
wound dressing. Patients admitted to MCW— RTD 10 percent; routine air transport 90 percent. 

C-23 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-38. Treatment Brief No. 15: Radiation at 125-530 cGy With Mild Burn (Without treatment 
90 percent mortality.) 

LEVEL 1A 

Assumptions: Significant radiation exposure; 75 percent ambulatory patients; VS stable, alert and 
oriented; additional radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild headache; 
mild fatigability and weakness 25—60 percent; pretreatment with antiemetics decrease vomiting; radiation 
does not contribute to mortality at this level. 

Treatment: Clean and dress burns; reassurance; 25 percent IM morphine; 75 percent oral pain 
medications; 100 percent priority ground transport. 

LEVEL IB 

Assumptions: Significant radiation exposure; 80 percent ambulatory patients; 20 percent litter 
patients; VS stable, alert and oriented; additional radiation effects include: apprehension and agitation; n/v 
50 to 90 percent; mild headache; mild fatigability and weakness 25 to 60 percent; pretreatment with 
antiemetics decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: VS: Stabilization, IV LR, and 25 percent IM morphine; reassurance; 90 percent IV 
antiemetics, 100 percent priority ground transport. 

LEVEL 2 

Assumptions: Significant radiation exposure; 75 percent ambulatory patients; 25 percent litter 
patients; VS stable, alert and oriented; additional radiation effects include: apprehension and agitation; n/v 
50 to 90 percent; mild headache; mild fatigability and weakness 25 to 60 percent; pretreatment with 
antiemetics decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: IV fluids LR (1 Liter) and IV/IM morphine; moist cool compress/bulky dressing, 
1 percent of patients receive 2 (carbon monoxide poison), rest, reassurance; counseling. LAB: CBC 
with differential twice daily until transferred; attempt reverse isolation; 100 percent priority ground 
transport. 

LEVEL 3 

Assumptions: Significant radiation exposure; no respiratory injuries; 75 percent ambulatory patients; 
25 percent litter patients; VS stable, alert and oriented; additional radiation effects include: apprehension 
and agitation; n/v 30 to 60 percent; mild headache; mild fatigability and weakness 25 to 60 percent; 
pretreatment with antiemetics decrease vomiting. 

Treatment: EMT: VS; primary assessment. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]) CBC with differential for radiation exposure prognosis, 
parenteral/oral morphine; tetanus toxoid; topical antibiotics. 

OR: 1 percent escharotomy, under MAC anesthesia, maintain IVs; topical burn 
agents; wound dressing; OR table time 60 minutes. 
WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3. CBC with differentials 
twice daily. Draw blood specimens for HLA typing (three yellow top tubes [ACD] [keep refrigerated]). 
Cytokines (G-CSF 480 meg subcutaneous daily). Sixty percent IV antiemetics. Reverse isolation. Patients 
admitted to ICW— 100 percent priority air transport. 

MCW: None. 

C-24 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-39. Treatment Brief No. 16: Radiation >530 cGy With Mild Burn (Without treatment 
100 percent mortality.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable, alert and 
oriented. Central neurological deficits will be indicative of extreme radiation doses. Additional radiation 
effects include: apprehension and agitation; n/v 90 to 100 percent; fatigue and weakness 90 to 100 percent; 
pretreatment with antiemetics may have no effects; radiation may contribute to morbidity at this level. 

Treatment: Clean and dress burns; IM morphine; reassurance; 100 percent priority ground 
transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patient; VS alert and oriented; 
central neurological deficits will be indicative of extreme radiation doses. Additional radiation effects 
include: apprehension and agitation; n/v 90 to 100 percent; fatigue and weakness 90 to 100 percent; 
pretreatment with antiemetics may have no effects; radiation will contribute to morbidity at this level. 
Critical radiation injury with persistent central neurological signs places patient in expectant category (10 
percent of patients at this level). 

Treatment: VS: start IV LR in nonexpectant patients (90 percent of patients); stabilization and IM 
morphine/IV antiemetics; reassurance; 90 percent priority ground transport; 10 percent routine ground 
transport. 

LEVEL 2 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable, alert and 
oriented. Central neurological deficits will be indicative of extreme radiation doses; additional radiation 
effects include: apprehension and agitation; n/v 90 to 100 percent; fatigue and weakness 90 to 100 percent; 
pretreatment with antiemetics may have no effect; radiation will contribute to morbidity at this level. 
Critical radiation injury with persistent central neurological signs places patient in expectant category (10 
percent of patients at this level). Automated differential cell counter available. 

Treatment: Maintain IV fluids LR and IV/IM morphine; 100 percent injectable antiemetics; moist 
cool compress/bulky dressing, 1 percent of patients receive 2 (carbon monoxide poison), rest, reassurance/ 
counseling. LAB: CBC with differentials twice daily until transferred; attempt reverse isolation; 10 
percent routine ground/air transport, 90 percent priority air transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patient; no respiratory injuries. 
VS stable; central neurological deficits will be indicative of extreme radiation doses; additional radiation 
effects include: apprehension and agitation; n/v 90 to 100 percent; fatigue and weakness 90 to 100 percent; 
pretreatment with antiemetics may have no effects; radiation will contribute to morbidity and mortality at 
this level. Critical radiation injury with persistent central neurological signs places patient in expectant 
category. 

Treatment: EMT: VS; primary assessment. LAB: 100 percent draw one blood specimen per 
patient for biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure 
prognosis; parenteral/oral morphine; tetanus toxoid; topical antibiotics. 

C-25 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



OR: 1 percent escharotomy, under MAC anesthesia, maintain IVs; topical burn 
agents; wound dressing; OR table time 60 minutes. Third degree burn excision skin grafts must be in place 
by 48 hours. 

WARDS: ICU: None. 

ICW: 80 percent of patients arriving at Level 3. CBC with differentials 
twice daily times four days. Administer cytokines (480 meg G-CSF) subcutaneous daily in 100 percent; 
CBC with differentials twice daily times four days. Draw blood specimens for HLA typing (three yellow top 
tubes [ACD] [keep refrigerated]); reverse isolation. Patients admitted to ICW— mortality 12 percent at this 
level at 5 to 7 days; 60 percent priority air transport; 38 percent routine air transport. 

MCW: 20 percent of patients arriving at Level 3; expectant patients only; 
IM morphine as needed. Patients admitted to MCW— mortality 100 percent by seven days. 

C-40. Treatment Brief No. 17: Radiation at 0-125 cGy With Moderate Burn 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; both upper 
extremities involved in burn; alert; oriented; VS: stable; no other apparent injuries. Radiation effects 
include: apprehension and agitation; n/v 5 to 30 percent; mild headache; pretreatment with antiemetics 
decrease vomiting; radiation does not contribute to mortality at this level. 

Treatment: Clean and dress burns; 80 percent IM morphine; reassurance; 100 percent priority 
ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 20 percent ambulatory patients; 80 percent 
litter patients; VS stable, alert and oriented. Radiation effects include: apprehension and agitation; n/v 
5 to 30 percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation does not 
contribute to mortality at this level. 

Treatment: VS: Stabilization, 100 percent IV LR; reassurance; 80 percent IM morphine/antiemetics; 
100 percent priority ground transport. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent ambulatory patients; VS stable, 
alert and oriented. Radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild headache; 
pretreatment with antiemetics decrease vomiting; radiation does not contribute to mortality at this level. 
Automated differential cell counter available. 

Treatment: VS: Stabilization; 100 percent IV LR and 80 percent IV/IM morphine; IV antiemetic; 
rest, reassurance, counseling. LAB: CBC with differentials twice daily until transferred; 100 percent 
priority ground/air transport. 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; 20 percent ambulatory patients; 80 percent 
litter patients; VS stable, alert and oriented. Radiation effects include: apprehension and agitation; n/v 
5 to 30 percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation does not 
contribute to morbidity and mortality at this level. 

C-26 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Treatment: EMT: VS; primary assessment. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]); CBC with differential for radiation exposure prognosis. 
Start IV in unburned area on 20 percent, give 3 liters LR; tetanus toxoid; topical antibiotics; debridement in 
EMT. 

OR: 10 percent escharotomy, under MAC anesthesia, maintain IV's; topical burn 
agents; wound dressing; OR table time 60 minutes. Comment: For 3d degree burn excision skin grafts must 
be in place by 48 hours (those with 6 to 10 percent 3d degree burns). 
WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3; CBC with differentials 
twice daily. IV/IM morphine; (topical antibiotic); IV LR 6 liters per day; general surgeon consult; PT 
consult; CBC with differentials twice daily times four days. Reverse isolation; culture surveillance beginning 
day 3. Patients admitted to ICW— mortality 5 percent estimated at this level at 5 to 7 days; 95 percent 
priority transport. 

MCW: None. 



C-41. Treatment Brief No. 18: Radiation at 125-530 cGy With Moderate Burn (Without treatment 
100 percent mortality.) 

LEVEL 1A 

Assumptions: Significant radiation exposure; 100 percent litter patients; both upper extremities 
involved in burn; alert; oriented; VS: stable; no other apparent injuries. Radiation effects include: 
apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; 
pretreatment with antiemetics decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: Clean and dress burns; 100 percent IV LR; pain medication prn, IM morphine; 
reassurance; 100 percent priority ground transport. 

LEVEL IB 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert and 
oriented. Radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue 
and weakness 25 to 60 percent; pretreatment with antiemetics decreases vomiting; radiation does not 
contribute to mortality at this level. 

Treatment: VS; stabilization, maintain IV LR; reassurance; injectable pain medication (IM 
morphine) antiemetic medication; 100 percent priority ground transport. 

LEVEL 2 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert and 
oriented. Radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue 
and weakness 25 to 60 percent; pretreatment with antiemetics decrease vomiting; radiation does not 
contribute to mortality at this level. Automated differential cell counter available. 

Treatment: VS: Stabilization, 100 percent IV LR, 90 percent IV antiemetics and pain medication 
(IV/IM morphine); reassurance; attempt reverse isolation as operational constraints and logistics allow; 
100 percent priority ground/air transport. 

C-27 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL 3 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert and 
oriented. Radiation effects include: apprehension and agitation; n/v 50 to 90 percent; mild headache; fatigue 
and weakness 25 to 60 percent; pretreatment with antiemetics decrease vomiting; radiation does contribute 
to morbidity and mortality at this level. 

Treatment: EMT: VS; primary assessment. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]); CBC with differential every 6 hours for radiation exposure 
prognosis, electrolytes every 12 hours. Start IV in unburned area on 20 percent, give 3 liters LR; tetanus 
toxoid; topical antibiotics; debridement in EMT. 

OR: 10 percent escharotomy, under MAC anesthesia, maintain IVs; topical burn 
agents; wound dressing; OR table time 60 minutes. Comment: For 3d degree burn excision skin grafts must 
be in place by 48 hours (those with 6 to 10 percent 3d degree burns and < 300 cGy). 

WARDS: ICU: None. 

ICW: 100 percent of patients arriving at Level 3; CBC with differentials 
twice daily. IV/IM morphine; (topical antibiotic); IV LR 6 liters per day; general surgeon consult; PT 
consult; administer cytokines (480 meg G-CSF) subcutaneous daily in 100 percent; CBC with differentials 
twice daily draw blood specimens for HLA typing (three yellow top tubes [ACD] [keep refrigerated]). 
Reverse isolation. Culture surveillance beginning day 3. Patients admitted to ICW— mortality 40 percent 
estimated at this level at 5 to 7 days, 30 percent to (MCW— Expectant), 60 percent priority air transport. 

MCW: 30 percent of patients arriving at Level 3 (transferred from ICW); 
100 percent IV/IM morphine for pain control. 

C-42. Treatment Brief No. 19: Radiation >530 cGy With Moderate Burn (With or without treat- 
ment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; both upper extremities 
involved in burn; alert; oriented; VS: stable; no other apparent injuries. Central neurological deficits will be 
indicative of extreme radiation doses; additional radiation effects include: apprehension and agitation; n/v 
100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics may have no effects; 
radiation may contribute to morbidity at this level. 

Treatment: Clean and dress burns; IM morphine; reassurance; 100 percent priority ground 
transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patient; VS stable, alert and 
oriented. Central neurological deficits will be indicative of extreme radiation doses; additional radiation 
effects include: apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment 
with antiemetics may have no effects; radiation will contribute to morbidity at this level. Critical radiation 
injury with persistent central neurological signs places the patient in expectant category (10 percent of 
patients at this level). 

Treatment: VS: IV LR in nonexpectant patients (70 percent of patients at this point); stabilization 
and injectable morphine/antiemetic medication; reassurance; 70 percent priority ground transport; 30 
percent routine ground transport. 

C-28 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL 2 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patients; VS stable. Central 
neurological deficits will be indicative of extreme radiation doses; additional radiation effects include: 
apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics 
may have no effects; radiation will contribute to morbidity at this level. Critical radiation injury with 
persistent central neurological signs places patient in expectant category (10 percent of patients at this level). 
Automated differential cell counter available. 

Treatment: 100 percent IV fluids LR and IV/IM morphine; 100 percent injectable antiemetics; rest, 
reassurance/counseling. LAB: CBC with differentials twice daily until transferred; attempt reverse 
isolation; 70 percent priority air transport; 30 percent routine ground transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure; 100 percent litter patient; VS stable. Central 
neurological deficits will be indicative of extreme radiation doses; additional radiation effects include: 
apprehension and agitation; n/v 100 percent; fatigue and weakness 100 percent; pretreatment with antiemetics 
may have no effects; radiation will contribute to mortality and morbidity at this level. Critical radiation 
injury with persistent central neurological signs places the patient in expectant category (10 percent of 
patients at this level). 

Treatment: EMT: VS; primary assessment, 100 percent IV antiemetics. LAB: Draw one blood 
specimen per patient for biodosimetry (red top [clot] [keep refrigerated]); CBC with differential every 6 
hours for radiation exposure prognosis, electrolytes every 12 hours. Start IV in unburned area on 20 
percent, give 3 liters LR; tetanus toxoid; topical antibiotics; debridement in EMT. 

OR: 10 percent escharotomy, under MAC anesthesia, maintain IV's; topical burn 
agents; wound dressing; OR table time 60 minutes. Comment: For 3d degree burn excision skin grafts must 
be in place by 48 hours. 

WARDS: ICU: 20 percent of patients arriving at Level 3; maintain IVs; topical burn 
agents; wound dressing; administer cytokines (480 meg G-CSF) subcutaneous daily in 100 percent; LAB: 
CBC with differentials twice daily. Draw blood for HLA typing (three yellow top tubes [ACD] [keep 
refrigerated]). Reverse isolation. Patients admitted to ICU— 100 percent to ICW after two days. 

ICW: 50 percent of patients arriving at Level 3; CBC with differentials 
twice daily. IV/IM morphine; (topical antibiotic); IV LR 6 liters per day; general surgeon consult; PT 
consult. Administer cytokines (480 meg G-CSF) subcutaneous daily in 100 percent; CBC with differentials 
twice daily. Draw blood specimens for HLA typing (three yellow top tubes [ACD]; keep refrigerated). 
Reverse isolation. Patients admitted to ICW at 5 to 7 days; 75 percent estimated mortality at this level; 30 
percent priority air transport. 

MCW: 30 percent of patients arriving at Level 3, expectant patients; IM/ 
IV morphine as needed. Patients admitted to MCW— mortality 100 percent by seven days. 

C-43. Treatment Brief No. 20: Radiation at 0-125 cGy With Severe Burn (Without treatment 
20 percent mortality.) 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; VS stable, alert, 
oriented, both extremities injured; no other traumatic injuries. Radiation effects include: apprehension and 

C-29 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



agitation; n/v 5 to 30 percent; pretreatment with antiemetics decreases vomiting; radiation does not contribute 
to mortality at this level. Deaths and expectant designation in accordance with burn protocols. 

Treatment: Clean and dress burns; 100 percent IV LR; IM morphine; reassurance; 100 percent 
priority ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; VS stable, alert, 
oriented, both extremities injured; no other traumatic injuries. Radiation effects include: apprehension and 
agitation; n/v 5 to 30 percent; pretreatment with antiemetics decreases vomiting; radiation does not contribute 
to mortality at this level. 

Treatment: VS: Stabilization, IV LR (1 Liter); reassurance; injectable morphine/antiemetic 
(Promethazine) medication; 100 percent priority ground transport. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; VS stable, alert, 
oriented, both extremities injured; no other traumatic injuries. Radiation effects include: apprehension and 
agitation; n/v 5 to 30 percent; pretreatment with antiemetics decreases vomiting; radiation does not contribute 
to mortality at this level. Automated differential cell counter available. 

Treatment: VS: Stabilization; IV fluids LR and IV/IM morphine; rest, reassurance/counseling. 90 
percent IV antiemetics. Moist cool compress/bulky dressing, 10 percent of patients 2 , splint. LAB: CBC 
with differentials twice daily until transferred; 100 percent priority air transport. 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; VS stable, alert, 
oriented, both extremities injured; no other traumatic injuries. Radiation effects include: apprehension 
and agitation; n/v 5 to 30 percent; pretreatment with antiemetics decreases vomiting; radiation does not 
contribute to morbidity and mortality at this level. Deaths and expectant designation in accordance with burn 
protocols. 

Treatment: EMT: VS; primary assessment. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure prognosis. 
Maintain LR IVs; topical antibiotics; IM/IV morphine; forced fluids; dressing changes. 

OR: 50 percent of patients arriving at Level 3 undergo debridement of the hands; 
MAC anesthesia; 2 liters LR; OR table time 60 minutes. 

WARDS: ICU: 50 percent of patients arriving at Level 3. LAB: CBC with 
differentials twice daily. Maintain LR IVs; topical antibiotics; IM/IV morphine; forced fluids; dressing 
changes. Reverse isolation. Patients admitted to ICU— 100 percent transferred out of ICU after two days 
(50 percent AIREVAC; 45 percent of patients to ICW; 5 percent to MCW). 

ICW: 70 percent of patients arriving at Level 3; VS; maintain IVs; physical 
therapy consult; topical antibiotics; IM/IV morphine; forced fluids; dressing changes. LAB: CBC with 
differentials twice daily. Reverse isolation; culture surveillance beginning day 3; patients admitted to 
ICW— 100 percent priority air transport. 

MCW: 10 percent of patients arriving at Level 3. Mortality 100 percent by 
day 7. 

C-30 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-44. Treatment Brief No. 21: Radiation at 125-530 cGy With Severe Burn (Without treatment 
100 percent mortality.) 

LEVEL 1A 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS: stable, alert, oriented, 
both extremities injured; no other traumatic injuries. Additional radiation effects include: apprehension and 
agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with 
antiemetics decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: Clean and dress burns; 100 percent IV LR; IM morphine; reassurance; 100 percent 
priority ground transport. 

LEVEL IB 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert, oriented, 
both extremities injured; no other traumatic injuries. Additional radiation effects include: apprehension and 
agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with 
antiemetics decreases vomiting; radiation does not contribute to mortality at this level. 

Treatment: VS: Stabilization, IV LR (1 Liter), and IM morphine; reassurance; 100 percent priority 
ground transport. 

LEVEL 2 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert, oriented, 
both extremities injured; no other traumatic injuries. Additional radiation effects include: apprehension and 
agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with 
antiemetics decrease vomiting; radiation will not contribute to mortality at this level. Third degree burn 
patients are expectant. Automated differential cell counter available. 

Treatment: Third degree burn patients (50 percent of patients arriving at Level 2); 100 percent IV/ 
IM morphine as needed for pain; 100 percent injectable antiemetic medication; reassurance; routine ground 
transport. Second degree burn patients (50 percent of patients arriving at Level 2): VS: Stabilization, 100 
percent IV LR (2 liters), and IV/IM morphine; moist cool compress/bulky dressing, 10 percent of patients 
2 , splint, CBC with differential. Reassurance; 100 percent priority air transport. 

LEVEL 3 

Assumptions: Significant radiation exposure; 100 percent litter patients; VS stable, alert, oriented, 
both extremities injured; no other traumatic injuries. Additional radiation effects include: apprehension and 
agitation; n/v 50 to 90 percent; mild headache; fatigue and weakness 25 to 60 percent; pretreatment with 
antiemetics decreases vomiting; radiation will significantly contribute to mortality at this level. Third 
degree burn patients are expectant. 

Treatment: EMT: VS; primary assessment. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure prognosis. 
Maintain LR IVs; topical antibiotics; IM/IV morphine; forced fluids; dressing changes. 

OR: 50 percent of patients arriving at Level 3 undergo debridement of the hands; 
MAC anesthesia; 2 liters LR; OR table time— 60 minutes. 
WARDS: ICU: None. 

ICW: 50 percent of patients arriving at Level 3; VS; maintain IVs; physical 
therapy consult; topical antibiotics; IM/IV morphine; forced fluids; dressing changes; CBC with differentials 

C-31 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



twice daily. Reverse isolation. Draw blood specimens for HLA typing (three yellow top tubes [CD] [keep 
refrigerated]). Cytokines (G-CSF 480 meg subcutaneous daily). Patients admitted to ICW— 100 percent 
priority air transport. 

MCW: 50 percent of patients arriving at Level 3 are expectant; IM/IV 
morphine for pain as needed. Patients admitted to MCW— mortality 100 percent by 15 days. Comment: 
Approximately 67 percent of expectant patients will have a prolonged dying process of greater than one 
week. Routine air transport when and if available. 

C-45. Treatment Brief No. 22: Radiation >530 cGy with Severe Burn (With or without treatment 
100 percent mortality.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; pretreatment with antiemetics may have no effects. 

Treatment: Clean and dress burns; IM morphine; reassurance; 100 percent routine ground transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 10 percent at this level. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 90 percent routine ground transport. 

LEVEL 2 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 50 percent within 24 hours. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 100 percent routine ground/air transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent. 

Treatment: EMT: Patients are all expectant. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure. 
OR: None. 

WARDS: ICU: None. 
ICW: None. 

C-32 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



MCW: 100 percent of patients arriving at Level 3 are expectant. IM pain 
medications (morphine) as needed. Patients admitted to MCW— mortality 100 percent by five days. 

C-46. Treatment Brief No. 23: Radiation at 0-125 cGy with Operative Trauma and Mild Burn 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; litter patient; alert, cooperative and oriented; 
VS pulse greater than 100, B/P 100/60, no respiratory distress, evidence of closed intra-abdominal 
hemorrhage and injury. Radiation effects include: apprehension and agitation, n/v 5 to 30 percent; mild 
headache; pretreatment with antiemetics decrease vomiting and possibly increase fatigability; radiation 
does not contribute to mortality at this echelon. 

Treatment: Dress open wounds; start IV 100 percent (LR); IM morphine; reassurance; 100 percent 
priority ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients, alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 5 to 30 
percent; mild headache; pretreatment with antiemetics decrease vomiting and possibly increase fatigability; 
radiation does not contribute to mortality at this level. 

Treatment: VS: Maintain IV LR in 100 percent; stabilization and IM morphine; reassurance; 
30 percent IV/IM antiemetics (Kytril); 10 percent cervical spine stabilized; 100 percent urgent air transport. 
Note: All surgery must be completed within 36 to 48 hours; evacuation to a level of care that can provide 
appropriate urgent surgery. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury; thermal burns to extremities. Radiation effects include: apprehension 
and agitation; n/v 5 to 30 percent; mild headache; mild fatigability and weakness 25 to 60 percent; 
pretreatment with antiemetics decrease vomiting and possibly increase fatigability; radiation may contribute 
to morbidity at this level due to immunosuppression. 

Treatment: 25 percent exploratory laparotomy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 
hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter, moist cool compress/bulky dressing, 1 percent 2 (carbon monoxide poison). Remaining 75 
percent: 30 percent IV/IM antiemetics (Kytril), topical antibiotic, counseling. LAB: CBC with differentials 
twice daily until transferred. Note: All surgery must be completed within 36 to 48 hours; evacuation to a 
level of care that can provide appropriate urgent surgery. If appropriate surgery has been provided at this 
level, then routine evacuation (25 percent) to Level 3; otherwise urgent air transport (75 percent). 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; litter patient; Class III hemorrhage; VS: pulse 
120, B/P 100/70, respirations normal; alert; oriented. 25 percent will receive appropriate surgery at Level 2. 

C-33 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Radiation effects include: apprehension and agitation; n/v 5 to 30 percent; mild headache; pretreatment with 
antiemetics decreases vomiting; radiation will contribute to morbidity at this level due to immuno- 
suppression. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube. LAB: CBC with differential, UA, 
TC for 4 units; x-rays: chest, 50 percent pelvis films, start IV in unburned area on 20 percent, give 3 liters 
LR; tetanus toxoid; topical antibiotics (sulfamylon); 10 percent debridement; 30 percent IV/IM antiemetics; 
100 percent draw one blood specimen per patient for biodosimetry (red top tube [clot] [keep refrigerated]) 
for radiation exposure prognosis. 

OR: 75 percent of patients arriving at Level 3. Laparotomy and drainage of liver 
injury and debridement under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters 
RL; 2 units blood; arterial line 10 percent. LAB: CBC, blood gases; OR table time— 150 minutes. Note: 
All surgery must be completed within 36 to 48 hours of radiation exposure. 

WARDS: ICU: 100 percent of patients arriving at Level 3; moist cool compress/ 
bulky dressing, 1 percent 2 (carbon monoxide poison). LAB: CBC with differential twice daily for 
radiation exposure prognosis. Consider cytokines (G-CSF 480 meg subcutaneous daily); maintain IV fluids; 
IV antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent 
maintain ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain 
central line and monitoring and arterial line; cardiac monitor and pulse oximeter; CBC with differentials 
twice daily. IV/IM morphine; topical antibiotic sulfamylon); IV LR 6 liters per day; dressing reinforcement; 
dc central/arterial line before leaving ICU; 90 percent to ICW by day 2; 10 percent transferred to MCW. 
Percentages based on patients admitted to ICU. 

ICW: 90 percent of patients arriving at Level 3 will be transferred from 
ICU by day 2. VS; IVs with IV antibiotics; 25 percent on 2 by mask; Foley catheter care; maintain NG 
tube; NPO; CBC with differentials twice daily. IV/IM morphine; topical antibiotic (sulfamylon); IV LR 6 
liters per day; dressing reinforcement; drain care, moist cool compress/bulky dressing, 1 percent 2 
(carbon monoxide poison). LAB: CBC with differential twice daily for radiation exposure prognosis. 
Consider cytokines (G-CSF 480 meg subcutaneous daily); routine air transport 40 percent, priority air 
transport 60 percent. Percentages based on patients admitted to ICW. 

MCW: 10 percent of patients arriving at Level 3. VS; supportive care; 
IV/IM morphine. LAB: CBC with differential twice daily; 100 percent mortality. Percentages based on 
patients admitted to MCW. 

C-47. Treatment Brief No. 24: Radiation at 125-530 cGy With Operative Trauma and Mild Burn 
(Without treatment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Significant and potentially lethal radiation exposure; 100 percent litter patients; alert, 
cooperative and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress, evidence of 
closed intra-abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 
50 to 90 percent; significant fatigability and weakness 25 to 60 percent; pretreatment with antiemetics 
decrease vomiting; radiation does not contribute to mortality at this level. 

Treatment: Dress open wounds; reassurance; start IV 100 percent (LR); IM morphine; 100 percent 
priority ground transport. 

C-34 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL IB 

Assumptions: Significant and potentially lethal radiation exposure; 100 percent litter patients; alert, 
cooperative and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of 
closed intra-abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 
50 to 90 percent; headache; significant fatigability and weakness 25 to 60 percent; pretreatment with 
antiemetics decrease vomiting; radiation does not contribute to mortality at this level. 

Treatment: VS: Maintain IV LR in 100 percent; stabilization and IV morphine; reassurance; IV 
antiemetics (Kytril); 10 percent cervical spine stabilized; 100 percent urgent air transport. Note: All 
surgery must be completed within 36 to 48 hours; evacuation to a level of care that can provide appropriate 
urgent surgery. 

LEVEL 2 

Assumptions: Significant and potentially lethal radiation exposure. 100 percent litter patients; alert, 
cooperative and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of 
closed intra-abdominal hemorrhage and injury; thermal burns to extremities. Radiation effects include: 
apprehension and agitation; n/v 50 to 90 percent; headache; significant fatigability and weakness 25 to 60 
percent; pretreatment with antiemetics decrease vomiting; radiation will contribute to morbidity at this level 
due to immunosuppression. 

Treatment: 25 percent exploratory laparotomy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 
hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter, moist cool compress/bulky dressing, 1 percent 2 (carbon monoxide poison). Remaining 75 
percent: 90 percent IV/IM antiemetics (Kytril), topical antibiotic (sulfamylon), counseling. LAB: CBC 
with differentials twice daily until transferred. If appropriate surgery has been provided at this level, then 
routine evacuation (25 percent) to Level 3; otherwise urgent air transport (75 percent). Note: All surgery 
must be completed within 36 to 48 hours; evacuation to a level of care that can provide appropriate urgent 
surgery. 

LEVEL 3 

Assumptions: Significant and potentially lethal radiation exposure; 100 percent litter patients; Class 
III hemorrhage; VS: pulse 120, B/P 100/70, respirations normal; alert; oriented. Radiation effects include: 
apprehension and agitation; n/v 50 to 90 percent; headache; fatigability and weakness 25 to 60 percent; 
pretreatment with antiemetics decreases vomiting; 25 percent will receive appropriate surgery at Level 2; 
radiation will contribute to morbidity at this level due to immunosuppression. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube. LAB: CBC with differential, UA, 
TC for 4 units; x-rays: chest, 50 percent pelvis films, start IV in unburned area on 20 percent, give 3 liters 
LR; tetanus toxoid; topical antibiotics (sulfamylon); 10 percent debridement; 30 percent IV/IM antiemetics; 
100 percent draw one blood specimen per patient for biodosimetry (red top tube [clot] [keep refrigerated]) 
for radiation exposure prognosis. 

OR: 75 percent of patients arriving at Level 3, laparotomy and drainage of liver injury 
and debridement under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters RL; 2 
units blood; arterial line 10 percent. LAB: CBC, blood gases; OR table time— 150 minutes. Note: All 
surgery must be completed within 36 to 48 hours of radiation exposure. 

C-35 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



WARDS: ICU: 100 percent of patients arriving at Level 3; moist cool compress/ 
bulky dressing, 1 percent 2 (carbon monoxide poison). LAB: CBC with differential twice daily for 
radiation exposure prognosis; 100 percent cytokines (G-CSF 480 meg subcutaneous daily); maintain IV 
fluids; IV antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 
percent maintain ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; 
maintain central line and monitoring and arterial line; cardiac monitor and pulse oximeter; CBC with 
differentials twice daily. IV/IM morphine; topical antibiotic (sulfamylon); IV LR 6 liters per day; dressing 
reinforcement; dc central/arterial line before leaving ICU; 20 percent to MCW, 50 percent priority air 
transport, and 30 percent to ICW by day 3. Percentages based on patients admitted to ICU. 

ICW: 30 percent of patients arriving at Level 3, VS; IVs with IV antibiotics; 
25 percent on 2 by mask; Foley catheter care; maintain NG tube; NPO; CBC with differentials twice 
daily. IV/IM morphine; topical antibiotic (sulfamylon); IV LR 6 liters per day; dressing reinforcement; 
drain care, moist cool compress/bulky dressing, 1 percent 2 (carbon monoxide poison). LAB: CBC with 
differential twice daily; 100 percent cytokines (G-CSF 480 meg subcutaneous daily); 70 percent mortality; 
30 percent priority air transport. Percentages based on patients admitted to ICW. 

MCW: 20 percent of patients arriving at Level 3, VS; supportive care; IV/ 
IM morphine. LAB: CBC with differential twice daily 100 percent mortality. Percentages based on 
patients admitted to MCW. 

C-48. Treatment Brief No. 25: Radiation > 530 cGy With Operative Trauma and Mild Burn (With 
or without treatment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; pretreatment with antiemetics may have no effects. 

Treatment: Clean and dress burns; IM morphine; reassurance; 100 percent routine ground transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 10 percent at this level. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 90 percent routine ground transport. 

LEVEL 2 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 50 percent within 24 hours. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 100 percent routine ground/air transport. 

C-36 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL 3 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent. 

Treatment: EMT: Patients are all expectant. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure. 
OR: None. 

WARDS: ICU: None. 
ICW: None. 

MCW: 100 percent of patients arriving at Level 3; expectant patients only; 
IM pain medications (morphine) as needed. Patients admitted to MCW— mortality 100 percent by five days. 

C-49. Treatment Brief No. 26: Radiation at 0-125 cGy With Operative Trauma and Moderate Burn 
(Without treatment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS pulse greater than 100, B/P 100/60, no respiratory distress, evidence of closed intra- 
abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 50 to 90 
percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation does not contribute to 
mortality at this level. 

Treatment: Dress open wounds; start IV 100 percent (LR); IM morphine; reassurance; 100 percent 
priority ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 50 to 90 
percent; mild headache; pretreatment with antiemetics decrease vomiting; radiation contributes to morbidity 
at this level. 

Treatment: VS: Maintain IV LR in 100 percent; stabilization and IM morphine; reassurance; 90 
percent Kytril IV; 10 percent cervical spine stabilized; 100 percent urgent air transport. Note: All surgery 
must be completed within 36 to 48 hours; evacuation to a level of care that can provide appropriate urgent 
surgery. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury; thermal burns to extremities. Radiation effects include: apprehension 
and agitation; n/v 50 to 90 percent; mild headache; pretreatment with antiemetics may decrease vomiting; 
radiation contributes to morbidity at this level. Automated cell counter available. 

Treatment: 25 percent exploratory laparotomy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 

C-37 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter. Remaining 75 percent: 90 percent IV antiemetics (Kytril), topical antibiotic (sulfamylon), 
counseling. LAB: CBC with differentials twice daily until transferred. Note: All surgery must be 
completed within 36 to 48 hours; evacuation to a level of care that can provide appropriate urgent surgery. If 
appropriate surgery has been provided at this level, then routine evacuation (25 percent) to Level 3; 
otherwise urgent air transport (75 percent). 



LEVEL 3 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; Class III hemorrhage; 
VS: pulse 120, B/P 100/70, respirations normal; alert; oriented. Radiation effects include: apprehension 
and agitation; n/v 50 to 90 percent; mild headache; pretreatment with antiemetics may decrease vomiting; 
radiation contributes to morbidity at this level; 25 percent will receive appropriate surgery at Level 2; 
radiation will contribute to mortality and morbidity at this level. Radiation at this level combined with 
trauma multiplies mortality rates over baseline values. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube. LAB: CBC with differential, UA, 
TC for 4 units; x-rays: chest, 50 percent pelvis films. Start IV in unburned area on 20 percent, give 3 liters 
LR; tetanus toxoid; topical antibiotics (sulfamylon); 10 percent debridement; 90 percent IV antiemetic 
(Kytril); 100 percent draw one blood specimen per patient for biodosimetry red top tube (clot) for radiation 
exposure prognosis. 

OR: 75 percent of patients arriving at Level 3. Laparotomy and drainage of liver 
injury and debridement under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters 
RL; 2 units blood; arterial line 10 percent. LAB: CBC, blood gases; OR table time— 150 minutes. Note: 
All surgery must be completed within 36 to 48 hours of radiation exposure. 

WARDS: ICU: 100 percent of patients arriving at Level 3. VS; IV antibiotics; 
parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent maintain ET tube and 
ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain central line and 
monitoring and arterial line; cardiac monitor and pulse oximeter. IV/IM morphine; topical antibiotic 
(sulfamylon); IV LR 6 liters per day; dressing reinforcement; dc central/arterial line before leaving ICU. 
LAB: CBC with differential twice daily, electrolytes, clotting studies, Amylase, LFTs on admission; x-ray: 
chest, 10 percent c-spine. Administer cytokines (G-CSF 480 meg subcutaneous daily) in 100 percent. 100 
percent draw blood specimens for HLA typing (three yellow top tubes [ACD] [keep refrigerated]). Reverse 
isolation. 

ICW: 90 percent of patients arriving at Level 3 will be transferred from 
ICU by day 2. VS; IV antibiotics; 25 percent on 2 by mask; Foley catheter care; maintain NG tube; NPO; 
CBC with differentials twice daily. IV/IM morphine; topical antibiotic (sulfamylon); IV LR 6 liters per day; 
dressing reinforcement; drain care. Administer cytokines (G-CSF 480 meg subcutaneous daily) in 100 
percent. LAB: CBC with differentials twice daily; 100 percent draw blood specimens for HLA typing (three 
yellow top tubes [ACD] [keep refrigerated]). Reverse isolation. Ten percent mortality; 90 percent priority 
air evacuation. 

MCW: 10 percent of patients arriving at Level 3 will become expectant 
and transferred from ICU by day 2. Mortality 100 percent. 

C-38 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C-50. Treatment Brief No. 27: Radiation at 0-125 cGy With Operative Trauma and Severe Burn 
(Without treatment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients; VS: pulse greater 
than 100, B/P 100/60, no respiratory distress; alert, oriented, both extremities burned, evidence of closed 
intra-abdominal hemorrhage and injury. Radiation effects include: apprehension and agitation; n/v 5 to 30 
percent; mild headache; pretreatment with antiemetics decrease vomiting and possibly increase fatigability; 
radiation does not contribute to mortality at this level. 

Treatment: Dress open wounds and burns; reassurance; start IV LR 100 percent, IM morphine; 100 
percent urgent ground transport. 

LEVEL IB 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients, alert, cooperative 
and oriented; VS: pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury, both extremities burned. Additional radiation effects include: 
apprehension and agitation; n/v 5 to 30 percent; mild headache; pretreatment with antiemetics decrease 
vomiting and possibly increase fatigability; radiation does not contribute to mortality at this level. 

Treatment: VS: Maintain IV LR in 100 percent; stabilization and IM morphine; 100 percent IV 
antiemetics (promethazine); reassurance; reevaluate dressing; 10 percent cervical spine stabilized; 100 
percent urgent air transport. 

LEVEL 2 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients, alert, cooperative 
and oriented; VS: Pulse greater than 100, B/P 100/60, no respiratory distress; evidence of closed intra- 
abdominal hemorrhage and injury. Additional radiation effects include: apprehension and agitation; n/v 
5 to 30 percent; mild headache; pretreatment with antiemetics decrease vomiting and possibly increase 
fatigability; radiation will contribute to morbidity at this level due to immunosuppression. 

Treatment: 25 percent exploratory laparotomy at this level; general anesthesia; 2d IV; NG tube, 
parenteral pain medications (morphine), HCT, type and cross, blood, irrigation and debridement, 
hemorrhage control, hemostatic agents, IV antibiotics, dressing, cardiac monitor, pulse oximeter, ventilator, 
Foley catheter, moist cool compress/bulky dressing, 10 percent escharotomy, 10 percent 2 , splint. 
Remaining 75 percent: IV fluids LR 100 percent; rest; 30 percent IV/IM antiemetics. LAB: CBC with 
differential; reassurance/counseling. Note: All surgery must be completed within 36 to 48 hours; evacuation 
to a level of care that can provide appropriate urgent surgery. If appropriate surgery has been provided at 
this level, then routine evacuation (25 percent) to Level 3; otherwise urgent air transport (75 percent). 

LEVEL 3 

Assumptions: Real or suspected radiation exposure; 100 percent litter patients, Class III hemorrhage, 
alert; oriented; VS pulse 120, B/P 100/70, respirations normal. Radiation effects include: apprehension and 
agitation; n/v 5 to 30 percent; mild headache; pretreatment with antiemetics decreases vomiting; 25 percent 
will receive appropriate wound closure surgery at Level 2; radiation will contribute to morbidity at this level 
due to immunosuppression. 

Treatment: EMT: VS; primary assessment, IV restarted in 20 percent, give 2 liters LR; 2d IV 
started; IV antibiotics; parenteral morphine; Foley catheter; NG tube. LAB: 100 percent CBC with 

C-39 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



differential, UA, TC for 4 units; x-rays: chest, 50 percent pelvis films; doppler assessment, tetanus toxoid, 
topical antibiotics (sulfamylon); LAB: 100 percent draw one blood specimen per patient for biodosimetry 
(red top tube [clot] [keep refrigerated]), for radiation exposure prognosis. 

OR: 75 percent of patients arriving at Level 3. Laparotomy and drainage of liver 
injury under general anesthesia; 50 percent large bore central line; IV antibiotics; 8 liters LR; 2 units blood; 
arterial line 10 percent. LAB: CBC, blood gases; 50 percent escharotomy for burn; MAC anesthesia; 2 
liters LR; OR table time— 120 minutes. Note: All surgery must be completed within 36 to 48 hours of 
radiation exposure. 

WARDS: 25 percent of patients arriving at Level 3— direct admit from Level 2. 

ICU: 100 percent of patients arriving at Level 3. VS; maintain IV fluids; 
IV antibiotics; parenteral morphine; Foley catheter care; drain care; NG tube care, NPO; 10 percent 
maintain ET tube and ventilator with 2 , extubate before leaving ICU; 90 percent on 2 by mask; maintain 
central line and monitoring and arterial line; cardiac monitor and pulse oximeter; dressing reinforcement; 
dc central/arterial line before leaving ICU; topical antibiotics; 20 percent cytokines (G-CSF 480 meg 
subcutaneous daily). LAB: CBC with differential twice daily, electrolytes, clotting studies, Amylase, LFTs 
on admission; x-ray: chest, 10 percent c-spine. Twenty -percent to ICW by day 3; 60 percent priority 
transport; 20 percent to MCW. Percentages based on patients admitted to ICU. 

ICW: 20 percent of patients arriving at Level 3; LAB: CBC with differential 
twice daily times four days for radiation exposure prognosis. VS; IVs with IV antibiotics; parenteral 
morphine; topical antibiotics (sulfamylon), 25 percent on 2 by mask; Foley catheter care; maintain NG 
tube; NPO; dressing reinforcement; drain care, doppler. Twenty-percent cytokines (G-CSF 480 meg 
subcutaneous daily). Mortality 50 percent, priority air transport 50 percent. Percentages based on patients 
admitted to ICW. 

MCW: 20 percent of patients arriving at Level 3; VS; supportive care. 
LAB: CBC with differential twice daily for radiation exposure prognosis. 100 percent mortality. 
Percentages based on patients admitted to MCW. 

C-51. Treatment Brief No. 28: Radiation >125 cGy With Operative Trauma and Moderate or 
Severe Burn (With or without treatment 100 percent mortality.) 

LEVEL 1A 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; pretreatment with antiemetics may have no effects. 

Treatment: Clean and dress burns; IM morphine; reassurance; 100 percent routine ground transport. 

LEVEL IB 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 10 percent at this level. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 90 percent routine ground transport. 

C-40 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LEVEL 2 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent; mortality 50 percent within 24 hours. 

Treatment: Comfort measures only; 100 percent morphine IV/IM as needed for pain, 100 percent 
injectable antiemetic medication; reassurance; 100 percent routine ground/air transport. 

LEVEL 3 

Assumptions: Critical to lethal radiation exposure, but 100 percent mortality when combined with 
this severity of burn injury; litter patient; central neurological deficits will be indicative of extreme radiation 
doses. Additional radiation effects include: apprehension and agitation; n/v 100 percent; fatigue and 
weakness 100 percent. 

Treatment: EMT: Patients are all expectant. LAB: Draw one blood specimen per patient for 
biodosimetry (red top [clot] [keep refrigerated]), CBC with differential for radiation exposure. 
OR: None. 

WARDS: ICU: None. 
ICW: None. 

MCW: 100 percent of patients arriving at Level 3; expectant patients only; 
IM pain medications (morphine) as needed. Patients admitted to MCW: Mortality 100 percent by five days. 



C-41 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

GLOSSARY 

Section I. ABBREVIATIONS AND ACRONYMS 

ABCA American, British, Canadian and Australian 

ACD acid-citrate dextrose 

ADM atomic demolition munition 

AFMAN United States Air Force Manual 

ALARA as low as reasonably achievable 

ALCM air launched cruise missile 

AMEDDC&S Army Medical Department Center and School 

ANC absolute neutrophil count 

ARS acute radiation syndrome 

ATC air transportable clinic 

ATH air transportable hospital 

atm atmospheres (of pressure) 

BAS battalion aid station 

BDO battle dress overgarment 

BEIR V Biological Effects of Ionizing Radiations, 5th Consensus Summary 

BID bis in die (twice a day) 

BP blood pressure 

Bq Becquerel 

BSA body surface area 

BUN blood urea nitrogen 

BW biological warfare 

Glossary-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



C Celsius/carbon 

C/kg-air coulombs per kilogram in air 

CaDTPA calcium diethylenetriaminepentaacetic acid 

CaEDTA calcium ethyl enediaminetetraacetate 

cal calorie 

CAM chemical agent monitor 

CBC complete blood count 

CBF cerebral blood flow 

cc cubic centimeter(s) 

CD-ROM compact disk-read-only memory 

CFU colony-forming units 

cGy centiGray 

cGy/hr centiGray per hour (0.01 Gy = 1 rad) 

ChRS chronic radiation syndrome 

Ci curie 

cm centimeter(s) 

CMV cytomegalovirus 

CNS central nervous system (syndrome) 

Co cobalt 

CONUS continental United States 

CRS Cutaneous Radiation Syndrome 

CRTS casualty receiving and treatment ship 

CSCU Combat Stress Control Unit 

CSF colony stimulating factor (s) 

Glossary-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



CSH combat support hospital 

cSv centiSievert (0.01 Sv = 1 rem) 

CT computed tomography 

CV cardiovascular 

CV/CVN aircraft carrier designation 

CW chemical warfare 

DA Department of the Army 

DECON decontamination 

DIA Defense Intelligence Agency 

DMPS 2,3-dimercapto-l-propanesulfonic acid 

DMSA meso-2,3-dimercaptosuccinic acid 

DNA deoxyribonucleic acid 

DNBI disease and nonbattle injury 

DOD Department of Defense 

DODI Department of Defense Instruction 

DOE Department of Energy 

DTPA diethylenetriaminepentaacetic acid (pentetic acid) 

DU depleted uranium 

D/W dextrose in water 



E energy 

1 8 

Ebq exabecquerel (10 Bq) 



EDTA ethylenediaminetetraacetic acid (edetic acid) 

Glossary-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



EMG electromyography 

EMP electromagnetic pulse 

EMT emergency medical treatment 

ER enhanced radiation 

erg electroretinogram 

ETI early transient incapacitation 

ETI-PD early transient incapacitation and performance decrement 

Ev electron volt 

F Fahrenheit 

FAST forward area surgical team 

FDA Food and Drug Administration 

FFP fresh frozen plasma 

FM field manual 

FSMC forward support medical company 

FST forward surgical team 

FSU former Soviet Union 

GBq Giga Bequerel 

G-CSF granulocyte-colony stimulating factor (s) 

GI gastrointestinal 

GLCM ground-launched cruise missile 

gm gram(s) 

GM-CSF granulocyte macrophage-colony stimulating factor 

Glossary -4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



gm/dl gram/deciliter 

GTX granulocyte transfusions 

GU genitourinary 

GVHD graft-versus-host disease 

Gy gray (1 Gy = 100 rads) 

H hydrogen 

HA heavy armor 

HCT hematocrit 

He helium 

HE high explosive 

HEPA high efficiency particulate air 

HEU highly enriched uranium 

HLA human leukocyte antigen 

HOB height of burst 

HQDA Headquarters, Department of the Army 

HREC health record 

hrs hours 

HSS health service support 

I iodine/Interservice 

IAEA International Atomic Energy Agency 

ICBM intercontinental ballistic missile 

ICRP International Council on Radiation Protection 



Glossary-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



ICU intensive care unit 

ICW intermediate care ward 

IFN interferon 

Ig immunoglobulin 

IL Interleukin 

IM intramuscular 

IND improvised nuclear devices 

IU international unit 

IV intravenous(ly) 

JRCAB Joint Readiness Clinical Advisory Board 

K potassium 
K10 potassium iodate 
kBq thousand becquerels 
KE kinetic energy 
kg kilogram(s) 
km kilometer(s) 
kPa kilopascals 
KT kiloton(s) 

1 liter 

LAB laboratory diagnostic tests 

LBRM long range ballistic missile (intercontinental ballistic missile [ICBM]) 

LD lethal dose 

Glossary-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



LET linear energy transfer 
LIHOPO a hydroxypridizone ligand 
LLR low-level radiation 
LR laboratory report 

m mass 

MASCAL mass casualty 

MASF mobile aeromedical staging facility 

MBq Mega Becquerel 

mCi millicurie 

meg microgram 

MCRP Marine Corps Reference Publication 

MCW minimal care ward 

MD doctor of medicine 

MES medical equipment sets 

mg milligram(s) 

MGDF/Tpo megakaryocyte growth and development factor/thrombopoietin 

mGy milligray (0.001 Gy; 10 mGy = 1 rad) 

ml milliliter(s) 

mm millimeter(s) 

mm3 cubic millimeter 

mo month 

MOLLE modular lightweight load-carrying equipment 

MOPP mission-oriented protective posture 



Glossary-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



MOX mixed oxide 

mph miles per hour 

mrad millirad 

MRBM medium range ballistic missile 

mrem millirem 

MRI magnetic resonance imaging 

mSv milliSievert (0.001 Sv; 10 mSv = 1 rem) 

MT megaton 

MTF medical treatment facility 

MUPS medically unexplained physical symptoms 

MW megawatt 

Na sodium 

NATO North Atlantic Treaty Organization 

NAVMED P US Navy Medical Publication 

NBC nuclear, biological, and chemical 

NCRP National Council on Radiation Protection 

NDI nondestructive inspection 

NIGA neutron-induced ground activity 

nm nanometer 

NPO nil per os (nothing by mouth) 

NRC Nuclear Regulatory Commission 

NTRP Navy Tactical Reference Publication 

n/v nausea/vomiting 

Glossary-8 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



n/v/d nausea/vomiting/diarrhea 
NVD night vision device 
NW nuclear warfare 

2 oxygen 

ODS Operation Desert Storm 

OEG operational exposure guidance 

OR operating room 

OSHA Occupational Safety and Health Act 

PAF platelet activating factor 

PBq pico Becquerel 

PBSC peripheral blood stem cell 

PBSCT peripheral blood stem cell transplantation 

PCC prematurely condensed chromosome 

PCR polymerase chain reaction 

PD performance decrement 

pg picograms 

PHS Public Health Service 

PIES proximity, immediacy, expectancy, simplicity (mnemonic for treatment of psychiatric casualties) 

PMN polymorphonuclear neutrophil 

PO per os (by mouth) 

P0 2 plutonium oxide 

ppm parts per million 

Glossary-9 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



PPW patient protective wrap 

PR per rectum 

PRBC peripheral red blood cell 

prn pro re nata (for the emergency, as needed) 

psi pounds per square inch 

PTSD post-traumatic stress disorder 

PTX pentoxifylline 

Pu plutonium 

PVNTMED preventive medicine 

PWR pressurized water reactor 

q quaque (every) 

QD quaque die (every day) 

QF quality factor 

QID quater in die (four times a day) 

QSTAG Quadripartite Standardization Agreement 

R roentgen 

Ra radium 

rad radiation absorbed dose 

RADIAC radiation detection, identification, and computation 

RBC red blood cell 

RBE relative biological effectiveness 

R&D research and development 

Glossary-10 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



RDD radiological dispersal device 

REAC/TS Radiation Emergency Assistance Center/Training Site 

rem roentgen equivalent in man/mammal 

RES radiation exposure status 

Rn radon 

RNA ribonucleic acid 

RPL radiophotoluminescent 

RTD return to duty 

Rx a medical prescription 

SAT serum-agglutinating titers 

SD skin dose 

sec second(s) 

SI systems international 

SLBM submarine launched ballistic missile 

SNM special nuclear material 

SOP standard operating procedure(s) 

SQ subcutaneous 

SRBM short range ballistic missile 

SSB single-strand break(s) 

STANAG Standardization Agreement 

Sv Sievert (SI unit of roentgen dose equivalent) 

TB Treatment Brief(s) 



Glossary-11 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



TBq Tera Bequerel 

TCDO tetrachlorodekaoxide 

TDM trehalose dimycolate 

TID ter in die (three times a day) 

TG Technical Guide 

TGF-beta transforming growth factor beta 

ThO thorium oxide 

TLAM/N Tomahawk land attack missile/nuclear 

TLD thermo-luminescent dosimeter 

TMP trimethoprim 

TNF tumor necrosis factor 

TNT trinitrotoluene 

TO theater of operations 

TPN total parenteral nutrition 

TSH thyroid-stimulating hormone 

TSST-1 toxic shock syndrome toxin- 1 

li microns 
jiCi microcurie 
Hg microgram 
jtl microliter 
U uranium 
U0 2 uranium oxide 
US United States 

Glossary-12 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



USACHPPM US Army Center for Health Promotion and Preventative Medicine 

USAF United States Air Force 

USAMRIID United States Army Medical Research Institute for Infectious Diseases 

USTRANSCOM United States Transportation Command 

UTC unit type code (United States Air Force) 

VA Department of Veterans Affairs 

VS vital signs 

vWf von Willenbrand factor, clotting factor 8 

WHO World Health Organizations 
WMD weapons of mass destruction 
WMDT wartime medical decontamination team 
W R radiation weighting factor 

yr year 

ZnDTPA zinc diethylenetriaminepentaacetic acid 



Section II. DEFINITIONS 

acute radiation syndrome a combination of clinical syndromes occurring in stages, during a period of 
hours to weeks after exposure, as radiation injury to various tissues and organs is expressed. 

agranulocytosis a complex of symptoms characterized by marked decrease in the number of granulocytes 
and by lesions of the throat and other mucous membranes, of the gastrointestinal tract, and of the skin. 

airburst an explosion of a bomb or projectile above the surface as distinguished from an explosion on 
contact with the surface or after penetration. 

Glossary-13 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



alpha particle a positively charged particle ejected from the nucleus of a radioactive atom, being a high- 
speed ionized atom of helium. A stream of these particles constitutes alpha rays. 

aplasia lack of development of an organ or tissue, or of the cellular products from an organ or tissue. 

atomic number the number of protons in an atomic nucleus. 

beta particle an electron emitted from an atomic nucleus during beta decay. 

bioassay sampling indirect means of measuring contamination in body tissue or fluids from which body 
burden is extrapolated. 

blast wave a pulse of air in which the pressure increases sharply at the front propagated by the explosion. 

bremsstrahlung the process by which a beta particle emits an x-ray photon during its interaction with an 
atomic nucleus. 

carcinogenesis the development of cancer; various malignant growths that manifest invasiveness and a 
tendency to metastasize to another location. 

cataractogenesis the development of cataracts; opacity of the lens causing blindness. 

cerebral anoxia absence of an oxygen supply to the brain despite adequate perfusion of the tissue by blood. 

congestion excessive or abnormal accumulation of blood in a tissue or organ. 

critical mass the minimum amount of fissile material capable of supporting a chain reaction under 
precisely specified conditions. 

critical organ body organ with an affinity for a particular substance and in which that substance 
concentrates. 

cytokine a nonantibody protein released by one cell population that acts as an intercellular mediator on 
another cell population(s). Synthetic cytokines are metabolically active in pico-molar concentrations. 

decontamination the process of making any person, object, or area safe by absorbing, destroying, 
neutralizing, making harmless, or removing chemical or biological agents, or by removing radioactive 
material clinging to or around it. 

delayed fallout radioactive fallout that returns to earth later than 24 hours after a nuclear detonation; 
usually ascends into the stratosphere and is distributed worldwide. 

desquamation the shedding of epithelial elements, chiefly of the skin, in scales or small sheets; exfoliation. 
Glossary-14 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



deterministic effect one that occurs after a certain dose threshold, with the severity of the effect 
determined by the dose; example: cataractogenesis. 

dose rate a measure of the amount of ionizing radiation an individual is exposed to, per unit of time; 
commonly expressed in units of gray (or rads) per hour. 

dynamic pressure pressure resulting from some medium in motion, such as the air following the shock 
front of a bast wave. 



early fallout radioactive fallout that returns to earth within 24 hours after a nuclear detonation; also 
referred to as local fallout. 

edema the presence of abnormally large amounts of fluid in the intercellular tissue. 

exposure a measure of the number of ionizations produced by gamma or x-rays in a volume of air; 
expressed in units of roentgen. 

fallout the precipitation to Earth of radioactive particulate matter from a nuclear cloud; also applied to the 
particulate matter itself. 

fireball the luminous sphere of hot gases which forms a few millionths of a second after detonation of a 
nuclear weapon and immediately starts expanding and cooling. 

fission the process whereby the nucleus of a heavy element splits into (generally) two nuclei of lighter 
elements, with the release of substantial amounts of energy. 

fission products a general term for the complex mixture of substances produced as a result of nuclear 
fission. 

flash burn a burn caused by excessive exposure of the skin to thermal radiation. 

free-in-air-dose radiation that would be measured in air at a certain point. Military tactical dosimeters 
measure free-in-air-doses. 

gamma rays high energy electromagnetic radiation emitted from atomic nuclei during a nuclear reaction. 
Gamma rays and very high energy X-rays differ only in origin. X-rays do not originate from atomic nuclei 
but are produced in other ways. 

granulocyte any cell containing granules in its cytoplasm, especially a leukocyte (neutrophil, basophil, or 
eosinophil). 

granulocytopenia agranulocytosis; a symptom complex consisting of a marked decrease in the number of 
circulating white blood cells, with lesions of the throat and mucous membranes. 

Glossary-15 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



hematopoietic pertaining to, or effecting, the formation of blood cells. 

hemorrhage the escape of blood from the vessels; hemorrhages, classified according to size: petechiae 
(pinpoint) or ecchymoses (larger than 1 centimeter in diameter). 

hyperpyrexia a highly elevated body temperature. 

hypotension abnormally low blood pressure. 

induced radiation radiation produced as a result of exposure to radioactive materials, particularly the 
capture of neutrons. 

ingestion pathway route for internalization of radioactive contaminants; the pathway most accessible for 
decontamination. 

inhalation pathway primary pathway for internalization of radioactive contaminants. 

ionization the process of stripping electrons from their atomic orbits by radiation. 

isotope one of two or more atoms whose nuclei have equal numbers of protons but different numbers of 
neutrons. 



late effect a biological effect that occurs long after radiation exposure ends; example: cancer. 

lymphocyte a mononuclear leukocyte; chiefly a product of lymphoid tissue and participates in humoral and 
cell-mediated immunity. 

malformation a birth defect; an abnormal structure or form; example: small head. 
morbidity the ratio of sick to well individuals in a community; the sick rate. 
mortality the ratio of people who die to those who survive irradiation; the death rate. 

nadir the point at which a blood count drops to, or closest to zero, before beginning to increase. 

neutron an electrically neutral or uncharged particle of matter existing along with protons in the atoms of 
all elements except the isotope of hydrogen with the mass of 1 . 

neutropenia a decrease in the number of neutrophilic leukocytes in the blood. 

nosocomial pertaining to or originating in a hospital. 

Glossary-16 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



nuclear material traditionally, uranium or plutonium used to produce a nuclear detonation via the fission 
or fusion process. The fuel is compressed into a given volume to cause supercriticality. The major products 
include blast effects, heat, nuclear radiation, and fallout. 

nucleated blood cell a blood cell that contains a nucleus, to include white cells and reticulocytes. 

nucleon a proton or neutron as part of an atomic nucleus. 

nuclide all nuclear species, both stable (about 270) and unstable (about 500), of the chemical elements, as 
distinguished from the two or more nuclear species of a single chemical element which are called "isotopes." 



orbital excitation change in energy level of an orbital electron that occurs when the energy lost by the 
incident radiation is insufficient to cause ionization. 

overpressure the pressure resulting from the blast wave of an explosion. It is referred to as "positive" 
when it exceeds atmospheric pressure and "negative" during the passage of the wave when resulting 
pressures are less than atmospheric pressure. 



pathognomonic specifically distinctive or characteristic of a disease or pathologic condition; a sign or 
symptom on which a diagnosis can be based. 

perceived threat a threat that is experienced by a person subjectively and out of proportion to the real 
threat or physical danger. 

phagocytosis the engulfing of microorganisms, other cells, and foreign particles by phagocytes. 

pressor tending to increase blood pressure. 

prodrome a premonitory symptom or precursor; a symptom indicating the onset of a disease. 

Prussian blue ferric ferrocyanide; a chemical that is not absorbed by the gastrointestinal system and is an 
effective means to reduce the body's uptake of cesium, thallium, and rubidium; approved as an 
investigational new drug by the United States Food and Drug Administration with the license held by 
Radiation Emergency Assistance Center/Training Site. 



radioactive cloud an all-inclusive term for the cloud of hot gases, smoke, dust, dirt, and debris from a 
weapon and the environment. The cloud is carried aloft in conjunction with the rising fireball produced by 
the detonation of a nuclear weapon. 

radioactive contamination radioactive material in an undesirable location such as on structures, areas, 
objects, or personnel. 

Glossary-17 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radionuclide a radioactive nuclide; one that disintegrates with the emission of particulate or 
electromagnetic radiations. 

rainout radioactive material in the atmosphere brought down by precipitation. 

relative biological effectiveness the ratio of the number of rads of gamma (or X) radiation of a certain 
energy which will produce a specified biological effect to the number of rads of another radiation required to 
produce the same effect is the relative biological effectiveness of the latter radiation. 

reproductive death the loss of the ability to reproduce. Many organs must have cells that can reproduce 
to function. Thus, even though injured cells may remain biologically viable, reproductive death may cause 
irreversible organ damage. 



scavenging the selective removal of material from the radioactive cloud by inert substances, such as 
precipitation, introduced into the fireball. 

sepsis the presence of pathogenic microorganisms (bacteria) or their toxins in the blood or other tissues. 

septicemia systemic disease associated with the presence and persistence of pathogenic microorganisms 
or their toxins in the blood. 

skin permeability the rate at which the skin absorbs a liquid; expressed as a coefficient. The lower a 
substance's coefficient, the greater the rate of absorption. 

Specific ionization number of ion pairs per unit distance formed along the path of a particle, often 
expressed as ion pairs per centimeter. 

stochastic effect an effect that has no-dose threshold and for which the severity of the effect is not dose- 
related, although its probability is; example: carcinogenesis 

stratosphere the layer of the atmosphere above the troposphere in which the change of temperature with 
height is relatively small. 

subsurface burst the explosion of a nuclear weapon beneath the surface of the earth. 

syndrome a set of symptoms that occur together. 

synergistic acting together to enhance the effect of another force or agent. 



thermal radiation the heat and light produced by a nuclear explosion. Electromagnetic radiations emitted 
from a heat or light source as a consequence of its temperature; it consists essentially of ultraviolet, visible, 
and infrared radiations. 

Glossary-18 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



total parenteral nutrition by injection through some route other than the alimentary canal. 



washout the removal of radioactive particles from a nuclear cloud by precipitation when the nuclear cloud 
is below a rain or snow cloud. 

weapon debris (nuclear) the residue of a nuclear weapon after it has exploded; that is, materials used for 
the casing and other components of the weapon, plus unexpended plutonium or uranium, together with fission 
products. 

wound contamination the presence of a radioactive substance in a wound, whether an abrasion, puncture, 
or laceration; condition in which the loss of intact skin increases the risk that the contaminant will be 
absorbed. 



Glossary-19 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



REFERENCES 



Joint Publications 

Joint Pub 3-11. Joint Doctrine for Operations in Nuclear, Biological, and Chemical (NBC) Environments. 

11 July 2000. 
Joint Pub 3-12. Doctrine for Joint Nuclear Operations. 15 December 1995. 
Joint Pub 3-12. 1 . Doctrine for Joint Theater Nuclear Operations. 9 February 1996. 



NATO STANAGs 

These agreements are available on request using DD Form 1425 from Standardization Document Order 
Desk, 700 Robin Avenue, Building 4, Section D. Philadelphia, Pennsylvania 19111-5094. 

2068. Emergency War Surgery. Edition 4. 28 October 1986. (Latest Amendment, 17 October 1991.) 
2083. Commander's Guide on Nuclear Radiation Exposure of Groups. Edition 5. 19 September 1986. 

(Latest Amendment, 26 June 1994.) 
2461. NATO Handbook on the Medical Aspects of NBC Defensive Operations AMedP-6 (C), Volume I— 

Nuclear. 30 May 2000. 
2473. Commanders Guide On Low Level Radiation (LLR) Exposure In Military Operations. Edition 1. 

3 May 2000. 
2475. Planning Guide for the Estimation of NBC Battle Casualties (Nuclear), AMedP-8 (A), Volume 1, 

Ratification Draft. 



ABCA QSTAG 

This agreement is available on request using DD Form 1425 from Standardization Document Order Desk, 
700 Robin Avenue, Building 4, Section D. Philadelphia, Pennsylvania 191 1 1-5094. 

1263. Common Principles and Procedures for Critical Aspects of the Medical and Dental Treatment of 
Personnel. May 2000. 



Multiservice Publications 

FM 3-4. NBC Protection. FMFM 11-9. 29 May 1992. (Reprinted with basic including Change 1, 

28 October 1992; Change 2, 21 February 1996.) 
FM 8-9. NATO Handbook on the Medical Aspects of NBC Defensive Operations. AMedP-6 (B)— 

Part I— Nuclear, Part II— Biological, Part III— Chemical; NAVMED P-5059; AFJMAN 

44-151 VI V2V3. 1 February 1996. 
FM 8-285. Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries. 

NAVMED P-5041; AFJMAN 44-149; FMFM 11-11. 22 December 1995. 

References-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Department of Defense Publications 

The Militarily Critical Technologies List, Part II: Weapons of Mass Destruction Technologies, Office of 
the Under Secretary of Defense for Acquisition and Technology, Washington, D.C., February 1998. 
DOD 5100.52-M. Nuclear Weapon Accident Response Procedures (NARP) Manual. September 1990. 
DODI 6055.8. Occupational Radiation Protection Program. March 1989. 
Emergency War Surgery NATO Handbook, 2d US Revision, 1988. 



Armed Forces Radiobiology Research Institute 

Jarrett, David, Editor. Medical Management of Radiological Casualties Handbook, 1st Edition. Armed Forces 

Radiobiology Research Institute, December 1999. 
Medical Effects of Ionizing Radiation Course (CD-ROM), January 1999. 



US Army Field Manuals (FMs) 

FM 8-10-1. The Medical Company— Tactics, Techniques, and Procedures. 29 September 1994. 

FM 8-10-6. Medical Evacuation in a Theater of Operations— Tactics, Techniques, and Procedures. 

14 April 2000. 
FM 8-10-7. Health Service Support in a Nuclear, Biological, and Chemical Environment. 22 April 1993. 

(Change 1, 26 November 1996.) 
FM 21-11. First Aid For Soldiers. 27 October 1988. (Reprinted with basic including Change 1—2, 

4 December 1991.) 



US Army Center for Health Promotion and Preventive Medicine Publication 

Technical Guide 238. Radiological Sources of Potential Exposure and/or Contamination. Draft, June 1999. 

Civilian Reference Material 
Books 

Bellamy, Ronald F., and Zajtchuk, Russ. Conventional Warfare: Ballistic, Blast, and Burn Injuries. 
(Textbook of Military Medicine Series, Part I, Warfare, Weaponry, and the Casualty, Volume 5.) 
Office of The Surgeon General, Textbook of Military Medicine Publications. Washington, DC: 
Borden Institute, 1991. 

Cerveny, T. Jan, and Walker, Richard I. Medical Consequences of Nuclear Warfare. (Textbook of 
Military Medicine Series, Part I, Warfare, Weaponry, and the Casualty, Volume 2.) Office of The 
Surgeon General, Textbook of Military Medicine Publications. Washington, DC: Borden 
Institute, 1989. 

References-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



Oak Ridge Institute for Science and Education. Reference Manual for Medical Planning and Care in 
Radiation Accidents. September 2000. 

O'Maonaigh, H., and Thaul, S. Potential Radiation Exposure in Military Operations. Institute of Medi- 
cine. Washington, DC: National Academy Press, 1999. 

Upton, Arthur C, Chairman. Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V, 
1990. National Academy Press, 1990. 

Voelz, George L., Chairman. Management of Persons Accidentally Contaminated With Radionuclides. 
National Council on Radiation Protection (NCRP) and Measurements Report No. 65, 1979. 

Wyngaarden, J.B., and Smith, L.H., Editors. Cecil Textbook of Medicine. W.B. Saunders Company, 
1982. 



Journal Articles/Worldwide Web Articles 

Federation of American Scientists. Nuclear Forces Guide (December 2000). 

Web address: http://www.fas.org/nuke/guide/index.html 
German, John. Palomares 'bomb number four'— it crashed, it fell, it sank, but (whew!) it never blew up. 

Sandia Lab News (19 January 1995). 

Web address: http://www.sandia.gov/LabNews/LN01-19-96/palo.html 
Gilmore, James III, Chairman. First Annual Report to The President and The Congress of the Advisory 

Panel to Assess Domestic Response Capabilities for Terrorism Involving Weapons of Mass 

Destruction, I. Assessing the Threat. The RAND Corporation (1999). 

Web address: http://www.rand.org/nsrd/terrpanel/terror.pdf 
Gray, Cleve J., and Tiwari, Jaya. US Nuclear Weapons Accidents. Center for Defense Informa- 
tion (January 1999). 

Web address : http : //www .cdi . org/issues/nukeaccidents/accidents .htm 
Harley, Naomi H., Foulkes, Ernest C, Hilborne, Lee H., Hudson, Arlene, and Anthony, C. Ross. A 

Review of the Scientific Literature as It Pertains to Gulf War Illnesses, Volume 7, Depleted 

Uranium. The RAND Corporation (1999). 

Web address: http://www.rand.Org/publications/MR/MR1018.7/MR1018.7.html 
International Atomic Energy Agency. Report on the Preliminary Fact Finding Mission Following the 

Accident at the Nuclear Fuel Processing Facility in Tokaimura, Japan. Vienna: International 

Atomic Energy Agency (November 1999). 

Web address : http : //www . iaea . org/worldatom/documents/tokaimura/iaea-toac .pdf 
Metivier, Dr. Henri (France) (Chair, Editing Committee). Chernobyl— Ten Years On Radiological and 

Health Impact. An Assessment by the NEA Committee on Radiation Protection and Public Health, 

OECD Nuclear Energy Agency (November 1995). 

Web address : http : //www . nea . fr/html/rp/reports/ 1 995 /chernobyl/allchernobyl .html 
Non-Proliferation Center, Director of Central Intelligence. Unclassified Report to Congress on the 

Acquisition of Technology Relating to Weapons of Mass Destruction and Advanced Conventional 

Munitions (February and August 2000). 

Web address: http://www.fas.org/irp/threat/bian_aug2000.htm 



References-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 

INDEX 

References are to paragraph numbers except where specified otherwise. 



acute 

local radiation injury, l-2a, 4-3 
radiation 

injury (summary of medical aspects), 3-17 
syndrome, l-2a, 3-6 

cardiovascular/central nervous system, 3-6c 
clinical findings/diagnosis, 3-8 
dosimetry, 3-9 
laboratory testing, 3-10 
lymphocyte levels, 3-10a 
signs and symptoms, 3-8 
first aid, 3-12 

gastrointestinal, 3-4b—c, 3-6c(2), 3-14 
hematopoietic, 3-6c, 3-13 

effects on combined injury, 3-24 
lethality/lethal dose, 3-6b 

with medical intervention, 3-6b(2) 
without medical intervention, 3-6b(l) 
phases, 3 -6a 

latent, 3-6a, 3-6c(2)(b) 
manifest illness, 3-6a(2)— (3), 3-14, 3-17 
prodromal, 3-6a(l), 3-6c(2)(b) 
recovery, 3-20d 
subsyndromes, 3-6^(3), 3-6c, 3-12—17 
antiemetic, 3 -8a, Tables 3-6—9, Appendix B and C 
Armed Forces Medical Services, l-la 
atomic, 2-2a 

demolition munitions, l-6b 

blast, 2-1, 2-5a, 2-6 
first aid, 3-20 
hazards, 2-6 

direct blast injury, 2-6a 
indirect blast wind drag forces, 2-6b 
crush and translational injuries, 2-6b(l) 
missile injury, 2-6b(2) 
range of damage, 2-9 
treatment of, 3-20 
bioassay/medical assay, 3-l0b, 4-2b, 4-2c(2) 
biological, 2-1-2, 2-3c, 2-9, 3-18, 3-24, 4-1, 4-4, 4-lOb 
warfare, 3-26 
weapons, 3-18, 3-26 

lndex-1 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



bone marrow, 3-3b(2), 3-4, 3-6c,f—g, 3-16—17 
effects (of radiation), 3-4a 
transplant, 3-13/— g, 3-17 

carcinogenesis, 5-3, 5-8 

cancer types, 5-8d 

excess radiation-induced cancers, 5-8b 

risk, 5-8b 
cataract formation, 5-9 
cellular effects of ionizing radiations, 3-3 
chemical, l-2d(l), l-2e(l), 4-4, 4-9, 4-10c(l), 5-14/ 

agent, 6-7a 

defense, 3-8 

weapons, l-5a, 1-7, 3-18, 3-25 
Chernobyl, l-2d(l)(b) 

psychological factors at, 6-5b 

treatment of cutaneous radiation syndrome at, 4-7 
combined injury, 2-1, 3-1, 3-lla(l), 3-18, 3-20-21, 3-24 

biological weapons and radiation, 3-26 

blast injuries, l-2a, 3-12, 3-19 
treatment of, 3-20 

chemical weapons and radiation, 3-25 

hematopoietic effects of, 3-24 

thermal injury, l-2a, 3-21 
determining severity of, 3-22 
treatment of, 3-23 
consequence management, 3-11 
cutaneous radiation syndrome, 4-5a, 4-6—7 

treatment of, 4-7 
cytokines, 3-4c(2), 3-l3d— e, 3-l4b, 3-16—17 

decontamination, 3-l0b, 3-l3b, 3-14c, 3-17, 4-3a, 4-4 

external, 4-2a, 4-3 

internal, 4-2b 

skin, 4-4a 

techniques, 4-4b 
delayed/late effects, 3-2, 5-lb, 5-2b, 5-3 

carcinogenesis, 5-3, 5-8 
risk of, 5-8b 

cataract formation, 5-9 

embryonic and fetal, 5-6 

principles of, 5-4 

reproductive cell kinetics and sterility, 5-7 

types of, 5-5 

lndex-2 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



depleted uranium, \-2d(\)(a), \-2e{\), Appendix A 
characteristics and uses, A-2 
health effects of exposure to, A-4 
chemical toxicity, \-2e{\), A-Ad 
external exposure, A-Ab 
internal exposure to, A-4c 
radiological toxicity, A-Ae 
patient management, A-5 
clinical treatment, k-5b 
determining presence of DU, k-5a 
toxicity, l-2e(l), A-3 
chemical, \-2e{\), A-4d 
internalization, A-3 
pyrophoric effect, A-3a 
radiological, A-4^ 
diagnosis, 3-8, 3-lOa, 3-11, 3-13c(3), 3-19, 5-12 
dose, 2-3c, 2-lOa 
absorbed, 2-3 
equivalent, 2-3c 
rate, 2-3d 
dosimeters, 3-9 
dosimetry, 3-9 

embryonic/fetal effects, 5-6 
enteric feeding, 3-14e 
exposure, definition of, 2-3a 

fallout, 2-8b(4), 3-8, 3-20a, 4-3 

base surge, 2-8b(4)(a) 

scavenging, 2-8b(4)(b) 
first aid, 3-12, 3-20a, 3-23a 
fission, l-2d, 2-2a(3), 2-5 

products, 1 -2d, 2-5Z?(l), 2-8 
fusion, 2-2a, 2-5 

gastrointestinal effects, 3-4, 3-6c, 3-14 

high-level waste, l-2d 
highly enriched uranium, l-5c 

immune system, 3-24, 3-27 
immunization, 3-13/(3), 3-20/, 3-27 
initial radiation, 2-5a, 2-8a 



lndex-3 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



internal irradiation (contamination), 4-8 
therapeutic agents, 4-10c 

blocking and diluting, 4-10c(2) 

chelating, 4-10c(4) 

mobilizing, 4-10c(3) 

Prussian blue, 4-10c(l) 
treatment of, 4-10 

immediate care, 4-lCta 

treatment procedures, 4- 10£ 
internalization of radioactive materials, l-2e(l), 4-9 
distribution, 4-4b 
intake, 4-2, 4-9 

metabolism and excretion, 4-9c 
International System of Units, l-lb, 2-3 

ionizing radiation, l-lb, 2-1—5, 2-9, 3-1—3, 3-4c(2), 3-6a, 3-6c(l) (a)—(b), 3-7, 3-26—27 
biological effects, 3-2 
cellular effects, 3-3 

direct action, 3-3a 

indirect action, 3-3a 

relative cellular radiosensitivity, 3-3b 
relative tissue radiosensitivity, 3-4 

cardiovascular/central nervous system, 3-4c, 3-6c(3), 3-15 

gastrointestinal system, 3-4b 

hematopoietic system, 3-4a, 3-6c 
systemic effects, 3-5 
types, 2-2 

alpha, l-2e(l), l-3a, 2-2a(l) 

beta, 2-2a(2) 

electromagnetic, 2-2b 

gamma, 2-2b, 

neutron, 1-2^(1), Table 2-1, 2-2a(3), 2-4d, 

x-ray, l-2b(l), l-2c, Table 1-2, l-3a 
isolation, Tables 3-8—9, Appendix C 

laboratory testing, 3-10 
leukemia, 5-2a, 5-8, 5-12—13 
level of care, Preface, C-2 
linear energy transfer, 2-3c(l) 
local tissue irradiation, 4-1, 4-5 
low-level radiation, l-la, l-2a, 3-8, Chapter 5 
definition of , 5 -la 
delayed/late effects, 5-1—3 
carcinogenesis, 5-8 

risk of, 5-8b 
cataract formation, 5-3, 5-9 

lndex-4 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



low-level radiation 

delayed/late effects {continued) 

embryonic and fetal, 5-6 

principles of, 5-4 

reproductive cell kinetics and sterility, 5-7 

types of, 5-5 
documentation of exposure records, 5-14 
exposure guidance, 5-2 
initial actions, 5-11 
medical care, 5-12 

early and delayed deterministic effects, 5- 12a 

stochastic effects, 5-\2b 
medical follow-up, 5-13 

medical assessment, 5- 13a 

medical monitoring, 5-13Z? 
prevention, 5-10 
threat of, \-\a, 5-\b 

management of the 

cardiovascular/central nervous system syndrome, 3-15 
gastrointestinal syndrome, 3-14 

antibiotics, use of, 3-14c 

cytokines, efficacy of, 3-l4b 

diarrhea, treatment of, 3- 14a 

fluids and electrolytes, 3- 14a 

gastric acid, bactericidal effect of, 3-140" 
hematopoietic syndrome, 3-13 

anemia, conventional therapy of, 3-13/(3) 

bone marrow/ stem cell transplantation, 3-13g 

hematopoietic growth factors, 3-13e 

immune globulin administration, 3-1 3d 

infection, 3-13 

prevention of, 3-l3b 

management of, 3- 13c 

neutropenia, conventional therapy of, 3- 13a 

thrombocytopenia, conventional therapy of, 3-13/(1) 
medical treatment facilities, l-6b 
medications, 3-1, 3-13a, 4-10c, Appendix B 
microvascular effects, 3-4b(2), 3-4c(2) 

nuclear 

and radiological threats, 1-1, 1-7 
global and regional, 1-7 
nuclear fuel cycle/processing, l-2d, 1-7 
nuclear reactors, l-2d, 1-7 



lndex-5 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



nuclear 

and radiological threats (continued) 

nuclear weapons incidents, \-\a, 1-3, 1-7 

special nuclear material, 1-5/?— c 

strategic nuclear war, l-la, l-6a 

terrorism and a single nuclear detonation, 1-5 

terrorism and radiological dispersal devices, 1-4 

theater nuclear war, l-6b 
detonation, l-3a, l-5a, l-6b, 2-5 

characteristics, 2-5a 

range of damage, 2-9 

single nuclear detonation, 1-5 

types of bursts, 2-5b 
fuel cycle/processing, 1-7, l-2d 
reactors, \-2d 

examples of accidents, l-2rf(3) 
war (fare), \-\a, 1-6 

strategic, I -6a 

theater, I -6b 
weapons, l-la, 1-3, 1-6—7 

incidents, 1-3 
Palomares, l-3b 

organs, 3-4, 3-22, 4-1 

target, 4- 10ft, 4-10c(2) 
orthopedic injuries, 3-2(te 

partial body irradiation, 3-5, 3-9 
patient management, l-6b 
penetration and shielding, 2-4 
alpha shielding, 2-4a 
beta shielding, 2-4b 
gamma shielding, 2-4c 
neutron shielding, 2-4d 
psychological 

effects, 1 -4a, 6-1, 6-2a 

of radiation dispersal devices, and nuclear incidents, 6-2 
of nuclear detonation, 6-3 
in a fallout field, 6-4 
prevention, 6-1 a 
risk communication, 6-7b 
factors at Chernobyl, 6-5 b 
psychosocial sequelae, 6-5a 
stress, 6-2, 6-4—5 
treatment of, 6-6 

lndex-6 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



radiation 

accidents, 1-2, 3 -6a 

biomedical sources, l-2c 
industrial sources and accidents, l-2b 

sources from United States forces commodities and foreign material, l-2e 
hazards, l-la, 2-8 
initial radiation, 2-8a 
residual radiation, 2-8b 
induced early transient incapacitation, 3-7 
radioactive contamination, l-2a and d, 2-10, Chapter 4 
external contamination, 2- 10a, 4-1 
external irradiation, 4-3 

cutaneous radiation syndrome, 4-6 

treatment of, 4-7 
local tissue irradiation, 4-5 
handling contaminated patients, 4-4 
internal contamination, 2-lOb, 4-8 

internalization of radioactive materials, 4-9 
treatment of, 4-10 
measuring levels of, 4-2 

direct external contamination assessment, 4-2a 
direct internal contamination measurement, 4-2b 
indirect contamination measurement, 4-2c 
radiological 

casualties, l-la, 3-1, 3-11—12 
dispersal device, 1-4 
injury, l-2e, l-4a, 1-6, 3-11, 3-24, 3-27 
recovery, 3-13^, 3-16 

relative tissue radiosensitivity of the cardiovascular/central nervous systems, 3-4c 
of the gastrointestinal system, 3-4b 
of the hematopoietic system, 3-4a 
reproductive cell kinetics and sterility, 5-7 
residual radiation, 2-5a, 2-8b 

fallout, 2-5a, 2-5b(l) and (2), 2-8b(4), 3-8, 3-20a 
fission products, 2-5b(l), 2-8 
neutron induced ground activity, 2-8b(3) 
unfissioned nuclear material, 2-8b(2) 
scavenging, 2-8b(4)(b) 
risk communication, 6-7b 

sources of radiation, 1-2 

biomedical sources, l-2c 

industrial sources, l-2b 

nuclear fuel cycle, l-2d 

nuclear reactors, l-2d 

US commodities and foreign material, l-2e 
special nuclear material, l-5b and c 



lndex-7 



FM 4-02.283/NTRP 4-02.21/AFMAN 44-161(l)/MCRP 4-11.1B 



terrorism, 1-4, 1-5 

thermal radiation, 1-2, 2-5a, 2-56(2), 2-7, 3-18—19, 3-21 
burns with radiation injury, 3-21 
evaluation of, 3-22 
area of burn, 3-22a 
depth of burn, 3-22c 
involvement of critical organs, 3-226 
eye injuries, 2-7c 
first aid, 3-23a 
flame burns, 2-7 
flash burns, 2-7 
treatment of, 3-23 

burn wound, care of, 3-23c 
fluid therapy, 3-236(2) 
input/output records, 3-236(3) 
maintenance of airway, 3-236(1) 
threats, global and regional, 1-7 
treatment 

briefs, 3-1, 3-17, Appendix C 
protocols, l-la 
triage of nuclear and radiological casualties, 3-11 
classification system, 3-1 la 

units of measure, 1-16, 2-3 
absorbed dose, 2-36 
activity, 2-3^ 
dose equivalent, 2-3c 

linear energy transfer, 2-3c(l) 
dose rate, 2-3<2 
exposure, 2-3a 
half-life, 2-3/ 
lethality/lethal dose, 3-66 

weapons of mass destruction (WMD), l-5a, 1-66 
whole body 

irradiation, 3-5 

radiation doses, 3-46(2), 3-8d 



lndex-8 



FM 4-02.283/NTRP 4-02.21 /AFMAN 44-161 (l)/MCRP 4-1 1.1 B 



By Order of the Secretary of the Army: 



Official: 

r JOEL B. HUDSON 

Administrative Assistant to the 
Secretary of the Army 



ERIC K. SHINSEKI 

General, United States Army 
Chief of Staff 



By Direction of the Chief of Naval Operations: 



Official: 



By Order of the Secretary of the Air Force: 



Official: 



By Direction of the Commandant of the Marine Corps: 




Rear Admiral / 
Commanc 
Navy Warfare Development Command 



PAUL K. CARLTON, JR. 

Lieutenant General, USAF, MC, CFS 
Surgeon General 



Official: 



EDWARD-HANL&W7JR/ 

Lieutenant General, U.Sj. Marj/e Corps 

Commanding Ggpefral 

Marine Corps Combat Development Command 



DISTRIBUTION: 



US Army: Active Army, USAR, and ARNG: To be distributed in accordance with the initial 
distribution number 1 1 5861 , requirements for FM 4-02.283. 
US Air Force: F 
US Marine Corps: PCN: 14400010600 



PCN: 14400010600